recommendation,class,level,table_number,table_name,guideline,year,page
"Diagnosis and risk stratiﬁcation It is recommended to base diagnosis and initial short-term risk stratiﬁcation on a combination of clinical history, symptoms, vital signs, other physical ﬁndings, ECG, and laboratory results including hs-cTn.",I,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
"It is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within 60 min of blood sampling.3,1013,29",I,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
It is recommended to obtain a 12-lead ECG within 10 min after ﬁrst medical contact and to have it immediately interpreted by an experienced physician.,I,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
It is recommended to obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty.,I,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
Additional testing after 3 h is recommended if the ﬁrst two cardiac troponin measurements of the 0 h/1 h algorithm are not conclusive and the clinical condition is still suggestive of ACS.,I,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
As an alternative to the,I,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
"Additional ECG leads (V3R, V4R, V7V9) are recommended if ongoing ischaemia is suspected when standard leads are inconclusive.",I,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
As an alternative to the,IIa,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
The routine use of copeptin as an additional biomarker for the early rule-out of MI should be considered where hs-cTn assays are not available.,IIa,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
It should be considered to use established risk scores for prognosis estimation.,IIa,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
"For initial diagnostic purposes, it is not recommended to routinely measure additional biomarkers such as h-FABP or copeptin, in addition to hs-cTn.",III,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,18
"In patients with no recurrence of chest pain, normal ECG ﬁndings, and normal levels of cardiac troponin (preferably high sensitivity), but still with a suspected ACS, a non-invasive stress test (preferably with imaging) for inducible ischaemia or CCTA is recommended before deciding on an invasive approach.91,92,98,101,105",I,B,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.c,I,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
"CCTA is recommended as an alternative to ICA to exclude ACS when there is a low-to-intermediate likelihood of CAD and when cardiac troponin and/or ECG are normal or inconclusive.105,108,110",I,A,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
Monitoring Continuous rhythm monitoring is recommended until the diagnosis of NSTEMI has been established or ruled out.,I,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
It is recommended to admit NSTEMI patients to a monitored unit.,I,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
Rhythm monitoring up to 24 h or to PCI (whichever comes ﬁrst) is recommended in NSTEMI patients at low risk for cardiac arrhythmias.d,I,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
Rhythm monitoring for >24 h is recommended in NSTEMI patients at increased risk for cardiac arrhythmias.e,I,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
"In the absence of signs or symptoms of ongoing ischaemia, rhythm monitoring in unstable angina may be considered in selected patients (e.g. suspicion of coronary spasm or associated symptoms suggestive of arrhythmic events).",IIb,C,1,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome",ACS NSTE,2020,19
"Antiplatelet treatment Aspirin is recommended for all patients without contraindications at an initial oral LD of 150300 mg (or 75250 mg i.v.), and at a MD of 75100 mg o.d. for long-term treatment.179",I,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
"A P2Y12 receptor inhibitor is recommended in addition to aspirin, and maintained over 12 months unless there are contraindications or an excessive risk of bleeding.170,171,182 Options are:",I,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
" Prasugrel in P2Y12 receptor inhibitor-naı¨ve patients proceeding to PCI (60 mg LD, 10 mg/d as standard dose, 5 mg/d for patients aged >_75 years or with a body weight <60 kg).",I,B,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
" Ticagrelor irrespective of the planned treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d.).",I,B,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
" Clopidogrel (300600 mg LD, 75 mg daily dose), only when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.",I,C,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Prasugrel should be considered in preference to ticagrelor for NSTE-ACS patients who proceed to PCI.,IIa,B,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
GP IIb/IIIa antagonists should be considered for bail-out if there is evidence of no-reﬂow or a thrombotic complication.,IIa,C,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Cangrelor may be considered in P2Y12 receptor inhibitor-naı¨ve patients undergoing PCI.184,IIb,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients with NSTE-ACS who are not planned to undergo an early invasive strategy and do not have an HBR.,IIb,C,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known is not recommended.,III,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned.,III,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
"Peri-interventional anticoagulant treatment Parenteral anticoagulation is recommended for all patients, in addition to antiplatelet treatment, at the time of diagnosis and, especially, during revascularization procedures according to both ischaemic and bleeding risks.",I,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
"UFH (weight-adjusted i.v. bolus during PCI of 70100 IU/kg, or 5070 IU/kg in combination with a GP IIb/IIIa inhibitor; activated clotting time target range of 250350 s, or 200250 s if a GP IIb/IIIa inhibitor is given) is recommended in patients undergoing PCI.",I,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
"In cases of medical treatment or logistical constraints for transferring the patient to PCI within the required time frame, fondaparinux is recommended and, in such cases, a single bolus of UFH is recommended at the time of PCI.",I,B,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
"It is recommended to select anticoagulation according to both ischaemic and bleeding risks, and according to the efﬁcacysafety proﬁle of the chosen agent.",I,C,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Enoxaparin (i.v.) should be considered in patients pre-treated with subcutaneous enoxaparin.194,IIa,B,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Discontinuation of parenteral anticoagulation should be considered immediately after an invasive procedure.,IIa,C,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Bivalirudin may be considered as an alternative to UFH.,IIb,A,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
Crossover of UFH and LMWH is not recommended.,III,B,2,antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention,ACS NSTE,2020,26
"In patients with NSTE-ACS treated with coronary stent implantation, DAPT with a P2Y12 receptor inhibitor on top of aspirin is recommended for 12 months unless there are contraindications such as excessive risk of bleeding.",I,A,3,post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,29
Prolonging antithrombotic treatment duration Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be considered in patients with a high risk of ischaemic events and without increased risk of major or life-threatening bleeding (see Tables 9 and 11 for options).,IIa,A,3,post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,29
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention may be considered in patients with moderately increased risk of ischaemic events and without increased risk of major or life-threatening bleeding (see Tables 9 and 11 for options).,IIb,A,3,post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,29
"In ACS patients with no prior stroke/transient ischaemic attack who are at high ischaemic risk and low bleeding risk and are receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg b.i.d. for approximately 1 year) may be considered after discontinuation of parenteral anticoagulation.",IIb,B,3,post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,29
"Shortening antithrombotic treatment duration After stent implantation with high risk of bleeding (e.g. PRECISE-DAPT >_25 or ARC-HBR criteria met), discontinuation of P2Y12 receptor inhibitor therapy after 3 months should be considered.",IIa,B,3,post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,29
"After stent implantation in patients undergoing a strategy of DAPT, stopping aspirin after 36 months should be considered, depending on the balance between the ischaemic and bleeding risk.",IIa,A,3,post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,29
"De-escalation of P2Y12 receptor inhibitor treatment (e.g. with a switch from prasugrel or ticagrelor to clopidogrel) may be considered as an alternative DAPT strategy, especially for ACS patients deemed unsuitable for potent platelet inhibition. De-escalation may be done unguided based on clinical judgment or guided by platelet function testing or CYP2C19 genotyping, depending on patient’s risk proﬁle and availability of respective assays.",IIb,A,3,post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,29
Sublingual or i.v. nitrates and early initiation of beta-blocker treatment are recommended in patients with ongoing ischaemic symptoms and without contraindications.,I,C,4,anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,30
It is recommended to continue chronic betablocker therapy unless the patient is in overt heart failure.,I,C,4,anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,30
i.v. nitrates are recommended in patients with uncontrolled hypertension or signs of heart failure.,I,C,4,anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,30
"In patients with suspected/conﬁrmed vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided.",IIa,B,4,anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,30
"Stroke prevention is recommended to AF patients with >_1 non-sex CHA2DS2-VASc stroke risk factors (score of >_1 in males or >_2 in females).For patients with >_2 non-sex stroke risk factors, OAC is recommended.255",I,A,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"For patients with 1 non-sex stroke risk factor, OAC should be considered and treatment may be individualized based on net clinical beneﬁt and consideration of patient values and preferences.260",IIa,B,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"An early ICA should be considered in HBR patients, irrespective of OAC exposure, to expedite treatment allocation (medical vs. PCI vs. CABG) and to determine the optimal antithrombotic regimen.",IIa,C,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"Patients undergoing coronary stenting Anticoagulation During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all NOACs and if INR is <2.5 in VKA-treated patients.",I,C,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"In patients with an indication for OAC with VKA in combination with aspirin and/or clopidogrel, the dose intensity of VKA should be carefully regulated with a target INR of 2.02.5 and a time in the therapeutic range >70%.236,238",IIa,B,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase.,IIa,C,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"Antiplatelet treatment In patients with AF and CHA2DS2-VASc score >_1 in men and >_2 in women, after a short period of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel).238",I,A,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
Periprocedural DAPT administration consisting of aspirin and clopidogrel up to 1 week is recommended.238,I,A,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.236,I,B,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"In patients treated with a VKA (e.g. mechanical prosthetic valves), clopidogrel alone should be considered in selected patients (HAS-BLED >_3 or ARC-HBR met and low risk of stent thrombosis) for up to 12 months.",IIa,B,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"When rivaroxaban is used and concerns about HBR prevail over stent thrombosis or ischaemic stroke, rivaroxaban 15 mg o.d. should be considered in preference to rivaroxaban 20 mg o.d. for the duration of concomitant SAPT or DAPT.",IIa,B,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"In patients at HBR (HAS-BLED >_3), dabigatran 110 mg b.i.d. should be considered in preference to dabigatran 150 mg b.i.d. for the duration of concomitant SAPT or DAPT to mitigate bleeding risk.",IIa,B,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"In patients treated with an OAC, aspirin plus clopidogrel for longer than 1 week and up to 1 month should be considered in those with high ischaemic risk or other anatomical/procedural characteristics which outweigh the bleeding risk (Table 11).",IIa,C,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"DAT (with an OAC and either ticagrelor or prasugrel) may be considered as an alternative to TAT (with an OAC, aspirin, and clopidogrel) in patients with a moderate or high risk of stent thrombosis, irrespective of the type of stent used.",IIb,C,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
The use of ticagrelor or prasugrel as part of TAT is not recommended.,III,C,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
Medically managed patients One antiplatelet agent in addition to an OAC should be considered for up to 1 year.,IIa,C,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"In patients with AF, apixaban 5 mg b.i.d. and SAPT (clopidogrel) for at least 6 months may be considered.",IIb,B,5,combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation,ACS NSTE,2020,33
"In patients with dabigatran-associated ongoing life-threatening bleeding, the administration of the speciﬁc antidote for dabigatran  idarucizumab  should be considered.",IIa,B,6,bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients,ACS NSTE,2020,34
"In patients with VKA-associated life-threatening bleeding events, rapid reversal of anticoagulation with four-factor prothrombin complex concentrate rather than with fresh frozen plasma or recombinant activated factor VII should be considered. In addition, repetitive 10 mg i.v. doses of vitamin K should be administered by slow injection.",IIa,C,6,bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients,ACS NSTE,2020,34
"In patients with NOAC-associated ongoing life-threatening bleeding, the administration of prothrombin complex concentrates or activated prothrombin complex concentrates should be considered when the speciﬁc antidote is unavailable.",IIa,C,6,bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients,ACS NSTE,2020,34
"In patients with rivaroxaban-, apixaban-, or edoxaban-associated ongoing life-threatening bleeding, the administration of the speciﬁc antidote  andexanet-alpha  may be considered.",IIb,B,6,bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients,ACS NSTE,2020,34
"In patients with anaemia and no evidence of active bleeding, blood transfusion may be considered in case of compromised haemodynamic status, haematocrit <25%, or haemoglobin level <8 g/dL.",IIb,C,6,bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients,ACS NSTE,2020,34
Timing of invasive strategy An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very high-risk criteria: • Haemodynamic instability or CS. • Recurrent or refractory chest pain despite medical treatment. • Life-threatening arrhythmias. • Mechanical complications of MI. • Heart failure clearly related to NSTE-ACS. • Presence of ST-segment depression >1 mm in >_6 leads additional to ST-segment elevation in aVR and/or V1.,I,C,7,coronary revascularization,ACS NSTE,2020,40
"An early invasive strategy within 24 h is recommended in patients with any of the following highrisk criteria: • Diagnosis of NSTEMI suggested by the diagnostic algorithm recommended in section 3. • Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing ischaemia. • Transient ST-segment elevation.273,362 • GRACE risk score >140.",I,A,7,coronary revascularization,ACS NSTE,2020,40
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive CAD by CCTA is recommended in patients considered at low risk.,I,A,7,coronary revascularization,ACS NSTE,2020,40
Delayed as opposed to immediate angiography should be considered among haemodynamically stable patients without ST-segment elevation successfully resuscitated after out-of-hospital cardiac arrest.,IIa,B,7,coronary revascularization,ACS NSTE,2020,40
DES are recommended over bare-metal stents for any PCI irrespective of: • Clinical presentation. • Lesion type. • Planned non-cardiac surgery. • Anticipated duration of DAPT. • Concomitant anticoagulant therapy.,I,A,7,coronary revascularization,ACS NSTE,2020,41
"It is recommended to base the revascularization strategy (ad hoc culprit lesion PCI/multivessel PCI/ CABG) on the patient’s clinical status and comorbidities, as well as their disease severity [i.e. the distribution and angiographic lesion characteristics (e.g. SYNTAX score)], according to the principles for stable CAD.350 However, the decision on immediate PCI of the culprit stenosis does not require Heart Team consultation.",I,B,7,coronary revascularization,ACS NSTE,2020,41
Complete revascularization should be considered in NSTE-ACS patients without CS and with multivessel CAD.,IIa,C,7,coronary revascularization,ACS NSTE,2020,41
Intracoronary imaging should be considered to diagnose SCAD if suspected.,IIa,C,7,coronary revascularization,ACS NSTE,2020,41
Complete revascularization during index PCI may be considered in NSTE-ACS patients with multivessel disease.,IIb,B,7,coronary revascularization,ACS NSTE,2020,41
FFR-guided revascularization of a non-culprit NSTE-ACS lesion may be used during index PCI.,IIb,B,7,coronary revascularization,ACS NSTE,2020,41
"In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to differentiate true MINOCA from alternative diagnoses.",I,C,8,myocardial infarction with non-obstructive coronary arteries,ACS NSTE,2020,43
It is recommended to perform CMR in all MINOCA patients without an obvious underlying cause.,I,B,8,myocardial infarction with non-obstructive coronary arteries,ACS NSTE,2020,43
It is recommended to manage patients with an initial diagnosis of MINOCA and a ﬁnal established underlying cause according to the disease-speciﬁc guidelines.,I,C,8,myocardial infarction with non-obstructive coronary arteries,ACS NSTE,2020,43
Patients with a ﬁnal diagnosis of MINOCA of unknown cause may be treated according to secondary prevention guidelines for atherosclerotic disease.,IIb,C,8,myocardial infarction with non-obstructive coronary arteries,ACS NSTE,2020,43
Emergency coronary angiography is recommended in patients with CS complicating ACS.,I,B,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
"Emergency PCI of the culprit lesion is recommended for patients with CS due to NSTE-ACS, independent of the time delay from symptom onset, if the coronary anatomy is amenable to PCI.",I,B,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
Emergency CABG is recommended for patients with CS if the coronary anatomy is not amenable to PCI.,I,B,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
It is recommended to perform emergency echocardiography without delay to assess LV and valvular function and exclude mechanical complications.,I,C,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
"In cases of haemodynamic instability, emergency surgical or catheter-based repair of mechanical complications of ACS is recommended, as decided by the Heart Team.",I,C,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
"For NSTE-ACS-related mechanical complications, the use of IABP should be considered.",IIa,C,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
"In selected patients with ACS and CS, short-term mechanical circulatory support may be considered, depending on patient age, comorbidities, neurological function, and the prospects for longterm survival and predicted quality of life.",IIb,C,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
Routine use of IABP in patients with CS and no mechanical complications due to ACS is not recommended.,III,B,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
Routine immediate revascularization of non-culprit lesions in NSTE-ACS patients with multivessel disease presenting with CS is not recommended.,III,B,9,non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock,ACS NSTE,2020,44
It is recommended to screen all patients with NSTE-ACS for diabetes and to monitor blood glucose levels frequently in patients with known diabetes or admission hyperglycaemia.,I,C,10,diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients,ACS NSTE,2020,45
Avoidance of hypoglycaemia is recommended.424,I,B,10,diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients,ACS NSTE,2020,45
"Glucose-lowering therapy should be considered in ACS patients with blood glucose >10 mmol/L (>180 mg/dL), with the target adapted to comorbidities, while episodes of hypoglycaemia should be avoided.422,428",IIa,B,10,diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients,ACS NSTE,2020,45
"A multifactorial approach to diabetes mellitus management, with treatment targets, should be considered in patients with diabetes and CVD.431",IIa,B,10,diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients,ACS NSTE,2020,45
"Less stringent glucose control should be considered, both in the acute phase and at follow-up, in patients with more advanced CVD, older age, longer diabetes duration, and more comorbidities.",IIa,C,10,diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients,ACS NSTE,2020,45
Risk stratiﬁcation in CKD It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD (dose adjustment may be necessary) as for patients with normal renal function.,I,C,11,patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,45
It is recommended to assess kidney function by eGFR in all patients.,I,C,11,patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,45
Myocardial revascularization in patients with CKD Use of low- or iso-osmolar contrast media (at lowest possible volume) are recommended in invasive strategies.,I,A,11,patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,45
Pre- and post-hydration with isotonic saline should be considered if the expected contrast volume is >100 mL in invasive strategies.,IIa,C,11,patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,45
"As an alternative to the pre- and post-hydration regimen, tailored hydration regimens may be considered.",IIb,B,11,patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,45
CABG should be considered over PCI in patients with multivessel CAD whose surgical risk proﬁle is acceptable and life expectancy is >1 year.,IIa,B,11,patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,45
It is recommended to apply the same diagnostic strategies in older patients as for younger patients.,I,B,12,older persons with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,46
It is recommended to apply the same interventional strategies in older patients as for younger patients.,I,B,12,older persons with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,46
"The choice of antithrombotic agent and dosage, as well as secondary preventions, should be adapted to renal function, as well as speciﬁc contraindications.",I,B,12,older persons with non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,46
Improvement of lifestyle factors in addition to appropriate pharmacological management is recommended in order to reduce allcause and cardiovascular mortality and morbidity and improve health-related quality of life.487,I,A,13,lifestyle managements after non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,47
Cognitive behavioural interventions are recommended to help individuals achieve a healthy lifestyle.498,I,A,13,lifestyle managements after non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,47
"Multidisciplinary exercise-based cardiac rehabilitation is recommended as an effective means for patients with CAD to achieve a healthy lifestyle and manage risk factors in order to reduce all-cause and cardiovascular mortality and morbidity, and improve healthrelated quality of life.",I,A,13,lifestyle managements after non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,47
"Involvement of multidisciplinary healthcare professionals (cardiologists, general practitioners, nurses, dieticians, physiotherapists, psychologists, pharmacists) is recommended in order to reduce all-cause and cardiovascular mortality and morbidity, and improve health-related quality of life.",I,A,13,lifestyle managements after non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,47
Psychological interventions are recommended to improve symptoms of depression in patients with CAD in order to improve healthrelated quality of life.,I,B,13,lifestyle managements after non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,47
"Annual inﬂuenza vaccination is recommended for patients with CAD, especially in the older person, in order to improve morbidity.505",I,B,13,lifestyle managements after non-ST-segment elevation acute coronary syndrome,ACS NSTE,2020,47
Lipid-lowering drugs Statins are recommended in all NSTE-ACS patients. The aim is to reduce LDL-C by >_50% from baseline and to achieve LDL-C <1.4 mmol/L (<55 mg/ dL).,I,A,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
"If the LDL-C goalc is not achieved after 46 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended.",I,B,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
"If the LDL-C goalc is not achieved after 46 weeks despite maximally tolerated statin therapy and ezetimibe, the addition of a PCSK9 inhibitor is recommended.",I,B,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
"If the current NSTE-ACS episode is a recurrence within less than 2 years of a ﬁrst ACS, while taking maximally tolerated statin-based therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) may be considered.",IIb,B,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
"ACE inhibitors or ARBs ACE inhibitors (or ARBs in cases of intolerance to ACE inhibitors) are recommended in patients with heart failure with reduced LVEF (<40%), diabetes, or CKD unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.) in order to reduce allcause and cardiovascular mortality and cardiovascular morbidity.536",I,A,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
Beta-blockers Beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced LVEF (<40%).539,I,A,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
"In patients with prior MI, long-term oral treatment with a beta-blocker should be considered in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.542",IIa,B,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
MRAs MRAs are recommended in patients with heart failure with reduced LVEF (<40%) in order to reduce allcause and cardiovascular mortality and cardiovascular morbidity.,I,A,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
"Proton pump inhibitors Concomitant use of a proton pump inhibitor is recommended in patients receiving aspirin monotherapy, DAPT, DAT, TAT, or OAC monotherapy who are at high risk of gastrointestinal bleeding in order to reduce the risk of gastric bleeds.",I,A,14,pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments),ACS NSTE,2020,48
"Diagnosis and risk stratiﬁcation It is recommended to base diagnosis and initial short-term risk stratiﬁcation on a combination of clinical history, symptoms, vital signs, other physical ﬁndings, ECG, and laboratory results including hs-cTn.",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,55
"It is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within 60 min of blood sampling.3,1013,29",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,55
It is recommended to obtain a 12-lead ECG within 10 min after ﬁrst medical contact and to have it immediately interpreted by an experienced physician.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,55
It is recommended to obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,55
Additional testing after 3 h is recommended if the ﬁrst two cardiac troponin measurements of the 0 h/1 h algorithm are not conclusive and the clinical condition is still suggestive of ACS.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
As an alternative to the,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"Additional ECG leads (V3R, V4R, V7V9) are recommended if ongoing ischaemia is suspected when standard leads are inconclusive.",I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"For initial diagnostic purposes, it is not recommended to routinely measure additional biomarkers such as h-FABP or copeptin, in addition to hs-cTn.",III,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"Imaging In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography is recommended and should be performed by trained physicians immediately following a 12-lead ECG.",I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"In patients with no recurrence of chest pain, normal ECG ﬁndings, and normal levels of cardiac troponin (preferably high sensitivity), but still with a suspected ACS, a non-invasive stress test (preferably with imaging) for inducible ischaemia or CCTA is recommended before deciding on an invasive approach.91,92,98,101,105",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.c,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"CCTA is recommended as an alternative to ICA to exclude ACS when there is a low-to-intermediate likelihood of CAD and when cardiac troponin and/or ECG are normal or inconclusive.105,108,110",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
Monitoring Continuous rhythm monitoring is recommended until the diagnosis of NSTEMI has been established or ruled out.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
It is recommended to admit NSTEMI patients to a monitored unit.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
Rhythm monitoring up to 24 h or to PCI (whichever comes ﬁrst) is recommended in NSTEMI patients at low risk for cardiac arrhythmias.d,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
Rhythm monitoring for >24 h is recommended in NSTEMI patients at increased risk for cardiac arrhythmias.e,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"Recommendations on biomarker measurements for prognostic stratiﬁcation Beyond its diagnostic role, it is recommended to measure hs-cTn serially for the estimation of prognosis.",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"The measurement of additional biomarkers, such as mid-regional pro-A-type natriuretic peptide, high-sensitivity C-reactive protein, mid-regional pro-adrenomedullin, GDF-15, copeptin, and h-FABP is not recommended for routine risk or prognosis assessment.",III,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"Recommendations for antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention Antiplatelet treatment Aspirin is recommended for all patients without contraindications at an initial oral LD of 150300 mg (or 75250 mg i.v.), and at a MD of 75100 mg o.d. for long-term treatment.179",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"A P2Y12 receptor inhibitor is recommended in addition to aspirin, and maintained over 12 months unless there are contraindications or an excessive risk of bleeding.170,171,182 Options are:",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
" Prasugrel in P2Y12 receptor inhibitor-naı¨ve patients proceeding to PCI (60 mg LD, 10 mg/d as standard dose, 5 mg/d for patients aged >_75 years or with a body weight <60 kg).",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
" Ticagrelor irrespective of the planned treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d.).",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
" Clopidogrel (300600 mg LD, 75 mg daily dose), only when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.",I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
Treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known and is not recommended.,III,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned.,III,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"Peri-interventional anticoagulant treatment Parenteral anticoagulation is recommended for all patients, in addition to antiplatelet treatment, at the time of diagnosis and, especially, during revascularization procedures according to both ischaemic and bleeding risks.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"UFH (weight-adjusted i.v. bolus during PCI of 70100 IU/kg, or 5070 IU/kg in combination with a GP IIb/IIIa inhibitor; activated clotting time target range of 250350 s, or 200250 s if a GP IIb/IIIa inhibitor is given) is recommended in patients undergoing PCI.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
"In cases of medical treatment or logistical constraints for transferring the patient to PCI within the required time frame, fondaparinux is recommended and, in such cases, a single bolus of UFH is recommended at the time of PCI.",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,56
Crossover of UFH and LMWH is not recommended.,III,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
"Recommendations for post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome In patients with NSTE-ACS treated with coronary stent implantation, DAPT with a P2Y12 receptor inhibitor on top of aspirin is recommended for 12 months unless there are contraindications such as excessive risk of bleeding.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
Recommendations for anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome Sublingual or i.v. nitrates and early initiation of beta-blocker treatment are recommended in patients with ongoing ischaemic symptoms and without contraindications.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
It is recommended to continue chronic beta-blocker therapy unless the patient is in overt heart failure.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
i.v. nitrates are recommended in patients with uncontrolled hypertension or signs of heart failure.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
"Recommendations for combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation Stroke prevention should be offered to AF patients with >_1 non-sex CHA2DS2-VASc stroke risk factors (score of >_1 in males or >_2 in females). For patients with >_2 non-sex stroke risk factors, OAC is recommended.255",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
"Patients undergoing coronary stenting Anticoagulation During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all NOACs and if INR is <2.5 in VKA-treated patients.",I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
"Antiplatelet treatment In patients with AF and CHA2DS2-VASc score >_1 in men and >_2 in women, after a short period of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel).238",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
Periprocedural DAPT administration consisting of aspirin and clopidogrel up to 1 week is recommended.238,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.236,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
The use of ticagrelor or prasugrel as part of TAT is not recommended.,III,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
Recommendations for coronary revascularization Timing of invasive strategy An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very high-risk criteria: • Haemodynamic instability or CS. • Recurrent or refractory chest pain despite medical treatment. • Life-threatening arrhythmias. • Mechanical complications of MI. • Heart failure clearly related to NSTE-ACS. • Presence of ST-segment depression >1 mm in >_6 leads additional to ST-segment elevation in aVR and/or V1.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
"An early invasive strategy within 24 h is recommended in patients with any of the following high-risk criteria: • Diagnosis of NSTEMI suggested by the diagnostic algorithm recommended in section 3. • Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing ischaemia. • Transient ST-segment elevation.273,362 • GRACE risk score >140.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive CAD by CCTA is recommended in patients considered at low risk.,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
"Technical aspects Radial access is recommended as the standard approach, unless there are overriding procedural considerations.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
DES are recommended over bare-metal stents for any PCI irrespective of: • Clinical presentation. • Lesion type. • Planned non-cardiac surgery. • Anticipated duration of DAPT. • Concomitant anticoagulant therapy.,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,57
"Recommendations for myocardial infarction with non-obstructive coronary arteries In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to differentiate true MINOCA from alternative diagnoses.",I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
It is recommended to perform CMR in all MINOCA patients without an obvious underlying cause.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
It is recommended to manage patients with an initial diagnosis of MINOCA and a ﬁnal established underlying cause according to the disease-speciﬁc guidelines.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Recommendations for non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock Emergency coronary angiography is recommended in patients with CS complicating ACS.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
"Emergency PCI of the culprit lesion is recommended for patients with CS due to NSTE-ACS, independent of the time delay from symptom onset, if the coronary anatomy is amenable to PCI.",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Emergency CABG is recommended for patients with CS if the coronary anatomy is not amenable to PCI.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
It is recommended to perform emergency echocardiography without delay to assess LV and valvular function and exclude mechanical complications.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
"In cases of haemodynamic instability, emergency surgical or catheter-based repair of mechanical complications of ACS is recommended, as decided by the Heart Team.",I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Routine use of IABP in patients with CS and no mechanical complications due to ACS is not recommended.,III,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Routine immediate revascularization of non-culprit lesions in NSTE-ACS patients with multivessel disease presenting with CS is not recommended.,III,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Recommendations for diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients It is recommended to screen all patients with NSTE-ACS for diabetes and to monitor blood glucose levels frequently in patients with known diabetes or admission hyperglycaemia.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Avoidance of hypoglycaemia is recommended.424,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Recommendations for patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome Risk stratiﬁcation in CKD It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD (dose adjustment may be necessary) as for patients with normal renal function.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
It is recommended to assess kidney function by eGFR in all patients.,I,C,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Myocardial revascularization in patients with CKD Use of low- or iso-osmolar contrast media (at lowest possible volume) are recommended in invasive strategies.,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Recommendations for older persons with non-ST-segment elevation acute coronary syndrome It is recommended to apply the same diagnostic strategies in older patients as for younger patients.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
It is recommended to apply the same interventional strategies in older patients as for younger patients.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
"The choice of antithrombotic agent and dosage, as well as secondary preventions, should be adapted to renal function, as well as speciﬁc contraindications.",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Recommendations for lifestyle managements after non-ST-segment elevation acute coronary syndrome Improvement of lifestyle factors in addition to appropriate pharmacological management is recommended in order to reduce allcause and cardiovascular mortality and morbidity and improve health-related quality of life.487,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Cognitive behavioural interventions are recommended to help individuals achieve a healthy lifestyle.498,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
"Multidisciplinary exercise-based cardiac rehabilitation is recommended as an effective means for patients with CAD to achieve a healthy lifestyle and manage risk factors in order to reduce all-cause and cardiovascular mortality and morbidity, and improve healthrelated quality of life.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
"Involvement of multidisciplinary healthcare professionals (cardiologists, general practitioners, nurses, dieticians, physiotherapists, psychologists, pharmacists) is recommended in order to reduce all-cause and cardiovascular mortality and morbidity, and improve health-related quality of life.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
Psychological interventions are recommended to improve symptoms of depression in patients with CAD in order to improve healthrelated quality of life.,I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
"Annual inﬂuenza vaccination is recommended for patients with CAD, especially in the older person, in order to improve morbidity.505",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,58
"If the LDL-C goalf is not achieved after 46 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended.",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,59
"If the LDL-C goalf is not achieved after 46 weeks despite maximally tolerated statin therapy and ezetimibe, the addition of a PCSK9 inhibitor is recommended.",I,B,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,59
"ACE inhibitors or ARBs ACE inhibitors (or ARBs in cases of intolerance to ACE inhibitors) are recommended in patients with heart failure with reduced LVEF (<40%), diabetes, or CKD unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.) in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.536",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,59
Beta-blockers Beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced LVEF (<40%).539,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,59
MRAs MRAs are recommended in patients with heart failure with reduced LVEF (<40%) in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.,I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,59
"Proton pump inhibitors Concomitant use of a proton pump inhibitor is recommended in patients receiving aspirin monotherapy, DAPT, DAT, TAT, or OAC monotherapy who are at high risk of gastrointestinal bleeding in order to reduce the risk of gastric bleeds.",I,A,15,"diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome",ACS NSTE,2020,59
"In patients with moderate and severe CHD complexity (Table 4) and documented arrhythmias, referral to a centre with a multidisciplinary team and expertise in ACHD patients and ACHDrelated arrhythmia is indicated.",I,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,19
"In CHD patients with documented arrhythmias or at high risk for post-procedural arrhythmias (e.g. ASD closure at older age) considered for percutaneous or surgical (re)interventions, referral to a centre with a multidisciplinary team with expertise in these interventions and in invasive treatment of arrhythmias is indicated.",I,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,19
"In mild CHD, catheter ablation is recommended over long-term medical therapy for symptomatic, sustained recurrent SVT (AVNRT, AVRT, AT, and IART), or if SVT is potentially related to SCD (Table 7).",I,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,19
"In moderate and severe CHD, catheter ablation should be considered for symptomatic, sustained recurrent SVT (AVNRT, AVRT, AT, and IART), or if SVT is potentially related to SCD (Table 7), provided that the procedure is performed in experienced centres.",IIa,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,19
"Catheter ablation should be considered for symptomatic, monomorphic sustained VT in patients for whom medical therapy is not desired, provided that the procedure is performed in experienced centres.",IIa,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
Implantable cardiac deﬁbrillator ICD implantation is indicated in adults with CHD who are survivors of an aborted cardiac arrest due to VF or haemodynamically untolerated VT after evaluation to deﬁne the cause of the event and exclusion of reversible causes.,I,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
ICD implantation is indicated in adults with CHD and sustained VT after haemodynamic evaluation and repair when indicated. EP evaluation is required to identify patients in whom catheter ablation or surgical ablation may be beneﬁcial as adjunctive treatment or in whom it may offer a reasonable alternative.,I,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
"ICD implantation should be considered in adults with CHD with biventricular physiology and a systemic LV presenting with symptomatic heart failure (NYHA II/III) and EF <_35% despite >_ 3 months of optimal medical treatment, provided they are expected to survive substantially longer than one year with good functional status.c",IIa,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
ICD implantation should be considered in patients with CHD and unexplained syncope and suspicion for arrhythmia aetiology and either advanced ventricular dysfunction or inducible VT/VF at programmed electrical stimulation.,IIa,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
"ICD implantation should be considered in selected TOF patients with multiple risk factors for SCD, including LV dysfunction, non-sustained, symptomatic VT, QRS duration >_180 ms, extensive RV scarring on CMR, or inducible VT at programmed electrical stimulation.",IIa,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
ICD implantation may be considered in patients with advanced single or systemic RV dysfunction (EF systemic RV <35%) in the presence of additional risk factors.d,IIb,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
"Pacemaker PM implantation should be considered in ACHD patients with bradycardia-tachycardia syndrome to prevent IART, if ablation fails or is not possible.",IIa,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
PM implantation should be considered for patients with severe CHD and sinus or,IIa,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
PM implantation may be considered for patients with moderate CHD and sinus or junctional bradycardia (daytime heart rate <40 beats per minute or pauses >3 s).,IIb,C,1,treatment of arrhythmias in adult congenital heart disease,Adult Congenital Heart Disease,2020,20
It is recommended that patients with CHD and conﬁrmed pre-capillary PHc are counselled against pregnancy.,I,C,2,treatment of pulmonary arterial hypertension associated with congenital heart disease,Adult Congenital Heart Disease,2020,22
Risk assessment is recommended in all patients with PAH-CHD.d,I,C,2,treatment of pulmonary arterial hypertension associated with congenital heart disease,Adult Congenital Heart Disease,2020,22
"In low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or sequential combination therapy is recommended and highrisk patients should be treated with initial combination therapy including parenteral prostanoids.e 63",I,A,2,treatment of pulmonary arterial hypertension associated with congenital heart disease,Adult Congenital Heart Disease,2020,22
"In Eisenmenger patients with reduced exercise capacity (6MWT distance <450 m), a treatment strategy with initial endothelin receptor antagonist monotherapy should be considered followed by combination therapy if patients fail to improve.67",IIa,B,2,treatment of pulmonary arterial hypertension associated with congenital heart disease,Adult Congenital Heart Disease,2020,22
"In patients with evidence of RV volume overloadc and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs) or LV disease, ASD closure is recommended regardless of symptoms.",I,B,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
Device closure is recommended as the method of choice for secundum ASD closure when technically suitable.,I,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"In elderly patients not suitable for device closure, it is recommended to carefully weigh the surgical risk against the potential beneﬁt of ASD closure.",I,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"In patients with non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory.",I,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"In patients with LV disease, it is recommended to perform balloon testing and carefully weigh the beneﬁt of eliminating LR shunt against the potential negative impact of ASD closure on outcome due to an increase in ﬁlling pressure (taking closure, fenestrated closure, and no closure into consideration).",I,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"In patients with suspicion of paradoxical embolism (exclusion of other causes), ASD closure should be considered regardless of size providing there is absence of PAH and LV disease.",IIa,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"In patients with PVR 35 WU, ASD closure should be considered when signiﬁcant LR shunt is present (Qp:Qs >1.5).",IIa,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"In patients with PVR >_5 WU, fenestrated ASD closure may be considered when PVR falls below 5 WU after targeted PAH treatment and signiﬁcant LR shunt is present (Qp:Qs >1.5).",IIb,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"ASD closure is not recommended in patients with Eisenmenger physiology, patients with PAH and PVR >_5 WU despite targeted PAH treatment, or desaturation on exercise.d",III,C,3,intervention in atrial septal defect (native and residual),Adult Congenital Heart Disease,2020,30
"In patients with evidence of LV volume overloadc and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs), VSD closure is recommended regardless of symptoms.",I,C,4,intervention in ventricular septal defect (native and residual),Adult Congenital Heart Disease,2020,33
"In patients with no signiﬁcant LR shunt, but a history of repeated episodes of IE, VSD closure should be considered.",IIa,C,4,intervention in ventricular septal defect (native and residual),Adult Congenital Heart Disease,2020,33
"In patients with VSD-associated prolapse of an aortic valve cusp causing progressive AR, surgery should be considered.",IIa,C,4,intervention in ventricular septal defect (native and residual),Adult Congenital Heart Disease,2020,33
"In patients who have developed PAH with PVR 35 WU, VSD closure should be considered when there is still signiﬁcant LR shunt (Qp:Qs >1.5).",IIa,C,4,intervention in ventricular septal defect (native and residual),Adult Congenital Heart Disease,2020,33
"In patients who have developed PAH with PVR >_5 WU, VSD closure may be considered when there is still signiﬁcant LR shunt (Qp:Qs >1.5), but careful individual decision in expert centres is required.",IIb,C,4,intervention in ventricular septal defect (native and residual),Adult Congenital Heart Disease,2020,33
VSD closure is not recommended in patients with Eisenmenger physiology and patients with severe PAH (PVR >_5 WU) presenting with desaturation on exercise.d,III,C,4,intervention in ventricular septal defect (native and residual),Adult Congenital Heart Disease,2020,33
"Complete AVSD Surgical repair is not recommended in patients with Eisenmenger physiology, and patients with PAH (PVR >_5 WU) presenting with desaturation on exercise.c",III,C,5,intervention in atrioventricular septal defect,Adult Congenital Heart Disease,2020,35
For recommendations on intervention see also recommendations for intervention in VSD (section 4.2). Partial AVSD (primum ASD) Surgical closure is recommended in patients with signiﬁcant RV volume overload and should only be performed by a congenital cardiac surgeon.,I,C,5,intervention in atrioventricular septal defect,Adult Congenital Heart Disease,2020,35
"For further details see recommendations for intervention in ASD (section 4.1). AV valve regurgitation Valve surgery, preferably AV valve repair, is recommended in symptomatic patients with moderate to severe AV valve regurgitation and should be performed by a congenital cardiac surgeon.",I,C,5,intervention in atrioventricular septal defect,Adult Congenital Heart Disease,2020,35
"In asymptomatic patients with severe leftsided AV valve regurgitation, valve surgery is recommended when LVESD >_45 mmd and/or LVEF <_60% provided other causes of LV dysfunction are excluded.",I,C,5,intervention in atrioventricular septal defect,Adult Congenital Heart Disease,2020,35
"In asymptomatic patients with severe leftsided AV valve regurgitation, preserved LV function (LVESD <45 mmd and/or LVEF >60%), high likelihood of successful valve repair, and low surgical risk, intervention should be considered when atrial ﬁbrillation or systolic PAP >50 mmHg is present.",IIa,C,5,intervention in atrioventricular septal defect,Adult Congenital Heart Disease,2020,35
"In patients with evidence of LV volume overloadc and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs), PDA closure is recommended regardless of symptoms.",I,C,6,intervention in patent ductus arteriosus,Adult Congenital Heart Disease,2020,36
Device closure is recommended as the method of choice when technically suitable.,I,C,6,intervention in patent ductus arteriosus,Adult Congenital Heart Disease,2020,36
"In patients who have developed PAH with PVR 35 WU, PDA closure should be considered when there is still signiﬁcant LR shunt (Qp:Qs >1.5).",IIa,C,6,intervention in patent ductus arteriosus,Adult Congenital Heart Disease,2020,36
"In patients who have developed PAH with PVR >_5 WU, PDA closure may be considered when there is still signiﬁcant LR shunt (Qp:Qs >1.5) but careful individual decision in expert centres is required.",IIb,C,6,intervention in patent ductus arteriosus,Adult Congenital Heart Disease,2020,36
PDA closure is not recommended in patients with Eisenmenger physiology and patients with lower limb desaturation on exercise.d,III,C,6,intervention in patent ductus arteriosus,Adult Congenital Heart Disease,2020,36
"Symptomatic patients with aortic valve stenosis In symptomatic patients with severe high-gradient AS (mean gradient >_40 mmHg), intervention is recommended.",I,B,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
"Intervention is indicated in symptomatic patients with severe low-ﬂow, low-gradient (mean gradient <40 mmHg) AS with reduced EF and evidence of ﬂow (contractile) reserve excluding pseudosevere AS.",I,C,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
Asymptomatic patients with severe aortic valve stenosis Intervention is indicated in asymptomatic patients with severe AS and an abnormal exercise test showing symptoms on exercise clearly related to AS.,I,C,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
Intervention is indicated in asymptomatic patients with severe AS and systolic LV dysfunction (LVEF <50%) not due to another cause.,I,C,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
Intervention should be considered in asymptomatic patients with severe AS when they present with a fall in blood pressure below baseline during exercise testing.,IIa,C,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
Intervention should be considered in asymptomatic patients with normal EF and none of the above-mentioned exercise test abnormalities if the surgical risk is low and one of the following ﬁndings is present: • Very severe AS deﬁned by a Vmax >5.5 m/s. • Severe valve calciﬁcation and a rate of Vmax progression >_0.3 m/s/year. • Markedly elevated BNP levels (>3-fold ageand sex-corrected normal range) conﬁrmed by repeated measurements without other explanation. • Severe PH (systolic PAP at rest >60 mmHg conﬁrmed by invasive measurement) without other explanation.,IIa,C,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
"Concomitant aortic valve surgery at the time of other cardiac/ ascending aorta surgery Surgery is recommended when patients with severe AS undergo surgery of the ascending aorta or of another valve, or CABG.",I,C,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
Patients with moderate AS undergoing CABG surgery or surgery of the ascending aorta or another valve should be considered for additional valve replacement.,IIa,C,7,intervention in valvular aortic stenosis,Adult Congenital Heart Disease,2020,38
"In symptomatic patients (spontaneous or on exercise test) with a mean Doppler gradient >_40 mmHgc or severe AR, surgery is recommended.",I,C,8,intervention in subaortic stenosis,Adult Congenital Heart Disease,2020,41
Asymptomatic patients should be considered for surgery when one or more of the following ﬁndings are present: • Mean gradient <40 mmHg but LVEF <50%. • AR is severe and LVESD >50 mm (or 25 mm/m2 BSA) and/or EF <50%d. • Mean Doppler gradient is >_40 mmHgc and marked LVH present. • Mean Doppler gradient is >_40 mmHgc and there is a fall in blood pressure below baseline on exercise.,IIa,C,8,intervention in subaortic stenosis,Adult Congenital Heart Disease,2020,41
"Asymptomatic patients may be considered for surgery when one or more of the following ﬁndings are present: • Mean Doppler gradient is >_40 mmHg,c LV is normal (EF >50% and no LVH), exercise testing is normal, and surgical risk is low. • Progression of AR is documented and AR becomes more than mild (to prevent further progression).",IIb,C,8,intervention in subaortic stenosis,Adult Congenital Heart Disease,2020,41
"Repair of coarctation or re-coarctation (surgically or catheter based) is indicated in hypertensive patientsc with an increased non-invasive gradient between upper and lower limbs conﬁrmed with invasive measurement (peak-topeak >_20 mmHg) with preference for catheter treatment (stenting), when technically feasible.",I,C,9,intervention in coarctation and re-coarctation of the aorta,Adult Congenital Heart Disease,2020,42
"Catheter treatment (stenting) should be considered in hypertensive patientsc with >_50% narrowing relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient is <20 mmHg, when technically feasible.",IIa,C,9,intervention in coarctation and re-coarctation of the aorta,Adult Congenital Heart Disease,2020,42
"Catheter treatment (stenting) should be considered in normotensive patientsc with an increased non-invasive gradient conﬁrmed with invasive measurement (peak-to-peak >_20 mmHg), when technically feasible.",IIa,C,9,intervention in coarctation and re-coarctation of the aorta,Adult Congenital Heart Disease,2020,42
"Catheter treatment (stenting) may be considered in normotensive patientsc with >_50% narrowing relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient is <20 mmHg, when technically feasible.",IIb,C,9,intervention in coarctation and re-coarctation of the aorta,Adult Congenital Heart Disease,2020,42
"Marfan syndrome and HTAD Aortic valve repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young patients with Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves, when performed by experienced surgeons.",I,C,10,aortic surgery in aortopathies,Adult Congenital Heart Disease,2020,46
Surgery is indicated in patients with Marfan syndrome who have aortic root disease with a maximal aortic sinus diameter >_50 mm.c,I,C,10,aortic surgery in aortopathies,Adult Congenital Heart Disease,2020,46
Surgery should be considered in patients with Marfan syndrome who have aortic root disease with maximal aortic sinus diameter >_45 mmc and additional risk factors.d,IIa,C,10,aortic surgery in aortopathies,Adult Congenital Heart Disease,2020,46
Surgery should be considered in patients with a TGFBR1 or TGFBR2 mutation (including LoeysDietz syndrome) who have aortic root disease with maximal aortic sinus diameter >_45mm.c,IIa,C,10,aortic surgery in aortopathies,Adult Congenital Heart Disease,2020,46
Bicuspid aortic disease Aortic surgery should be considered if the ascending aorta is: • >_50 mm in the presence of a bicuspid valve with additional risk factorse or coarctation. • >_55 mm for all other patients.,IIa,C,10,aortic surgery in aortopathies,Adult Congenital Heart Disease,2020,46
"Turner syndrome Elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered for women with Turner syndrome who are >16 years of age, have an ascending aortic size index >25 mm/m2, and have associated risk factors for aortic dissection.f",IIa,C,10,aortic surgery in aortopathies,Adult Congenital Heart Disease,2020,46
"Elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women with Turner syndrome who are >16 years of age, have an ascending aortic size index >25 mm/m2, and do not have associated risk factors for aortic dissection.f",IIb,C,10,aortic surgery in aortopathies,Adult Congenital Heart Disease,2020,46
"In valvular PS, balloon valvuloplasty is the intervention of choice, if anatomically suitable.",I,C,11,intervention in right ventricular outﬂow tract obstruction,Adult Congenital Heart Disease,2020,47
"Provided that no valve replacement is required, RVOTO intervention at any level is recommended regardless of symptoms when the stenosis is severe (Doppler peak gradient is >64 mmHgc).",I,C,11,intervention in right ventricular outﬂow tract obstruction,Adult Congenital Heart Disease,2020,47
"If surgical valve replacement is the only option, it is indicated in patients with severe stenosis who are symptomatic.d",I,C,11,intervention in right ventricular outﬂow tract obstruction,Adult Congenital Heart Disease,2020,47
"If surgical valve replacement is the only optiond in patients with severe stenosis who are asymptomatic, it is indicated in the presence of one or more of the following. • Objective decrease in exercise capacity. • Decreasing RV function and/or progression of TR to at least moderate. • RVSP >80 mmHg. • RL shunting via an ASD or VSD.",I,C,11,intervention in right ventricular outﬂow tract obstruction,Adult Congenital Heart Disease,2020,47
Intervention in patients with a Doppler peak gradient <64 mmHg should be considered in the presence of one or more of the following. • Symptoms related to PS. • Decreasing RV function and/or progressive TR to at least moderate. • RL shunting via an ASD or VSD.,IIa,C,11,intervention in right ventricular outﬂow tract obstruction,Adult Congenital Heart Disease,2020,47
"Peripheral PS, regardless of symptoms, should be considered for catheter interventional treatment if >50% diameter narrowing, and RVSP >50 mmHg, and/or related reduced lung perfusion is present.",IIa,C,11,intervention in right ventricular outﬂow tract obstruction,Adult Congenital Heart Disease,2020,47
Indications for surgery Surgical repair is recommended in patients with severe TR and symptoms or objective deterioration of exercise capacity.,I,C,12,intervention in Ebstein anomaly,Adult Congenital Heart Disease,2020,49
It is recommended that surgical repair is performed by a congenital surgeon with speciﬁc experience in Ebstein surgery.,I,C,12,intervention in Ebstein anomaly,Adult Congenital Heart Disease,2020,49
"If there is an indication for TV surgery, ASD/ PFO closure is recommended at the time of valve repair if it is expected to be haemodynamically tolerated.",I,C,12,intervention in Ebstein anomaly,Adult Congenital Heart Disease,2020,49
Surgical repair should be considered regardless of symptoms in patients with progressive right heart dilation or reduction of RV systolic function.,IIa,C,12,intervention in Ebstein anomaly,Adult Congenital Heart Disease,2020,49
"Indications for catheter intervention In patients with symptomatic arrhythmias, or pre-excitation on the ECG, electrophysiologic testing followed by ablation therapy, if feasible, or surgical treatment of the arrhythmias in the case of planned heart surgery is recommended.",I,C,12,intervention in Ebstein anomaly,Adult Congenital Heart Disease,2020,49
"In the case of documented systemic embolism, probably caused by paradoxical embolism, isolated device closure of ASD/PFO should be considered but requires careful evaluation before intervention to exclude induction of RA pressure increase or fall in cardiac output.",IIa,C,12,intervention in Ebstein anomaly,Adult Congenital Heart Disease,2020,49
"If cyanosis (oxygen saturation at rest <90%) is the leading problem, isolated device closure of ASD/PFO may be considered but requires careful evaluation before intervention to exclude induction of RA pressure increase or fall in cardiac output.",IIb,C,12,intervention in Ebstein anomaly,Adult Congenital Heart Disease,2020,49
PVRep is recommended in symptomatic patients with severe PRc and/or at least moderate RVOTO.d,I,C,13,intervention after repair of tetralogy of Fallot,Adult Congenital Heart Disease,2020,52
"In patients with no native outﬂow tract,e catheter intervention (TPVI) should be preferred if anatomically feasible.",I,C,13,intervention after repair of tetralogy of Fallot,Adult Congenital Heart Disease,2020,52
"PVRep should be considered in asymptomatic patients with severe PR and/or RVOTO when one of the following criteria is present. • Decrease in objective exercise capacity. • Progressive RV dilation to RVESVi >_80 mL/ m2, and/or RVEDVi >_160 mL/m2 f, and/or progression of TR to at least moderate. • Progressive RV systolic dysfunction. • RVOTO with RVSP >80 mmHg.",IIa,C,13,intervention after repair of tetralogy of Fallot,Adult Congenital Heart Disease,2020,52
"In patients with sustained VT who are undergoing surgical PVRep or transcutaneous valve insertion, pre-operative catheter mapping and transsection of VT-related anatomical isthmuses before or during the intervention should be considered.",IIa,C,13,intervention after repair of tetralogy of Fallot,Adult Congenital Heart Disease,2020,52
"Electrophysiologic evaluation, including programmed electrical stimulation, should be considered for risk stratiﬁcation for SCD in patients with additional risk factors (LV/RV dysfunction; non-sustained, symptomatic VT; QRS duration >_180 ms, extensive RV scarring on CMR).",IIa,C,13,intervention after repair of tetralogy of Fallot,Adult Congenital Heart Disease,2020,52
"ICD implantation should be considered in selected TOF patients with multiple risk factors for SCD, including LV dysfunction, non-sustained, symptomatic VT, QRS duration >_180 ms, extensive RV scarring on CMR, or inducible VT at programmed electrical stimulation.",IIa,C,13,intervention after repair of tetralogy of Fallot,Adult Congenital Heart Disease,2020,52
"Catheter ablation or concomitant surgical ablation for symptomatic monomorphic sustained VT may be considered in those with a preserved biventricular function as an alternative to ICD therapy, provided that the procedure is performed in highly experienced centres and that established ablation endpoints have been reached (e.g. non-inducibility, conduction block across ablation lines).",IIb,C,13,intervention after repair of tetralogy of Fallot,Adult Congenital Heart Disease,2020,52
"Indications for surgical intervention In symptomatic patients with pulmonary venous atrium obstruction, surgical repair (catheter intervention rarely possible) is recommended.",I,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In symptomatic patients with bafﬂe stenosis not amenable to catheter intervention, surgical repair is recommended.",I,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In symptomatic patients with bafﬂe leaks not amenable to catheter-based closure, surgical repair is recommended.",I,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In patients with severe systemic (tricuspid) AV valve regurgitation, without signiﬁcant ventricular systolic dysfunction (EF >40%), valve repair or replacement should be considered, regardless of symptoms.",IIa,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"PA banding in adults, as LV training with subsequent arterial switch procedure, is not recommended.",III,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"Indications for catheter intervention In symptomatic patients with bafﬂe stenosis, stenting is recommended when technically feasible.",I,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In symptomatic patients with bafﬂe leaks and cyanosis at rest or during exercise, or with strong suspicion of paradoxical emboli, stenting (covered) or device closure is recommended when technically feasible.",I,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In patients with bafﬂe leaks and symptoms due to LR shunt, stenting (covered) or device closure is recommended when technically feasible.",I,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In asymptomatic patients with bafﬂe leaks with substantial ventricular volume overload due to LR shunt, stenting (covered) or device closure should be considered when technically feasible.",IIa,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In patients with a bafﬂe leak who require a PM/ICD, closure of the bafﬂe leak with a covered stent should be considered, when technically feasible, prior to insertion of transvenous leads.",IIa,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
"In asymptomatic patients with bafﬂe stenosis, stenting may be considered when technically feasible.",IIb,C,14,intervention in transposition of the great arteries after atrial switch operation,Adult Congenital Heart Disease,2020,57
Stenting or surgery (depending on substrate) is recommended for coronary artery stenosis causing ischaemia.,I,C,15,intervention in transposition of the great arteries after arterial switch operation,Adult Congenital Heart Disease,2020,58
"Neo-aortic root surgery should be considered when the neo-aortic root is >55 mm, providing average adult stature (for neo-aortic valve replacement for severe neo-aortic AR see valvular heart disease guidelines with special considerationsc).",IIa,C,15,intervention in transposition of the great arteries after arterial switch operation,Adult Congenital Heart Disease,2020,58
"Stenting should be considered for PA branch stenosis, regardless of symptoms, if >50% diameter narrowing and RVSP >50 mmHg and/or related reduced lung perfusion are present.",IIa,C,15,intervention in transposition of the great arteries after arterial switch operation,Adult Congenital Heart Disease,2020,58
"In symptomatic patients with severe TR and preserved or mildly impaired systemic RV systolic function (EF >40%), TV replacement is indicated.",I,C,16,intervention in congenitally corrected transposition of the great arteries,Adult Congenital Heart Disease,2020,59
"In asymptomatic patients with severe TR and progressive systemic RV dilatation and/or mildly impaired systemic RV systolic function (EF >40%), TV replacement should be considered.",IIa,C,16,intervention in congenitally corrected transposition of the great arteries,Adult Congenital Heart Disease,2020,59
Biventricular pacing should be considered in case of complete AV block or >40% ventricular pacing requirement.,IIa,C,16,intervention in congenitally corrected transposition of the great arteries,Adult Congenital Heart Disease,2020,59
"In symptomatic patients with severe TR and more than mildly reduced systemic RV systolic function (EF <_40%), TV replacement may be considered.",IIb,C,16,intervention in congenitally corrected transposition of the great arteries,Adult Congenital Heart Disease,2020,59
Symptomatic patients with RVSP >60 mmHg (may be lower in case of reduced ﬂow) and/or severe PRc should undergo intervention with preference for catheter intervention (TPVI) if anatomically feasible.,I,C,17,intervention in right ventricular to pulmonary artery conduits,Adult Congenital Heart Disease,2020,60
"Asymptomatic patients with severe RVOTO and/ or severe PR should be considered for intervention, preferably catheter intervention (TPVI) if anatomically feasible, when at least one of the following criteria is present: • Decrease in objective exercise capacity (CPET). • Progressive RV dilation to RVESVi >_80 mL/m2, and/or RVEDVi >_160 mL/m2, and/ or progression of TR to at least moderate. • Progressive RV systolic dysfunction. • RVSP >80 mmHg.",IIa,C,17,intervention in right ventricular to pulmonary artery conduits,Adult Congenital Heart Disease,2020,60
"Non-pharmacological functional imaging (e.g. nuclear study, echocardiography, or CMR with physical stress) is recommended in patients with coronary anomalies to conﬁrm/exclude myocardial ischaemia.",I,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
Anomalous coronary arteries from the pulmonary artery Surgery is recommended in patients with ALCAPA.,I,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
Surgery is recommended in patients with ARCAPA and symptoms attributable to anomalous coronary artery.,I,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
"Surgery should be considered for ARCAPA in asymptomatic patients with ventricular dysfunction, or myocardial ischaemia attributable to coronary anomaly.",IIa,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
Anomalous aortic origin of the coronary artery Surgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced myocardial ischaemia in a matching territory or high-risk anatomy.c,I,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
Surgery should be considered in asymptomatic patients with AAOLCA and no evidence of myocardial ischaemia but a highrisk anatomy.c,IIa,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
Surgery may be considered for symptomatic patients with AAOCA even if there is no evidence of myocardial ischaemia or highrisk anatomy.c,IIb,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
Surgery may be considered for asymptomatic patients with AAOLCA without myocardial ischaemia and without high-risk anatomyc when they present at young age (<35 years).,IIb,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
Surgery is not recommended for AAORCA in asymptomatic patients without myocardial ischaemia and without high-risk anatomy.c,III,C,18,the management of patients with anomalous coronary arteries,Adult Congenital Heart Disease,2020,66
ECG documentation is required to establish the diagnosis of AF. • A standard 12-lead ECG recording or a single-lead ECG tracing of >_30 s showing heart rhythm with no discernible repeating P waves and irregular RR intervals (when atrioventricular conduction is not impaired) is diagnostic of clinical AF.,I,B,1,diagnosis of AF,Atrial Fibrillation,2020,14
"Structured characterization of AF, which includes clinical assessment of stroke risk, symptom status, burden of AF, and evaluation of substrate, should be considered in all AF patients, to streamline the assessment of AF patients at different healthcare levels, inform treatment decision-making, and facilitate optimal management of AF patients.",IIa,C,2,structured characterization of AF,Atrial Fibrillation,2020,19
Recommendation Opportunistic screening for AF by pulse taking or ECG rhythm strip is recommended in patients >_65 years of age.,I,B,3,screening to detect AF,Atrial Fibrillation,2020,23
It is recommended to interrogate pacemakers and implantable cardioverter deﬁbrillators on a regular basis for AHRE.c,I,B,3,screening to detect AF,Atrial Fibrillation,2020,23
"When screening for AF it is recommended that:217,218 • The individuals undergoing screening are informed about the signiﬁcance and treatment implications of detecting AF. • A structured referral platform is organized for screen-positive cases for further physician-led clinical evaluation to conﬁrm the diagnosis of AF and provide optimal management of patients with conﬁrmed AF. • Deﬁnite diagnosis of AF in screen-positive cases is established only after physician reviews the single-lead ECG recording of >_30 s or 12-lead ECG and conﬁrms that it shows AF.",I,B,3,screening to detect AF,Atrial Fibrillation,2020,23
"Systematic ECG screening should be considered to detect AF in individuals aged >_75 years, or those at high risk of stroke.",IIa,B,3,screening to detect AF,Atrial Fibrillation,2020,23
"Recommendation In patients with AF, it is recommended to: • Evaluate AF-related symptoms (including fatigue, tiredness, exertional shortness of breath, palpitations, and chest pain) and quantify the patient symptom status using the modiﬁed EHRA symptom scale before and after initiation of treatment.230,232 • Evaluate AF-related symptoms before and after cardioversion of persistent AF to aid rhythm control treatment decisions.",I,C,4,diagnostic evaluation of patients with AF,Atrial Fibrillation,2020,25
"For stroke prevention in AF patients who are eligible for OAC, NOACs are recommended in preference to VKAs (excluding patients with mechanical heart valves or moderate-to-severe mitral stenosis).",I,A,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,36
"For stroke risk assessment, a risk-factor-based approach is recommended, using the CHA2DS2-VASc clinical stroke risk score to initially identify patients at ‘low stroke risk’ (CHA2DS2-VASc score = 0 in men, or 1 in women) who should not be offered antithrombotic therapy.",I,A,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,36
OAC is recommended for stroke prevention in AF patients with CHA2DS2-VASc score >_2 in men or >_3 in women.,I,A,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,36
OAC should be considered for stroke prevention in AF patients with a CHA2DS2-VASc score of 1 in men or 2 in women. Treatment should be individualized based on net clinical beneﬁt and consideration of patient values and preferences.,IIa,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,36
"For bleeding risk assessment, a formal structured risk-score-based bleeding risk assessment is recommended to help identify nonmodiﬁable and address modiﬁable bleeding risk factors in all AF patients, and to identify patients potentially at high risk of bleeding who should be scheduled for early and more frequent clinical review and follow-up.",I,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,36
Stroke and bleeding risk reassessment at periodic intervals is recommended to inform treatment decisions (e.g. initiation of OAC in patients no longer at low risk of stroke) and address potentially modiﬁable bleeding risk factors.c,I,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
"In patients with AF initially at low risk of stroke, ﬁrst reassessment of stroke risk should be made at 4 - 6 months after the index evaluation.385",IIa,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
"If a VKA is used, a target INR of 2.0 - 3.0 is recommended, with individual TTR>_70%.",I,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
"In patients on VKAs with low time in INR therapeutic range (e.g. TTR<70%), recommended options are: • Switching to a NOAC but ensuring good adherence and persistence with therapy415,416; or",I,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
• Efforts to improve TTR (e.g. education/counselling and more frequent INR checks).,IIa,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
Antiplatelet therapy alone (monotherapy or aspirin in combination with clopidogrel) is not recommended for stroke prevention in AF.,III,A,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
"Estimated bleeding risk, in the absence of absolute contraindications to OAC, should not in itself guide treatment decisions to use OAC for stroke prevention.",III,A,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
"Clinical pattern of AF (i.e. ﬁrst detected, paroxysmal, persistent, long-standing persistent, permanent) should not condition the indication to thromboprophylaxis.",III,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
Recommendations for occlusion or exclusion of the LAA LAA occlusion may be considered for stroke prevention in patients with AF and contraindications for long-term anticoagulant treatment (e.g. intracranial bleeding without a reversible cause).,IIb,B,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
Surgical occlusion or exclusion of the LAA may be considered for stroke prevention in patients with AF undergoing cardiac surgery.,IIb,C,5,the prevention of thrombo-embolic events in AF,Atrial Fibrillation,2020,37
"Classb Levelc Beta-blockers, diltiazem, or verapamil are recommended as ﬁrst-choice drugs to control heart rate in AF patients with LVEF>_40%.",I,B,6,ventricular rate control in patients with AFa,Atrial Fibrillation,2020,40
"Beta-blockers and/or digoxin are recommended to control heart rate in AF patients with LVEF<40%.486,491,502,512,530",I,B,6,ventricular rate control in patients with AFa,Atrial Fibrillation,2020,40
Combination therapy comprising different rate controlling drugsd should be considered if a single drug does not achieve the target heart rate.,IIa,B,6,ventricular rate control in patients with AFa,Atrial Fibrillation,2020,40
A resting heart rate of <110 bpm (i.e. lenient rate control) should be considered as the initial heart rate target for rate control therapy.,IIa,B,6,ventricular rate control in patients with AFa,Atrial Fibrillation,2020,40
"Atrioventricular node ablation should be considered to control heart rate in patients unresponsive or intolerant to intensive rate and rhythm control therapy, and not eligible for rhythm control by LA ablation, accepting that these patients will become pacemaker dependent.",IIa,B,6,ventricular rate control in patients with AFa,Atrial Fibrillation,2020,40
"In patients with haemodynamic instability or severely depressed LVEF, intravenous amiodarone may be considered for acute control of heart rate.",IIb,B,6,ventricular rate control in patients with AFa,Atrial Fibrillation,2020,40
Rhythm control therapy is recommended for symptom and QoL improvement in symptomatic patients with AF.551,I,A,7,rhythm control,Atrial Fibrillation,2020,42
"For pharmacological cardioversion of recentonset AF, i.v. vernakalant (excluding patients with recent ACS or severe HF) or ﬂecainide or propafenone (excluding patients with severe structural heart disease) is recommended.569,573,579,582,588",I,A,8,cardioversion,Atrial Fibrillation,2020,45
"Intravenous amiodarone is recommended for cardioversion of AF in patients with HF or structural heart disease, if delayed cardioversion is consistent with clinical situation.",I,A,8,cardioversion,Atrial Fibrillation,2020,45
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent AF as part of rhythm control therapy.,I,B,8,cardioversion,Atrial Fibrillation,2020,45
"Pharmacological cardioversion of AF is indicated only in a haemodynamically stable patient, after consideration of the thromboembolic risk.",I,B,8,cardioversion,Atrial Fibrillation,2020,45
"Pre-treatment with amiodarone, ﬂecainide, ibutilide, or propafenone should be considered to facilitate the success of electrical cardioversion.556,596",IIa,B,8,cardioversion,Atrial Fibrillation,2020,45
"In selected patients with infrequent and recentonset AF and no signiﬁcant structural or ischaemic heart disease, a single self-administered oral dose of ﬂecainide or propafenone (‘pill in the pocket’ approach) should be considered for patient-led cardioversion, but only following efﬁcacy and safety assessment.",IIa,B,8,cardioversion,Atrial Fibrillation,2020,45
"For patients with sick-sinus syndrome, atrioventricular conduction disturbances or prolonged QTc (>500 ms), pharmacological cardioversion should not be attempted unless risks for proarrhythmia and bradycardia have been considered.",III,C,8,cardioversion,Atrial Fibrillation,2020,45
"General recommendations For the decision on AF catheter ablation, it is recommended to take into consideration the procedural risks and the major risk factors for AF recurrence following the procedure and discuss them with the patient.235",I,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
Repeated PVI procedures should be considered in patients with AF recurrence provided the patient’s symptoms were improved after the initial PVI.812,IIa,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"AF catheter ablation after failure of drug therapy AF catheter ablation for PVI is recommended for rhythm control after one failed or intolerant class I or III AAD, to improve symptoms of AF recurrences in patients with235238,247,605609,612,613,615617,654,677,678,680,682,685,758,779,780,815: • Paroxysmal AF, or • Persistent AF without major risk factors for AF recurrence, or • Persistent AF with major risk factors for AF recurrence. AF catheter ablation for PVI should be considered for rhythm control after one failed or intolerant to beta-blocker treatment to improve symptoms of AF recurrences in patients with paroxysmal and persistent AF.",IIa,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"First-line therapy AF catheter ablation for PVI should/may be considered as ﬁrst-line rhythm control therapy to improve symptoms in selected patients with symptomatic: • Paroxysmal AF episodes,240242,614,615 or",IIa,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"• Persistent AF without major risk factors for AF recurrence.253255,264,598",IIb,C,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"as an alternative to AAD class I or III, considering patient choice, beneﬁt, and risk. AF catheter ablation: • Is recommended to reverse LV dysfunction in AF patients when tachycardia-induced cardiomyopathy is highly probable, independent of their symptom status.",I,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"• Should be considered in selected AF patients with HF with reduced LVEF to improve survival and reduce HF hospitalization.612,659,662666,668671,817",IIa,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
AF catheter ablation for PVI should be considered as a strategy to avoid pacemaker implantation in patients with AF-related bradycardia or symptomatic pre-automaticity pause after AF conversion considering the clinical situation.816,IIa,C,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"Techniques and technologies Complete electrical isolation of the pulmonary veins is recommended during all AF catheter-ablation procedures.235237,239,606,608",I,A,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"If patient has history of CTI-dependent AFL or if typical AFL is induced at the time of AF ablation, delivery of a CTI lesion may be considered.731733,819",IIb,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"Use of additional ablation lesions beyond PVI (low voltage areas, lines, fragmented activity, ectopic foci, rotors, and others) may be considered but is not well established.677,680,708,711",IIb,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"Lifestyle modiﬁcation and other strategies to improve outcomes of ablation Weight loss is recommended in obese patients with AF, particularly those who are being evaluated to undergo AF ablation.636,638,639,643,646,772,786",I,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
Strict control of risk factors and avoidance of triggers are recommended as part of a rhythm control strategy.,I,B,9,rhythm control/catheter ablation of AF,Atrial Fibrillation,2020,49
"Concomitant AF ablation should be considered in patients undergoing cardiac surgery, balancing the beneﬁts of freedom from atrial arrhythmias and the risk factors for recurrence (left atrial dilatation, years in AF, age, renal dysfunction, and other cardiovascular risk factors).461,843,857",IIa,A,10,surgical ablation of AF,Atrial Fibrillation,2020,50
"Thoracoscopic—including hybrid surgical ablation—procedures should be considered in patients who have symptomatic paroxysmal or persistent AF refractory to AAD therapy and have failed percutaneous AF ablation, or with evident risk factors for catheter ablation failure, to maintain long-term sinus rhythm. The decision must be supported by an experienced team of electrophysiologists and surgeons.",IIa,B,10,surgical ablation of AF,Atrial Fibrillation,2020,50
"Thoracoscopic—including hybrid surgical ablation—procedures may be considered in patients with persistent AF with risk factors for recurrence, who remain symptomatic during AF despite at least one failed AAD and who prefer further rhythm control therapy.",IIb,C,10,surgical ablation of AF,Atrial Fibrillation,2020,50
"In patients with AF undergoing cardioversion, NOACs are recommended with at least similar efﬁcacy and safety to warfarin.868",I,A,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
"For cardioversion of AF/AFL, effective anticoagulation is recommended for a minimum of 3 weeks before cardioversion.866",I,B,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
"TOE is recommended to exclude cardiac thrombus as an alternative to 3-week pre-procedural anticoagulation when early cardioversion is planned.866,868",I,B,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
"In patients at risk of stroke, it is recommended that OAC therapy is",I,B,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
"When thrombus is identiﬁed on TOE, effective anticoagulation is recommended for at least 3 weeks before cardioversion of AF.",I,B,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
It is recommended that the importance of adherence and persistence to NOAC treatment both before and after cardioversion is strongly emphasized to patients.,I,C,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
Effective anticoagulation should be initiated as soon as possible before every cardioversion of AF or AFL.866,IIa,B,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
Early cardioversion can be performed without TOE in patients with an AF duration of <48 h.,IIa,B,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
"In patients with AF duration of >24 h undergoing cardioversion, therapeutic anticoagulation should be",IIa,B,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
"When thrombus is identiﬁed on TOE, a repeat TOE to ensure thrombus resolution should be considered before cardioversion.",IIa,C,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
In patients with a deﬁnite duration of AF <_24 h and a very low stroke risk (CHA2DS2-VASc of 0 in men or 1 in women) post-cardioversion anticoagulation for 4 weeks may be omitted.,IIb,C,11,stroke risk management pericardioversion,Atrial Fibrillation,2020,51
"In AF patients with stroke risk factors not taking OAC before ablation, it is recommended that pre-procedural management of stroke risk includes initiation of anticoagulation and: • Preferably, therapeutic OAC for at least 3 weeks before ablation, or • Alternatively, the use of TOE to exclude LA thrombus before ablation.",I,C,12,stroke risk management peri-catheter ablation,Atrial Fibrillation,2020,52
"For patients undergoing AF catheter ablation who have been therapeutically anticoagulated with warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban, performance of the ablation procedure without OAC interruption is recommended.",I,A,12,stroke risk management peri-catheter ablation,Atrial Fibrillation,2020,52
"After AF catheter ablation, it is recommended that: • Systemic anticoagulation with warfarin or a NOAC is",I,C,12,stroke risk management peri-catheter ablation,Atrial Fibrillation,2020,52
"Long-term OAC therapy is recommended in patients after AF surgery and appendage closure, based on the patient’s thrombo-embolic risk assessed with the CHA2DS2-VASc score.",I,C,13,postoperative anticoagulation after AF surgery,Atrial Fibrillation,2020,52
"Amiodarone is recommended for long-term rhythm control in all AF patients, including those with HFrEF. However, owing to its extracardiac toxicity, other AADs should be considered ﬁrst whenever possible.",I,A,14,long-term antiarrhythmic drugs,Atrial Fibrillation,2020,57
"Dronedarone is recommended for long-term rhythm control in AF patients with: • Normal or mildly impaired (but stable) LV function, or • HFpEF, ischaemic, or VHD.",I,A,14,long-term antiarrhythmic drugs,Atrial Fibrillation,2020,57
"Flecainide or propafenone is recommended for long-term rhythm control in AF patients with normal LV function and without structural heart disease, including signiﬁcant LVH and myocardial ischaemia.",I,A,14,long-term antiarrhythmic drugs,Atrial Fibrillation,2020,57
"In AF patients treated with sotalol, close monitoring of QT interval, serum potassium levels, CrCl, and other proarrhythmia risk factors is recommended.",I,B,14,long-term antiarrhythmic drugs,Atrial Fibrillation,2020,57
"In AF patients treated with ﬂecainide for long-term rhythm control, concomitant use of an atrioventricular nodal-blocking drug (if tolerated) should be considered.",IIa,C,14,long-term antiarrhythmic drugs,Atrial Fibrillation,2020,57
"Sotalol may be considered for long-term rhythm control in patients with normal LV function or with ischaemic heart disease if close monitoring of QT interval, serum potassium levels, CrCl, and other proarrhythmia risk factors is provided.",IIb,A,14,long-term antiarrhythmic drugs,Atrial Fibrillation,2020,57
AAD therapy is not recommended in patients with permanent AF under rate control and in patients with advanced conduction disturbances unless antibradycardia pacing is provided.,III,C,14,long-term antiarrhythmic drugs,Atrial Fibrillation,2020,57
Identiﬁcation and management of risk factors and concomitant diseases is recommended as an integral part of treatment in AF patients.,I,B,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
Modiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.,I,B,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
Opportunistic screening for AF is recommended in hypertensive patients.,I,B,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
Attention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and bleeding.,I,B,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
"In obese patients with AF, weight loss together with management of other risk factors should be considered to reduce AF incidence, AF progression, AF recurrences, and symptoms.",IIa,B,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
Advice and management to avoid alcohol excess should be considered for AF prevention and in AF patients considered for OAC therapy.,IIa,B,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
"Physical activity should be considered to help prevent AF incidence or recurrence, with the exception of excessive endurance exercise, which may promote AF.1027",IIa,C,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
Opportunistic screening for AF should be considered in patients with OSA.,IIa,C,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
"Optimal management of OSA may be considered, to reduce AF incidence, AF progression, AF recurrences, and symptoms.650,651,1047",IIb,C,15,lifestyle interventions and management of risk factors and concomitant diseases in patients with AF,Atrial Fibrillation,2020,59
Emergency electrical cardioversion is recommended in AF patients with acute or worsening haemodynamic instability.,I,B,16,management of AF with haemodynamic instability,Atrial Fibrillation,2020,59
"In AF patients with haemodynamic instability, amiodarone may be considered for acute control of heart rate.",IIb,B,16,management of AF with haemodynamic instability,Atrial Fibrillation,2020,59
"General recommendations for patients with AF and an indication for concomitant antiplatelet therapy In AF patients eligible for NOACs, it is recommended to use a NOACc in preference to a VKA in combination with antiplatelet therapy.",I,A,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"In patients at high bleeding risk (HAS-BLED >_3), rivaroxaban 15 mg o.d. should be considered in preference to rivaroxaban 20 mg o.d. for the duration of concomitant single or DAPT, to mitigate bleeding risk.",IIa,B,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"In patients at high bleeding risk (HAS-BLED >_3), dabigatran 110 mg b.i.d. should be considered in preference to dabigatran 150 mg b.i.d. for the duration of concomitant single or DAPT, to mitigate bleeding risk.",IIa,B,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"In AF patients with an indication for a VKA in combination with antiplatelet therapy, the VKA dosing should be carefully regulated with a target INR of 2.0 - 2.5 and TTR>70%.",IIa,B,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"Recommendations for AF patients with ACS In AF patients with ACS undergoing an uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with an OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 12 months is recommended if the risk of stent thrombosisd is low or if concerns about bleeding riske prevail over concerns about risk of stent thrombosis,d irrespective of the type of stent used.1090,1092",I,A,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"Triple therapy with aspirin, clopidogrel, and an OACf for longer than 1 week after an ACS should be considered when risk of stent thrombosisd outweighs the bleeding risk,e with the total duration (<_1 month) decided according to assessment of these risks, and the treatment plan should be clearly speciﬁed at hospital discharge.",IIa,C,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"Recommendations in AF patients with a CCS undergoing PCI After uncomplicated PCI, early cessation (<_1 week) of aspirin and continuation of dual therapy with OAC for up to 6 months and clopidogrel is recommended if the risk of stent thrombosisd is low or if concerns about bleeding riske prevail over concerns about risk of stent thrombosis,d irrespective of the type of stent used.1076,1078",I,A,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"Triple therapy with aspirin, clopidogrel, and an OACf for longer than 1 week should be considered when risk of stent thrombosisd outweighs the bleeding risk,e with the total duration (<_1 month) decided according to assessment of these risks, and the treatment plan should be clearly speciﬁed at hospital discharge.",IIa,C,17,"patients with AF and an ACS, PCI, or CCS1068",Atrial Fibrillation,2020,62
"In patients with acute ischaemic stroke or TIA and without previously known AF, monitoring for AF is recommended using a short-term ECG recording for at least the ﬁrst 24 h, followed by continuous ECG monitoring for at least 72 h whenever possible.1113",I,B,18,the search for AF in patients with cryptogenic stroke,Atrial Fibrillation,2020,64
"In selectedc stroke patients without previously known AF, additional ECG monitoring using long-term non-invasive ECG monitors or insertable cardiac monitors should be considered, to detect AF.",IIa,B,18,the search for AF in patients with cryptogenic stroke,Atrial Fibrillation,2020,64
"In AF patients with an ischaemic stroke or TIA, long-term secondary prevention of stroke using OAC is recommended if there is no strict contraindication to OAC use, with a preference for NOACs over VKAs in NOAC-eligible patients.1125",I,A,19,secondary stroke prevention in AF patients after acute ischaemic stroke,Atrial Fibrillation,2020,65
"In AF patients presenting with acute ischaemic stroke, very early anticoagulation (<48 h) using UFH, LMWH, or VKAs is not recommended.",III,B,19,secondary stroke prevention in AF patients after acute ischaemic stroke,Atrial Fibrillation,2020,65
"Recommendations for stroke prevention in AF patients after intracranial haemorrhage In AF patients at high risk of ischaemic stroke, (re-)initiation of OAC, with preference for NOACs over VKAs in NOAC-eligible patients, should be considered in consultation with a neurologist/stroke specialist after: • A trauma-related ICH • Acute spontaneous ICH (which includes subdural, subarachnoid, or intracerebral haemorrhage), after careful consideration of risks and beneﬁts.c",IIa,C,19,secondary stroke prevention in AF patients after acute ischaemic stroke,Atrial Fibrillation,2020,65
"In an AF patient with severe active bleeding, it is recommended to: • Interrupt OAC until the cause of bleeding is identiﬁed and active bleeding is resolved; and • Promptly perform speciﬁc diagnostic and treatment interventions to identify and manage the cause(s) and source(s) of bleeding.",I,C,20,the management of active bleeding on OAC,Atrial Fibrillation,2020,67
Four-factor prothrombin complex concentrates should be considered in AF patients on VKA who develop a severe bleeding complication.,IIa,C,20,the management of active bleeding on OAC,Atrial Fibrillation,2020,67
NOACs are contraindicated in patients with a prosthetic mechanical valve.,III,B,21,patients with valvular heart disease and AF,Atrial Fibrillation,2020,67
Use of NOACs is not recommended in patients with AF and moderate-to-severe mitral stenosis.,III,C,21,patients with valvular heart disease and AF,Atrial Fibrillation,2020,67
"• Oral anticoagulation should be considered in all adult patients with intracardiac repair, cyanosis, Fontan palliation, or systemic right ventricle and a history of AF, AFL, or intra-atrial re-entrant tachycardia.1273 • In patients with AF and other congenital heart diseases, anticoagulation should be considered in the presence of one or more non-sex stroke risk factor(s).",IIa,C,22,the management of AF in patients with congenital heart disease,Atrial Fibrillation,2020,70
Surgery for AF should be considered in patients: • Who need surgical closure of an atrial septal defect and who have a history of symptomatic atrial arrhythmia (atrial ablation should be considered at the time of surgical closure).12801282 • Cox maze surgery should be considered in patients with symptomatic AF and an indication for corrective repair of congenital heart defects. The surgery should be done in experienced centres.1280,IIa,C,22,the management of AF in patients with congenital heart disease,Atrial Fibrillation,2020,70
AF catheter ablation of atrial arrhythmias associated with congenital heart defects may be considered when performed in experienced centres.,IIb,C,22,the management of AF in patients with congenital heart disease,Atrial Fibrillation,2020,70
"In patients with congenital heart disease, TOE may be considered together with 3-week anticoagulation therapy before cardioversion.",IIb,C,22,the management of AF in patients with congenital heart disease,Atrial Fibrillation,2020,70
Acute management Immediate electrical cardioversionc is recommended in case of haemodynamic instability or pre-excited AF.,I,C,23,the management of AF during pregnancy,Atrial Fibrillation,2020,71
"In pregnant women with HCM, cardioversionc should be considered for persistent AF.",IIa,C,23,the management of AF during pregnancy,Atrial Fibrillation,2020,71
Ibutilide or ﬂecainide i.v. may be considered for termination of AF in stable patients with structurally normal hearts.,IIb,C,23,the management of AF during pregnancy,Atrial Fibrillation,2020,71
Long-term management (oral administration of drugs) Therapeutic anticoagulation with heparin or VKA according to the stage of pregnancy is recommended for patients with AF.,I,C,23,the management of AF during pregnancy,Atrial Fibrillation,2020,71
Beta-selective blockers are recommended for rate control in AF.d,I,C,23,the management of AF during pregnancy,Atrial Fibrillation,2020,71
"Flecainide,e propafenone,e or sotalolf should be considered to prevent AF if atrioventricular nodal-blocking drugsf fail.",IIa,C,23,the management of AF during pregnancy,Atrial Fibrillation,2020,71
Digoxing or verapamilg should be considered for rate control if beta-blockers fail.,IIa,C,23,the management of AF during pregnancy,Atrial Fibrillation,2020,71
"AF Recommendation It is recommended to counsel professional athletes that long-lasting intense sports participation may promote AF, while moderate physical activity is recommended to prevent AF.35,38,1020,1360,1366",I,B,24,sports activity in patients with,Atrial Fibrillation,2020,71
Perioperative amiodarone or beta blocker therapy is recommended for the prevention of postoperative AF after cardiac surgery.,I,A,25,postoperative AF,Atrial Fibrillation,2020,73
"Long-term OAC therapy to prevent thromboembolic events should be considered in patients at risk for stroke with postoperative AF after non-cardiac surgery, considering the anticipated net clinical beneﬁt of OAC therapy and informed patient preferences.",IIa,B,25,postoperative AF,Atrial Fibrillation,2020,73
"Long-term OAC therapy to prevent thromboembolic events may be considered in patients at risk for stroke with postoperative AF after cardiac surgery, considering the anticipated net clinical beneﬁt of OAC therapy and informed patient preferences.",IIb,B,25,postoperative AF,Atrial Fibrillation,2020,73
Beta-blockers should not be used routinely for the prevention of postoperative AF in patients undergoing non-cardiac surgery.,III,B,25,postoperative AF,Atrial Fibrillation,2020,73
AF The introduction of tools to measure quality of care and identify opportunities for improved treatment quality and AF patient outcome should be considered by practitioners and institutions.,IIa,B,26,quality measures in patients with,Atrial Fibrillation,2020,74
"AHRE In patients with AHRE/subclinical AF detected by CIED or insertable cardiac monitor, it is recommended to conduct: • Complete cardiovascular evaluation with ECG recording, clinical risk factors/comorbidity evaluation, and thrombo-embolic risk assessment using the CHA2DS2-VASc score.469 •",I,B,27,management of patients with,Atrial Fibrillation,2020,77
"Among individuals with low to moderate CVD risk, the participation in all recreational sports should be considered without further CV evaluation.",IIa,C,1,cardiovascular evaluation and regular exercise in healthy individuals aged >35 years,Sports Cardiology,2020,18
"Cardiac screening with family history, symptoms, physical examination, and 12-lead resting ECG should be considered for competitive athletes.",IIa,C,1,cardiovascular evaluation and regular exercise in healthy individuals aged >35 years,Sports Cardiology,2020,18
"Clinical evaluation, including maximal exercise testing, should be considered for prognostic purposes in sedentary people and individuals with high or very high CV risk who intend to engage in intensive exercise programmes or competitive sports.",IIa,C,1,cardiovascular evaluation and regular exercise in healthy individuals aged >35 years,Sports Cardiology,2020,18
"In selected individuals without known CAD who have very high CVD risk (e.g. SCORE>10%, strong family history, or familial hypercholesterolaemia) and want to engage in high- or very high-intensity exercise, risk assessment with a functional imaging test, coronary CCTA, or carotid or femoral artery ultrasound imaging may be considered.",IIb,B,1,cardiovascular evaluation and regular exercise in healthy individuals aged >35 years,Sports Cardiology,2020,18
"Among adults aged 65 years or older who are ﬁt and have no health conditions that limit their mobility, moderate-intensity aerobic exercise for at least 150 min/week is recommended.",I,A,2,exercise in ageing individuals,Sports Cardiology,2020,22
"In older adults at risk of falls, strength training exercises to improve balance and coordination on at least 2 days a week are recommended.",I,B,2,exercise in ageing individuals,Sports Cardiology,2020,22
A full clinical assessment including a maximal exercise test should be considered in sedentary adults aged 65 years or older who wish to participate in high-intensity activity.,IIa,C,2,exercise in ageing individuals,Sports Cardiology,2020,22
"Continuation of high- and very high-intensity activity, including competitive sports, may be considered in asymptomatic elderly athletes (master athletes) at low or moderate CV risk.",IIb,C,2,exercise in ageing individuals,Sports Cardiology,2020,22
"Among individuals with asymptomatic CCS, deﬁned as CAD without inducible myocardial ischaemia on a functional imaging or conventional exercise stress test, 233 participation in all types of exercise, including competitive sports, should be considered based on individual assessment.",IIa,C,3,exercise in individuals at risk of atherosclerotic coronary artery disease and asymptomatic individuals in whom coronary artery disease is detected at screening,Sports Cardiology,2020,24
Risk stratiﬁcation for exercise-induced adverse events is recommended in individuals with established (long-standing) chronic coronary syndrome (CCS) prior to engaging in exercise.,I,C,4,exercise in individuals with long-standing chronic coronary syndrome,Sports Cardiology,2020,25
Regular follow-up and risk stratiﬁcation of patients with CCS is recommended.,I,B,4,exercise in individuals with long-standing chronic coronary syndrome,Sports Cardiology,2020,25
It is recommended that individuals at high risk of an adverse event from CAD are managed according to the current Guidelines on CCS.,I,C,4,exercise in individuals with long-standing chronic coronary syndrome,Sports Cardiology,2020,25
Competitive or leisure sports activities (with some exceptions such as older athletes and sports with extreme CV demands) should be considered in individuals at low risk of exercise-induced adverse events (Table 11).,IIa,C,4,exercise in individuals with long-standing chronic coronary syndrome,Sports Cardiology,2020,25
"Leisure-time exercise, below the angina and ischaemic thresholds, may be considered in individuals at high risk of exerciseinduced adverse events (Table 11), including those with persisting ischaemia.",IIb,C,4,exercise in individuals with long-standing chronic coronary syndrome,Sports Cardiology,2020,25
"Competitive sports are not recommended in individuals at high risk of exercise-induced adverse events or those with residual ischaemia, with the exception of individually recommended skill sports.",III,C,4,exercise in individuals with long-standing chronic coronary syndrome,Sports Cardiology,2020,25
Exercise-based cardiac rehabilitation is recommended in all individuals with CAD to reduce cardiac mortality and rehospitalization.,I,A,5,return to exercise after acute coronary syndrome,Sports Cardiology,2020,26
"During the initial period, motivational and psychological support, and individualized recommendations on how to progress the amount and intensity of sports activities, should be considered in patients with CAD.",IIa,B,5,return to exercise after acute coronary syndrome,Sports Cardiology,2020,26
"All sports activities should be considered, at an individually adapted intensity level in low-risk individuals with CCS.",IIa,C,5,return to exercise after acute coronary syndrome,Sports Cardiology,2020,26
"When considering sports activities, evaluation with imaging tests to identify high-risk patterns and an exercise stress test to check for ischaemia should be considered in individuals with AOCA.",IIa,C,6,exercise in young individuals/athletes with anomalous origins of coronary arteries,Sports Cardiology,2020,27
"In asymptomatic individuals with an anomalous coronary artery that does not course between the large vessels, does not have a slitlike oriﬁce with reduced lumen and/or intramural course, competition may be considered, after adequate counselling on the risks, provided there is absence of inducible ischaemia.",IIb,C,6,exercise in young individuals/athletes with anomalous origins of coronary arteries,Sports Cardiology,2020,27
"After surgical repair of an AOCA, participation in all sports may be considered, at the earliest 3 months after surgery, if they are asymptomatic and there is no evidence of inducible myocardial ischaemia or complex cardiac arrhythmias during maximal exercise stress test.",IIb,C,6,exercise in young individuals/athletes with anomalous origins of coronary arteries,Sports Cardiology,2020,27
Participation in most competitive sports with a moderate and high cardiovascular demand among individuals with AOCA with an acutely angled take-off or an anomalous course between the large vessels is not recommended.c,III,C,6,exercise in young individuals/athletes with anomalous origins of coronary arteries,Sports Cardiology,2020,27
Participation in competitive and leisure-time sports should be considered in asymptomatic individuals with myocardial bridging and without inducible ischaemia or ventricular arrhythmia during maximal exercise testing.,IIa,C,7,exercise/sports in individuals with myocardial bridging,Sports Cardiology,2020,28
Competitive sports are not recommended in individuals with myocardial bridging and persistent ischaemia or complex cardiac arrhythmias during maximal exercise stress testing.,III,C,7,exercise/sports in individuals with myocardial bridging,Sports Cardiology,2020,28
Regular discussion about exercise participation and provision of an individualized exercise prescription is recommended in all individuals with heart failure.,I,A,8,exercise prescription in heart failure with reduced or mid-range ejection fraction,Sports Cardiology,2020,30
"Exercise-based cardiac rehabilitation is recommended in all stable individuals to improve exercise capacity, quality of life, and to reduce the frequency of hospital readmission.",I,A,8,exercise prescription in heart failure with reduced or mid-range ejection fraction,Sports Cardiology,2020,30
"Beyond annual cardiac assessment, clinical reassessment should be considered when the intensity of exercise is increased.",IIa,C,8,exercise prescription in heart failure with reduced or mid-range ejection fraction,Sports Cardiology,2020,30
Motivational and psychological support and individualized recommendations on how to progress the amount and intensity of sports activities should be considered.,IIa,C,8,exercise prescription in heart failure with reduced or mid-range ejection fraction,Sports Cardiology,2020,30
Low- to moderate-intensity recreational sporting activities and participation in structured exercise programmes may be considered in stable individuals.,IIb,C,8,exercise prescription in heart failure with reduced or mid-range ejection fraction,Sports Cardiology,2020,30
High-intensity interval training programmes may be considered in low-risk patients who want to return to high-intensity aerobic and mixed endurance sports.,IIb,C,8,exercise prescription in heart failure with reduced or mid-range ejection fraction,Sports Cardiology,2020,30
"Before considering a sport activity, a preliminary optimization of heart failure risk factor control and therapy, including device implantation (if appropriate), is recommended.",I,C,9,participation in sports in heart failure,Sports Cardiology,2020,30
"Participation in sports activities should be considered in individuals with heart failure who are at low risk, based on a complete assessment and exclusion of all contraindications, in stable condition for at least 4 weeks, optimal treatment, and NYHA functional class I status.",IIa,C,9,participation in sports in heart failure,Sports Cardiology,2020,30
"Non-competitive (low- to moderate-intensity recreational) skill, power, mixed, or endurance sports may be considered in stable, asymptomatic, and optimally treated individuals with HFmrEF.",IIb,C,9,participation in sports in heart failure,Sports Cardiology,2020,30
"High-intensity recreational sports, adapted to the capabilities of the individual patient, may be considered in selected stable, asymptomatic, and optimally treated individuals with HFmrEF with an age-matched exercise capacity beyond average.",IIb,C,9,participation in sports in heart failure,Sports Cardiology,2020,30
High-intensity power and endurance sports are not recommended in patients with HFrEF irrespective of symptoms.,III,C,9,participation in sports in heart failure,Sports Cardiology,2020,31
"Moderate endurance and dynamic resistance exercise, together with lifestyle intervention and optimal treatment of cardiovascular risk factors (i.e. arterial hypertension and type 2 diabetes) are recommended.287,289",I,C,10,exercise and participation in sport in individuals with heart failure with preserved ejection fraction,Sports Cardiology,2020,31
Competitive sports may be considered in selected stable patients without abnormalities on maximal exercise testing.,IIb,C,10,exercise and participation in sport in individuals with heart failure with preserved ejection fraction,Sports Cardiology,2020,31
"Regular exercise through cardiac rehabilitation, combining moderate-intensity aerobic and resistance exercise, is recommended to revert pathophysiology to pre-transplantation time, reduce cardiovascular risk induced by post-transplantation medical treatment, and improve clinical outcome.305",I,B,11,exercise and participation in sport in heart transplant recipients,Sports Cardiology,2020,32
"Recreational (low-intensity recreational) sports participation should be considered and encouraged in stable, asymptomatic individuals after therapy optimization.",IIa,C,11,exercise and participation in sport in heart transplant recipients,Sports Cardiology,2020,32
"Eligibility for competitive sports involving lowand moderate-intensity exercise may be considered in selected, asymptomatic individuals with an uncomplicated follow-up.",IIb,C,11,exercise and participation in sport in heart transplant recipients,Sports Cardiology,2020,32
"Aortic stenosisc Recommendation Mild Participation in all recreational sports, if desired, is recommended.",I,C,12,exercise and participation in recreational/leisure-time sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
"Moderate Participation in all recreational sports involving low to moderate intensity, if desired, should be considered in individuals with LVEF>_50%, good functional capacity, and normal exercise test.",IIa,C,12,exercise and participation in recreational/leisure-time sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
"Severe Participation in all recreational sports/exercise involving low intensity, if desired, may be considered in individuals with LVEF>_50% and normal BP response during exercise.",IIb,C,12,exercise and participation in recreational/leisure-time sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
Participation in competitive or recreational sports/exercise of moderate and high intensity is not recommended.,III,C,12,exercise and participation in recreational/leisure-time sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
"Aortic stenosisc Recommendation Mild Participation in all competitive sports, if desired, is recommended.",I,C,13,participation in competitive sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
"Moderate Participation in all competitive sports involving low to moderate effort, if desired, may be considered in individuals with LVEF>_50%, good functional capacity, and normal BP response during exercise.",IIb,C,13,participation in competitive sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
Severe Participation in low-intensity skill sports may be considered in a select group of individuals with LVEF>_50%.,IIb,C,13,participation in competitive sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
Participation in sports or exercise of moderate or high intensity is not recommended.,III,C,13,participation in competitive sports in asymptomatic individuals with aortic stenosis,Sports Cardiology,2020,33
"Aortic regurgitationc Recommendation Mild Participation in all recreational sports, if desired, is recommended.",I,C,14,participation in recreational/leisure-time sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
"Moderate Participation in all recreational sports, if desired, should be considered in asymptomatic individuals with a non-dilated LV with LVEF>50% and normal exercise stress test.",IIa,C,14,participation in recreational/leisure-time sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
"Severe Participation in all recreational sports involving low and moderate intensity, if desired, may be considered with a mild or moderately dilated LV with LVEF>50% and normal exercise stress test.",IIb,C,14,participation in recreational/leisure-time sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
Participation in any moderate- or high-intensity recreational exercise is not recommended with LVEF<_50% and/or exercise-induced arrhythmias.,III,C,14,participation in recreational/leisure-time sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
"Aortic regurgitationc Recommendation Mild Participation in all competitive sports, if desired, is recommended.",I,C,15,participation in competitive sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
"Moderate Participation in all competitive sports, if desired, should be considered in individuals with LVEF>50% and normal exercise test.",IIa,C,15,participation in competitive sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
Severe Participation in most competitive sports involving low to moderate intensity may be considered in individuals with a mild or moderately dilated LV with LVEF>50% and normal exercise stress test.,IIb,C,15,participation in competitive sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
Participation in any moderate- or high-intensity competitive sports is not recommended in individuals with severe AR and/or LVEF<_50% and/or exercise-induced arrhythmias,III,C,15,participation in competitive sports in asymptomatic individuals with aortic regurgitation,Sports Cardiology,2020,34
"Mitral regurgitationc,d Recommendation Mild Participation in all sports, if desired, is recommended.",I,C,16,participation in recreational/leisure-time sports in asymptomatic individuals with mitral regurgitation,Sports Cardiology,2020,35
"Moderate Participation in all recreational sports, if desired, should be considered in individuals fulﬁlling the following: • LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women • LVEF>_60% • Resting sPAP<50 mmHg • Normal exercise test",IIa,C,16,participation in recreational/leisure-time sports in asymptomatic individuals with mitral regurgitation,Sports Cardiology,2020,35
"Severe Participation in all recreational sports involving low and moderate intensity, if desired, may be considered in individuals fulﬁlling the following: • LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women • LVEF>_60% • Resting sPAP<50 mmHg • Normal exercise test",IIb,C,16,participation in recreational/leisure-time sports in asymptomatic individuals with mitral regurgitation,Sports Cardiology,2020,35
"Mitral regurgitationc,d Recommendation Mild Participation in all competitive sports, if desired, is recommended.",I,C,17,participation in competitive sports in asymptomatic individuals with mitral regurgitation,Sports Cardiology,2020,35
"Moderate Participation in all competitive sports, if desired, should be considered in individuals fulﬁlling the following: • LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women • LVEF>_60% • Resting sPAP<50 mmHg • Normal exercise test",IIa,C,17,participation in competitive sports in asymptomatic individuals with mitral regurgitation,Sports Cardiology,2020,35
"Severe Participation in competitive sports involving low exercise intensity, if desired, may be considered in individuals fulﬁlling the following: • LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women • LVEF>_60% • Resting sPAP<50 mmHg • Normal exercise test",IIb,C,17,participation in competitive sports in asymptomatic individuals with mitral regurgitation,Sports Cardiology,2020,35
Participation in competitive sports is not recommended in individuals with a LVEF<60%,III,C,17,participation in competitive sports in asymptomatic individuals with mitral regurgitation,Sports Cardiology,2020,35
"Mitral stenosisc,d Recommendation Mild (MVA 1.52.0 cm2) Participation in all recreational sports, if desired, is recommended in individuals with a resting sPAP<40 mmHg and normal exercise test.",I,C,18,participation in recreational/leisure-time sports in individuals with mitral stenosis,Sports Cardiology,2020,37
"Moderate (MVA 1.01.5 cm2) Participation in all recreational sports involving low and moderate intensity, if desired, may be considered in individuals with resting sPAP<40 mmHg and a normal exercise test.",IIb,C,18,participation in recreational/leisure-time sports in individuals with mitral stenosis,Sports Cardiology,2020,37
Severe (MVA<1 cm2) Participation in leisure sports of moderate or high intensity is not recommended.,III,C,18,participation in recreational/leisure-time sports in individuals with mitral stenosis,Sports Cardiology,2020,37
"Mitral stenosisc,d Recommendation Mild (MVA 1.52.0 cm2) Participation in all competitive sports, if desired, is recommended in individuals with a resting sPAP<40 mmHg and a normal exercise test.",I,C,19,participation in competitive sports in asymptomatic individuals with mitral stenosis,Sports Cardiology,2020,37
Moderate (MVA 1.01.5 cm2) Participation in all competitive sports involving low intensity may be considered in individuals with a resting sPAP<40 mmHg and normal exercise test.,IIb,C,19,participation in competitive sports in asymptomatic individuals with mitral stenosis,Sports Cardiology,2020,37
Severe (MVA<1.0 cm2) Participation in competitive sports is not recommended.,III,C,19,participation in competitive sports in asymptomatic individuals with mitral stenosis,Sports Cardiology,2020,37
"Exercise recommendations Participation in high-intensity exercise/competitive sports, if desired (with the exception of those where occurrence of syncope may be associated with harm or death), may be considered for individuals who do not have any markers of increased riskc following expert assessment.",IIb,C,20,exercise and sports participation in individuals with hypertrophic cardiomyopathy,Sports Cardiology,2020,41
"Participation in low- or moderate-intensity recreational exercise, if desired, may be considered for individuals who have any markers of increased riskc following expert assessment .",IIb,C,20,exercise and sports participation in individuals with hypertrophic cardiomyopathy,Sports Cardiology,2020,41
"Participation in all competitive sports, if desired, may be considered for individuals who are gene positive for HCM but phenotype negative.",IIb,C,20,exercise and sports participation in individuals with hypertrophic cardiomyopathy,Sports Cardiology,2020,41
Participation in high-intensity exercise (including recreational and competitive sports) is not recommended for individuals who have ANY markers of increased riskc.,III,C,20,exercise and sports participation in individuals with hypertrophic cardiomyopathy,Sports Cardiology,2020,41
Follow-up and further considerations relating to risk Annual follow-up is recommended for individuals who exercise on a regular basis.,I,C,20,exercise and sports participation in individuals with hypertrophic cardiomyopathy,Sports Cardiology,2020,41
Six-monthly follow-up should be considered in adolescent individuals and young adults who are more vulnerable to exercise-related SCD.,IIa,C,20,exercise and sports participation in individuals with hypertrophic cardiomyopathy,Sports Cardiology,2020,41
Annual assessment should be considered for genotype-positive/phenotype-negative individuals for phenotypic features and risk stratiﬁcation purposes.,IIa,C,20,exercise and sports participation in individuals with hypertrophic cardiomyopathy,Sports Cardiology,2020,41
Exercise recommendations Participation in 150 min of low-intensity exercise per week should be considered for all individuals.,IIa,C,21,exercise and sports participation in individuals with arrhythmogenic cardiomyopathy,Sports Cardiology,2020,42
"Participation in low- to moderate-intensity recreational exercise/sports, if desired, may be considered for individuals with no history of cardiac arrest/VA, unexplained syncope, minimal structural cardiac abnormalities, <500 PVCs/24 h and no evidence of exercise-induced complex VAs.",IIb,C,21,exercise and sports participation in individuals with arrhythmogenic cardiomyopathy,Sports Cardiology,2020,42
"Participation in high-intensity recreational exercise/ sports or any competitive sports is not recommended in individuals with ACM, including those who are gene positive but phenotype negative.",III,B,21,exercise and sports participation in individuals with arrhythmogenic cardiomyopathy,Sports Cardiology,2020,42
Follow-up and further considerations relating to risk Annual follow-up is recommended for individuals who exercise on a regular basis.,I,C,21,exercise and sports participation in individuals with arrhythmogenic cardiomyopathy,Sports Cardiology,2020,42
Six-monthly follow-up should be considered in adolescent individuals and young adults who are more vulnerable to exercise-related SCD.,IIa,C,21,exercise and sports participation in individuals with arrhythmogenic cardiomyopathy,Sports Cardiology,2020,42
Annual assessment should be considered for genotype-positive/phenotype-negative individuals for phenotypic features and risk stratiﬁcation purposes.,IIa,C,21,exercise and sports participation in individuals with arrhythmogenic cardiomyopathy,Sports Cardiology,2020,42
"Six-monthly follow-up should also be considered in individuals with high arrhythmic risk genotypes such as DSP, TMEM43, and carriers of multiple pathogenic variants.",IIa,C,21,exercise and sports participation in individuals with arrhythmogenic cardiomyopathy,Sports Cardiology,2020,42
"Recommendation for diagnosis A diagnosis of LVNC in athletic individuals should be considered if they fulﬁl imaging criteria, in association with cardiac symptoms, family history of LVNC or cardiomyopathy, LV systolic (EF<50%) or diastolic (E’<9 cm/s) dysfunction, a thin compacted epicardial layer (<5 mm in end-diastole on CMR, or <8 mm in systole on echocardiography), or abnormal 12-lead ECG.",IIa,B,22,exercise in individuals with left ventricular non-compaction cardiomyopathy,Sports Cardiology,2020,43
"Exercise recommendations Participation in high-intensity exercise and all competitive sports, if desired, with the exception where syncope may cause serious harm or death, may be considered in asymptomatic individuals with LVNC and LVEF>_50% and absence of frequent and/or complex VAs.",IIb,C,22,exercise in individuals with left ventricular non-compaction cardiomyopathy,Sports Cardiology,2020,43
"Participation in recreational exercise programmes of low to moderate intensity, if desired, may be considered in individuals with LVEF 4049% in the absence of syncope and frequent or complex VAs on ambulatory Holter monitoring or exercise testing.",IIb,C,22,exercise in individuals with left ventricular non-compaction cardiomyopathy,Sports Cardiology,2020,43
"Participation in high-intensity exercise or competitive sports is not recommended in individuals with any of the following: symptoms, LVEF<40% and/or frequent and/or complex VAs on ambulatory Holter monitoring or exercise testing.",III,C,22,exercise in individuals with left ventricular non-compaction cardiomyopathy,Sports Cardiology,2020,43
Follow-up and further considerations Annual assessment for risk stratiﬁcation is recommended for individuals with LVNC and genotypepositive/phenotype-negative individuals who exercise on a regular basis.,I,C,22,exercise in individuals with left ventricular non-compaction cardiomyopathy,Sports Cardiology,2020,43
"Participation in low- to moderate-intensity recreational exercise should be considered in all individuals with DCM, regardless of the EF, in the absence of limiting symptoms, and exercise-induced VAs.",IIa,C,23,exercise in individuals with dilated cardiomyopathy,Sports Cardiology,2020,44
Participation in high- or very high-intensity exercise including competitive sports (with the exception of those where occurrence of syncope may be associated with harm or death) may be considered in asymptomatic individuals who fulﬁl all of the following: (i) mildly reduced LV systolic function (EF 4550%); (ii) absence of frequent and/or complex VAs on ambulatory Holter monitoring or exercise testing; (iii) absence of LGE on CMR; (iv) ability to increase EF by 1015% during exercise; and (v) no evidence of high-risk genotype (lamin A/C or ﬁlamin C).,IIb,C,23,exercise in individuals with dilated cardiomyopathy,Sports Cardiology,2020,44
Participation in high- or very high-intensity exercise including competitive sports is not recommended for individuals with a DCM and any of the following: (i) symptoms or history of cardiac arrest or unexplained syncope; (ii) LVEF<45%; (iii) frequent and/or complex VAs on ambulatory Holter monitoring or exercise testing; (iv) extensive LGE (>20%) on CMR; or (v) high-risk genotype (lamin A/C or ﬁlamin C).,III,C,23,exercise in individuals with dilated cardiomyopathy,Sports Cardiology,2020,44
Follow-up recommendations Annual follow-up is recommended for individuals with DCM who exercise on a regular basis.,I,C,23,exercise in individuals with dilated cardiomyopathy,Sports Cardiology,2020,44
Six-monthly follow-up should be considered in individuals with high-risk mutations and adolescent individuals and young adults whose DCM phenotype may still be evolving and who are more vulnerable to exercise-related SCD.,IIa,C,23,exercise in individuals with dilated cardiomyopathy,Sports Cardiology,2020,44
Annual assessment should be considered for genotype-positive/phenotype-negative individuals for phenotypic features and risk stratiﬁcation purposes.,IIa,C,23,exercise in individuals with dilated cardiomyopathy,Sports Cardiology,2020,44
"Comprehensive evaluation, using imaging studies, exercise stress test and Holter monitoring, is recommended following recovery from acute myocarditis to assess the risk of exercise-related SCD.",I,B,24,exercise in individuals with myocarditis,Sports Cardiology,2020,46
"Return to all forms of exercise including competitive sports should be considered after 36 months in asymptomatic individuals, with normal troponin and biomarkers of inﬂammation, normal LV systolic function on echocardiography and CMR, no evidence of ongoing inﬂammation or myocardial ﬁbrosis on CMR, good functional capacity, and absence of frequent and/or complex VAs on ambulatory Holter monitoring or exercise testing.",IIa,C,24,exercise in individuals with myocarditis,Sports Cardiology,2020,46
"Among individuals with a probable or deﬁnitive diagnosis of recent myocarditis, participation in leisure-time or competitive sports while active inﬂammation is present is not recommended.",III,C,24,exercise in individuals with myocarditis,Sports Cardiology,2020,46
Participation in moderate- to high-intensity exercise for a period of 36 months after acute myocarditis is not recommended.459,III,B,24,exercise in individuals with myocarditis,Sports Cardiology,2020,46
Participation in leisure exercise or competitive sports involving high intensity in individuals with residual myocardial scar and persistent LV dysfunction is not recommended.,III,C,24,exercise in individuals with myocarditis,Sports Cardiology,2020,46
"Return to all forms of exercise including competitive sports is recommended after 30 days to 3 months for individuals who have recovered completely from acute pericarditis, depending on clinical severity.",I,C,25,exercise in individuals with pericarditis,Sports Cardiology,2020,46
"Participation in leisure-time or competitive sports is not recommended for individuals with a probable or deﬁnitive diagnosis of recent pericarditis while active inﬂammation is present, regardless of age, sex, or extent of LV systolic dysfunction.",III,C,25,exercise in individuals with pericarditis,Sports Cardiology,2020,46
"Participation in moderate- to high-intensity exercise, including competitive sports, is not recommended for individuals with constrictive pericarditis.",III,C,25,exercise in individuals with pericarditis,Sports Cardiology,2020,46
"ﬁbrillation Regular physical activity is recommended to prevent AF.297,470",I,A,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"Evaluation and management of structural heart disease, thyroid dysfunction, alcohol or drug abuse, or other primary causes of AF is recommended before engaging in sports.",I,A,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"Counselling about the effect of long-lasting intense sports participation on (recurrence of) AF is recommended in individuals with AF who exercise vigorously for prolonged periods, especially in middle-aged men.",I,B,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"AF ablation is recommended in exercising individuals with recurrent symptomatic AF, and/ or in those who do not want drug therapy, given its impact on athletic performance.",I,B,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"The ventricular rate while exercising with AF should be considered in every exercising individual (by symptoms and/or by ECG monitoring), and titrated rate control should be instituted.",IIa,C,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"Participation in sports without antiarrhythmic therapy should be considered in individuals without structural heart disease, and in whom AF is well tolerated.",IIa,C,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"Cavo-tricuspid isthmus ablation should be considered in those with documented ﬂutter who want to engage in intensive exercise, to prevent atrial ﬂutter 1 : 1 atrioventricular conduction.",IIa,C,26,exercise in individuals with atrial,Sports Cardiology,2020,47
Prophylactic cavo-tricuspid isthmus ablation to prevent ﬂutter should be considered in individuals with AF who want to engage in intensive exercise and in whom class I drug therapy is initiated.,IIa,C,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"The use of class I antiarrhythmic drugs as monotherapy, without proof of adequate rate control of AF/AFL during vigorous exercise, is not recommended.",III,C,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"After ingestion of pill-in-the-pocket ﬂecainide or propafenone, participation in intensive sports is not recommended until two half-lives of the antiarrhythmic drug have elapsed (i.e. up to 2 days).",III,C,26,exercise in individuals with atrial,Sports Cardiology,2020,47
Sports with direct bodily contact or prone to trauma are not recommended in exercising individuals with AF who are anticoagulated.,III,A,26,exercise in individuals with atrial,Sports Cardiology,2020,47
"In individuals with palpitations, a comprehensive assessment to exclude (latent) pre-excitation, structural heart disease, and VAs is recommended.",I,B,27,exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation,Sports Cardiology,2020,49
Participation in all sports activities is recommended in individuals PSVT without preexcitation.,I,C,27,exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation,Sports Cardiology,2020,49
Ablation of the accessory pathway is recommended in competitive and recreational athletes with pre-excitation and documented arrhythmias.,I,C,27,exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation,Sports Cardiology,2020,49
"In competitive/professional athletes with asymptomatic pre-excitation, an EP study is recommended to evaluate the risk for sudden death.",I,B,27,exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation,Sports Cardiology,2020,49
"In competitive athletes with PSVT but without pre-excitation, curative treatment by ablation should be considered.",IIa,C,27,exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation,Sports Cardiology,2020,49
In exercising individuals with >_2 PVCs on a baseline ECG (or >_1 PVC in the case of high-endurance athletes) thorough evaluation (including a detailed family history) to exclude underlying structural or arrhythmogenic conditions is recommended.,I,C,28,exercise in individuals with premature ventricular contractions or non-sustained ventricular tachycardia,Sports Cardiology,2020,50
"Among individuals with frequent PVCs and nonsustained VT a thorough investigation with Holter monitoring, 12-lead ECG, exercise test, and suitable imaging is recommmended.",I,C,28,exercise in individuals with premature ventricular contractions or non-sustained ventricular tachycardia,Sports Cardiology,2020,50
"It is recommended that all competitive and leisure-time sports activities are permitted, with periodic re-evaluation in individuals without familial or structural underlying disease.",I,C,28,exercise in individuals with premature ventricular contractions or non-sustained ventricular tachycardia,Sports Cardiology,2020,50
It is recommended that all exercising individuals with LQTS with prior symptoms or prolonged QTc be on therapy with beta-blockers at target dose.,I,B,29,exercise in long QT syndrome,Sports Cardiology,2020,51
It is recommended that exercising individuals with LQTS should avoid QT prolonging drugs (www.crediblemeds.org) and electrolyte imbalance such as hypokalaemia and hypomagnesaemia.,I,B,29,exercise in long QT syndrome,Sports Cardiology,2020,51
"Shared decision making should be considered regarding sports participation in patients with genotype-positive/phenotype-negative LQTS (i.e. <470/480 ms in men/women). Type and setting of sports (individual vs. team), type of mutation, and extent of precautionary measures should be considered in this context.",IIa,C,29,exercise in long QT syndrome,Sports Cardiology,2020,51
"Participation in high-intensity recreational and competitive sports, even when on beta-blockers, is not recommended in individuals with a QTc>500 ms or a genetically conﬁrmed LQTS with a QTc>_470 ms in men or >_480 ms in women.",III,B,29,exercise in long QT syndrome,Sports Cardiology,2020,51
Participation in competitive sports (with or without ICD) is not recommended in individuals with LQTS and prior cardiac arrest or arrhythmic syncope.,III,C,29,exercise in long QT syndrome,Sports Cardiology,2020,51
ICD implantation is recommended in patients with BrS with episodes of arrhythmic syncope and/or aborted SCD.,I,C,30,exercise in Brugada syndrome,Sports Cardiology,2020,51
"Following implantation of an ICD, resumption of leisure or competitive sports should be considered after shared decision making in individuals who have not experienced recurrent arrhythmias over 3 months after ICD implantation.",IIa,C,30,exercise in Brugada syndrome,Sports Cardiology,2020,51
"In asymptomatic individuals with BrS, asymptomatic mutation carriers and asymptomatic athletes with only an inducible ECG pattern, participation in sports activities that are not associated with an increase in core temperature >39C (e.g. endurance events under extremely hot and/or humid conditions) may be considered.",IIb,C,30,exercise in Brugada syndrome,Sports Cardiology,2020,51
"Prescription of drugs that may aggravate BrSc, electrolyte abnormalities, and sports practice that increases core temperature >39 C are not recommended in individuals with overt BrS or phenotypically negative mutation carriers.",III,C,30,exercise in Brugada syndrome,Sports Cardiology,2020,51
It is recommended that individuals with implanted devices with/without resynchronization and underlying disease follow the recommendations pertaining to the underlying disease.,I,B,31,exercise in individuals with pacemakers and implantable cardioverter deﬁbrillators,Sports Cardiology,2020,53
Participation in sports and exercise (except collision sports) should be considered in individuals with pacemaker therapy who do not have pathological substrates for fatal arrhythmias.,IIa,C,31,exercise in individuals with pacemakers and implantable cardioverter deﬁbrillators,Sports Cardiology,2020,53
"Prevention of direct impact to the implanted device by adapting the site of lead and/or device implantation, padding, or restricting direct impact sports should be considered.",IIa,C,31,exercise in individuals with pacemakers and implantable cardioverter deﬁbrillators,Sports Cardiology,2020,53
"Holter recordings and device interrogation during and after resuming sports should be considered to allow appropriate tailoring of rateresponsive pacing parameters, exclusion of myopotential or electromagnetic inhibition, and detection of VAs.",IIa,C,31,exercise in individuals with pacemakers and implantable cardioverter deﬁbrillators,Sports Cardiology,2020,53
"Shared decision making should be considered during decisions relating to continuation of intensive or competitive sports participation in individuals with an ICD, taking into account the effect of sports on the underlying substrate, the fact that intensive sports will trigger more appropriate and inappropriate shocks, the psychological impact of shocks on the athlete/patient, and the potential risk for third parties.",IIa,C,31,exercise in individuals with pacemakers and implantable cardioverter deﬁbrillators,Sports Cardiology,2020,53
An ICD is not recommended as a substitute for disease-related recommendations when these mandate sports restrictions.,III,C,31,exercise in individuals with pacemakers and implantable cardioverter deﬁbrillators,Sports Cardiology,2020,53
"Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor (i.e. family history of premature CVD, FH, CVD risk factors such as smoking, arterial hypertension, DM, raised lipid level, obesity, or comorbidities increasing CVD risk).",I,C,1,CVD risk assessment,CVD Prevention,2021,16
Systematic or opportunistic CV risk assessment in the general population in men >40 years of age and in women >50 years of age or postmenopausal with no known ASCVD risk factors may be considered.,IIb,C,1,CVD risk assessment,CVD Prevention,2021,16
"In those individuals who have undergone CVD risk assessment in the context of opportunistic screening, a repetition of screening after 5 years (or sooner if risk was close to treatment thresholds) may be considered.",IIb,C,1,CVD risk assessment,CVD Prevention,2021,16
"Opportunistic screening of BP in adults at risk for the development of hypertension, such as those who are overweight or with a known family history of hypertension, should be considered.",IIa,B,1,CVD risk assessment,CVD Prevention,2021,16
Systematic CVD risk assessment in men <40 years of age and women <50 years of age with no known CV risk factors is not recommended.,III,C,1,CVD risk assessment,CVD Prevention,2021,16
"In apparently healthy people <70 years without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation of 10-year fatal and non-fatal CVD risk with SCORE2 is recommended.",I,B,2,CVD risk estimation,CVD Prevention,2021,30
"In apparently healthy people >_70 years without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation of 10-year fatal and non-fatal CVD risk with SCORE2-OP is recommended.",I,B,2,CVD risk estimation,CVD Prevention,2021,30
"In apparently healthy people, after estimation of 10-year fatal and non-fatal CVD risk, lifetime risk and treatment beneﬁt, risk modiﬁers, frailty, polypharmacy, and patient preferences should be considered.",IIa,C,2,CVD risk estimation,CVD Prevention,2021,30
"Patients with established ASCVD and/or DM and/or moderate-to-severe renal disease and/or genetic/rarer lipid or BP disorders are to be considered at high or very high CVD risk.75,77,81,88",I,A,2,CVD risk estimation,CVD Prevention,2021,30
"A stepwise treatment-intensiﬁcation approach aiming at intensive risk factor treatment is recommended for apparently healthy people at high or very high CVD risk, as well as patients with established ASCVD and/or DM, with consideration of CVD risk, treatment beneﬁt of risk factors, risk modiﬁers, comorbidities, and patient preferences.",I,B,2,CVD risk estimation,CVD Prevention,2021,30
"Treatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP disorders who are at very high CVD risk (SCORE2 >_7.5% for age under 50; SCORE2 >_10% for age 5069; SCORE2-OP >_15% for age >_70 years).",I,C,2,CVD risk estimation,CVD Prevention,2021,30
"Treatment of ASCVD risk factors should be considered in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP disorders who are at high CVD risk (SCORE2 2.5 to <7.5% for age under 50; SCORE2 5 to <10% for age 5069; SCORE2-OP 7.5 to <15% for age >_70 years), taking CVD risk modiﬁers, lifetime risk and treatment beneﬁt, and patient preferences into account.",IIa,C,2,CVD risk estimation,CVD Prevention,2021,30
Stress symptoms and psychosocial stressors modify CVD risk. Assessment of these stressors should be considered.100,IIa,B,3,CVD risk modiﬁers,CVD Prevention,2021,31
CAC scoring may be considered to improve risk classiﬁcation around treatment decision thresholds. Plaque detection by carotid ultrasound is an alternative when CAC scoring is unavailable or not feasible.,IIb,B,3,CVD risk modiﬁers,CVD Prevention,2021,31
Multiplication of calculated risk by RR for speciﬁc ethnic subgroups should be considered.,IIa,B,3,CVD risk modiﬁers,CVD Prevention,2021,31
"The routine collection of other potential modiﬁers, such as genetic risk scores, circulating or urinary biomarkers, or vascular tests or imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended.",III,B,3,CVD risk modiﬁers,CVD Prevention,2021,31
Patients at (very) high risk for CVD may be encouraged to try to avoid long-term exposure to regions with high air pollution.,IIb,C,4,cardiovascular disease risk related to air pollution,CVD Prevention,2021,34
"In regions where people have long-term exposure to high levels of air pollution, (opportunistic) CVD risk screening programmes may be considered.",IIb,C,4,cardiovascular disease risk related to air pollution,CVD Prevention,2021,34
"Clinical condition CKD In all CKD patients, with or without DM, appropriate screening for ASCVD and kidney disease progression, including monitoring changes in albuminuria is recommended.",I,C,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
"Cancer It is recommended to monitor cardiac dysfunction using imaging techniques and circulating biomarkers before, periodically during, and after cancer treatment.",I,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Cardioprotection in high-risk patients (those receiving high cumulative doses or combined radiotherapy) receiving anthracycline chemotherapy may be considered for prevention of LV dysfunction.,IIb,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Screening for ASCVD risk factors and optimization of the CVD risk proﬁle is recommended in patients on treatment for cancer.,I,C,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Inﬂammatory conditions Assessment of total CVD risk may be considered in adults with chronic inﬂammatory conditions.,IIb,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Multiplication of calculated total CVD risk by a factor of 1.5 should be considered in adults with rheumatoid arthritis.,IIa,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Migraine Presence of migraine with aura should be considered in CVD risk assessment.179,IIa,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Avoidance of combined hormonal contraceptives may be considered in women with migraine with aura.,IIb,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
"Sleep disorders and OSA In patients with ASCVD, obesity, and hypertension, regular screening for non-restorative sleep is indicated (e.g. by the question: ‘how often have you been bothered by trouble falling or staying asleep, or sleeping too much?’).",I,C,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
"If there are signiﬁcant sleep problems, which are not responding within 4 weeks to sleep hygiene, referral to a specialist is recommended.",I,C,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Mental disorders It is recommended that mental disorders with either signiﬁcant functional impairment or decreased use of healthcare systems be considered as inﬂuencing total CVD risk.,I,C,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
"Sex-speciﬁc conditions In women with a history of preeclampsia and/or pregnancyinduced hypertension, periodic screening for hypertension and DM should be considered.184",IIa,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
"In women with a history of polycystic ovary syndrome or gestational DM, periodic screening for DM should be considered.188",IIa,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
"In women with a history of premature or stillbirth, periodic screening for hypertension and DM may be considered.",IIb,B,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
Assessment of CVD risk should be considered in men with ED.,IIa,C,5,cardiovascular disease assessment in speciﬁc clinical conditions,CVD Prevention,2021,35
"It is recommended for adults of all ages to strive for at least 150 - 300 min a week of moderateintensity or 75 - 150 min a week of vigorousintensity aerobic PA, or an equivalent combination thereof, to reduce all-cause mortality, CV mortality, and morbidity.",I,A,6,physical activity,CVD Prevention,2021,42
It is recommended that adults who cannot perform 150 min of moderate-intensity PA a week should stay as active as their abilities and health condition allow.,I,B,6,physical activity,CVD Prevention,2021,42
It is recommended to reduce sedentary time to engage in at least light activity throughout the day to reduce all-cause and CV mortality and morbidity.375,I,B,6,physical activity,CVD Prevention,2021,42
"Performing resistance exercise, in addition to aerobic activity, is recommended on 2 or more days per week to reduce all-cause mortality.",I,B,6,physical activity,CVD Prevention,2021,42
"Lifestyle interventions, such as group or individual education, behaviour-change techniques, telephone counselling, and use of consumer-based wearable activity trackers, should be considered to increase PA participation.380",IIa,B,6,physical activity,CVD Prevention,2021,42
A healthy diet is recommended as a cornerstone of CVD prevention in all individuals.,I,A,7,nutrition and alcohol,CVD Prevention,2021,43
It is recommended to replace saturated with unsaturated fats to lower the risk of CVD.405,I,A,7,nutrition and alcohol,CVD Prevention,2021,44
It is recommended to reduce salt intake to lower BP and risk of CVD.,I,A,7,nutrition and alcohol,CVD Prevention,2021,44
"It is recommended to choose a more plantbased food pattern, rich in ﬁbre, that includes whole grains, fruits, vegetables, pulses, and nuts.",I,B,7,nutrition and alcohol,CVD Prevention,2021,44
It is recommended to restrict alcohol consumption to a maximum of 100 g per week.413,I,B,7,nutrition and alcohol,CVD Prevention,2021,44
"It is recommended to eat ﬁsh, preferably fatty, at least once a week and restrict (processed) meat.406,416",I,B,7,nutrition and alcohol,CVD Prevention,2021,44
"It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake.",I,B,7,nutrition and alcohol,CVD Prevention,2021,44
"It is recommended that overweight and obese people aim for a reduction in weight to reduce BP, dyslipidaemia, and risk of type 2 DM, and thus improve their CVD risk proﬁle.",I,A,8,body weight,CVD Prevention,2021,46
"While a range of diets are effective for weight loss, it is recommended that a healthy diet in regard to CVD risk is maintained over time.452",I,A,8,body weight,CVD Prevention,2021,46
Patients with mental disorders need intensiﬁed attention and support to improve adherence to lifestyle changes and drug treatment.,I,C,9,mental healthcare and psychosocial interventions at the individual level,CVD Prevention,2021,47
"In ASCVD patients with mental disorders, evidence-based mental healthcare and interdisciplinary cooperation are recommended.",I,B,9,mental healthcare and psychosocial interventions at the individual level,CVD Prevention,2021,47
ASCVD patients with stress should be considered for referral to psychotherapeutic stress management to improve CV outcomes and reduce stress symptoms.467,IIa,B,9,mental healthcare and psychosocial interventions at the individual level,CVD Prevention,2021,47
Patients with CHD and moderate-to-severe major depression should be considered for antidepressive treatment with an SSRI.,IIa,B,9,mental healthcare and psychosocial interventions at the individual level,CVD Prevention,2021,47
"In patients with HF and major depression, SSRIs, SNRIs, and tricyclic antidepressants are not recommended.472,473 c",III,B,9,mental healthcare and psychosocial interventions at the individual level,CVD Prevention,2021,47
"All smoking of tobacco should be stopped, as tobacco use is strongly and independently causal of ASCVD.",I,A,10,smoking intervention strategies,CVD Prevention,2021,47
"In smokers, offering follow-up support, nicotine replacement therapy, varenicline, and bupropion individually or in combination should be considered.489",IIa,A,10,smoking intervention strategies,CVD Prevention,2021,47
"Smoking cessation is recommended regardless of weight gain, as weight gain does not lessen the ASCVD beneﬁts of cessation.",I,B,10,smoking intervention strategies,CVD Prevention,2021,47
"(for recommendations for persons aged 70 years, see respective recommendations tables). It is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the LDL-C goals set for the speciﬁc risk group.",I,A,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,52
An ultimatec LDL-C goal of <1.4 mmol/L (55 mg/ dL) and LDL-C reduction of >_50% from baseline should be considered in apparently healthy persons <70 years at very high risk.,IIa,C,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,52
An ultimatec LDL-C goal of <1.8 mmol/L (70 mg/dL) and LDL-C reduction of >_50% from baseline should be considered in apparently healthy persons <70 years at high risk.,IIa,C,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,52
"In patients with established ASCVD, lipid-lowering treatment with an ultimatec LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >_50% reduction in LDLC vs. baseline is recommended.21,508,515",I,A,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,52
"If the goals are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended.",I,B,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,52
"For primary prevention patients at very high risk, but without FH, if the LDL-C goal is not achieved on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor may be considered.",IIb,C,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,52
"For very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who do not achieve their goals on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended.",I,C,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,53
"If a statin-based regimen is not tolerated at any dosage (even after rechallenge), ezetimibe should be considered.515,523",IIa,B,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,53
"If a statin-based regimen is not tolerated at any dosage (even after rechallenge), a PCSK9 inhibitor added to ezetimibe may be considered.",IIb,C,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,53
"If the goal is not achieved, statin combination with a bile acid sequestrant may be considered.",IIb,C,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,53
Statin therapy is not recommended in premenopausal female patients who are considering pregnancy or are not using adequate contraception.,III,C,11,pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age,CVD Prevention,2021,53
Treatment with statins is recommended for older people with ASCVD in the same way as for younger patients.,I,A,12,the treatment of dyslipidaemias in older people (70 years).,CVD Prevention,2021,54
"Initiation of statin treatment for primary prevention in older people aged >_70 may be considered, if at high risk or above.",IIb,B,12,the treatment of dyslipidaemias in older people (70 years).,CVD Prevention,2021,54
It is recommended that the statin is started at a low dose if there is signiﬁcant renal impairment and/or the potential for drug interactions.,I,C,12,the treatment of dyslipidaemias in older people (70 years).,CVD Prevention,2021,54
Statin treatment is recommended as the ﬁrst drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridaemia [triglycerides >2.3 mmol/L (200 mg/dL)].,I,A,13,drug treatments of patients with hypertriglyceridaemia.,CVD Prevention,2021,54
"In patients taking statins who are at LDL-C goal with triglycerides >2.3 mmol/L (200 mg/dL), fenoﬁbrate or bezaﬁbrate may be considered.534",IIb,B,13,drug treatments of patients with hypertriglyceridaemia.,CVD Prevention,2021,54
"In high-risk (or above) patients with triglycerides >1.5 mmol/L (135 mg/dL) despite statin treatment and lifestyle measures, n-3 PUFAs (icosapent ethyl 2  2 g/day) may be considered in combination with a statin.",IIb,B,13,drug treatments of patients with hypertriglyceridaemia.,CVD Prevention,2021,54
"In patients with type 2 DM at very high risk (e.g. with established ASCVD and/or severe TODc), intensive lipid-lowering therapy, ultimatelyd aiming at >_50% LDL-C reduction and an LDL-C of <1.4 mmol/L (55 mg/dL) is recommended.",I,A,14,the treatment of dyslipidaemias in diabetes mellitus.,CVD Prevention,2021,54
"Statin therapy may be considered in persons aged <_40 years with type 1 or type 2 DM with evidence of TOD and/or an LDL-C level >2.6 mmol/L (100 mg/dL), as long as pregnancy is not being planned.",IIb,C,14,the treatment of dyslipidaemias in diabetes mellitus.,CVD Prevention,2021,55
"If the LDL-C goal is not reached, statin combination with ezetimibe should be considered.",IIa,B,14,the treatment of dyslipidaemias in diabetes mellitus.,CVD Prevention,2021,55
"Disease Outcomes Quality Initiative stages 35). The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent, stage 35 CKD.",I,A,15,lipid management in patients with moderate-to-severe chronic kidney disease (Kidney,CVD Prevention,2021,55
"In patients already on statins, ezetimibe, or a statin/ezetimibe combination at the time of dialysis initiation, continuation of these drugs should be considered, particularly in patients with ASCVD.",IIa,C,15,lipid management in patients with moderate-to-severe chronic kidney disease (Kidney,CVD Prevention,2021,55
"In patients with dialysis-dependent CKD who are free of ASCVD, commencing statin therapy is not recommended.",III,A,15,lipid management in patients with moderate-to-severe chronic kidney disease (Kidney,CVD Prevention,2021,55
"Screening When screening for DM in individuals with or without ASCVD, assessment of HbA1c (which can be done non-fasting) or fasting blood glucose should be considered.",IIa,A,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,62
"Lifestyle Lifestyle changes including smoking cessation, a low saturated fat, high-ﬁbre diet, aerobic PA, and strength training are recommended.",I,A,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,62
"Reduction in energy intake is recommended to patients, to help achieve lower body weight or prevent or slow weight gain.",I,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,62
"For those motivated to try, considerable weight loss with use of low-calorie diets followed by food reintroduction and weight-maintenance phases early after diagnosis can lead to DM remission and should be considered.",IIa,A,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,62
"For patients with a long duration of DM and in old or frail adults, a relaxing of the HbA1c targets (i.e. less stringent) should be considered.",IIa,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
A target HbA1c of <_6.5% (48 mmol/mol) should be considered at diagnosis or early in the course of type 2 DM in persons who are not frail and do not have ASCVD.,IIa,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
"Treatment of hyperglycaemia and ASCVD/cardiorenal risks Metformin is recommended as ﬁrst-line therapy, following evaluation of renal function, in the majority of patients without previous ASCVD, CKD, or HF.",I,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
"In persons with type 2 DM with ASCVD, metformin should be considered, unless contraindications are present.5,590",IIa,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
Avoidance of hypoglycaemia and excessive weight gain should be considered.,IIa,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
"In persons with type 2 DM and ASCVD, the use of a GLP-1RA or SGLT2 inhibitor with proven outcome beneﬁts is recommended to reduce CV and/or cardiorenal outcomes.590",I,A,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
"In patients with type 2 DM and TOD,c the use of an SGLT2 inhibitor or GLP-1RA with proven outcome beneﬁts may be considered to reduce future CV and total mortality.594",IIb,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
"In patients with type 2 DM and CKD, the use of an SGLT2 inhibitor is recommended to improve ASCVD and/or cardiorenal outcomes.",I,A,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
"In patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor with proven outcome beneﬁts is recommended to lessen HF hospitalizations and CV death.",I,A,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
"In patients with type 2 DM but without ASCVD, HF, or CKD, use of an SGLT2 inhibitor or GLP1RA should be considered based on estimated future risks (e.g. with the ADVANCE risk score or DIAL model) for adverse CVD or cardiorenal outcomes from risk factor proﬁles.",IIa,B,16,the treatment of patients with diabetes mellitus,CVD Prevention,2021,63
Aspirin 75 - 100 mg daily is recommended for secondary prevention of CVD.,I,A,17,antithrombotic therapy,CVD Prevention,2021,64
Clopidogrel 75 mg daily is recommended as an alternative to aspirin in secondary prevention in case of aspirin intolerance.,I,B,17,antithrombotic therapy,CVD Prevention,2021,64
Clopidogrel 75 mg daily may be considered in preference to aspirin in patients with established ASCVD.,IIb,A,17,antithrombotic therapy,CVD Prevention,2021,64
Concomitant use of a proton pump inhibitor is recommended in patients receiving antiplatelet therapy who are at high risk of gastrointestinal bleeding.,I,A,17,antithrombotic therapy,CVD Prevention,2021,64
"Participation in a medically supervised, structured, comprehensive, multidisciplinary EBCR and prevention programme for patients after ASCVD events and/or revascularization, and for patients with HF (mainly HFrEF), is recommended to improve patient outcomes.638",I,A,18,cardiac rehabilitation,CVD Prevention,2021,66
"Methods to increase CR and prevention referral and uptake should be considered (i.e. electronic prompts or automatic referrals, referral and liaison visits, structured follow-up by nurses or health professionals, and early programme initiation after discharge).643",IIa,B,18,cardiac rehabilitation,CVD Prevention,2021,66
"Home-based CR, telehealth, and mHealth interventions may be considered to increase patient participation and long-term adherence to healthy behaviours.",IIb,B,18,cardiac rehabilitation,CVD Prevention,2021,66
"Levelb,c Policies and population approaches to PA, diet, smoking and tobacco use, and alcohol in governmental restrictions and mandates, media and education, labelling and information, economic incentives, schools, worksites, and community settings follow different levels of recommendations (see speciﬁc tables in the supplementary material for section 5). Putting in place measures to reduce air pollution, including reducing PM emission and gaseous pollutants, reducing the use of fossil fuels, and limiting carbon dioxide emissions, are recommended, to reduce CVD mortality and morbidity.",I,C,19,policy interventions at the population level,CVD Prevention,2021,66
Aspirin 75 - 100 mg daily is recommended for patients with a previous myocardial infarction or revascularization.,I,A,20,patients with coronary artery disease,CVD Prevention,2021,68
"Aspirin 75 - 100 mg daily may be considered in patients without a history of myocardial infarction or revascularization, but with deﬁnitive evidence of CAD on imaging.",IIb,C,20,patients with coronary artery disease,CVD Prevention,2021,68
"In ACS, DAPT with a P2Y12 inhibitor in addition to aspirin is recommended for 12 months, unless there are contraindications such as excessive risk of bleeding.681",I,A,20,patients with coronary artery disease,CVD Prevention,2021,68
"In patients with CCS, clopidogrel 75 mg daily is recommended, in addition to aspirin, for 6 months following coronary stenting, irrespective of stent type, unless a shorter duration (1 - 3 months) is indicated due to risk or occurrence of life-threatening bleeding.",I,A,20,patients with coronary artery disease,CVD Prevention,2021,68
"Adding a second antithrombotic drug (a P2Y12 inhibitor or low-dose rivaroxaban) to aspirin for long-term secondary prevention should be considered in patients with a high risk of ischaemic events and without high bleeding risk.83,622,687",IIa,A,20,patients with coronary artery disease,CVD Prevention,2021,68
"ACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hypertension, or DM).",I,A,20,patients with coronary artery disease,CVD Prevention,2021,69
Beta-blockers are recommended in patients with LV dysfunction or systolic HF.,I,A,20,patients with coronary artery disease,CVD Prevention,2021,69
"In patients with established ASCVD, oral lipidlowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >_50% reduction in LDL-C vs. baseline is recommended.",I,A,20,patients with coronary artery disease,CVD Prevention,2021,69
"In patients with a cerebrovascular event, improvement of lifestyle factors in addition to appropriate pharmacological management is recommended.",I,A,21,patients with cerebrovascular disease,CVD Prevention,2021,71
"In patients with ischaemic stroke or TIA, prevention with antithrombotics is recommended; choice of antithrombotic depends on the mechanism of event. Use of an antiplatelet is recommended for patients with non-cardioembolic ischaemic stroke or TIA, and use of an anticoagulant is recommended in patients with cardioembolic ischaemic stroke or TIA.",I,A,21,patients with cerebrovascular disease,CVD Prevention,2021,71
"In patients with non-cardioembolic ischaemic stroke or TIA, prevention with aspirin only, or dipyridamole plus aspirin, or clopidogrel alone is recommended.620,743",I,A,21,patients with cerebrovascular disease,CVD Prevention,2021,71
"In patients with minor ischaemic strokec or TIA, DAPT with aspirin and clopidogrel or with aspirin and ticagrelor, for 3 weeks after the acute event should be considered.",IIa,A,21,patients with cerebrovascular disease,CVD Prevention,2021,71
"In patients with stroke or TIA who have BP of 140/90 mmHg or higher, BP lowering is recommended.",I,A,21,patients with cerebrovascular disease,CVD Prevention,2021,71
Smoking cessation is recommended in all patients with LEAD.,I,B,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
Healthy diet and PA are recommended for all patients with LEAD.,I,C,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
In patients with intermittent claudication:  Supervised exercise training is recommended782,I,A,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
 Non-supervised exercise training is recommended when supervised exercise training is not feasible or available.,I,C,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
Antiplatelet therapy is recommended in patients with symptomatic LEAD.c,I,C,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
"In patients with LEAD and hypertension, it is recommended to control BP at <140/90 mmHg.",I,A,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
"In patients with LEAD and DM, strict glycaemic control is recommended.",I,A,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
ACE inhibitors or ARBs should be considered as ﬁrst-line therapy in patients with PAD and hypertension.d,IIa,B,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
"In patients with DM and chronic symptomatic LEAD without high bleeding risk, a combination of low-dose rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) may be considered.",IIb,B,22,patients with lower extremity artery disease: best medical therapy,CVD Prevention,2021,71
Identiﬁcation and management of risk factors and concomitant diseases are recommended to be an integral part of treatment.,I,B,23,lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215,CVD Prevention,2021,73
"Modiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.216,795",I,B,23,lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215,CVD Prevention,2021,73
Attention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and bleeding.,I,B,23,lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215,CVD Prevention,2021,73
"In obese patients with AF, weight loss together with management of other risk factors should be considered to reduce AF incidence, AF progression, AF recurrences, and symptoms.795",IIa,B,23,lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215,CVD Prevention,2021,73
Advice and management to avoid alcohol excess should be considered for AF prevention and in AF patients considered for oral anticoagulant therapy.,IIa,B,23,lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215,CVD Prevention,2021,73
"PA should be considered to help prevent AF incidence or recurrence, with the exception of excessive endurance exercise, which may promote AF.805",IIa,C,23,lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215,CVD Prevention,2021,73
"Optimal management of OSA may be considered to reduce AF incidence, AF progression, AF recurrences, and symptoms.813",IIb,C,23,lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215,CVD Prevention,2021,73
"Once carotid stenosis is ruled out,c CSM is recommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area.68",I,B,1,non-invasive evaluation,Cardiac Pacing CRT,2021,18
"Exercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after exertion.62,74",I,C,2,exercise testing,Cardiac Pacing CRT,2021,19
"In patients with suspected chronotropic incompetence, exercise testing should be considered to conﬁrm the diagnosis.",IIa,B,2,exercise testing,Cardiac Pacing CRT,2021,19
"In patients with intraventricular conduction disease or AVB of unknown level, exercise testing may be considered to expose infranodal block.",IIb,C,2,exercise testing,Cardiac Pacing CRT,2021,19
"In addition to pre-implantation laboratory tests,c speciﬁc laboratory tests are recommended in patients with clinical suspicion for potential underlying causes of reversible bradycardia (e.g. thyroid function tests, Lyme titre, digitalis level, potassium, calcium, and pH) to diagnose and treat these conditions.90",I,C,3,laboratory tests,Cardiac Pacing CRT,2021,20
Genetic testing should be considered in patients with early onset (age <50 years) of progressive cardiac conduction disease.c,IIa,C,4,genetic testing,Cardiac Pacing CRT,2021,21
Genetic testing should be considered in family members following the identiﬁcation of a pathogenic genetic variant that explains the clinical phenotype of cardiac conduction disease in an index case.,IIa,C,4,genetic testing,Cardiac Pacing CRT,2021,21
"In patients with syncope and bifascicular block, EPS should be considered when syncope remains unexplained after non-invasive evaluation or when an immediate decision about pacing is needed due to severity, unless empirical pacemaker implantation is preferred (especially in elderly and frail patients).115",IIa,B,5,electrophysiology study,Cardiac Pacing CRT,2021,23
"In patients with syncope and sinus bradycardia, EPS may be considered when non-invasive tests have failed to show a correlation between syncope and bradycardia.",IIb,B,5,electrophysiology study,Cardiac Pacing CRT,2021,23
"In patients with SND and a DDD pacemaker, minimization of unnecessary ventricular pacing through programming is recommended.144,151,159,164,166",I,A,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"Pacing is indicated in SND when symptoms can clearly be attributed to bradyarrhythmias.14,128",I,B,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"Pacing is indicated in symptomatic patients with the bradycardiatachycardia form of SND in order to correct bradyarrhythmias and enable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred.17,20,21,136",I,B,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"In patients who present chronotropic incompetence and have clear symptoms during exercise, DDD with rate-responsive pacing should be considered.",IIa,B,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"AF ablation should be considered as a strategy to avoid pacemaker implantation in patients with AF-related bradycardia or symptomatic preautomaticity pauses, after AF conversion, taking into account the clinical situation.136",IIa,C,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"In patients with the bradycardiatachycardia variant of SND, programming of atrial ATP may be considered.",IIb,B,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"In patients with syncope, cardiac pacing may be considered to reduce recurrent syncope when asymptomatic pause(s) >6 s due to sinus arrest is documented.",IIb,C,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"Pacing may be considered in SND when symptoms are likely to be due to bradyarrhythmias, when the evidence is not conclusive.",IIb,C,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
Pacing is not recommended in patients with bradyarrhythmias related to SND that are asymptomatic or due to transient causes that can be corrected and prevented.,III,C,6,pacing in sinus node dysfunction,Cardiac Pacing CRT,2021,26
"Pacing is indicated in patients in SR with permanent or paroxysmal third- or second-degree type 2, infranodal 2:1, or high-degree AVB, irrespective of symptoms.c 9",I,C,7,pacing for atrioventricular block,Cardiac Pacing CRT,2021,27
Pacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB irrespective of symptoms.,I,C,7,pacing for atrioventricular block,Cardiac Pacing CRT,2021,27
"In patients with permanent AF in need of a pacemaker, ventricular pacing with rate response function is recommended.201",I,C,7,pacing for atrioventricular block,Cardiac Pacing CRT,2021,27
Pacing should be considered in patients with second-degree type 1 AVB that causes symptoms or is found to be located at intra- or infra-His levels at EPS.177,IIa,C,7,pacing for atrioventricular block,Cardiac Pacing CRT,2021,27
"In patients with AVB, DDD should be preferred over single-chamber ventricular pacing to avoid pacemaker syndrome and to improve quality of life.",IIa,A,7,pacing for atrioventricular block,Cardiac Pacing CRT,2021,27
Permanent pacemaker implantation should be considered for patients with persistent symptoms similar to those of pacemaker syndrome and clearly attributable to ﬁrst-degree AVB (PR >0.3 s).205,IIa,C,7,pacing for atrioventricular block,Cardiac Pacing CRT,2021,27
Pacing is not recommended in patients with AVB due to transient causes that can be corrected and prevented.,III,C,7,pacing for atrioventricular block,Cardiac Pacing CRT,2021,27
"In patients with unexplained syncope and bifascicular block, a pacemaker is indicated in the presence of either a baseline HV of >_70 ms, second- or third-degree intra- or infra-Hisian block during incremental atrial pacing, or an abnormal response to pharmacological challenge.",I,B,8,pacing in patients with bundle branch block,Cardiac Pacing CRT,2021,29
Pacing is indicated in patients with alternating BBB with or without symptoms.,I,C,8,pacing in patients with bundle branch block,Cardiac Pacing CRT,2021,29
"Pacing may be considered in selected patients with unexplained syncope and bifascicular block without EPS (elderly, frail patients, high-risk and/ or recurrent syncope).",IIb,B,8,pacing in patients with bundle branch block,Cardiac Pacing CRT,2021,29
Pacing is not recommended for asymptomatic BBB or bifascicular block.,III,B,8,pacing in patients with bundle branch block,Cardiac Pacing CRT,2021,29
"Dual-chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40 years, with severe, unpredictable, recurrent syncope who have: • spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest or AVB; or • cardioinhibitory carotid sinus syndrome; or • asystolic syncope during tilt testing.",I,A,9,pacing for reﬂex syncope,Cardiac Pacing CRT,2021,32
Dual-chamber cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensitive syncope.,IIb,B,9,pacing for reﬂex syncope,Cardiac Pacing CRT,2021,32
Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reﬂex.,III,B,9,pacing for reﬂex syncope,Cardiac Pacing CRT,2021,32
"In patients with recurrent unexplained falls, the same assessment as for unexplained syncope should be considered.",IIa,C,10,cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls,Cardiac Pacing CRT,2021,32
Pacing is not recommended in patients with unexplained falls in the absence of any other documented indication.,III,B,10,cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls,Cardiac Pacing CRT,2021,32
Pacing is not recommended in patients with unexplained syncope without evidence of SND or conduction disturbance.,III,C,10,cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls,Cardiac Pacing CRT,2021,32
"LBBB QRS morphology CRT is recommended for symptomatic patients with HF in SR with LVEF <_35%, QRS duration >_150 ms, and LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity and mortality.37,39,40,254",I,A,11,cardiac resynchronization therapy in patients in sinus rhythm,Cardiac Pacing CRT,2021,34
"CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS duration 130149 ms, and LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity and mortality.37,39,40,254",IIa,B,11,cardiac resynchronization therapy in patients in sinus rhythm,Cardiac Pacing CRT,2021,34
"Non-LBBB QRS morphology CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS duration >_150 ms, and non-LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity.37,39,40,254",IIa,B,11,cardiac resynchronization therapy in patients in sinus rhythm,Cardiac Pacing CRT,2021,34
"CRT may be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS duration 130149 ms, and non-LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity.273",IIb,B,11,cardiac resynchronization therapy in patients in sinus rhythm,Cardiac Pacing CRT,2021,34
QRS duration CRT is not indicated in patients with HF and QRS duration <130 ms without an indication for RV pacing.,III,A,11,cardiac resynchronization therapy in patients in sinus rhythm,Cardiac Pacing CRT,2021,34
"ﬁbrillation 1) In patients with HF with permanent AF who are candidates for CRT: 1A) CRT should be considered for patients with HF and LVEF <_35% in NYHA class III or IV despite OMT if they are in AF and have intrinsic QRS >_130 ms, provided a strategy to ensure biventricular capture is in place, in order to improve symptoms and reduce morbidity and mortality.",IIa,C,12,cardiac resynchronization therapy in patients with persistent or permanent atrial,Cardiac Pacing CRT,2021,37
1B) AVJ ablation should be added in the case of incomplete biventricular pacing (<9095%) due to conducted AF.297,IIa,B,12,cardiac resynchronization therapy in patients with persistent or permanent atrial,Cardiac Pacing CRT,2021,37
2) In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ ablation (irrespective of QRS duration): 2A) CRT is recommended in patients with HFrEF.,I,B,12,cardiac resynchronization therapy in patients with persistent or permanent atrial,Cardiac Pacing CRT,2021,37
2B) CRT rather than standard RV pacing should be considered in patients with HFmrEF.,IIa,C,12,cardiac resynchronization therapy in patients with persistent or permanent atrial,Cardiac Pacing CRT,2021,37
2C) RV pacing should be considered in patients with HFpEF.,IIa,B,12,cardiac resynchronization therapy in patients with persistent or permanent atrial,Cardiac Pacing CRT,2021,37
2D) CRT may be considered in patients with HFpEF.,IIb,C,12,cardiac resynchronization therapy in patients with persistent or permanent atrial,Cardiac Pacing CRT,2021,37
"In patients who are candidates for an ICD and who have CRT indication, implantation of a CRT-D is recommended.",I,A,13,adding a deﬁbrillator with cardiac resynchronization therapy,Cardiac Pacing CRT,2021,39
"In patients who are candidates for CRT, implantation of a CRT-D should be considered after individual risk assessment and using shared decision-making.",IIa,B,13,adding a deﬁbrillator with cardiac resynchronization therapy,Cardiac Pacing CRT,2021,39
"In patients treated with HBP, device programming tailored to speciﬁc requirements of HBP is recommended.",I,C,14,using His bundle pacing,Cardiac Pacing CRT,2021,43
"In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered as a treatment option along with other techniques such as surgical epicardial lead.",IIa,B,14,using His bundle pacing,Cardiac Pacing CRT,2021,43
"In patients treated with HBP, implantation of an RV lead used as ‘backup’ for pacing should be considered in speciﬁc situations (e.g. pacemaker dependency, high-grade AVB, infranodal block, high pacing threshold, planned AVJ ablation) or for sensing in the case of issues with detection (e.g. risk of ventricular undersensing or oversensing of atrial/His potentials).",IIa,C,14,using His bundle pacing,Cardiac Pacing CRT,2021,43
"HBP with a ventricular backup lead may be considered in patients in whom a ‘pace-and-ablate’ strategy for rapidly conducted supraventricular arrhythmia is indicated, particularly when the intrinsic QRS is narrow.",IIb,C,14,using His bundle pacing,Cardiac Pacing CRT,2021,43
"Leadless pacemakers should be considered as an alternative to transvenous pacemakers when no upper extremity venous access exists or when risk of device pocket infection is particularly high, such as previous infection and patients on haemodialysis.45,47",IIa,B,15,using leadless pacing (leadless pacemaker),Cardiac Pacing CRT,2021,44
"Leadless pacemakers may be considered as an alternative to standard single-lead ventricular pacing, taking into consideration life expectancy and using shared decision-making.45,47",IIb,C,15,using leadless pacing (leadless pacemaker),Cardiac Pacing CRT,2021,44
Implantation of a permanent pacemaker is indicated with the same recommendations as in a general population (section 5.2) when AVB does not resolve within a waiting period of at least 5 days after MI.,I,C,16,cardiac pacing after acute myocardial infarction,Cardiac Pacing CRT,2021,44
"In selected patients with AVB in the context of anterior wall MI and acute HF, early device implantation (CRT-D/CRT-P) may be considered.",IIb,C,16,cardiac pacing after acute myocardial infarction,Cardiac Pacing CRT,2021,44
Pacing is not recommended if AVB resolves after revascularization or spontaneously.454,III,B,16,cardiac pacing after acute myocardial infarction,Cardiac Pacing CRT,2021,44
"1) High-degree or complete AVB after cardiac surgery A period of clinical observation of at least 5 days is indicated to assess whether the rhythm disturbance is transient and resolves. However, in the case of complete AVB with low or no escape rhythm when resolution is unlikely, this observation period can be shortened.",I,C,17,cardiac pacing after cardiac surgery and heart transplantation,Cardiac Pacing CRT,2021,46
"2) Surgery for valvular endocarditis and intraoperative complete AVB Immediate epicardial pacemaker implantation should be considered in patients with surgery for valvular endocarditis and complete AVB if one of the following predictors of persistence is present: pre-operative conduction abnormality, Staphylococcus aureus infection, intracardiac abscess, tricuspid valve involvement, or previous valvular surgery.",IIa,C,17,cardiac pacing after cardiac surgery and heart transplantation,Cardiac Pacing CRT,2021,46
"3) SND after cardiac surgery and heart transplantation Before permanent pacemaker implantation, a period of observation of up to 6 weeks should be considered.",IIa,C,17,cardiac pacing after cardiac surgery and heart transplantation,Cardiac Pacing CRT,2021,46
4) Chronotropic incompetence after heart transplantation Cardiac pacing should be considered for chronotropic incompetence persisting for >6 weeks after heart transplantation to improve quality of life.,IIa,C,17,cardiac pacing after cardiac surgery and heart transplantation,Cardiac Pacing CRT,2021,46
"5) Patients requiring pacing at the time of tricuspid valve surgery Transvalvular leads should be avoided and epicardial ventricular leads used. During tricuspid valve surgery, removal of pre-existing transvalvular leads should be considered and preferred over sewing in the lead between the annulus and a bioprosthesis or annuloplasty ring. In the case of an isolated tricuspid annuloplasty based on an individual riskbeneﬁt analysis, a preexisting RV lead may be left in place without jailing it between ring and annulus.",IIa,C,17,cardiac pacing after cardiac surgery and heart transplantation,Cardiac Pacing CRT,2021,46
"6) Patients requiring pacing after biological tricuspid valve replacement/tricuspid valve ring repair When ventricular pacing is indicated, transvenous implantation of a coronary sinus lead or minimally invasive placement of an epicardial ventricular lead should be considered and preferred over a transvenous transvalvular approach.",IIa,C,17,cardiac pacing after cardiac surgery and heart transplantation,Cardiac Pacing CRT,2021,46
CMR CMR is recommended for the assessment of myocardial structure and function in those with poor echocardiogram acoustic windows.,I,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
"CMR is recommended for the characterization of myocardial tissue in suspected inﬁltrative disease, Fabry disease, inﬂammatory disease (myocarditis), LV non-compaction, amyloid, sarcoidosis, iron overload/haemochromatosis.",I,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
CMR with LGE should be considered in DCM to distinguish between ischaemic and non-ischaemic myocardial damage.,IIa,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Invasive coronary angiography (in those who are considered eligible for potential coronary revascularization) Invasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.,I,B,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Invasive coronary angiography may be considered in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests.,IIb,B,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Non-invasive testing CTCA should be considered in patients with a low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.,IIa,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
"Non-invasive stress imaging (CMR, stress echocardiography, SPECT, PET) may be considered for the assessment of myocardial ischaemia and viability in patients with CAD who are considered suitable for coronary revascularization.90",IIb,B,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Exercise testing may be considered to detect reversible myocardial ischaemia and investigate the cause of dyspnoea.94,IIb,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Cardiopulmonary exercise testing Cardiopulmonary exercise testing is recommended as a part of the evaluation for heart transplantation and/or MCS.94,I,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Cardiopulmonary exercise testing should be considered to optimize prescription of exercise training.94,IIa,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Cardiopulmonary exercise testing should be considered to identify the cause of unexplained dyspnoea and/or exercise intolerance.94,IIa,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
Right heart catheterization Right heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or MCS.,I,C,1,specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure,Heart Failure,2021,20
"Secondary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.162",I,A,2,an implantable cardioverterdeﬁbrillator in patients with heart failure,Heart Failure,2021,27
"Primary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class IIIII) of an ischaemic aetiology (unless they have had a MI in the prior 40 days—see below), and an LVEF <_35% despite >_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.",I,A,2,an implantable cardioverterdeﬁbrillator in patients with heart failure,Heart Failure,2021,27
"An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class IIIII) of a non-ischaemic aetiology, and an LVEF <_35% despite >_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.",IIa,A,2,an implantable cardioverterdeﬁbrillator in patients with heart failure,Heart Failure,2021,27
"Patients should be carefully evaluated by an experienced cardiologist before generator replacement, because management goals, the patient’s needs and clinical status may have changed.168",IIa,B,2,an implantable cardioverterdeﬁbrillator in patients with heart failure,Heart Failure,2021,27
A wearable ICD may be considered for patients with HF who are at risk of sudden cardiac death for a limited period or as a bridge to an implanted device.173,IIb,B,2,an implantable cardioverterdeﬁbrillator in patients with heart failure,Heart Failure,2021,27
ICD implantation is not recommended within 40 days of a MI as implantation at this time does not improve prognosis.,III,A,2,an implantable cardioverterdeﬁbrillator in patients with heart failure,Heart Failure,2021,27
"ICD therapy is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a VAD, or cardiac transplantation.179",III,C,2,an implantable cardioverterdeﬁbrillator in patients with heart failure,Heart Failure,2021,27
CRT is recommended for symptomatic patients with HF in SR with a QRS duration >_150 ms and LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.205,I,A,3,cardiac resynchronization therapy implantation in patients with heart failure,Heart Failure,2021,29
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with AF.216,I,A,3,cardiac resynchronization therapy implantation in patients with heart failure,Heart Failure,2021,29
CRT should be considered for symptomatic patients with HF in SR with a QRS duration >_150 ms and non-LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.205,IIa,B,3,cardiac resynchronization therapy implantation in patients with heart failure,Heart Failure,2021,29
CRT should be considered for symptomatic patients with HF in SR with a QRS duration of 130149 ms and LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.,IIa,B,3,cardiac resynchronization therapy implantation in patients with heart failure,Heart Failure,2021,29
Patients with an LVEF <_35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a signiﬁcant proportion of RV pacing should be considered for ‘upgrade’ to CRT.,IIa,B,3,cardiac resynchronization therapy implantation in patients with heart failure,Heart Failure,2021,29
CRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high degree AV block.222,III,A,3,cardiac resynchronization therapy implantation in patients with heart failure,Heart Failure,2021,29
"Screening for, and treatment of, aetiologies, and cardiovascular and non-cardiovascular comorbidities is recommended in patients with HFpEF (see relevant sections of this document).",I,C,4,the treatment of patients with heart failure with preserved ejection fraction,Heart Failure,2021,34
Diuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs.,I,C,4,the treatment of patients with heart failure with preserved ejection fraction,Heart Failure,2021,34
"Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations.287",I,A,5,the primary prevention of heart failure in patients with risk factors for its development,Heart Failure,2021,34
"Treatment with statins is recommended in patients at high risk of CV disease or with CV disease in order to prevent or delay the onset of HF, and to prevent HF hospitalizations.",I,A,5,the primary prevention of heart failure in patients with risk factors for its development,Heart Failure,2021,34
"SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with diabetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations.293",I,A,5,the primary prevention of heart failure in patients with risk factors for its development,Heart Failure,2021,34
"Counselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the onset of HF.298",I,C,5,the primary prevention of heart failure in patients with risk factors for its development,Heart Failure,2021,34
"Exercise is recommended for all patients who are able in order to improve exercise capacity, QOL, and reduce HF hospitalization.c 324328,335",I,A,6,exercise rehabilitation in patients with chronic heart failure,Heart Failure,2021,38
"A supervised, exercise-based, cardiac rehabilitation programme should be considered in patients with more severe disease, frailty, or with comorbidities.95,324",IIa,C,6,exercise rehabilitation in patients with chronic heart failure,Heart Failure,2021,38
Non-invasive HTM may be considered for patients with HF in order to reduce the risk of recurrent CV and HF hospitalizations and CV death.,IIb,B,7,telemonitoring,Heart Failure,2021,39
Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF in order to improve clinical outcomes.,IIb,B,7,telemonitoring,Heart Failure,2021,39
"Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.414",I,C,8,the treatment of patients with advanced heart failure,Heart Failure,2021,45
"Heart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not have absolute contraindications.",I,C,8,the treatment of patients with advanced heart failure,Heart Failure,2021,45
"Long-term MCS should be considered in patients with advanced HFrEF despite optimal medical and device therapy, not eligible for heart transplantation or other surgical options, and without severe right ventricular dysfunction, to reduce the risk of death and improve symptoms.",IIa,A,8,the treatment of patients with advanced heart failure,Heart Failure,2021,45
"Long-term MCS should be considered in patients with advanced HFrEF refractory to optimal medical and device therapy as a bridge to cardiac transplantation in order to improve symptoms, reduce the risk of HF hospitalization and the risk of premature death.398",IIa,B,8,the treatment of patients with advanced heart failure,Heart Failure,2021,45
Renal replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure.,IIa,C,8,the treatment of patients with advanced heart failure,Heart Failure,2021,45
Continuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypoperfusion as bridge to MCS or heart transplantation.,IIb,C,8,the treatment of patients with advanced heart failure,Heart Failure,2021,45
Ultraﬁltration may be considered in refractory volume overload unresponsive to diuretic treatment.,IIb,C,8,the treatment of patients with advanced heart failure,Heart Failure,2021,45
Oxygen and ventilatory support Oxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia.,I,C,9,the initial treatment of acute heart failure,Heart Failure,2021,57
Intubation is recommended for progressive respiratory failure persisting in spite of oxygen administration or non-invasive ventilation.,I,C,9,the initial treatment of acute heart failure,Heart Failure,2021,57
"Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2 <90%) and started as soon as possible in order to decrease respiratory distress and reduce the rate of mechanical endotracheal intubation.",IIa,B,9,the initial treatment of acute heart failure,Heart Failure,2021,57
Diuretics Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of ﬂuid overload to improve symptoms.,I,C,9,the initial treatment of acute heart failure,Heart Failure,2021,57
Combination of a loop diuretic with thiazidetype diuretic should be considered in patients with resistant oedema who do not respond to an increase in loop diuretic doses.,IIa,B,9,the initial treatment of acute heart failure,Heart Failure,2021,57
"Vasodilators In patients with AHF and SBP >110 mmHg, i.v. vasodilators may be considered as initial therapy to improve symptoms and reduce congestion.475",IIb,B,9,the initial treatment of acute heart failure,Heart Failure,2021,57
"Inotropic agents are not recommended routinely, due to safety concerns, unless the patient has symptomatic hypotension and evidence of hypoperfusion.",III,C,9,the initial treatment of acute heart failure,Heart Failure,2021,58
"Vasopressors A vasopressor, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ perfusion.485",IIb,B,9,the initial treatment of acute heart failure,Heart Failure,2021,58
"Other drugs Thromboembolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contraindication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.",I,A,9,the initial treatment of acute heart failure,Heart Failure,2021,58
"Routine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety.",III,C,9,the initial treatment of acute heart failure,Heart Failure,2021,58
"Short-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD, BTB. Further indications include treatment of the cause of cardiogenic shock or long-term MCS or transplantation.",IIa,C,10,the use of short-term mechanical circulatory support in patients with cardiogenic shock,Heart Failure,2021,58
"IABP may be considered in patients with cardiogenic shock as a BTR, BTD, BTB, including treatment of the cause of cardiogenic shock (i.e. mechanical complication of acute MI) or longterm MCS or transplantation.",IIb,C,10,the use of short-term mechanical circulatory support in patients with cardiogenic shock,Heart Failure,2021,58
IABP is not routinely recommended in post-MI cardiogenic shock.500,III,B,10,the use of short-term mechanical circulatory support in patients with cardiogenic shock,Heart Failure,2021,58
It is recommended that patients hospitalized for HF be carefully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment.,I,C,11,pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure,Heart Failure,2021,59
It is recommended that evidence-based oral medical treatment be administered before discharge.,I,C,11,pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure,Heart Failure,2021,59
"An early follow-up visit is recommended at 12 weeks after discharge to assess signs of congestion, drug tolerance and start and/or uptitrate evidence-based therapy.",I,C,11,pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure,Heart Failure,2021,59
"Ferric carboxymaltose should be considered for iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100299 ng/mL with TSAT <20%, to improve symptoms and reduce rehospitalizations.",IIa,B,11,pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure,Heart Failure,2021,59
"Anticoagulation Long-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and CHA2DS2-VASc score >_2 in men or >_3 in women.",I,A,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
"DOACs are recommended in preference to VKAs in patients with HF, except in those with moderate or severe mitral stenosis or mechanical prosthetic heart valves.",I,A,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
Long-term treatment with an oral anticoagulant should be considered for stroke prevention in AF patients with a CHA2DS2-VASc score of 1 in men or 2 in women.,IIa,B,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
Rate control Beta-blockers should be considered for shortand long-term rate control in patients with HF and AF.,IIa,B,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
"Digoxin should be considered when the ventricular rate remains high, despite beta-blockers, or when beta-blockers are contraindicated or not tolerated.",IIa,C,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
Cardioversion Urgent ECV is recommended in the setting of acute worsening of HF in patients presenting with rapid ventricular rates and haemodynamic instability.,I,C,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
Cardioversion may be considered in patients in whom there is an association between AF and worsening of HF symptoms despite optimal medical treatment.,IIb,B,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
"AF catheter ablation In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite MT, catheter ablation should be considered for the prevention or treatment of AF.552",IIa,B,12,the treatment of atrial ﬁbrillation in patients with heart failure,Heart Failure,2021,62
"CABG should be considered as the ﬁrst-choice revascularization strategy, in patients suitable for surgery, especially if they have diabetes and for those with multivessel disease.",IIa,B,13,myocardial revascularization in patients with heart failure with reduced ejection fraction,Heart Failure,2021,64
"Coronary revascularization should be considered to relieve persistent symptoms of angina (or an angina-equivalent) in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, despite OMT including anti-anginal drugs.",IIa,C,13,myocardial revascularization in patients with heart failure with reduced ejection fraction,Heart Failure,2021,64
"In LVAD candidates needing coronary revascularization, CABG should be avoided, if possible.",IIa,C,13,myocardial revascularization in patients with heart failure with reduced ejection fraction,Heart Failure,2021,64
"Coronary revascularization may be considered to improve outcomes in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, after careful evaluation of the individual risk to beneﬁt ratio, including coronary anatomy (i.e. proximal stenosis >90% of large vessels, stenosis of left main or proximal LAD), comorbidities, life expectancy, and patient’s perspectives.",IIb,C,13,myocardial revascularization in patients with heart failure with reduced ejection fraction,Heart Failure,2021,64
"PCI may be considered as an alternative to CABG, based on Heart Team evaluation, considering coronary anatomy, comorbidities, and surgical risk.",IIb,C,13,myocardial revascularization in patients with heart failure with reduced ejection fraction,Heart Failure,2021,64
"Aortic stenosis Aortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe highgradient aortic stenosis to reduce mortality and improve symptoms.",I,B,14,the management of valvular heart disease in patients with heart failure,Heart Failure,2021,67
"It is recommended that the choice between TAVI and SAVR be made by the Heart Team, according to individual patient preference and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and beneﬁts of each approach.",I,C,14,the management of valvular heart disease in patients with heart failure,Heart Failure,2021,67
"Secondary mitral regurgitation Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomaticc despite OMT and who fulﬁl criteriad for achieving a reduction in HF hospitalizations.",IIa,B,14,the management of valvular heart disease in patients with heart failure,Heart Failure,2021,67
"In patients with HF, severe secondary mitral regurgitation and CAD who need revascularization, CABG and mitral valve surgery should be considered.",IIa,C,14,the management of valvular heart disease in patients with heart failure,Heart Failure,2021,67
"Percutaneous edge-to-edge mitral valve repair may be considered to improve symptoms in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, highly symptomatic despite OMT and who do not fulﬁl criteria for reducing HF hospitalization.",IIb,C,14,the management of valvular heart disease in patients with heart failure,Heart Failure,2021,67
"Recommendation SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with T2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.293",I,A,15,the treatment of diabetes in heart failure,Heart Failure,2021,69
"SGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.",I,A,15,the treatment of diabetes in heart failure,Heart Failure,2021,69
"It is recommended that all patients with HF be periodically screened for anaemia and iron deﬁciency with a full blood count, serum ferritin concentration, and TSAT.",I,C,16,the management of anaemia and iron deﬁciency in patients with heart failure,Heart Failure,2021,71
"Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic patients with LVEF <45% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100299 ng/mL with TSAT <20%, to alleviate HF symptoms, improve exercise capacity and QOL.",IIa,A,16,the management of anaemia and iron deﬁciency in patients with heart failure,Heart Failure,2021,71
"Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic HF patients recently hospitalized for HF and with LVEF <50% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100299 ng/mL with TSAT <20%, to reduce the risk of HF hospitalization.",IIa,B,16,the management of anaemia and iron deﬁciency in patients with heart failure,Heart Failure,2021,71
"Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.",I,B,17,the treatment of transthyretin amyloidosis-cardiac amyloidosis,Heart Failure,2021,88
"Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.",I,B,17,the treatment of transthyretin amyloidosis-cardiac amyloidosis,Heart Failure,2021,88
"VHD are provided below and are detailed in specific sections (section 5 and section 6.2) of this guideline document, as well as in other dedicated guideline documents.45,46,72,73 Recommendations for management of CAD in patients with VHD. Diagnosis of CAD Coronary angiography is recommended before valve surgery in patients with severe VHD and any of the following: • History of cardiovascular disease. • Suspected myocardial ischaemia.c • LV systolic dysfunction. • In men >40 years of age and postmenopausal women. • One or more cardiovascular risk factors.",I,C,1,the management of CAD associated with,Valvular Heart Disease,2021,16
Coronary CT angiography should be considered as an alternative to coronary angiography before valve surgery in patients with severe VHD and low probability of CAD.d,IIa,C,1,the management of CAD associated with,Valvular Heart Disease,2021,17
"Indications for myocardial revascularization CABG is recommended in patients with a primary indication for aortic/mitral/tricuspid valve surgery and coronary artery diameter stenosis >_70%.e,f",I,C,1,the management of CAD associated with,Valvular Heart Disease,2021,17
CABG should be considered in patients with a primary indication for aortic/mitral/tricuspid valve surgery and coronary artery diameter stenosis >_5070%.,IIa,C,1,the management of CAD associated with,Valvular Heart Disease,2021,17
PCI should be considered in patients with a primary indication to undergo TAVI and coronary artery diameter stenosis >70% in proximal segments.,IIa,C,1,the management of CAD associated with,Valvular Heart Disease,2021,17
PCI should be considered in patients with a primary indication to undergo transcatheter mitral valve intervention and coronary artery diameter stenosis >70% in proximal segments.,IIa,C,1,the management of CAD associated with,Valvular Heart Disease,2021,17
Mechanical prostheses A mechanical prosthesis is recommended according to the desire of the informed patient and if there are no contraindications to longterm anticoagulation.c,I,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A mechanical prosthesis is recommended in patients at risk of accelerated SVD.d,I,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A mechanical prosthesis should be considered in patients already on anticoagulation because of a mechanical prosthesis in another valve position.,IIa,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A mechanical prosthesis should be considered in patients with a reasonable life expectancy for whom future redo valve surgery or TAVI (if appropriate) would be at high risk.f,IIa,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A mechanical prosthesis may be considered in patients already on long-term anticoagulation due to the high risk for thromboembolism.f,IIb,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
Biological prostheses A bioprosthesis is recommended according to the desire of the informed patient.,I,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
"A bioprosthesis is recommended when goodquality anticoagulation is unlikely (adherence problems, not readily available), contraindicated because of high bleeding risk (previous major bleed, comorbidities, unwillingness, adherence problems, lifestyle, occupation) and in those patients whose life expectancy is lower than the presumed durability of the bioprosthesis.g",I,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A bioprosthesis is recommended in case of reoperation for mechanical valve thrombosis despite good long-term anticoagulant control.,I,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A bioprosthesis should be considered in patients for whom there is a low likelihood and/or a low operative risk of future redo valve surgery.,IIa,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A bioprosthesis should be considered in young women contemplating pregnancy.,IIa,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A bioprosthesis should be considered in patients aged >65 years for a prosthesis in the aortic position or aged >70 years in a mitral position.,IIa,C,2,prosthetic valve selection,Valvular Heart Disease,2021,40
A bioprosthesis may be considered in patients already on long-term NOACs due to the high risk for thromboembolism.466469 f,IIb,B,2,prosthetic valve selection,Valvular Heart Disease,2021,40
Management of antithrombotic therapy in the perioperative period It is recommended that VKAs are timely dis,I,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,42
"Bridging of OAC, when interruption is needed, is recommended in patients with any of the following indications: • Mechanical prosthetic heart valve. • AF with signiﬁcant mitral stenosis. • AF with a CHA2DS2-VASc score >_3 for women or 2 for men.d • Acute thrombotic event within the previous 4 weeks. • High acute thromboembolic risk.e",I,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,42
Therapeutic doses of either UFH or subcutaneous LMWH are recommended for bridging.,I,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,42
"In patients with MHVs, it is recommended to (re)- initiate the VKA on the ﬁrst postoperative day.",I,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,42
"In patients undergoing surgery, it is recommended that aspirin therapy, if indicated, is maintained during the periprocedural period.",I,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"In patients treated with DAPT after recent PCI (within 1 month) who need to undergo heart valve surgery in the absence of an indication for OAC, it is recommended to resume the P2Y12 inhibitor postoperatively, as soon as there is no concern over bleeding.",I,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"In patients treated with DAPT after recent PCI (within 1 month) who need to undergo heart valve surgery in the absence of an indication for OAC, bridging P2Y12 inhibitors with short-acting glycoprotein IIb/IIIa inhibitors or cangrelor may be considered.",IIb,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"Patients with an indication to concomitant antiplatelet therapy After uncomplicated PCI or ACS in patients requiring long-term OAC, early cessation (<_1 week) of aspirin and continuation of dual therapy with OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 6 months (or up to 12 months in ACS) is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis, irrespective of the type of stent used.505",I,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.74,510",I,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"After uncomplicated PCI or ACS in patients requiring both OAC and antiplatelet therapy, triple therapy with aspirin, clopidogrel and OAC for longer than 1 week should be considered when the risk of stent thrombosis outweighs the risk of bleeding, with the total duration (<_1 month) decided according to assessment of these risks and clearly speciﬁed at hospital discharge.",IIa,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"In patients treated with a VKA (e.g. MHVs), clopidogrel alone should be considered in selected patients (e.g. HAS-BLED >_3 or ARC-HBR met and low risk of stent thrombosis) for up to 12 months.",IIa,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"In patients requiring aspirin and/or clopidogrel in addition to VKA, the dose intensity of VKA should be considered and carefully regulated with a target INR in the lower part of the recommended target range and a time in the therapeutic range >6570%.",IIa,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
Surgical valve replacement OAC using a VKA is recommended lifelong for all patients with an MHV prosthesis.,I,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
OAC is recommended for patients undergoing implantation of a surgical BHV who have other indications for anticoagulation.f,I,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"NOACs should be considered over VKA after 3 months following surgical implantation of a BHV in patients with AF.74,499,500,515",IIa,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"In patients with no baseline indications for OAC, low-dose aspirin (75100 mg/day) or OAC using a VKA should be considered for the ﬁrst 3 months after surgical implantation of an aortic BHV.",IIa,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
"In patients with no baseline indications for OAC, OAC using a VKA should be considered for the ﬁrst 3 months after surgical implantation of a bioprosthesis in the mitral or tricuspid position.",IIa,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
The addition of low-dose aspirin (75100 mg/ day) to VKA may be considered in selected patients with MHVs in case of concomitant atherosclerotic disease and low risk of bleeding.,IIb,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
The addition of low-dose aspirin (75100 mg/ day) to VKA should be considered after thromboembolism despite an adequate INR.,IIa,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
NOACs may be considered over VKA within 3 months following surgical implantation of a BHV in mitral position in patients with AF.,IIb,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
NOACs are not recommended in patients with a mechanical valve prosthesis.,III,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
Surgical valve repair OAC with VKA should be considered during the ﬁrst 3 months after mitral and tricuspid repair.,IIa,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
SAPT with low-dose ASA (75100 mg/day) should be considered for the ﬁrst 3 months after valve-sparing aortic surgery when there are no other baseline indications to OAC.,IIa,C,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
Transcatheter aortic valve implantation OAC is recommended lifelong for TAVI patients who have other indications for OAC.501 f,I,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
Lifelong SAPT is recommended after TAVI in patients with no baseline indication for OAC.,I,A,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
Routine use OAC is not recommended after TAVI in patients with no baseline indication for OAC.,III,B,3,management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods,Valvular Heart Disease,2021,43
CV toxicity risk stratiﬁcationc before starting potentially cardiotoxic anticancer therapy is recommended in all patients with cancer.,I,B,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
Communicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is recommended.,I,C,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
The use of HFA-ICOS risk assessment should be considered to stratify CV toxicity risk in patients with cancer scheduled to receive cardiotoxic anticancer therapy.,IIa,C,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
It is recommended that patients categorized to be at low CV toxicity risk should proceed to anticancer therapy without delay.,I,C,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
"In patients categorized at moderate CV toxicity risk, cardiology referrald may be considered.e",IIb,C,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
Cardiology referrald is recommended in high-risk and very high-risk patients before anticancer therapy.f,I,C,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
Discussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary approach prior to starting treatment is recommended.,I,C,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
Cardiology referrald is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk assessmentg who require potentially cardiotoxic anticancer therapy.,I,C,1,Recommendations for a general approach to cardiovascular toxicity risk categorization,Cardio Oncology,2022,21
An ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment.,I,C,2,Recommendations for electrocardiogram baseline assessment,Cardio Oncology,2022,23
"In patients with an abnormal baseline ECG,c referral to a cardiologistd is recommended.",I,C,2,Recommendations for electrocardiogram baseline assessment,Cardio Oncology,2022,23
Recommendation Baseline measurement of NPc and/or cTnd is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to be measured during treatment to detect CTRCD.e,I,C,3,Recommendation for cardiac biomarker assessment prior to potentially cardiotoxic therapies,Cardio Oncology,2022,24
General Echocardiography is recommended as the ﬁrst-line modality for the assessment of cardiac function in patients with cancer.,I,C,4,Recommendations for cardiac imaging modalities in patients with cancer,Cardio Oncology,2022,25
3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF.77–,I,B,4,Recommendations for cardiac imaging modalities in patients with cancer,Cardio Oncology,2022,25
"GLS is recommended in all patients with cancer having echocardiography, if available.",I,C,4,Recommendations for cardiac imaging modalities in patients with cancer,Cardio Oncology,2022,25
CMR should be considered for the assessment of cardiac function when echocardiography is unavailable or non-diagnostic.,IIa,C,4,Recommendations for cardiac imaging modalities in patients with cancer,Cardio Oncology,2022,25
MUGA may be considered when TTE is not diagnostic and CMR is not available.106–,IIb,C,4,Recommendations for cardiac imaging modalities in patients with cancer,Cardio Oncology,2022,25
Baseline cardiac imaging prior to potentially cardiotoxic therapiesc Baseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting anticancer therapy.d,I,C,4,Recommendations for cardiac imaging modalities in patients with cancer,Cardio Oncology,2022,25
"Management of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before,c during, and after cancer therapy.",I,C,5,Recommendations for primary prevention of cancer therapy-related cardiovascular toxicity,Cardio Oncology,2022,28
Dexrazoxane should be considered in adult patients with cancer at high and very high CV toxicity risk when anthracycline chemotherapy is indicated.d,IIa,B,5,Recommendations for primary prevention of cancer therapy-related cardiovascular toxicity,Cardio Oncology,2022,28
Liposomal anthracyclines should be considered in adult patients with cancer at high and very high CV toxicity risk when anthracycline chemotherapy is indicated.e,IIa,B,5,Recommendations for primary prevention of cancer therapy-related cardiovascular toxicity,Cardio Oncology,2022,28
"Recommendation Management of CVD according to applicable ESC Guidelines is recommended before,c during, and after cancer therapy.",I,C,6,Recommendation for secondary prevention of cancer therapy-related cardiovascular toxicity,Cardio Oncology,2022,29
"TTE Baseline echocardiographyc is recommended in all patients with cancer before anthracycline chemotherapy.12,24,208–",I,B,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
"In all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment.",I,B,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
"In high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing treatment.24,208–",I,C,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
"In moderate-risk patients, additional echocardiography should be considered after a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent.",IIa,C,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
"In low-risk patients, additional echocardiography may be considered after a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent.",IIb,C,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
Cardiac serum biomarkers Baseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy.,I,B,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
cTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is recommended in highand very high-risk patients.,I,B,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion should be considered in moderate-risk patients and in low-risk patients receiving a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent.,IIa,C,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion may be considered in low-risk patients.,IIb,C,7,Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,31
TTE Baseline echocardiographyc is recommended before HER2-targeted therapies in all patients.,I,B,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,32
"In low-risk HER2+ EBC patientsd who are asymptomatic and with a normal assessment after 3 months, reducing monitoring to every 4 months may be considered.",IIb,C,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
"In high- and very high-risk HER2+ EBC patients,d more frequent echocardiography monitoringe should be considered during treatment.",IIa,C,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
"In metastatic HER2+ disease, echocardiography is recommended every 3 months during the ﬁrst year; if the patient remains asymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment.f",I,C,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
"In metastatic HER2+ disease patients at high- and very high-risk, more frequent echocardiography monitoringe may be considered.",IIb,C,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
Cardiac biomarkers Baseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies.,I,C,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
NP and cTn monitoring every 2–3 cycles during therapy and 3 and 12 months after the end of therapy should be considered in high- and very high-risk HER2+ EBC patients.d,IIa,C,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
Baseline cTn measurement should be considered in low- and moderate-risk patients post-anthracycline chemotherapy but prior to starting anti-HER2-targeted therapies.,IIa,A,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
"NP and cTn monitoring at baseline, every 3 months, and 12 months after therapy may be considered in low- and moderate-risk HER2+ EBC patients.d",IIb,C,8,Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy,Cardio Oncology,2022,33
"Baseline CV risk assessment and evaluation including BP measurement, ECG, lipid proﬁle, HbA1c measurement, and SCORE2/ SCORE2-OPc or equivalent is recommended19 before starting ﬂuoropyrimidines.",I,C,9,Recommendations for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy,Cardio Oncology,2022,33
A baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting ﬂuoropyrimidines.,I,C,9,Recommendations for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy,Cardio Oncology,2022,33
Screening for CADd may be considered in patients at high and very high risk of CADc before ﬂuoropyrimidines.,IIb,C,9,Recommendations for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy,Cardio Oncology,2022,33
"BP monitoring BP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit.",I,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
"Daily home monitoring of BP for patients treated with VEGFi during the ﬁrst cycle, after each increase of VEGFi dose, and every 2–3 weeks thereafter is recommended.",I,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
"ECG monitoring In patients treated with VEGFi at moderate or high risk of QTc prolongation, QTcc monitoring is recommended monthly during the ﬁrst 3 months and every 3–6 months thereafter.d",I,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
Echocardiography Baseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab.,I,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
Baseline echocardiography should be considered in low- and moderate-risk patients treated with a VEGFi or bevacizumab.,IIa,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
Echocardiography should be considered every 3 months during the ﬁrst year in high- and very high-risk patients receiving a VEGFi or bevacizumab.e,IIa,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
Echocardiography every 6–12 months should be considered in moderate- and high-risk patients with cancer who require long-term treatment with a VEGFi.,IIa,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
Cardiac biomarker NP may be considered at baseline and then every 4 months during the ﬁrst year in moderate-risk patients receiving a VEGFi.,IIb,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
"NP should be considered at baseline, 4 weeks after starting treatment, and them every 3 months during the ﬁrst year in high- and very high-risk patients receiving a VEGFi.",IIa,C,10,Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors,Cardio Oncology,2022,36
Baseline CV risk assessmentc is recommended in patients who require second- or third-generation BCR-ABL TKI.,I,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
"In patients treated with nilotinib or ponatinib, CV risk assessmentc is recommended every 3 months during the ﬁrst year and every 6–12 months thereafter.",I,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
"QTcd measurement should be considered at baseline, at 2 and 4 weeks after starting nilotinib, and 2 weeks after any dose increase.",IIa,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
Baseline echocardiography should be considered in all patients before starting second- and third-generation BCR-ABL TKI.,IIa,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
Baseline echocardiography is recommended in patients scheduled to receive dasatinib.,I,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
Echocardiography should be considered every 3 months during the ﬁrst year in high- and very high-risk patients receiving dasatinib or ponatinib.,IIa,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
Echocardiography may be considered every 6–12 months in patients who require long-term (.12 months) ponatinib or dasatinib.,IIb,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
Serial assessment of ankle brachial index may be considered to detect subclinical peripheral vascular disease.,IIb,C,11,Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors,Cardio Oncology,2022,39
Bruton tyrosine kinase inhibitor therapy BP monitoring and management BP measurement is recommended for patients treated with BTK inhibitors at every clinical visit.,I,B,12,Recommendations for baseline risk assessment and monitoring during,Cardio Oncology,2022,39
Weekly home monitoring of BP during the ﬁrst 3 months and every month thereafter should be considered for patients treated with BTK inhibitors.,IIa,C,12,Recommendations for baseline risk assessment and monitoring during,Cardio Oncology,2022,39
Echocardiography Baseline echocardiography is recommended in high-risk patientsc scheduled to receive BTK inhibitors.,I,C,12,Recommendations for baseline risk assessment and monitoring during,Cardio Oncology,2022,39
TTE is recommended in all patients who develop AF during BTK inhibitor therapy.,I,C,12,Recommendations for baseline risk assessment and monitoring during,Cardio Oncology,2022,39
BP monitoring BP measurement is recommended for patients treated with PI at every clinical visit.,I,C,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
Home monitoring of BP weekly during the ﬁrst 3 months and monthly thereafter should be considered for patients treated with PI.,IIa,C,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
Cardiac serum biomarkers Measurement of NP is recommended prior to PI in high- and very high-risk patients.,I,C,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
Measurement of NP should be considered prior to PI in low- and moderate-risk patients.,IIa,C,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
"In patients receiving carﬁlzomib or bortezomib, measurement of NP should be considered at baseline and every cycle during the ﬁrst 6 cycles.c",IIa,B,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
NP and cTn measurements are recommended at baseline and every 3–6 months in patients with AL-CA.d,I,B,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
"TTE Baseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI.",I,C,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
Echocardiography surveillance every 3 cycles should be considered in high- and very high-risk patients receiving carﬁlzomib.,IIa,B,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
Echocardiography surveillance every 3 cycles may be considered in low- and moderate-risk patients receiving carﬁlzomib.,IIb,C,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
Echocardiography surveillance should be considered every 3–6 months in patients with AL-CA treated with PI.d,IIa,C,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
VTE prophylaxis Therapeutic doses of LMWH are recommended in patients with MM with previous VTE.,I,B,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
Prophylactic doses of LMWH are recommended in patients with MM with VTE-related risk factorse (excluding previous VTE) at least during the ﬁrst 6 months of therapy.,I,A,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
"Aspirin should be considered as an alternative to LMWH in patients with MM with no risk factors or one VTE-related risk factore (excluding previous VTE) at least during the ﬁrst 6 months of therapy.296,304–",IIa,B,13,Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies,Cardio Oncology,2022,43
BP monitoring at each clinical visit and weekly outpatient monitoring during the ﬁrst 3 months of treatment and monthly thereafter is recommended.,I,C,14,Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy,Cardio Oncology,2022,44
"In patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3 months thereafter.c",I,C,14,Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy,Cardio Oncology,2022,44
Baseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK inhibitors.,I,C,14,Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy,Cardio Oncology,2022,44
Baseline echocardiography may be considered in low- and moderate-risk patients scheduled to receive combined RAF and MEK inhibitors.,IIb,C,14,Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy,Cardio Oncology,2022,44
Echocardiography should be considered every 4 months during the ﬁrst year in high- and very high-risk patients receiving combined RAF and MEK inhibitors.,IIa,C,14,Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy,Cardio Oncology,2022,44
"ECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy.",I,B,15,Recommendations for baseline risk assessment and monitoring during immunotherapy,Cardio Oncology,2022,46
Baseline echocardiography is recommended in high-risk patientsc before starting ICI therapy.,I,B,15,Recommendations for baseline risk assessment and monitoring during immunotherapy,Cardio Oncology,2022,46
Baseline echocardiography may be considered in all patients before starting ICI therapy.,IIb,C,15,Recommendations for baseline risk assessment and monitoring during immunotherapy,Cardio Oncology,2022,46
CV assessmentd is recommended every 6–12 months in high-risk patientsc who require long-term (.12 months) ICI treatment.321–,I,C,15,Recommendations for baseline risk assessment and monitoring during immunotherapy,Cardio Oncology,2022,46
CV assessmentd may be considered every 6–12 months in all patients who require long-term (.12 months) ICI treatment.,IIb,C,15,Recommendations for baseline risk assessment and monitoring during immunotherapy,Cardio Oncology,2022,46
Baseline CV risk assessmentc and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OPd is recommended in patients treated with ADT without pre-existing CVD.,I,B,16,Recommendations for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer,Cardio Oncology,2022,48
"Baseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy.e,339–",I,B,16,Recommendations for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer,Cardio Oncology,2022,48
A GnRH antagonist should be considered in patients with pre-existing symptomatic CADf who require ADT.,IIa,B,16,Recommendations for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer,Cardio Oncology,2022,48
Annual CV risk assessmentc is recommended during ADT.,I,B,16,Recommendations for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer,Cardio Oncology,2022,48
"Baseline CV risk assessmentc and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OPd,e is recommended in BC patients receiving endocrine therapies without pre-existing CVD.",I,C,17,Recommendations for baseline risk assessment and monitoring during endocrine therapy for breast cancer,Cardio Oncology,2022,48
"Annual CV risk assessmentc is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV events according to SCORE2/SCORE2-OP.d,e",I,C,17,Recommendations for baseline risk assessment and monitoring during endocrine therapy for breast cancer,Cardio Oncology,2022,48
"CV risk assessmentc should be considered every 5 years in BC patients with low or moderate 10-year risk of (fatal and non-fatal) CV events according to SCORE2/SCORE2-OP.d,e",IIa,C,17,Recommendations for baseline risk assessment and monitoring during endocrine therapy for breast cancer,Cardio Oncology,2022,48
"QTcc,d monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib.",I,A,18,Recommendations for baseline risk assessment and monitoring during cyclindependent kinase 4/6 inhibitor therapy,Cardio Oncology,2022,49
"QTcc,d monitoring is recommended in patients treated with ribociclib with any dose increase.",I,B,18,Recommendations for baseline risk assessment and monitoring during cyclindependent kinase 4/6 inhibitor therapy,Cardio Oncology,2022,49
QTcc monitoring should be considered in patients treated with palbociclib or abemaciclib who have a baseline QTc above the normal rangec or other conditions that may prolong the QTc interval.e,IIa,C,18,Recommendations for baseline risk assessment and monitoring during cyclindependent kinase 4/6 inhibitor therapy,Cardio Oncology,2022,49
Baseline CV risk assessmentc is recommended in patients before ALK inhibitors and EGFR inhibitors.,I,C,19,Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors,Cardio Oncology,2022,49
Baseline echocardiography is recommended in all patients with cancer before starting osimertinib.,I,B,19,Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors,Cardio Oncology,2022,49
"Home BP monitoring should be considered for patients treated with brigatinib, crizotinib, or lorlatinib.",IIa,C,19,Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors,Cardio Oncology,2022,49
Cholesterol proﬁle assessment every 3–6 months should be considered for patients on crizotinib and lorlatinib.,IIa,C,19,Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors,Cardio Oncology,2022,49
Echocardiography should be considered every 3 months in patients during osimertinib therapy.,IIa,B,19,Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors,Cardio Oncology,2022,49
ECG should be considered 4 weeks after starting therapy and every 3–6 months in patients during ALK inhibitor therapy.,IIa,C,19,Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors,Cardio Oncology,2022,49
"Baseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies.",I,C,20,Recommendations for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumourinﬁltrating lymphocytes therapies,Cardio Oncology,2022,51
A baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies.,I,C,20,Recommendations for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumourinﬁltrating lymphocytes therapies,Cardio Oncology,2022,51
A baseline echocardiography should be considered before starting CAR-T and TIL therapies.,IIa,C,20,Recommendations for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumourinﬁltrating lymphocytes therapies,Cardio Oncology,2022,51
"Measurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2.c",I,C,20,Recommendations for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumourinﬁltrating lymphocytes therapies,Cardio Oncology,2022,51
Baseline CV risk assessmentc and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OPd is recommended.,I,B,21,Recommendations for baseline risk assessment of patients before radiotherapy to a volume including the heart,Cardio Oncology,2022,51
Baseline echocardiography should be considered in patients with previous CVD before RT to a volume including the heart.,IIa,C,21,Recommendations for baseline risk assessment of patients before radiotherapy to a volume including the heart,Cardio Oncology,2022,51
"Baseline and serial CV risk assessment (3 and 12 months, then yearly) including BP measurement, ECG, lipid measurement, and HbA1c is recommended in HSCT patients.",I,C,22,Recommendations for baseline risk assessment in haematopoietic stem cell transplantation patients,Cardio Oncology,2022,53
Echocardiography is recommended in all patients before HSCT.,I,C,22,Recommendations for baseline risk assessment in haematopoietic stem cell transplantation patients,Cardio Oncology,2022,53
Baseline NP measurement should be considered before HSCT.,IIa,C,22,Recommendations for baseline risk assessment in haematopoietic stem cell transplantation patients,Cardio Oncology,2022,53
Recommendation A specialist CV assessmentc is recommended for optimal diagnostic workup and management of patients with cancer who present with new CV toxicity during and after cancer treatment.,I,C,23,Recommendation for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in patients receiving anticancer treatment,Cardio Oncology,2022,54
Anthracycline chemotherapy-induced symptomatic CTRCD HF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy.c,I,B,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Discontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD.c,I,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Temporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCDc and a multidisciplinary approach regarding the decision to restart is recommended.,I,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
A multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who develop mild symptomatic CTRCD.c,I,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Anthracycline chemotherapy-induced asymptomatic CTRCD Temporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop asymptomatic moderate or severe CTRCD.c,I,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
A multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe asymptomatic CTRCD.c,I,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Continuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have developed a signiﬁcant fall in GLSc or a troponin or a NP elevation . ULN.,I,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Asymptomatic patients who have LVEF ≥50% and who have developed a signiﬁcant fall in GLSc should be considered for ACE-I/ARB and/or beta-blockers.d,IIa,B,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Asymptomatic patients who have LVEF ≥50% and who have developed a troponin elevation .ULN should be considered for ACE-I/ARB and/ or beta-blockers.d,IIa,B,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Strategies for restarting anthracycline chemotherapy in patients with CTRCD Liposomal anthracyclinee may be considered in patients with moderate or severe symptomatic or asymptomatic CTRCDc who require further anthracycline chemotherapy to reduce the risk of further CV toxicity.,IIb,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
Dexrazoxanef may be considered in patients with moderate or severe symptomatic or asymptomatic CTRCDc who require further anthracycline chemotherapy to reduce the risk of further CV toxicity.,IIb,C,24,Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy,Cardio Oncology,2022,56
"HER2-targeted therapy-induced symptomatic CTRCD HF therapy is recommended for patients who develop symptomatic moderate-to-severe CTRCD with LVEF , 50%c during HER2-targeted treatment.",I,B,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
Temporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCDc and the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved.d,I,C,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
"In patients who develop mild symptomatic CTRCD,c HF therapy and a multidisciplinary approach regarding the decision to continue vs. interrupt HER2-targeted therapy are recommended.d",I,C,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
HER2-targeted therapy-induced asymptomatic CTRCD Temporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic severe CTRCD.c,I,C,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
A multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe asymptomatic CTRCD.c,I,C,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
Continuation of HER2-targeted therapy should be considered in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc with more frequent cardiac monitoring.,IIa,B,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
Continuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDc with more frequent cardiac monitoring.,I,C,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
ACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc during HER2-targeted treatment.e,I,C,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
ACE-I/ARB and/or beta-blockers should be considered in asymptomatic patients receiving HER2-targeted therapies who have LVEF ≥50% but develop a signiﬁcant fall in GLSc while continuing HER2-targeted therapy.e,IIa,B,25,Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies,Cardio Oncology,2022,58
"Levelb cTn, ECG, and CV imaging (echocardiography and CMR) are recommended to diagnose ICI-associated myocarditis.",I,B,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
"In patients with suspected ICI-associated myocarditis, temporary interruption of ICI treatment is recommended until the diagnosis is conﬁrmed or refuted.",I,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
Interruption of ICI treatment is recommended in patients with conﬁrmed ICI-associated myocarditis.,I,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
Continuous ECG monitoring to assess for new AV block and tachyarrhythmias during the acute phase is recommended for all patients with symptomatic ICI-associated myocarditis.,I,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
Early high-dose corticosteroidsd are recommended in patients with cancer and conﬁrmed ICI-associated myocarditis.,I,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
"Continuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of symptoms, LV systolic dysfunction, conduction abnormalities, and signiﬁcant cTn reduction.e",I,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
"Switching from i.v. to oral prednisolone should be considered after clinical improvement (resolution of: symptoms, LV systolic dysfunction, conduction abnormalities, and signiﬁcant cTn reductione).f",IIa,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
Second-line immunosuppression treatment should be considered in patients with steroid-refractory ICI-associated myocarditis.g,IIa,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
"Admission to ICU (level 3), treatment with i.v. methylprednisolone, and optimal CV treatment including mechanical support (when indicated) is recommended for patients with ICI-associated fulminant myocarditis.",I,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
A single dose of i.v. methylprednisoloned should be considered in unstableh patients with cancer where ICI-induced myocarditis is suspected.,IIa,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
A multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated ICI-associated myocarditis.,I,C,26,Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis,Cardio Oncology,2022,61
Coronary angiography (invasive or CCTA) is recommended to exclude ACS.,I,C,27,Recommendations for the diagnosis and management of Takotsubo syndrome in patients with cancer,Cardio Oncology,2022,63
CMR is recommended to exclude myocarditis and MI.,I,B,27,Recommendations for the diagnosis and management of Takotsubo syndrome in patients with cancer,Cardio Oncology,2022,63
QT-prolonging drugs are not recommended during the acute TTS phase.c,III,C,27,Recommendations for the diagnosis and management of Takotsubo syndrome in patients with cancer,Cardio Oncology,2022,63
An invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk NSTE-ACS with life expectancy ≥6 months.,I,B,28,Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment,Cardio Oncology,2022,64
"A conservative non-invasive strategy should be considered in patients with poor cancer prognosisc (with life expectancy ,6 months) and/ or very high bleeding risk presenting with STEMI or NSTE-ACS.",IIa,C,28,Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment,Cardio Oncology,2022,64
A temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause.d,I,C,28,Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment,Cardio Oncology,2022,64
A short DAPT strategy should be considered in patients with cancer with very high bleeding risk treated with PCI for an ACS.e,IIa,C,28,Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment,Cardio Oncology,2022,64
"In patients with cancer, thrombocytopaenia, and ACS, clopidogrel is not recommended if platelets ,30 000/µL and prasugrel or ticagrelor are not recommended if platelets ,50 000/µL.",III,C,28,Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment,Cardio Oncology,2022,65
Ticagrelor or prasugrel may be considered in patients with cancer with low bleeding risk and excessive thrombotic risk who are treated with PCI for ACS.,IIb,C,28,Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment,Cardio Oncology,2022,65
"Recommendation Individualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/ ischaemic and bleeding risk, type and stage of cancer, and current cancer treatment.",I,C,29,Recommendation for the management of chronic coronary syndromes in patients receiving anticancer treatment,Cardio Oncology,2022,65
"In patients with cancer and pre-existing severe VHD, management according to the 2021 ESC/ EACTS Guidelines for the management of VHD is recommended, taking into consideration cancer prognosis and patient preferences.",I,C,30,Recommendations for the management of valvular heart disease in patients receiving anticancer treatment,Cardio Oncology,2022,65
CHA2DS2-VASc score should be considered for risk stratiﬁcation for stroke/systemic thromboembolism taking into account that it may underestimate the actual thromboembolic risk.,IIa,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
Long-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a CHA2DS2-VASc score ≥2 (men) or ≥3 (women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.,I,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
"Patients with cancer,c AF, and CHA2DS2-VASc score 0 (men) or 1 (women) may have a higher thrombotic risk than patients without cancer and may be considered for therapeutic anticoagulation after consideration of the bleeding risk.",IIb,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
Thromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF.d,I,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
"NOAC should be considered for stroke prevention in preference to LMWH and VKA (excluding patients with mechanical heart valves or moderate-to-severe mitral stenosis) in patients without a high bleeding risk, signiﬁcant drug–drug interactions, or severe renal dysfunction.531–",IIa,B,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
LMWH should be considered in patients with active cancere and AF who are not suitable for NOACf.,IIa,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
LAA occlusion may be considered for stroke prevention in patients with cancer with AF and contraindications for long-term anticoagulation with a life expectancy .12 months.,IIb,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
Antiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with cancer.,III,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
"Heart rate control strategy, preferably with beta-blockers, should be considered in patients who develop well-tolerated AF while they are receiving active cancer treatmentg.",IIa,C,31,Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment,Cardio Oncology,2022,69
How to manage QTc prolongation in patients with cancer Discontinuation of QTc-prolonging cancer therapy is recommended in patients who develop TdP or sustained ventricular tachyarrhythmias during treatment.,I,C,32,Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment,Cardio Oncology,2022,72
Temporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms and an ECG should be repeated every 24 h until resolution of the QTcF prolongation.,I,C,32,Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment,Cardio Oncology,2022,72
Immediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factorsc is recommended in patients with cancer who develop QTcF ≥500 ms.,I,C,32,Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment,Cardio Oncology,2022,72
Weekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480–500 ms who are treated with a QTc-prolonging cancer therapy.,I,C,32,Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment,Cardio Oncology,2022,72
A 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy.,I,C,32,Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment,Cardio Oncology,2022,72
"In patients who experienced signiﬁcant QTcF prolongation, restarting the culprit QTc-prolonging cancer treatment may be considered, ideally at a reduced dose according to each drug recommendation.",IIb,C,32,Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment,Cardio Oncology,2022,72
Weekly ECG monitoring during the ﬁrst 4–6 weeks and then monthly thereafter is recommended in patients with cancer after restarting QTc-prolonging cancer therapy.,I,C,32,Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment,Cardio Oncology,2022,72
General Effective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is recommended.,I,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
"A BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy.",I,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
"A BP target ,130 mmHg systolic and ,80 mmHg diastolic may be considered during cancer therapy provided that the treatment is well tolerated.",IIb,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
"In selected asymptomatic patients with metastatic cancer, a systolic BP 140–160 mmHg and diastolic BP 90–100 mmHg treatment threshold may be considered provided there is ongoing BP monitoring.",IIb,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
"The competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any cancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values ,160 mmHg (systolic) and ,100 mmHg (diastolic).",I,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
Dihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP.,I,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
Combination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic BP ≥160 mmHg and diastolic BP ≥100 mmHg.,I,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
Diltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug–drug interactions.d,III,C,33,Recommendations for the management of arterial hypertension in patients receiving anticancer treatment,Cardio Oncology,2022,74
"Apixaban, edoxaban, or rivaroxabanc are recommended for the treatment of symptomatic or incidental VTE in patients with cancer without contraindications.d,578–",I,A,34,Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment,Cardio Oncology,2022,77
"LMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL.298,299,578–",I,A,34,Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment,Cardio Oncology,2022,77
"In patients with cancer with platelet counts of 25 000–50 000/µL, anticoagulation with half-dose LMWH may be considered after a multidisciplinary discussion.",IIb,C,34,Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment,Cardio Oncology,2022,77
Prolongation of anticoagulation therapy beyond 6 months should be considered in selected patients with active cancere including metastatic disease.,IIa,A,34,Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment,Cardio Oncology,2022,77
Catheter-associated VTE Duration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and continuing longer if the catheter remains in situ.,I,C,34,Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment,Cardio Oncology,2022,77
Recommendation Extended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or laparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk.c,I,B,35,Recommendations for venous thromboembolism prophylaxis during anticancer treatment,Cardio Oncology,2022,78
Prophylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bedrest or reduced mobility in the absence of bleeding or other contraindications.,I,B,35,Recommendations for venous thromboembolism prophylaxis during anticancer treatment,Cardio Oncology,2022,78
"For ambulatory patients with cancer at high risk of thrombosis receiving systemic therapy,d primary thromboprophylaxis with a NOAC (apixaban or rivaroxaban) or LMWH may be considered, provided there are no signiﬁcant contraindications.e",IIb,B,35,Recommendations for venous thromboembolism prophylaxis during anticancer treatment,Cardio Oncology,2022,78
"A discussion with the patient about the relative beneﬁts and harms, cancer prognosis, drug cost, and duration of treatment is recommended prior to prophylactic anticoagulation for the primary prevention of VTE.",I,C,35,Recommendations for venous thromboembolism prophylaxis during anticancer treatment,Cardio Oncology,2022,78
"Recommendation In patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt culprit cancer therapyc is recommended.",I,C,36,Recommendation for management of peripheral artery disease during anticancer treatment,Cardio Oncology,2022,79
Right-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic increase in peak TRV .3.4 m/s.,I,C,37,Recommendations for the management of pulmonary hypertension during anticancer treatment,Cardio Oncology,2022,80
Dasatinib dose reduction and close monitoring of peak TRV with echocardiography should be considered in patients who develop new asymptomatic peak TRV ranging from 2.9 to 3.4 m/s.,IIa,C,37,Recommendations for the management of pulmonary hypertension during anticancer treatment,Cardio Oncology,2022,80
"In patients with conﬁrmed dasatinib-induced PAHc or new asymptomatic peak TRV .3.4 m/s, an alternative BCR-ABL inhibitor is recommended after peak TRV recovery to ,2.8 m/s.",I,C,37,Recommendations for the management of pulmonary hypertension during anticancer treatment,Cardio Oncology,2022,80
General Diagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC Guidelines for the diagnosis and management of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy.,I,C,38,Recommendations for the management of pericardial diseases in patients receiving anticancer treatment,Cardio Oncology,2022,81
A surgical pericardial window should be considered if the percutaneous approach is not feasible or in cases of recurrent malignant pericardial effusions.,IIa,C,38,Recommendations for the management of pericardial diseases in patients receiving anticancer treatment,Cardio Oncology,2022,81
Intrapericardial instillation of cytostatic or sclerosing agents may be considered for prevention of recurrence.,IIb,C,38,Recommendations for the management of pericardial diseases in patients receiving anticancer treatment,Cardio Oncology,2022,81
"Diagnosis and management of ICI-associated pericarditis Multimodality CV imaging (echocardiography, CMR + CT), ECG and measurement of cardiac biomarkers are recommended to conﬁrm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis.",I,C,38,Recommendations for the management of pericardial diseases in patients receiving anticancer treatment,Cardio Oncology,2022,81
Prednisolone and colchicine are recommended for patients with ICI-associated pericarditis.,I,C,38,Recommendations for the management of pericardial diseases in patients receiving anticancer treatment,Cardio Oncology,2022,81
Interruption of ICI treatment in patients with conﬁrmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is recommended.,I,C,38,Recommendations for the management of pericardial diseases in patients receiving anticancer treatment,Cardio Oncology,2022,81
A multidisciplinary discussion is recommended before restarting ICI treatment.,I,C,38,Recommendations for the management of pericardial diseases in patients receiving anticancer treatment,Cardio Oncology,2022,81
Educating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended.c,I,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
Education is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD.,I,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
"CVRF assessment is recommended during the ﬁrst year after cancer therapyc,12,22,31,632,643 and thereafter according to the 2021 ESC Guidelines on CVD prevention in clinical practice.",I,B,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
"In asymptomatic high-risk patients,d echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after completion of cancer therapy.",I,B,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
"In asymptomatic moderate-risk patients,e echocardiography and cardiac serum biomarkers should be considered within 12 months after completion of cancer therapy.",IIa,B,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
"In asymptomatic low-risk patients,e echocardiography and cardiac serum biomarkers may be considered within 12 months after completion of cancer therapy.",IIb,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
Cardiology referralf is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in echocardiography and/or cardiac serum biomarkers at the end of therapy assessment.,I,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
"In selected patients with exercise intolerance persisting at 12 months after cancer treatment and with normal resting echocardiogram and cardiac biomarkers, exercise stress echocardiography and/or CPET may be considered.",IIb,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
Targeted cardiac rehabilitation should be considered in CS with high CV risk.638–,IIa,B,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
Long-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy.,I,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
CV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer therapy.,I,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
CV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy.,I,C,39,Recommendations for end-of-cancer therapy cardiovascular risk assessment,Cardio Oncology,2022,84
"Education of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including the heart and their healthcare providers regarding their increased CV risk is recommended.655–",I,B,40,Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors,Cardio Oncology,2022,85
"Annual screening for modiﬁable CVRFc is recommended in adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including the heart.",I,C,40,Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors,Cardio Oncology,2022,85
CV assessmentd is recommended in female childhood and adolescent CS prior to pregnancy or in the ﬁrst trimester.,I,C,40,Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors,Cardio Oncology,2022,85
Echocardiography surveillance should be considered every 2 years in adults who are high-risk childhood and adolescente CS.,IIa,B,40,Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors,Cardio Oncology,2022,85
Echocardiography surveillance should be considered every 5 years in adults who are moderate-risk childhood and adolescente CS.,IIa,B,40,Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors,Cardio Oncology,2022,85
"Annual CV risk assessment,c including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially cardiotoxic cancer drug or RT.d,631–",I,B,41,Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors,Cardio Oncology,2022,86
CV toxicity risk restratiﬁcatione is recommended 5 years after therapy to organize long-term follow-up.,I,C,41,Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors,Cardio Oncology,2022,86
"Echocardiography at years 1, 3, and 5 after completion of cardiotoxic cancer therapy and every 5 years thereafter should be considered in asymptomatic very high- and early high-risk adult CS.f",IIa,C,41,Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors,Cardio Oncology,2022,86
Echocardiography should be considered in asymptomatic late high-risk adult CSf starting at 5 years after radiation to a volume including the heart and then every 5 years.,IIa,C,41,Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors,Cardio Oncology,2022,86
Echocardiography may be considered every 5 years in asymptomatic moderate-risk adult CS.f,IIb,C,41,Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors,Cardio Oncology,2022,86
"Non-invasive screening for CADg should be considered every 5–10 years in asymptomatic patients who received .15 Gy MHD,d starting at 5 years after radiation.",IIa,C,41,Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors,Cardio Oncology,2022,86
"Carotid ultrasound imaging should be considered every 5 years in asymptomatic patients with a history of head/neck RT, starting at 5 years after radiation and every 5–10 years thereafter.",IIa,C,41,Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors,Cardio Oncology,2022,86
"ACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD.c,208,425,675–",I,C,42,Recommendations for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic cancer therapy,Cardio Oncology,2022,88
ACE-I/ARB and/or beta-blockers may be considered in adult CS with mild asymptomatic CTRCD.d,IIb,C,42,Recommendations for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic cancer therapy,Cardio Oncology,2022,88
Asymptomatic radiation-induced CAD detected during surveillance Non-invasive stress testingc is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on CCTA to guide ischaemia-directed management.,I,C,43,Recommendations for adult cancer survivors with coronary artery disease,Cardio Oncology,2022,88
A MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or severe left main CAD.,I,C,43,Recommendations for adult cancer survivors with coronary artery disease,Cardio Oncology,2022,88
"Symptomatic CAD Pre-operative assessment of LIMA and RIMA viability, venous access, and sternal wound healing is recommended in CS with radiation-induced CAD where CABG is considered.",I,C,43,Recommendations for adult cancer survivors with coronary artery disease,Cardio Oncology,2022,88
A MDT approach is recommended to discuss and deﬁne the surgical riskc in CS with severe VHD.,I,C,44,Recommendations for adult cancer survivors with valvular heart disease,Cardio Oncology,2022,89
"Recommendation Patients with acute pericarditis during RT to a volume including the heart are at higher risk of developing chronic constrictive pericarditis, hence echocardiography surveillance every 5 years may be considered.",IIb,C,45,Recommendation for adult cancer survivors with pericardial complications,Cardio Oncology,2022,90
"In high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary pregnancy heart team is recommended.",I,C,46,Recommendations for cardiovascular monitoring in cancer survivors during pregnancy,Cardio Oncology,2022,91
"A baseline CV evaluation including history, physical examination, ECG, NP, and echocardiography is recommended in female CS with a history of CTRCD who are considering pregnancy.",I,C,46,Recommendations for cardiovascular monitoring in cancer survivors during pregnancy,Cardio Oncology,2022,91
"A baseline CV evaluation including history, physical examination, ECG, and echocardiography should be considered in all female CS who received potentially cardiotoxic cancer therapy and are considering pregnancy.",IIa,C,46,Recommendations for cardiovascular monitoring in cancer survivors during pregnancy,Cardio Oncology,2022,91
A CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female CS who are either high-risk or who received potentially cardiotoxic cancer therapy and did not have a baseline CV assessment.,I,C,46,Recommendations for cardiovascular monitoring in cancer survivors during pregnancy,Cardio Oncology,2022,91
A second CV evaluation including echocardiography should be considered at 20 weeks of pregnancy in high-risk female CSc who received potentially cardiotoxic cancer therapy.,IIa,C,46,Recommendations for cardiovascular monitoring in cancer survivors during pregnancy,Cardio Oncology,2022,91
Management by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who require cardiotoxic cancer therapy.,I,C,47,Recommendations for cardiovascular assessment and monitoring of pregnant women with cancer,Cardio Oncology,2022,95
"Cardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical examination, ECG, and echocardiography.",I,C,47,Recommendations for cardiovascular assessment and monitoring of pregnant women with cancer,Cardio Oncology,2022,95
"Monthly or bimonthly CV evaluation, including TTE, should be considered during cardiotoxic cancer therapyc in pregnant women with cancer.",IIa,C,47,Recommendations for cardiovascular assessment and monitoring of pregnant women with cancer,Cardio Oncology,2022,95
cTn may be considered at baseline and during anthracycline chemotherapy in pregnant women with cancer.,IIb,C,47,Recommendations for cardiovascular assessment and monitoring of pregnant women with cancer,Cardio Oncology,2022,95
"Echocardiographyc is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and elevated NP levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of cardiac involvement and clinical status.",I,B,48,Recommendations for carcinoid valvular heart diseases,Cardio Oncology,2022,95
NP should be considered for screening and surveillance of carcinoid heart disease every 6 months.777–,IIa,B,48,Recommendations for carcinoid valvular heart diseases,Cardio Oncology,2022,95
A MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac procedure.,I,C,48,Recommendations for carcinoid valvular heart diseases,Cardio Oncology,2022,95
Valve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an expected survival ≥12 months.d,I,C,48,Recommendations for carcinoid valvular heart diseases,Cardio Oncology,2022,95
"Valve replacement surgery should be considered in patients with asymptomatic severe carcinoid tricuspid or pulmonary VHD, progressive RV dysfunction/dilatation, and an expected survival ≥12 months.d",IIa,C,48,Recommendations for carcinoid valvular heart diseases,Cardio Oncology,2022,95
"Echocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia.290,820–",I,B,49,Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring,Cardio Oncology,2022,98
CMR is recommended in patients with suspected AL-CA.,I,A,49,Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring,Cardio Oncology,2022,98
EMB should be considered in patients with suspected AL-CA involvement if CMR is not diagnostic.,IIa,C,49,Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring,Cardio Oncology,2022,98
Admission with inpatient ECG monitoring should be considered for high-risk patients with AL-CA requiring PI during their ﬁrst cycle of therapy.c,IIa,C,49,Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring,Cardio Oncology,2022,98
"Risk stratiﬁcation including planned radiation type and energy, dose to CIED, the patient’s device type, and pacing dependence is recommended prior to starting treatment.",I,C,50,Recommendations for riskstratiﬁcationandmonitoringforpatientswithcardiac implantable electronic devices undergoing radiotherapy,Cardio Oncology,2022,102
"In patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to individual risk.",I,C,50,Recommendations for riskstratiﬁcationandmonitoringforpatientswithcardiac implantable electronic devices undergoing radiotherapy,Cardio Oncology,2022,102
"In patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG monitoring and/or pulse oximetry are recommended during every RT session.",I,C,50,Recommendations for riskstratiﬁcationandmonitoringforpatientswithcardiac implantable electronic devices undergoing radiotherapy,Cardio Oncology,2022,102
"Endovascular or video-assisted procedures should be considered for patients with high CV risk undergoing vascular or pulmonary surgery.21,35–",IIa,B,1,Recommendations for selection of surgical approach and impact on risk,Non Cardiac Surgery,2022,18
"In all patients scheduled for NCS, an accurate history and clinical examination are recommended.",I,C,2,Recommendations for all patients scheduled for non-cardiac surgery,Non Cardiac Surgery,2022,20
"It is recommended to perform a pre-operative risk assessment, ideally at the same time as the NCS is proposed.46–",I,B,2,Recommendations for all patients scheduled for non-cardiac surgery,Non Cardiac Surgery,2022,20
"If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS.",I,C,2,Recommendations for all patients scheduled for non-cardiac surgery,Non Cardiac Surgery,2022,20
"In patients with a family history of genetic cardiomyopathy, it is recommended to perform an ECG and TTE before NCS, regardless of age and symptoms.",I,C,3,"Recommendations for patients aged ,65 years without signs, symptoms, or history of cardiovascular disease",Non Cardiac Surgery,2022,20
"In patients aged 45–65 years without signs, symptoms, or history of CVD, ECG and biomarkers should be considered before high-risk NCS.",IIa,C,3,"Recommendations for patients aged ,65 years without signs, symptoms, or history of cardiovascular disease",Non Cardiac Surgery,2022,20
"Newly detected murmur In patients with a newly detected murmur and symptoms or signs of CVD, TTE is recommended before NCS.",I,C,4,"Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema",Non Cardiac Surgery,2022,20
"In patients with a newly detected murmur, but without other signs or symptoms of CVD, TTE should be considered before moderate-risk NCS.",IIa,C,4,"Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema",Non Cardiac Surgery,2022,21
"Previously unknown angina If a patient scheduled for elective NCS has chest pain or other symptoms suggestive of undetected CAD, further diagnostic work-up before NCS is recommended.",I,C,4,"Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema",Non Cardiac Surgery,2022,21
"If a patient in need of acute NCS also has chest pain or other symptoms suggestive of undetected CAD, a multidisciplinary assessment approach is recommended to choose the treatment with lowest total risk for the patient.",I,C,4,"Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema",Non Cardiac Surgery,2022,21
"Dyspnoea and/or peripheral oedema In patients with dyspnoea and/or peripheral oedema, an ECG and an NT-proBNP/BNP test is indicated before NCS, unless there is a certain non-cardiac explanation.",I,C,4,"Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema",Non Cardiac Surgery,2022,21
"In patients with dyspnoea and/or peripheral oedema and elevated NT-proBNP/BNP, TTE is recommended before NCS.c",I,C,4,"Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema",Non Cardiac Surgery,2022,21
"It is recommended to give patients individualized instructions for pre-operative and post-operative changes in medication, in verbal and written formats with clear and concise directions.",I,C,5,Recommendations for patient information,Non Cardiac Surgery,2022,22
It should be considered to set up a structured information list (e.g. a check list to help with common issues) for patients with CVD or at high risk of CV complications scheduled for NCS.,IIa,C,5,Recommendations for patient information,Non Cardiac Surgery,2022,22
"In patients aged ≥70 years and scheduled to undergo intermediate- or high-risk NCS, frailty screening should be considered using a validated screening tool.84–",IIa,B,6,Recommendations for pre-operative assessment of frailty and functional capacity,Non Cardiac Surgery,2022,24
"In patients who have known CVD or CV risk factors (including age ≥65 years), or symptoms or signs suggestive of CVD it is recommended to obtain a pre-operative 12-lead ECG before intermediate- and high-risk NCS.97–",I,C,7,Recommendations for pre-operative risk assessment—electrocardiography and biomarkers,Non Cardiac Surgery,2022,26
"In patients who have known CVD, CV risk factors (including age ≥65 years), or symptoms suggestive of CVD it is recommended to measure hs-cTn T or hs-cTn I before intermediate- and high-risk NCS, and at 24 h and 48 h afterwards.53,105–107,109–",I,B,7,Recommendations for pre-operative risk assessment—electrocardiography and biomarkers,Non Cardiac Surgery,2022,26
"In low-risk patients undergoing low- and intermediate-risk NCS, it is not recommended to routinely obtain pre-operative ECG, hs-cTn T/I, or BNP/NT-proBNP concentrations.109,111,117–",III,B,7,Recommendations for pre-operative risk assessment—electrocardiography and biomarkers,Non Cardiac Surgery,2022,26
"TTE is recommended in patients with poor functional capacityc and/or high NT-proBNP/ BNP,d or if murmurs are detected before high-risk NCS, in order to undertake risk-reduction strategies.121,124,127,141–",I,B,8,Recommendations for transthoracic echocardiography,Non Cardiac Surgery,2022,27
TTE should be considered in patients with suspected new CVD or unexplained signs or symptoms before high-risk NCS.,IIa,B,8,Recommendations for transthoracic echocardiography,Non Cardiac Surgery,2022,27
"TTE may be considered in patients with poor functional capacity, abnormal ECG, high NT-proBNP/BNP,d or ≥1 clinical risk factor before intermediate-risk NCS.126–",IIb,B,8,Recommendations for transthoracic echocardiography,Non Cardiac Surgery,2022,27
"To avoid delaying surgery, a FOCUS exam performed by trained specialists may be considered as an alternative to TTE for pre-operative triage.",IIb,B,8,Recommendations for transthoracic echocardiography,Non Cardiac Surgery,2022,27
Routine pre-operative evaluation of LV function is not recommended.,III,C,8,Recommendations for transthoracic echocardiography,Non Cardiac Surgery,2022,27
"Stress imaging is recommended before high-risk elective NCS in patients with poor functional capacityc and high likelihood of CADd or high clinical risk.e,146,156–",I,B,9,Recommendations for stress imaging,Non Cardiac Surgery,2022,28
"Stress imaging should be considered before high-risk NCS in asymptomatic patients with poor functional capacity,d and previous PCI or CABG.",IIa,C,9,Recommendations for stress imaging,Non Cardiac Surgery,2022,28
Stress imaging may be considered before intermediate-risk NCS when ischaemia is of concern in patients with clinical risk factors and poor functional capacity.d,IIb,B,9,Recommendations for stress imaging,Non Cardiac Surgery,2022,28
Stress imaging is not recommended routinely before NCS.,III,C,9,Recommendations for stress imaging,Non Cardiac Surgery,2022,28
It is recommended to use the same indications for ICA and revascularization pre-operatively as in the non-surgical setting.,I,C,10,Recommendations for coronary angiography,Non Cardiac Surgery,2022,28
"CCTA should be considered to rule out CAD in patients with suspected CCS or biomarker-negative NSTE-ACS in case of low-to-intermediate clinical likelihood of CAD, or in patients unsuitable for non-invasive functional testing undergoing non-urgent, intermediate-, and high-risk NCS.",IIa,C,10,Recommendations for coronary angiography,Non Cardiac Surgery,2022,28
Smoking cessation .4 weeks before NCS is recommended to reduce post-operative complications and mortality.,I,B,11,Recommendations for lifestyle and cardiovascular risk factors,Non Cardiac Surgery,2022,29
"Control of CV risk factors—including blood pressure, dyslipidaemia, and diabetes—is recommended before NCS.173,176–",I,B,11,Recommendations for lifestyle and cardiovascular risk factors,Non Cardiac Surgery,2022,29
"Initiation In patients with an indication for statins, it should be considered to initiate statins peri-operatively.",IIa,C,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,31
"Pre-operative initiation of beta-blockers in advancec of high-risk NCS may be considered in patients who have two or more clinical risk factors,d in order to reduce the incidence of peri-operative myocardial infarction.188,190–",IIb,A,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,31
"Pre-operative initiation of beta-blocker in advance of NCS may be considered in patients who have known CAD or myocardial ischaemia.e,230–",IIb,B,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,31
Routine initiation of beta-blocker peri-operatively is not recommended.,III,A,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,31
"Continuation Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.190,196–",I,B,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,31
"In patients already on statins, it is recommended to continue statins during the peri-operative period.",I,B,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,31
"In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered.",IIb,C,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,31
"For patients on diuretics to treat hypertension, transient discontinuation of diuretics on the day of NCS should be considered.",IIa,B,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,32
It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS.,IIa,C,12,Recommendations for pharmacological treatment,Non Cardiac Surgery,2022,32
It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS.,I,A,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of DAPT treatment has been given.",I,B,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"In patients with a recent PCI scheduled for NCS, it is recommended that management of antiplatelet therapy is discussed between the surgeon, anaesthesiologist, and cardiologist.",I,C,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"In high-risk patients with a recent PCI (e.g. STEMI patients or high-risk NSTE-ACS patients), a DAPT duration of at least 3 months should be considered before time-sensitive NCS.",IIa,C,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"Continuation of medication In patients with a previous PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows.",I,B,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"Recommended time interval for drug interruption before NCS If interruption of P2Y12 inhibitor is indicated, it is recommended to withhold ticagrelor for 3–5 days, clopidogrel for 5 days, and prasugrel for 7 days prior to NCS.262–",I,B,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"For patients undergoing high bleeding risk surgery (e.g. intracranial, spinal neurosurgery, or vitreoretinal eye surgery), it is recommended to interrupt aspirin for at least 7 days pre-operatively.",I,C,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"In patients without a history of PCI, interruption of aspirin at least 3 days before NCS may be considered if the bleeding risk outweighs the ischaemic risk, to reduce the risk of bleeding.",IIb,B,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"Resumption of medication If antiplatelet therapy has been interrupted before a surgical procedure, it is recommended to restart therapy as soon as possible (within 48 h) post-surgery, according to interdisciplinary risk assessment.",I,C,13,Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery,Non Cardiac Surgery,2022,37
"Interruption of anticoagulation When an urgent surgical intervention is required, it is recommended that NOAC therapy is immediately interrupted.",I,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
Idarucizumab should be considered in patients on dabigatran and requiring urgent surgical intervention with intermediate to high bleeding risk.,IIa,B,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"For interventions with a very high risk of bleeding, such as spinal or epidural anaesthesia, interruption of NOACs for up to ﬁve half-lives and re-initiation after 24 h should be considered.",IIa,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"When speciﬁc reversal agents are unavailable, PCC or activated PCC should be considered for reversing NOAC effects.",IIa,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"If an urgent surgical intervention is required, speciﬁc coagulation tests and assessment of NOAC plasma levels should be considered to interpret routine coagulation tests and waning of anticoagulant effect.",IIa,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"Continuation of medication In minor bleeding risk surgery and other procedures where bleeding can be easily controlled, it is recommended to perform surgery without interruption of OAC therapy.240,296–",I,B,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"LMWH is recommended, as an alternative to UFH, for bridging in patients with MHVs and high surgical risk.",I,B,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels (typically 12–24 h after last intake).",I,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"For patients with mechanical prosthetic heart valves undergoing NCS, bridging with UFH or LMWH should be considered if OAC interruption is needed and patients have: (i) mechanical AVR and any thromboembolic risk factor; (ii) old-generation mechanical AVR; or (iii) mechanical mitral or tricuspid valve replacement.",IIa,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"Bridging of OAC therapy is not recommended in patients with low/moderate thrombotic risk undergoing NCS.290,292,293,306–",III,B,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
"Start/resumption of medication If bleeding risk with resumption of full-dose anticoagulation outweighs the risk of thromboembolic events, postponing therapeutic anticoagulation 48–72 h after the procedure may be considered, using post-operative thromboprophylaxis until resumption of full OAC dose is deemed safe.",IIb,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended.,III,C,14,Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,43
It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-speciﬁc risk factors.,I,A,15,Recommendations for thromboprophylaxis,Non Cardiac Surgery,2022,44
"If thromboprophylaxis is deemed necessary, it is recommended to choose the type and duration of thromboprophylaxis (LMWH, NOAC, or fondaparinux) according to type of NCS, duration of immobilization, and patient-related factors.",I,A,15,Recommendations for thromboprophylaxis,Non Cardiac Surgery,2022,44
"In patients with a low bleeding risk, peri-operative thromboprophylaxis should be considered for a duration of up to 14 or 35 days, for total knee or hip arthroplasty, respectively.334–",IIa,A,15,Recommendations for thromboprophylaxis,Non Cardiac Surgery,2022,44
NOACs in thromboprophylaxis dose may be considered as alternative treatments to LMWH after total knee and hip arthroplasty.,IIb,A,15,Recommendations for thromboprophylaxis,Non Cardiac Surgery,2022,44
It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate- to high-risk NCS.,I,B,16,Recommendations for intra- and post-operative complications associated with anaemia,Non Cardiac Surgery,2022,45
"It is recommended to treat anaemia in advance of NCS, in order to reduce the need for RBC transfusion during NCS.",I,A,16,Recommendations for intra- and post-operative complications associated with anaemia,Non Cardiac Surgery,2022,45
The use of an algorithm to diagnose and treat anaemic patients before NCS should be considered.,IIa,C,16,Recommendations for intra- and post-operative complications associated with anaemia,Non Cardiac Surgery,2022,45
"In patients undergoing surgery with expected blood loss of ≥500 mL, use of washed cell salvage is recommended.",I,A,17,Recommendations for intra- and post-operative complications associated with blood loss,Non Cardiac Surgery,2022,46
"It is recommended to use point-of-care diagnostics for guidance of blood component therapy, when available.370,379–",I,A,17,Recommendations for intra- and post-operative complications associated with blood loss,Non Cardiac Surgery,2022,46
Use of closed-loop arterial blood sampling systems should be considered to avoid blood loss.,IIa,B,17,Recommendations for intra- and post-operative complications associated with blood loss,Non Cardiac Surgery,2022,46
Application of meticulous haemostasis should be considered a routine procedure.,IIa,B,17,Recommendations for intra- and post-operative complications associated with blood loss,Non Cardiac Surgery,2022,46
A feedback/monitoring programme or clinical decision support system should be considered to be assessed before blood transfusion.392–,IIa,B,18,Recommendations for intra- and post-operative complications associated with allogeneic blood transfusion,Non Cardiac Surgery,2022,46
"Before allogenic blood transfusion, it should be considered to obtain an extensive consent about risks asssociated with transfusion.",IIa,C,18,Recommendations for intra- and post-operative complications associated with allogeneic blood transfusion,Non Cardiac Surgery,2022,46
"Patients with CCS If PCI is indicated before NCS, the use of new-generation DES is recommended over BMS and balloon angioplasty.",I,A,19,Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease,Non Cardiac Surgery,2022,49
Pre-operative evaluation of patients with an indication for PCI by an expert team (surgeon and cardiologist) should be considered before elective NCS.,IIa,C,19,Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease,Non Cardiac Surgery,2022,49
"Myocardial revascularization before high-risk elective NCS may be considered, depending on the amount of ischaemic myocardium, refractory symptoms, and ﬁndings at coronary angiography (as in the case of left main disease).",IIb,B,19,Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease,Non Cardiac Surgery,2022,49
Routine myocardial revascularization before lowand intermediate-risk NCS in patients with CCS is not recommended.,III,B,19,Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease,Non Cardiac Surgery,2022,49
"Patients with ACS If NCS can safely be postponed (e.g. at least 3 months), it is recommended that patients with ACS being scheduled for NCS undergo diagnostic and therapeutic interventions as recommended for ACS patients in general.",I,A,19,Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease,Non Cardiac Surgery,2022,49
"In the unlikely combination of a life-threatening clinical condition requiring urgent NCS, and NSTE-ACS with an indication for revascularization, the priorities for surgery on a case-by-case basis should be considered by the expert team.",IIa,C,19,Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease,Non Cardiac Surgery,2022,49
"In patients with suspected or known HF scheduled for high-risk NCS, it is recommended to evaluate LV function with echocardiography and measurement of NT-proBNP/BNP levels, unless this has recently been performed.",I,B,20,Recommendations for management of heart failure in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,50
It is recommended that patients with HF undergoing NCS receive optimal medical treatment according to current ESC guidelines.,I,A,20,Recommendations for management of heart failure in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,50
"In patients with HF undergoing NCS, it is recommended to regularly assess volume status and signs of organ perfusion.",I,C,20,Recommendations for management of heart failure in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,50
A multidisciplinary team including VAD specialists is recommended for peri-operative management of patients with HF receiving mechanical circulatory support.,I,C,20,Recommendations for management of heart failure in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,50
Clinical and echocardiographic evaluation (if not recently performed) is recommended in all patients with known or suspected VHD who are scheduled for elective intermediate- or high-risk NCS.,I,C,21,Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,53
Aortic valve stenosis AVR (SAVR or TAVI) is recommended in symptomatic patients with severe AS who are scheduled for elective intermediate- or high-risk NCS.,I,C,21,Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,53
"In patients with severe symptomatic AS in need of time-sensitive NCS or in whom the TAVI and SAVR are unfeasible, BAV may be considered before NCS as a bridge to deﬁnitive aortic valve repair.",IIb,C,21,Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,53
"Aortic valve regurgitation In patients with symptomatic severe AR or asymptomatic severe AR and LVESD .50 mm or LVESDi (LVESD/BSA) .25 mm/m2 (in patients with small body size) or resting LVEF ≤50%, valve surgery is recommended prior to elective intermediate- or high-risk NCS.",I,C,21,Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,53
"Mitral valve stenosis In patients with moderate-to-severe rheumatic MS and symptoms or SPAP .50 mmHg, valve intervention (PMC or surgery) is recommended before elective intermediate- or high-risk NCS.",I,C,21,Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,53
"Mitral valve regurgitation In patients with symptomatic severe primary MR or asymptomatic severe primary MR with LV dysfunction (LVESD ≥40 mm and/or LVEF ≤60%), valve intervention (surgical or transcatheter) should be considered prior to intermediate- or high-risk NCS, if time allows.",IIa,C,21,Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,53
"In patients with severe secondary MR who remain symptomatic despite guideline-directed medical therapy (including CRT if indicated), valve intervention (transcatheter or surgical) should be considered before NCS, in eligible patients with an acceptable procedural risk.",IIa,C,21,Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery,Non Cardiac Surgery,2022,53
"Supraventricular arrhythmias In patients with SVT controlled by medication, it is recommended that AADs are",I,C,22,Recommendations for management of known or newly diagnosed arrhythmias,Non Cardiac Surgery,2022,55
"Ablation should be considered in symptomatic patients with recurrent or persistent SVT, despite treatment, prior to high-risk, non-urgent NCS.437–",IIa,B,22,Recommendations for management of known or newly diagnosed arrhythmias,Non Cardiac Surgery,2022,55
"AF with haemodynamic instability in patients undergoing NCS In AF patients with acute or worsening haemodynamic instability undergoing NCS, emergency electrical cardioversion is recommended.",I,B,22,Recommendations for management of known or newly diagnosed arrhythmias,Non Cardiac Surgery,2022,55
"In AF patients with haemodynamic instability, amiodarone may be considered for acute control of heart rate.",IIb,B,22,Recommendations for management of known or newly diagnosed arrhythmias,Non Cardiac Surgery,2022,55
It is not recommended to initiate treatment of asymptomatic PVC during NCS.,III,C,22,Recommendations for management of known or newly diagnosed arrhythmias,Non Cardiac Surgery,2022,56
If indications for pacing exist according to the surgery should be deferred and implantation of a permanent pacemaker should be considered.,IIa,C,23,Recommendations for management of bradyarrhythmia and patients carrying cardiac implantable devices,Non Cardiac Surgery,2022,57
"It is recommended that patients with temporarily deactivated ICDs have continuous ECG monitoring, and during the peri-operative period are accompanied by personnel skilled in early detection and treatment of arrhythmias. In high-risk patients (e.g. pacemaker-dependant or ICD patients), or if access to the torso will be difﬁcult during the procedure, it is recommended to place transcutaneous pacing/deﬁbrillation pads prior to NCS.",I,C,23,Recommendations for management of bradyarrhythmia and patients carrying cardiac implantable devices,Non Cardiac Surgery,2022,57
It is recommended that all patients with CIEDs that are reprogrammed before surgery have a re-check and necessary reprogramming as soon as possible after the procedure.,I,C,23,Recommendations for management of bradyarrhythmia and patients carrying cardiac implantable devices,Non Cardiac Surgery,2022,57
"In patients with ACHD, a consultation with an ACHD specialist is recommended before intermediate- or high-risk surgery.",I,C,24,Recommendations for management of patients with adult congenital heart disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,58
"In patients with ACHD, it is recommended that intermediate- and high-risk elective surgery is performed in a centre with experience in the care of ACHD patients.",I,C,24,Recommendations for management of patients with adult congenital heart disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,58
"In patients with acute pericarditis, deferring elective NCS until complete resolution of the underlying process should be considered.",IIa,C,25,Recommendations for pericardial diseases,Non Cardiac Surgery,2022,59
Avoiding elective NCS procedures under general anaesthesia until colchicine or the immunosuppressive treatment course for pericardial disease is completed may be considered.,IIb,C,25,Recommendations for pericardial diseases,Non Cardiac Surgery,2022,59
It is recommended to continue chronic therapy for PAH in the peri-operative phase of NCS.,I,C,26,Recommendations for patients with pulmonary arterial hypertension undergoing non-cardiac surgery,Non Cardiac Surgery,2022,60
It is recommended that haemodynamic monitoring of patients with severe PAH continues for at least 24 h in the post-operative period.,I,C,26,Recommendations for patients with pulmonary arterial hypertension undergoing non-cardiac surgery,Non Cardiac Surgery,2022,60
"In the case of progression of right HF in the post-operative period in patients with PAH, it is recommended that the diuretic dose be optimized and, if necessary, i.v. prostacyclin analogues be initiated under the guidance of a physician experienced in the management of PAH.",I,C,26,Recommendations for patients with pulmonary arterial hypertension undergoing non-cardiac surgery,Non Cardiac Surgery,2022,60
"Inodilator drugs (dobutamine, milrinone, levosimendan), which increase cardiac output and lower pulmonary vascular resistance, should be considered peri-operatively according to the haemodynamic status of the patient.",IIa,C,26,Recommendations for patients with pulmonary arterial hypertension undergoing non-cardiac surgery,Non Cardiac Surgery,2022,60
"In patients with chronic hypertension undergoing elective NCS, it is recommended to avoid large peri-operative ﬂuctuations in blood pressure, particularly hypotension, during the peri-operative period.",I,A,27,Recommendations for pre-operative management of hypertension,Non Cardiac Surgery,2022,61
It is recommended to perform pre-operative screening for hypertension-mediated organ damage and CV risk factors in newly diagnosed hypertensive patients who are scheduled for elective high-risk NCS.,I,C,27,Recommendations for pre-operative management of hypertension,Non Cardiac Surgery,2022,61
It is not recommended to defer NCS in patients with stage 1 or 2 hypertension.,III,C,27,Recommendations for pre-operative management of hypertension,Non Cardiac Surgery,2022,61
"In patients with poor functional capacity or signiﬁcant risk factors or symptoms (such as moderate-to-severe angina pectoris, decompensated HF, valvular disease, and signiﬁcant arrhythmia), referral for cardiac work-up and optimization is recommended prior to elective surgery for PAD or AAA.",I,C,28,Recommendations for management of patients with peripheral artery disease and/or abdominal aortic aneurysm undergoing non-cardiac surgery,Non Cardiac Surgery,2022,62
"Routine referral for cardiac work-up, coronary angiography, or CPET prior to elective surgery for PAD or AAA is not recommended.",III,C,28,Recommendations for management of patients with peripheral artery disease and/or abdominal aortic aneurysm undergoing non-cardiac surgery,Non Cardiac Surgery,2022,62
Pre-operative carotid artery and cerebral imaging is recommended in patients with a history of TIA or stroke in the previous 6 months and who have not undergone ipsilateral revascularization.,I,C,29,Recommendations for management of patients with suspected or established carotid artery disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,62
"For patients with carotid artery disease undergoing NCS, the same indications for carotid revascularization should be considered as for other patients with carotid stenosis.",IIa,C,29,Recommendations for management of patients with suspected or established carotid artery disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,62
Pre-operative carotid artery imaging is not recommended routinely in patients undergoing NCS.,III,C,29,Recommendations for management of patients with suspected or established carotid artery disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,62
"In patients with renal disease requiring peri-operative contrast-enhanced radiography, balanced hydration with i.v. isotonic ﬂuids, the use of a minimal volume of contrast media, and the use of low-osmolar or iso-osmolar contrast media should be considered.547,553–",IIa,B,30,Recommendations for management of patients with renal disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,63
"In patients with known risk factors (age .65 years, BMI .30 kg/m2, diabetes, hypertension, hyperlipidaemia, CV disease, or smoking) undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease by measuring serum creatinine and GFR.",I,C,30,Recommendations for management of patients with renal disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,63
"If a cystatin C measurement assay is available, cystatin C measurement should be considered in patients with impaired eGFR (,45–59 mL/min/ 1.73 m2) to conﬁrm kidney disease.",IIa,C,30,Recommendations for management of patients with renal disease undergoing non-cardiac surgery,Non Cardiac Surgery,2022,63
"It is recommended to assess cardiorespiratory ﬁtness to estimate peri-operative CV risk in obese patients, with particular attention to those undergoing intermediate- and high-risk NCS.",I,B,31,Recommendations for management of patients with obesity undergoing noncardiac surgery,Non Cardiac Surgery,2022,63
"In patients at high risk of obesity hypoventilation syndrome, additional specialist investigation before major elective NCS should be considered.",IIa,C,31,Recommendations for management of patients with obesity undergoing noncardiac surgery,Non Cardiac Surgery,2022,63
"In patients with diabetes or disturbed glucose metabolism, a pre-operative HbA1c test is recommended, if this measurement has been not performed in the previous 3 months. In case of HbA1c ≥8.5% (≥69 mmol/mol), elective NCS should be postponed, if safe and practical.578–",I,B,32,Recommendations for management of patients with diabetes mellitus undergoing non-cardiac surgery,Non Cardiac Surgery,2022,64
"In order to preserve optimal CV stability, it is recommended to apply goal-directed haemodynamic therapy in patients undergoing high-risk NCS.614–",I,A,33,Recommendations for peri-operative monitoring and anaesthesia,Non Cardiac Surgery,2022,68
It is recommended to avoid post-operative acute pain.,I,B,33,Recommendations for peri-operative monitoring and anaesthesia,Non Cardiac Surgery,2022,68
"In order to minimize the risk of post-operative organ dysfunction, it is recommended to avoid an intra-operative mean arterial pressure decrease of .20% from baseline values or ,60–70 mmHg for ≥10 min.214,600–",I,B,33,Recommendations for peri-operative monitoring and anaesthesia,Non Cardiac Surgery,2022,68
Non-aspirin NSAIDs are not recommended as ﬁrst-line analgesics in patients with established or high risk of CVD.,III,B,33,Recommendations for peri-operative monitoring and anaesthesia,Non Cardiac Surgery,2022,68
"It is recommended to have high awareness of peri-operative CV complications, combined with surveillance for PMI in patients undergoing intermediate- or high-risk NCS.41,101,109– 111,118,413,636–",I,B,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
"Systematic PMI work-up is recommended to identify the underlying pathophysiology and deﬁne therapy.41,101,109–111,118,413,636–",I,B,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
"It is recommended to treat post-operative STEMI, NSTE-ACS, acute HF, and tachyarrhythmias in accordance with guidelines for the non-surgical setting, after interdisciplinary discussion with the surgeon about bleeding risk.",I,C,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
"In patients with post-operative PE of high or intermediate clinical probability, initiation of anticoagulation is recommended without delay, while diagnostic work-up is in progress, if bleeding risk is low.",I,C,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
Post-operative oral anticoagulation for PE is recommended to be administered for a period of at least 3 months.,I,C,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
"In patients with a post-operative indication for OAC, NOAC is generally recommended over VKA.",I,A,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
"In patients with post-operative AF after NCS, long-term OAC therapy should be considered in all patients at risk of stroke, considering the anticipated net clinical beneﬁt of OAC therapy, and informed patient preferences.",IIa,B,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
"In patients with MINS and at low risk of bleeding, treatment with dabigatran 110 mg orally b.i.d. may be considered from ≏1 week after NCS.",IIb,B,34,Recommendations for peri-operative cardiovascular complications,Non Cardiac Surgery,2022,74
Right heart catheterization It is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or CTEPH) and to support treatment decisions,I,B,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
"In patients with suspected or known PH, it is recommended that RHC is performed in experienced centres",I,C,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
It is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols,I,C,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
Vasoreactivity testing Vasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB,I,B,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
It is recommended that vasoreactivity testing is performed at PH centres,I,C,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
It is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg with an increased or unchanged COc,I,C,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
"Inhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing129–",I,C,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
"Vasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH, and in PH groups 2, 3, 4, and",III,C,1,Recommendations for right heart catheterization and vasoreactivity testing,Pulmonary Hypertension,2022,31
"Recommendation Echocardiography Echocardiography is recommended as the ﬁrst-line, non-invasive, diagnostic investigation in suspected PH",I,B,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
"It is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other echocardiographic signs suggestive of PH (see Table 10)",I,B,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
It is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the updated haemodynamic deﬁnition,I,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
"Based on the probability of PH by echocardiography, further testing should be considered in the clinical context (i.e. symptoms and risk factors or associated conditions for PAH/ CTEPH)",IIa,B,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
"In symptomatic patients with intermediate echocardiographic probability of PH, CPET may be considered to further determine the likelihood of PH",IIb,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
CT pulmonary angiography is recommended in the work-up of patients with suspected CTEPH,I,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
"Routine biochemistry, haematology, immunology, HIV testing, and thyroid function tests are recommended in all patients with PAH, to identify associated conditions",I,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
Abdominal ultrasound is recommended for the screening of portal hypertension,I,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
Chest CT should be considered in all patients with PH,IIa,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
Digital subtraction angiography should be considered in the work-up of patients with CTEPH,IIa,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
Other diagnostic tests Pulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH,I,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
Open or thoracoscopic lung biopsy is not recommended in patients with PAH,III,C,2,Recommendations for diagnostic strategy,Pulmonary Hypertension,2022,35
"Systemic sclerosis In patients with SSc, an annual evaluation of the risk of having PAH is recommended",I,B,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"In patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude PAH185–",I,C,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"Assessing the risk of having PAH based on an evaluation of breathlessness, in combination with echocardiogram or PFTs and BNP/NT-proBNP, should be considered in patients with SSc",IIa,B,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
Policies to evaluate the risk of having PAH should be considered in hospitals managing patients with SSc,IIa,C,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"In symptomatic patients with SSc, exercise echocardiography or CPET, or CMR may be considered to aid decisions to perform RHC",IIb,C,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"In patients with CTD with overlap features of SSc, an annual evaluation of the risk of PAH may be considered",IIb,C,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"CTEPH/CTEPD In patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for CTEPH/ CTEPD is recommended",I,C,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"For symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/ CTEPH centre is recommended after considering the results of echocardiography, BNP/ NT-proBNP, and/or CPET",I,C,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
Other Counselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing mutations and in ﬁrst-degree relatives of patients with HPAH,I,B,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"In patients referred for liver transplantation, echocardiography is recommended as a screening test for PH",I,C,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"Further tests (echocardiography, BNP/ NT-proBNP, PFTs, and/or CPET) should be considered in symptomatic patients with CTD, portal hypertension, or HIV to screen for PAH",IIa,B,3,Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension,Pulmonary Hypertension,2022,37
"It is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests, biochemical markers, echocardiography, and haemodynamic evaluations",I,B,4,Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension,Pulmonary Hypertension,2022,43
Achieving and maintaining a low-risk proﬁle on optimized medical therapy is recommended as a treatment goal in patients with PAH,I,B,4,Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension,Pulmonary Hypertension,2022,43
"For risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking into account all available data, including haemodynamics",I,B,4,Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension,Pulmonary Hypertension,2022,43
"For risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–high, and high risk) based on WHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary",I,B,4,Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension,Pulmonary Hypertension,2022,43
"In some PAH aetiologies and patients with comorbidities, optimization of therapy should be considered on an individual basis, while acknowledging that a low-risk proﬁle is not always achievable",IIa,B,4,Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension,Pulmonary Hypertension,2022,43
General measures Supervised exercise training is recommended in patients with PAH under medical therapy,I,A,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,45
"Immunization of patients with PAH against SARS-CoV-2, inﬂuenza, and Streptococcus pneumoniae is recommended",I,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
Diuretic treatment is recommended in patients with PAH with signs of RV failure and ﬂuid retention,I,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
"Long-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)c",I,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
"In the presence of iron-deﬁciency anaemia, correction of iron status is recommended in patients with PAH",I,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
"In the absence of anaemia, iron repletion may be considered in patients with PAH with iron deﬁciency",IIb,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
Anticoagulation is not generally recommended in patients with PAH but may be considered on an individual basis,IIb,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
"The use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers, or ivabradine is not recommended in patients with PAH unless required by comorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias)",III,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
"Special circumstances In-ﬂight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa (60 mmHg) at sea level",I,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
"For interventions requiring anaesthesia, multidisciplinary consultation at a PH centre to assess risk and beneﬁt should be considered",IIa,C,5,Recommendations for general measures and special circumstances,Pulmonary Hypertension,2022,46
"It is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and uncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological support where needed",I,C,6,Recommendations for women of childbearing potential,Pulmonary Hypertension,2022,46
"It is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an experienced PH centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients and their families where needed",I,C,6,Recommendations for women of childbearing potential,Pulmonary Hypertension,2022,46
"For women with PAH having a termination of pregnancy, it is recommended that this be performed in PH centres, with psychological support provided to the patients and their families",I,C,6,Recommendations for women of childbearing potential,Pulmonary Hypertension,2022,46
"For women with PAH who desire to have children, where available, adoption and surrogacy with preconception genetic counselling may be considered",IIb,C,6,Recommendations for women of childbearing potential,Pulmonary Hypertension,2022,46
"As teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not recommended during pregnancy",III,B,6,Recommendations for women of childbearing potential,Pulmonary Hypertension,2022,46
"High doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing",I,C,7,"Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,47
"Close follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH, HPAH, or DPAH treated with high doses of CCBs",I,C,7,"Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,47
"Continuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II with marked haemodynamic improvement (mPAP ,30 mmHg and PVR ,4 WU)",I,C,7,"Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,47
Initiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic improvement after high doses of CCBs,I,C,7,"Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,47
"In patients with a positive vasoreactivity test but insufﬁcient long-term response to CCBs who require additional PAH therapy, continuation of CCB therapy should be considered",IIa,C,7,"Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,47
"CCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g. Raynaud’s phenomenon)",III,C,7,"Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,47
Initial combination therapy with ambrisentan and tadalaﬁl is recommended,I,B,9,"Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities",Pulmonary Hypertension,2022,52
Initial combination therapy with macitentan and tadalaﬁl is recommended,I,B,9,"Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities",Pulmonary Hypertension,2022,52
Initial combination therapy with other ERAs and PDE5is should be considered,IIa,B,9,"Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities",Pulmonary Hypertension,2022,52
"Initial combination therapy with macitentan, tadalaﬁl, and selexipag is not recommended",III,B,9,"Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities",Pulmonary Hypertension,2022,52
General recommendation for sequential combination therapy It is recommended to base treatment escalations on risk assessment and general treatment strategies (see Figure 9),I,C,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
Evidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure The addition of macitentan to PDE5is or oral/ inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality events,I,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of selexipag to ERAsc and/or PDE5is is recommended to reduce the risk of morbidity/ mortality events,I,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of oral treprostinil to ERA or PDE5i/ riociguat monotherapy is recommended to reduce the risk of morbidity/mortality events,I,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/ mortality events419a,III,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
Evidence from studies with change in 6MWD as the primary outcome measure The addition of sildenaﬁl to epoprostenol is recommended to improve exercise capacity,I,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of inhaled treprostinil to sildenaﬁl or bosentan monotherapy should be considered to improve exercise capacity,IIa,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of riociguat to bosentan should be considered to improve exercise capacity,IIa,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of inhaled iloprost to bosentan may be considered to improve exercise capacity,IIb,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of ambrisentan to sildenaﬁl may be considered to improve exercise capacity,IIb,C,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of bosentan to sildenaﬁl may be considered to improve exercise capacity,IIb,C,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
The addition of sildenaﬁl to bosentan may be considered to improve exercise capacity444–,IIb,C,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
Other sequential double- or triple-combination therapies may be considered to improve exercise capacity and/or alleviate PH symptoms,IIb,C,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
Evidence from studies with safety of combination therapy as the primary outcome measure Combining riociguat and PDE5is is not recommendedd,III,B,10,"Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension",Pulmonary Hypertension,2022,53
"Classb Levelc Recommendations for initial therapy In patients with IPAH/HPAH/DPAH and cardiopulmonary comorbidities, initial monotherapy with a PDE5i or an ERA should be considered",IIa,C,11,"Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesa",Pulmonary Hypertension,2022,54
"Recommendations for treatment decisions during follow-up In patients with IPAH/HPAH/DPAH with cardiopulmonary comorbidities who present at intermediate or high risk of death while receiving PDE5i or ERA monotherapy, additional PAH medication may be considered on an individual basis",IIb,C,11,"Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesa",Pulmonary Hypertension,2022,54
"When managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and use supportive measures, including inotropes and vasopressors, ﬂuid management, and PAH drugs, as appropriate",I,C,12,Recommendations for intensive care management for pulmonary arterial hypertension,Pulmonary Hypertension,2022,55
"Mechanical circulatory support may be an option for selected patients as a bridge to transplantation or recovery, and interhospital transfer should be considered if such resources are unavailable on site",IIa,C,12,Recommendations for intensive care management for pulmonary arterial hypertension,Pulmonary Hypertension,2022,55
"It is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral combination therapy, indicated by an intermediate– high or high risk or by a REVEAL risk score .",I,C,13,Recommendations for lung transplantation,Pulmonary Hypertension,2022,56
It is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10 despite receiving optimized medical therapy including s.c. or i.v. prostacyclin analogues,I,C,13,Recommendations for lung transplantation,Pulmonary Hypertension,2022,56
It is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other causes of PH have been excluded,I,C,14,Recommendations for pulmonary arterial hypertension associated with drugs or toxins,Pulmonary Hypertension,2022,57
"In patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever possible",I,C,14,Recommendations for pulmonary arterial hypertension associated with drugs or toxins,Pulmonary Hypertension,2022,57
"Patients with low-risk PAH should be re-evaluated 3–4 months after discontinuing the suspected drug or toxin, and PAH therapy may be considered when the haemodynamics have not normalized",IIb,C,14,Recommendations for pulmonary arterial hypertension associated with drugs or toxins,Pulmonary Hypertension,2022,58
"In patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended",I,A,15,Recommendations for pulmonary arterial hypertension associated with connective tissue disease,Pulmonary Hypertension,2022,58
"In patients with PAH associated with HIV infection, antiretroviral treatment according to current guidelines is recommended",I,A,16,Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection,Pulmonary Hypertension,2022,59
"In patients with PAH associated with HIV infection, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration comorbidities and drug–drug interactions",IIa,C,16,Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection,Pulmonary Hypertension,2022,59
"Echocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as a screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt",I,C,17,Recommendations for pulmonary arterial hypertension associated with portal hypertension,Pulmonary Hypertension,2022,60
It is recommended that patients with PAH associated with portal hypertension are referred to centres with expertise in managing both conditions,I,C,17,Recommendations for pulmonary arterial hypertension associated with portal hypertension,Pulmonary Hypertension,2022,60
"In patients with PAH associated with portal hypertension, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration the underlying liver disease and indication for liver transplantation",IIa,C,17,Recommendations for pulmonary arterial hypertension associated with portal hypertension,Pulmonary Hypertension,2022,60
"Liver transplantation should be considered on an individual basis in patients with PAH associated with portal hypertension, as long as PVR is normal or near normal with PAH therapy",IIa,C,17,Recommendations for pulmonary arterial hypertension associated with portal hypertension,Pulmonary Hypertension,2022,60
"Drugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e. elevated mPAP, high CO, and a normal PVR)",III,C,17,Recommendations for pulmonary arterial hypertension associated with portal hypertension,Pulmonary Hypertension,2022,60
"ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance In patients with an ASD, VSD, or PDA and a PVR ,3 WU, shunt closure is recommended",I,C,18,Recommendations for shunt closure in patients with pulmonary–systemic,Pulmonary Hypertension,2022,63
"In patients with an ASD, VSD, or PDA and a PVR of 3–5 WU, shunt closure should be considered",IIa,C,18,Recommendations for shunt closure in patients with pulmonary–systemic,Pulmonary Hypertension,2022,63
"In patients with an ASD and a PVR .5 WU that declines to ,5 WU with PAH treatment, shunt closure may be considered",IIb,C,18,Recommendations for shunt closure in patients with pulmonary–systemic,Pulmonary Hypertension,2022,63
"In patients with a VSD or PDA and a PVR .5 WU, shunt closure may be considered after careful evaluation in specialized centres",IIb,C,18,Recommendations for shunt closure in patients with pulmonary–systemic,Pulmonary Hypertension,2022,63
"In patients with an ASD and a PVR .5 WU despite PAH treatment, shunt closure is not recommended",III,C,18,Recommendations for shunt closure in patients with pulmonary–systemic,Pulmonary Hypertension,2022,63
Risk assessment Risk assessment is recommended for patients with persistent PAH after defect closure,I,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
Risk assessment should be considered in patients with Eisenmenger syndrome,IIa,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
Treatment Bosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity,I,B,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
"In patients with Eisenmenger syndrome, the use of supplemental oxygen therapy should be considered in cases where it consistently increases arterial oxygen saturation and reduces symptoms",IIa,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
Supplemental iron treatment should be considered in patients with iron deﬁciency,IIa,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
"In patients with adult CHD, including Eisenmenger syndrome, other ERAs, PDE5is, riociguat, prostacyclin analogues, and prostacyclin receptor agonists should be considered",IIa,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
"In the absence of signiﬁcant haemoptysis, oral anticoagulant treatment may be considered in patients with Eisenmenger syndrome with pulmonary artery thrombosis",IIb,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
"In women with Eisenmenger syndrome, pregnancy is not recommended",III,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
"In patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended",III,C,19,Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease,Pulmonary Hypertension,2022,63
"capillary involvement A combination of clinical and radiological ﬁndings, ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous and/or capillary involvement (PVOD/PCH)",I,A,20,Recommendations for pulmonary arterial hypertension with signs of venous/,Pulmonary Hypertension,2022,64
Identiﬁcation of biallelic EIF2AK4 mutations is recommended to conﬁrm a diagnosis of heritable PVOD/PCH,I,A,20,Recommendations for pulmonary arterial hypertension with signs of venous/,Pulmonary Hypertension,2022,64
Referral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established,I,C,20,Recommendations for pulmonary arterial hypertension with signs of venous/,Pulmonary Hypertension,2022,64
"In patients with PVOD/PCH, the use of drugs approved for PAH may be considered with careful monitoring of clinical symptoms and gas exchange",IIb,C,20,Recommendations for pulmonary arterial hypertension with signs of venous/,Pulmonary Hypertension,2022,64
Lung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH,III,C,20,Recommendations for pulmonary arterial hypertension with signs of venous/,Pulmonary Hypertension,2022,64
"Children It is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at centres with speciﬁc expertise in paediatric PH",I,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"In children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults, but adapted for age)",I,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"For conﬁrming PH diagnosis, RHC is recommended, preferably before initiating any PAH therapy",I,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"In children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from CCB therapy",I,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"It is recommended to similarly deﬁne a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO",I,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"In children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended, extrapolated from that in adults but adapted for age",I,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"It is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical assessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests",I,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
Achieving and maintaining a low-risk proﬁle should be considered as an adequate treatment response for children with PAH,IIa,C,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
Infants It is recommended to screen infants with bronchopulmonary dysplasia for PH,I,B,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"In infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural airway disease —and optimizing respiratory support is recommended before initiating PAH therapy",I,B,21,Recommendations for paediatric pulmonary hypertension,Pulmonary Hypertension,2022,68
"It is recommended that PH centres provide care by a multidisciplinary team (cardiologist, pneumologist, rheumatologist, nurse specialist, radiologist, psychological and social work support, and appropriate on-call expertise)",I,C,25,Recommendations for pulmonary hypertension centres,Pulmonary Hypertension,2022,85
"It is recommended that PH centres have direct links and quick referral patterns to other services (such as genetic counselling, PEA/BPA, LTx, and adult congenital heart disease service)",I,C,25,Recommendations for pulmonary hypertension centres,Pulmonary Hypertension,2022,85
It is recommended that PH centres maintain a patient registry,I,C,25,Recommendations for pulmonary hypertension centres,Pulmonary Hypertension,2022,85
It is recommended that PH centres collaborate with patient associations,I,C,25,Recommendations for pulmonary hypertension centres,Pulmonary Hypertension,2022,85
Accreditation of the PH centres should be considered (e.g. https://ec.europa.eu/health/ern/ assessment_en),IIa,C,25,Recommendations for pulmonary hypertension centres,Pulmonary Hypertension,2022,85
PH centres’ participation in collaborative clinical research should be considered,IIa,C,25,Recommendations for pulmonary hypertension centres,Pulmonary Hypertension,2022,85
"PH centres should follow-up a sufﬁcient number of patients to maintain expertise (at least 50 patients with PAH or CTEPH and at least two new referrals per month with documented PAH or CTEPH), and consider establishing collaborations with high-volume centres",IIa,C,25,Recommendations for pulmonary hypertension centres,Pulmonary Hypertension,2022,85
"It is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c,90–",I,B,1,Recommendations for public basic life support and access to automated external deﬁbrillators,Ventricular Arrhythmias SCD,2022,18
Prompt CPR by bystanders is recommended at OHCA.93–,I,B,1,Recommendations for public basic life support and access to automated external deﬁbrillators,Ventricular Arrhythmias SCD,2022,18
It is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.,I,B,1,Recommendations for public basic life support and access to automated external deﬁbrillators,Ventricular Arrhythmias SCD,2022,18
Mobile phone-based alerting of basic life support-trained bystander volunteers to assist nearby OHCA victims should be considered.101–,IIa,B,1,Recommendations for public basic life support and access to automated external deﬁbrillators,Ventricular Arrhythmias SCD,2022,18
"In patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG, whenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.",I,C,3,Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia,Ventricular Arrhythmias SCD,2022,22
"In patients with newly documented VA (frequent PVCs, NSVT, SMVT) and suspicion of SHD other than CAD after initial evaluation, a CMR should be considered.",IIa,B,3,Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia,Ventricular Arrhythmias SCD,2022,22
"In patients with an incidental ﬁnding of a NSVT, a ≥24 h Holter ECG should be considered.",IIa,C,3,Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia,Ventricular Arrhythmias SCD,2022,22
Genetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA and SCD.,I,B,2,Recommendations for genetic testing,Ventricular Arrhythmias SCD,2022,22
"When a putative causative variant is ﬁrst identiﬁed, evaluation for pathogenicity is recommended using an internationally accepted framework.",I,C,2,Recommendations for genetic testing,Ventricular Arrhythmias SCD,2022,22
"When a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD, genetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.",I,C,2,Recommendations for genetic testing,Ventricular Arrhythmias SCD,2022,22
It is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert multidisciplinary team.,I,C,2,Recommendations for genetic testing,Ventricular Arrhythmias SCD,2022,22
"It is recommended that Class III (variants of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families where possible, and the variant re-evaluated periodically.",I,C,2,Recommendations for genetic testing,Ventricular Arrhythmias SCD,2022,22
It is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.,III,C,2,Recommendations for genetic testing,Ventricular Arrhythmias SCD,2022,22
"In patients presenting with a ﬁrst SMVT episode, electrophysiological study, electroanatomical mapping, and mapping-guided biopsies may be considered for aetiological evaluation.197–",IIb,C,4,Recommendations for evaluation of patients presenting with a ﬁrst episode of sustained monomorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,24
"Diagnostic evaluation The investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.177,251–",I,B,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,26
"In electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.",I,C,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,26
"In SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.",I,B,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,27
Retrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors.,I,B,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,27
"In SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG), as well as continuous cardiac monitoring, are recommended.",I,B,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,27
Echocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.,I,C,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,27
Coronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a clear underlying cause.,I,B,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,27
"Sodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.117,222,258–",I,B,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,27
"In SCA survivors, ergonovine, acetylcholine, or hyperventilation testing may be considered for the diagnosis of coronary vasospasm.",IIb,B,5,Recommendations for evaluation of sudden cardiac arrest survivors,Ventricular Arrhythmias SCD,2022,27
"Investigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"In cases of SD, it is recommended to collect a detailed description of circumstances of death, symptoms prior to death, the family history, and to review prior medical ﬁles.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"A comprehensive autopsy is recommended, ideally, in all cases of unexpected SD, and always in those ,50 years of age.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"In cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited cause is suspected or the cause of death unexplained.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
Toxicology screens are recommended in SD cases with uncertain cause of death.,I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"For SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"Following SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50) and/or the circumstances and/or family history support a primary electrical disease.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"When an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"In non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.",I,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"Following SADS, post-mortem genetic testing in the decedent for additional genes may be considered.",IIb,C,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"Following SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended.",III,B,6,Recommendations for evaluation of sudden death victims,Ventricular Arrhythmias SCD,2022,27
"Familial evaluation of SADS decedents is recommended: • for ﬁrst-degree relatives • for relatives who must carry a mutation based on analysis of the family history • for relatives with suspicious symptoms • when the decedent’s age is ,50 years, or if there is other circumstantial data or family history to suggest heritable disease.",I,B,7,Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents,Ventricular Arrhythmias SCD,2022,31
Familial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS decedent detects a pathogenic mutation.,I,B,7,Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents,Ventricular Arrhythmias SCD,2022,31
"Baseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination, standard and high precordial lead ECG, echocardiography, and exercise testing.",I,B,7,Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents,Ventricular Arrhythmias SCD,2022,31
"In SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach adulthood.",I,C,7,Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents,Ventricular Arrhythmias SCD,2022,31
Pharmacological testing with a sodium channel blocker should be considered in relatives of SADS decedents who are 16 years or older when baseline testing and/or proband ﬁndings increase the suspicion of BrS.,IIa,B,7,Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents,Ventricular Arrhythmias SCD,2022,31
Pharmacological testing including epinephrine challenge (if exercise testing is impractical) and sodium channel blocker challenge may be considered in ﬁrst-degree relatives of SADS decedents with normal baseline testing.,IIb,B,7,Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents,Ventricular Arrhythmias SCD,2022,31
"In SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be discharged with advice to return if they develop symptoms or if the family history changes.",III,C,7,Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents,Ventricular Arrhythmias SCD,2022,31
Withdrawal of offending agents is recommended whenever drug-induced VAs are suspected.,I,B,8,Recommendations for treatment of reversible conditions,Ventricular Arrhythmias SCD,2022,33
"Investigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)c is recommended in patients with VA.",I,C,8,Recommendations for treatment of reversible conditions,Ventricular Arrhythmias SCD,2022,33
"Despite a possible correctable cause for the presenting VA, the need for ICD implantation should be considered based on an individual evaluation of the risk of subsequent VA/ SCD.",IIa,C,8,Recommendations for treatment of reversible conditions,Ventricular Arrhythmias SCD,2022,33
Acute management of sustained VT DC cardioversion is recommended as the ﬁrst-line treatment for patients with haemodynamically not-tolerated SMVT.,I,B,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,37
DC cardioversion is recommended as the ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the anaesthetic/ sedation risk is low.,I,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,37
"In patients presenting with a regular haemodynamically tolerated wide QRS complex tachycardia suspected for SVT, administration of adenosine or vagal manoeuvres should be considered.",IIa,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
"In patients presenting with a haemodynamically tolerated SMVT and known or suspected SHD, intravenous procainamide should be considered.",IIa,B,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
"In patients presenting with a haemodynamically tolerated SMVT in the absence of an established diagnosis, intravenous amiodarone may be considered.",IIb,B,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
"In patients presenting with a haemodynamically tolerated SMVT in the absence of signiﬁcant SHD, ﬂecainide, ajmaline, or sotalol may be considered.",IIb,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Intravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism.,III,B,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Management of electrical storm Mild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic tone.,I,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Antiarrhythmic therapy with beta-blockers (non-selective preferred) in combination with intravenous amiodarone is recommended in patients with SHD and electrical storm unless contraindicated.,I,B,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Intravenous magnesium with supplementation of potassium is recommended in patients with TdP.,I,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Isoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent TdP despite correction of precipitating conditions and magnesium.,I,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Catheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs.,I,B,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Deep sedation/intubation should be considered in patients with an intractable electrical storm refractory to drug treatment.,IIa,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
"Catheter ablation should be considered in patients with recurrent episodes of PVT/VF triggered by a similar PVC, non-responsive to medical treatment or coronary revascularization.",IIa,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Quinidine may be considered in patients with CAD and electrical storm due to recurrent PVT when other AAD therapy fails.,IIb,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
Institution of mechanical circulatory support may be considered in the management of drug-refractory electrical storm and cardiogenic shock.,IIb,C,9,Recommendations for the acute management of sustained ventricular tachycardia and electrical storm,Ventricular Arrhythmias SCD,2022,38
"Optimal medical treatment including ACE-I/ARB/ ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure patients with reduced EF.343–",I,A,10,Recommendations for treatment with heart failure medication,Ventricular Arrhythmias SCD,2022,38
ICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible causes.349–,I,A,12,Recommendations for secondary prevention of sudden cardiac death*,Ventricular Arrhythmias SCD,2022,44
"In patients with VT/VF, an indication for ICD, and no contraindication for amiodarone, amiodarone may be considered when an ICD is not available, contraindicated for concurrent medical reasons, or declined by the patient.",IIb,C,12,Recommendations for secondary prevention of sudden cardiac death*,Ventricular Arrhythmias SCD,2022,44
"In patients with SMVT or SPVT/VF triggered by a PVC with similar morphology and an indication for ICD, catheter ablation may be considered when an ICD is not available, contraindicated for concurrent medical reasons, or declined by the patient.",IIb,C,12,Recommendations for secondary prevention of sudden cardiac death*,Ventricular Arrhythmias SCD,2022,44
"When an ICD is indicated, it is recommended to evaluate whether the patient could beneﬁt from CRT-deﬁbrillator.",I,C,14,Recommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator,Ventricular Arrhythmias SCD,2022,44
(general aspects) Implantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good quality survival .1 year.,I,C,11,Recommendations for implantable cardioverter deﬁbrillator implantation,Ventricular Arrhythmias SCD,2022,44
It is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled.,III,C,11,Recommendations for implantable cardioverter deﬁbrillator implantation,Ventricular Arrhythmias SCD,2022,44
"The WCD should be considered for adult patients with a secondary prevention ICD indication, who are temporarily not candidates for ICD implantation.",IIa,C,15,Recommendations for wearable cardioverter deﬁbrillator,Ventricular Arrhythmias SCD,2022,44
"Subcutaneous deﬁbrillator should be considered as an alternative to transvenous deﬁbrillator in patients with an indication for an ICD when pacing therapy for bradycardia, cardiac resynchronization, or ATP is not needed.",IIa,B,13,Recommendations for subcutaneous implantable cardioverter deﬁbrillator,Ventricular Arrhythmias SCD,2022,44
Optimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality.373–,I,A,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
Programming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30 intervals).,I,A,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
It is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients.,I,A,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
"In patients with SHD, programming of at least one ATP therapy is recommended in all tachyarrhythmias zones.",I,A,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
It is recommended to program algorithms for SVT vs. VT discrimination for tachycardias with rates up to 230 b.p.m.383–,I,B,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
It is recommended to activate lead failure alerts.397–,I,B,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
Remote monitoring is recommended to reduce the incidence of inappropriate shocks.,I,B,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
Programming of burst ATP as ﬁrst attempt is recommended over ramp ATP.,I,B,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
"For S-ICDs, a dual detection zone conﬁguration is recommended with activation of discrimination algorithm in the lower conditional shock zone.388–",I,B,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
"For routine ICD programming, activation of more than one tachycardia detection zone should be considered.",IIa,B,16,Recommendations for optimization of device programming,Ventricular Arrhythmias SCD,2022,45
Catheter ablation is recommended for ICD patients with recurrent SVT resulting in inappropriate ICD therapies.,I,C,17,Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy,Ventricular Arrhythmias SCD,2022,46
Pharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite optimal ICD programming.,I,C,17,Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy,Ventricular Arrhythmias SCD,2022,46
Assessment of psychological status and treatment of distress is recommended in ICD patients.421–,I,C,18,Recommendations for psychosocial management after implantable cardioverter deﬁbrillator implantation,Ventricular Arrhythmias SCD,2022,46
Communication between patient and physician/ healthcare professional is recommended to address ICD-related concerns and to discuss quality-of-life issues before ICD implantation and during disease progression.,I,C,18,Recommendations for psychosocial management after implantable cardioverter deﬁbrillator implantation,Ventricular Arrhythmias SCD,2022,46
ICD implantation should be considered in LVAD recipients with symptomatic sustained VAs.,IIa,B,19,Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular assist device recipients,Ventricular Arrhythmias SCD,2022,46
Informed discussion with patient and family about ICD deactivation options and shared decision-making is indicated prior to implantation and in case of signiﬁcant health status deterioration.,I,C,21,Recommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers,Ventricular Arrhythmias SCD,2022,47
Single-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication for atrial or AV sequential pacing due to a lower risk of device-related complications.,I,A,20,Recommendations for prevention of implantable cardioverter deﬁbrillator complications,Ventricular Arrhythmias SCD,2022,47
The use of single-coil leads over dual-coil ICD leads should be considered due to lower complication rate during transvenous lead extraction.,IIa,C,20,Recommendations for prevention of implantable cardioverter deﬁbrillator complications,Ventricular Arrhythmias SCD,2022,47
Treatment of VAs in ACS Intravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI unless contraindicated.,I,B,22,Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm,Ventricular Arrhythmias SCD,2022,50
Intravenous amiodarone treatment should be considered for patients with recurrent PVT/VF during the acute phase of ACS.,IIa,C,22,Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm,Ventricular Arrhythmias SCD,2022,50
"Intravenous lidocaine may be considered for the treatment of recurrent PVT/VF not responding to beta-blockers or amiodarone, or if amiodarone is contraindicated during the acute phase of ACS.",IIb,C,22,Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm,Ventricular Arrhythmias SCD,2022,50
Prophylactic treatment with AADs (other than beta-blockers) is not recommended in ACS.,III,B,22,Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm,Ventricular Arrhythmias SCD,2022,50
"Vasospasm In SCA survivors with coronary artery spasm, implantation of an ICD should be considered.562–",IIa,C,22,Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm,Ventricular Arrhythmias SCD,2022,50
Risk stratiﬁcation Early (before discharge) assessment of LVEF is recommended in all patients with acute MI.,I,B,23,Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmias early after myocardial infarction,Ventricular Arrhythmias SCD,2022,50
"In patients with pre-discharge LVEF ≤40%, re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for primary prevention ICD implantation.",I,C,23,Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmias early after myocardial infarction,Ventricular Arrhythmias SCD,2022,50
Treatment of VAs Catheter ablation should be considered in patients with recurrent episodes of PVT/VF triggered by a similar PVC non-responsive to medical treatment or coronary revascularization in the subacute phase of MI.,IIa,C,23,Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmias early after myocardial infarction,Ventricular Arrhythmias SCD,2022,50
"and treatment of ventricular arrhythmias in chronic coronary artery disease Risk stratiﬁcation and primary prevention of SCD In patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation.",I,C,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"ICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% despite ≥3 months of OMT.",I,A,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"ICD therapy should be considered in patients with CAD, NYHA class I, and LVEF ≤30% despite ≥3 months of OMT.",IIa,B,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"ICD implantation should be considered in patients with CAD, LVEF ≤40% despite ≥3 months of OMT, and NSVT, if they are inducible for SMVT by PES.",IIa,B,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"In patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended.",III,A,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
Secondary prevention of SCD and treatment of VAs ICD implantation is recommended in patients without ongoing ischaemia with documented VF or haemodynamically not-tolerated VT occurring later than 48 h after MI.349–,I,A,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"In patients with CAD and recurrent, symptomatic SMVT, or ICD shocks for SMVT despite chronic amiodarone therapy, catheter ablation is recommended in preference to escalating AAD therapy.",I,B,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"In patients with CAD and haemodynamically well-tolerated SMVT and LVEF ≥40%, catheter ablationinexperiencedcentresshouldbeconsidered as an alternative to ICD therapy, provided that established endpoints have been reached.c",IIa,C,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"ICD implantation should be considered in patients with a haemodynamically tolerated SMVT and an LVEF ≥40% if VT ablation fails, is not available, or is not desired.",IIa,C,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"Catheter ablation should be considered in patients with CAD and recurrent, symptomatic SMVT, or ICD shocks for SMVT despite beta-blockers or sotalol treatment.",IIa,C,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
"In patients with CAD eligible for ICD implantation, catheter ablation may be considered just before (or immediately after) ICD implantation to decrease subsequent VT burden and ICD shocks.",IIb,B,24,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,51
Diagnostic evaluation Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous aortic origin of a coronary artery with an interarterial course to conﬁrm/exclude myocardial ischaemia.,I,C,25,Recommendations for sudden cardiac death prevention in patients with coronary anomalies,Ventricular Arrhythmias SCD,2022,54
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients with anomalous aortic origin of a coronary artery with a history of aborted CA.,I,C,25,Recommendations for sudden cardiac death prevention in patients with coronary anomalies,Ventricular Arrhythmias SCD,2022,54
"Treatment Surgery is recommended in patients with anomalous aortic origin of a coronary artery with CA, syncope suspected to be due to VAs, or angina when other causes have been excluded.",I,C,25,Recommendations for sudden cardiac death prevention in patients with coronary anomalies,Ventricular Arrhythmias SCD,2022,54
Surgery should be considered in asymptomatic patients with anomalous aortic origin of a coronary artery and evidence of myocardial ischaemia or abnormal aortic origin of the left coronary artery with high-risk anatomy.c,IIa,C,25,Recommendations for sudden cardiac death prevention in patients with coronary anomalies,Ventricular Arrhythmias SCD,2022,54
General recommendations Regular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated.,I,C,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
"In patients with PVCs/VT and a presentation not typical for an idiopathic origin,c CMR should be considered, despite a normal echocardiogram.",IIa,C,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
Treatment Catheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/ PVCs from the RVOT or the left fascicles.d,I,B,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
Beta-blockers or non-dihydropyridine CCBs are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.,I,C,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
"Beta-blockers, non-dihydropyridine CCBs, or ﬂecainide should be considered when catheter ablation is not available, desired, or is particularly risky in symptomatic patients with idiopathic VT/ PVCs from the RVOT or the left fascicles.",IIa,B,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
Catheter ablation or ﬂecainide should be considered in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.,IIa,C,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
Catheter ablation may be considered for idiopathic VT/PVCs in asymptomatic patients with repeatedly more than 20% of PVCs per day at follow-up.,IIb,B,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
"Catheter ablation of idiopathic VT/PVCs is not recommended in children ,5 years of age or ,10 kg weight except when previous medical therapy fails or when VT is not haemodynamically tolerated.",III,C,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
Amiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/ PVCs.,III,C,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
"Verapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use of other AADs.",III,C,26,Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia,Ventricular Arrhythmias SCD,2022,56
"Recommendation Diagnostic evaluation In patients with an unexplained reduced EF and a PVC burden of at least 10%, PVC-induced cardiomyopathy should be considered.",IIa,C,27,Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complexaggravated cardiomyopathy,Ventricular Arrhythmias SCD,2022,57
"In patients with suspected PVC-induced cardiomyopathy, CMR should be considered.",IIa,B,27,Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complexaggravated cardiomyopathy,Ventricular Arrhythmias SCD,2022,57
"Treatment In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is recommended.",I,C,27,Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complexaggravated cardiomyopathy,Ventricular Arrhythmias SCD,2022,57
"In patients with SHD in whom predominately monomorphic frequent PVCs are suspected to be contributing to the cardiomyopathy, AAD (amiodarone) treatment or catheter ablation should be considered.",IIa,B,27,Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complexaggravated cardiomyopathy,Ventricular Arrhythmias SCD,2022,58
"In non-responders to CRT with frequent, predominately monomorphic PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation or AADs should be considered.",IIa,C,27,Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complexaggravated cardiomyopathy,Ventricular Arrhythmias SCD,2022,58
"Recommendation Diagnostic evaluation and general recommendations Genetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV conduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a ﬁrst-degree relative (at age ,50 years).641–",I,B,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
CMR with LGE should be considered in DCM/ HNDCM patients for assessing the aetiology and the risk of VA/SCD.,IIa,B,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
"Genetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) should be considered for risk stratiﬁcation in patients with apparently sporadic DCM/HNDCM, who present at young age, or with signs suspicious for an inherited aetiology.641–",IIa,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
Participation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a LMNA mutation.,III,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
"Risk stratiﬁcation and primary prevention of SCD ICD implantation should be considered in patients with DCM/HNDCM, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% after ≥3 months of OMT.",IIa,A,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
"ICD implantation should be considered in DCM/ HNDCM patients with a pathogenic mutation in LMNA gene, if the estimated 5-year risk of life-threatening VA is ≥10%c and in the presence of NSVT or LVEF , 50% or AV conduction delay.",IIa,B,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
"ICD implantation should be considered in DCM/ HNDCM patients with a LVEF ,50% and ≥2 risk factors (syncope, LGE on CMR, inducible SMVT at PES, pathogenic mutations in LMNA,d PLN, FLNC, and RBM20 genes).",IIa,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
"In DCM/HNDM patients, electrophysiological evaluation should be considered when syncope remains unexplained after non-invasive evaluation.",IIa,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,61
"Catheter ablation in specialized centres should be considered in patients with DCM/HNDCM and recurrent, symptomatic SMVT or ICD shocks for SMVT, in whom AADs are ineffective, contraindicated, or not tolerated.",IIa,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,62
"The addition of oral amiodarone or replacement of beta-blockers by sotalol should be considered in patients with DCM/HNDCM and an ICD who experience recurrent, symptomatic VA despite optimal device programming and beta-blocker treatment.",IIa,B,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,62
ICD implantation should be considered in patients with DCM/HNDCM and haemodynamically tolerated SMVT.,IIa,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,62
"Management of relatives of a patient or SCD victim with DCM/HNDCM In a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG and an echocardiogram are recommended if: •theindexpatientwasdiagnosed,50yearsofageor hasclinicalfeaturessuggestiveofaninheritedcause,or • there is family history of DCM/HNDCM, or premature unexpected SD.",I,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,62
"In a ﬁrst-degree relative of a patient with apparently sporadic DCM/HNDCM, an ECG and an echocardiogram may be considered.",IIb,C,28,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy",Ventricular Arrhythmias SCD,2022,62
"Diagnostic evaluation and general recommendations In patients with suspected ARVC, CMR is recommended.676–",I,B,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"In patients with a suspected or deﬁnite diagnosis of ARVC, genetic counselling and testing are recommended.",I,B,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
Avoidance of high-intensity exercise is recommended in patients with a deﬁnite diagnosis of ARVC.683–,I,B,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
Avoidance of high-intensityc exercise may be considered in carriers of ARVC-related pathogenic mutations and no phenotype.,IIb,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
Beta-blocker therapy may be considered in all patients with a deﬁnite diagnosis of ARVC.,IIb,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"Risk stratiﬁcation and primary prevention of SCD ICD implantation should be considered in patients with deﬁnite ARVC and an arrhythmic syncope.696,701,711–",IIa,B,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
ICD implantation should be considered in patients with deﬁnite ARVC and severe RV or LV systolic dysfunction.,IIa,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"ICD implantation should be considered in symptomaticd patients with deﬁnite ARVC, moderate right or left ventricular dysfunction, and",IIa,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
Secondary prevention of SCD and treatment of VAs ICD implantation is recommended in ARVC patients with haemodynamically not-tolerated VT or VF.,I,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"In patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended.",I,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"In patients with ARVC and recurrent, symptomatic SMVT or ICD shocks for SMVT despite beta-blockers, catheter ablation in specialized centres should be considered.",IIa,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"In ARVC patients with indication for ICDs, a device with the capability of ATP programming for SMVT up to high rates should be considered.",IIa,B,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
ICD implantation should be considered in ARVC patients with a haemodynamically tolerated SMVT.,IIa,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"In patients with ARVC and recurrent, symptomatic VT despite beta-blockers, AAD treatment should be considered.",IIa,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
"Management of relatives of a patient with ARVC In a ﬁrst-degree relative of a patient with ARVC, ECG and echocardiogram are recommended.",I,C,29,"Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy",Ventricular Arrhythmias SCD,2022,64
and treatment of ventricular arrhythmias in hypertropic cardiomyopathy Recommendation Diagnostic evaluation and general recommendations CMR with LGE is recommended in HCM patients for diagnostic work-up.716–,I,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
Genetic counselling and testing are recommended in HCM patients.721–,I,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
Participation in high-intensity exercise may be considered for asymptomatic adult HCM patients without risk markers.,IIb,C,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"Risk stratiﬁcation and primary prevention of SCD It is recommended that the 5-year risk of SCD is assessed at ﬁrst evaluation and at 1–3-year intervals, or when there is a change in clinical status.",I,C,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
ICD implantation should be considered in patients aged 16 years or more with an estimated 5-year risk of SD ≥6%.c,IIa,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"ICD implantation should be considered in HCM patients aged 16 years or more with an intermediate 5-year risk of SCD (≥4 to ,6%)c and with (a) signiﬁcant LGE at CMR (usually ≥15% of LV mass); or (b) LVEF , 50%; or (c) abnormal blood pressure response during exercise testd; or (d) LV apical aneurysm; or (e) presence of sarcomeric pathogenic mutation.716,717,722,736–",IIa,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"In children less than 16 years of age with HCM and an estimated 5-year risk of SD ≥6% (based on HCM Risk-Kids scoree), ICD implantation should be considered.",IIa,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"ICD implantation may be considered in HCM patients aged 16 years or more with an estimated 5-year risk of SCD of ≥4 to ,6%.c",IIb,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"ICD implantation may be considered in HCM patients aged 16 years or more with a low estimated 5-year risk of SCD (,4%)c and with (a) signiﬁcant LGE at CMR (usually ≥15% of LV mass); or (b) LVEF , 50%; or (c) LV apical aneurysm.716,717,722,736–",IIb,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
Secondary prevention of SCD and treatment of VAs ICD implantation is recommended in HCM patients with haemodynamically not-tolerated VT or VF.744–,I,B,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"In patients with HCM presenting with haemodynamically tolerated SMVT, ICD implantation should be considered.",IIa,C,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"In patients with HCM and recurrent, symptomatic VA, or recurrent ICD therapy, AAD treatment should be considered.",IIa,C,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,66
"Management of relatives of a patient with HCM In a ﬁrst-degree relative of a patient with HCM, ECG and echocardiogram are recommended.",I,C,30,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,67
"In patients with a LVNC cardiomyopathy phenotype based on CMR or echocardiography, implantation of an ICD for primary prevention of SCD should be considered to follow DCM/ HNDCM recommendations.",IIa,C,31,Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular non-compaction,Ventricular Arrhythmias SCD,2022,67
An ICD should be considered in patients with light-chain amyloidosis or transthyretin-associated cardiac amyloidosis and haemodynamically not-tolerated VT.,IIa,C,32,Recommendations for implantable cardioverter deﬁbrillator implantation in patients with cardiac amyloidosis,Ventricular Arrhythmias SCD,2022,67
"and treatment of ventricular arrhythmias in neuromuscular diseases General recommendations Annual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the disease.",I,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
It is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for arrhythmia as patients without neuromuscular disorders.,I,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"Risk stratiﬁcation, primary and secondary prevention of SCD Invasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of VA or surviving a CA.",I,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a sudden increase in the PR interval or QRS duration.,IIa,B,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a PR interval ≥240 ms or QRS duration ≥120 ms or who are older than 40 years and have supraventricular arrhythmiasc or who are older than 40 years and have signiﬁcant LGE on CMR.c,IIa,B,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"In myotonic dystrophy patients without AV conduction delay and a syncope highly suspicious for VA, ICD implantation should be considered.",IIa,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"In myotonic dystrophy patients with palpitations highly suspicious for VA and induction of a non-BBR-VT, ICD implantation should be considered.",IIa,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"In patients with limb–girdle type 1B or Emery– Dreifuss muscular dystrophies and indication for pacing, ICD implantation should be considered.",IIa,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
Implantation of an ICD may be considered in patients with Duchenne/Becker muscular dystrophy and signiﬁcant LGE at CMR.,IIb,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
Implantation of an ICD over a permanent pacemaker may be considered in myotonic dystrophy patients with additional risk factorsd for VAs and SCD.,IIb,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"In myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended without arrhythmia suspicion or progression of ECG conduction disorders.",III,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"Management of VA In symptomatic patients with BBR-VT, catheter ablation is recommended.e",I,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"In patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD implantation is recommended.",I,C,33,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,69
"General recommendations In conﬁrmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VAs are referred to a specialized centre.",I,C,34,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis,Ventricular Arrhythmias SCD,2022,70
"Secondary prevention of SCD and treatment of VA In patients with haemodynamically not-tolerated SMVT occurring in the chronic phase of myocarditis, an ICD implantation is recommended.",I,C,34,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis,Ventricular Arrhythmias SCD,2022,70
"In patients with haemodynamically not-tolerated sustained VT or VF during the acute phase of myocarditis, ICD implantation before hospital discharge should be considered.",IIa,C,34,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis,Ventricular Arrhythmias SCD,2022,70
AADs should be considered (preferably amiodarone and beta-blockers) in patients with symptomatic non-sustained or sustained VAs during the acute phase of myocarditis.,IIa,C,34,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis,Ventricular Arrhythmias SCD,2022,70
"In post-myocarditis patients with recurrent, symptomatic VT, AAD treatment should be considered.",IIa,C,34,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis,Ventricular Arrhythmias SCD,2022,70
"Catheter ablation, performed in specialized centres, should be considered in post-myocarditis patients with recurrent, symptomatic SMVT or ICD shocks for SMVT in whom AADs are ineffective, not tolerated, or not desired.",IIa,C,34,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis,Ventricular Arrhythmias SCD,2022,70
"In patients with haemodynamically tolerated SMVT occurring in the chronic phase of myocarditis, ICD implantation should be considered.",IIa,C,34,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis,Ventricular Arrhythmias SCD,2022,70
"and treatment of ventricular arrhythmias in cardiac sarcoidosis Risk stratiﬁcation and primary prevention of SCD ICD implantation is recommended in patients with cardiac sarcoidosis who have a LVEF ≤35%.812,828–",I,B,35,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,71
"In patients with cardiac sarcoidosis who have an indication for permanent cardiac pacing related to high-degree AV block, ICD implantation should be considered, regardless of LVEF.",IIa,C,35,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,71
"In patients with cardiac sarcoidosis who have a LVEF .35% but signiﬁcant LGE at CMR after resolution of acute inﬂammation, ICD implantation should be considered.817–",IIa,B,35,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,71
"In patients with cardiac sarcoidosis who have a LVEF 35–50% and minor LGE at CMR, after resolution of acute inﬂammation, PES for risk stratiﬁcation should be considered.",IIa,C,35,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,71
"In patients with cardiac sarcoidosis, LVEF 35–50% and inducible SMVT at PES, ICD implantation should be considered.823–",IIa,C,35,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,71
"In patients with cardiac sarcoidosis and recurrent, symptomatic VA, AAD treatment should be considered.",IIa,C,35,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,72
"Catheter ablation, in specialized centres, may be considered in cardiac sarcoidosis ICD-recipients with recurrent, symptomatic SMVT or ICD shocks for SMVT, in whom AADs are ineffective, contraindicated, or not tolerated.",IIb,C,35,"Recommendations for risk stratiﬁcation, sudden cardiac death prevention,",Ventricular Arrhythmias SCD,2022,72
Chagas’ cardiomyopathy Amiodarone should be considered to reduce arrhythmia burden in patients with Chagas’ cardiomyopathy who present with symptomatic PVCs or VT.,IIa,C,36,Recommendations for the treatment of ventricular arrhythmias in,Ventricular Arrhythmias SCD,2022,74
"In patients with Chagas’ cardiomyopathy and recurrent, symptomatic SMVT or ICD shocks for SMVT in whom AADs are ineffective, contraindicated, or not tolerated, catheter ablation in specialized centres should be considered.",IIa,C,36,Recommendations for the treatment of ventricular arrhythmias in,Ventricular Arrhythmias SCD,2022,74
"In patients with Chagas’ cardiomyopathy and symptomatic VT in whom AADs (amiodarone and beta-blockers) are ineffective or not tolerated, ICD implantation may be considered.851,854–",IIb,C,36,Recommendations for the treatment of ventricular arrhythmias in,Ventricular Arrhythmias SCD,2022,74
"PES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT, especially if it occurs following a valve intervention.",I,C,37,Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in valvular heart disease,Ventricular Arrhythmias SCD,2022,74
"Risk stratiﬁcation and primary prevention of SCD All CHD patients In adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III) and EF ≤35% despite ≥3 months of OMT, ICD implantation is indicated.",I,C,38,Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"In patients with advanced single ventricle or systemic RV dysfunction with additional risk factors,c ICD implantation may be considered.",IIb,C,38,Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"Tetralogy of Fallot In patients after repair of TOF with arrhythmia symptoms and NSVT, electrophysiologic evaluation including PES should be considered.889,903–",IIa,C,38,Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"In patients after repair of TOF with arrhythmia symptoms and a positive PES, or a combination of other risk factorsd and a positive PES, ICD implantation should be considered.",IIa,C,38,Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"In patients after repair of TOF without arrhythmia symptoms, but with a combination of other risk factors,d electrophysiologic evaluation, including PES, may be considered.",IIb,C,38,Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"In patients with repaired TOF undergoing surgical or transcutaneous pulmonary valve replacement, pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention may be considered.",IIb,C,38,Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"Secondary prevention of SCD and treatment of VA All CHD patients In patients with CHD presenting with sustained VAs, evaluation for residual lesions or new structural abnormalities is recommended.",I,B,39,Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"In patients with CHD with not tolerated VT/ aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes.",I,C,39,Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease,Ventricular Arrhythmias SCD,2022,76
"In selected patients with CHD (including atrial bafﬂe repair for transposition of the great arteries, Fontan operation and Ebstein anomaly) presenting with CA, evaluation and treatment of SVT with rapid ventricular conduction should be considered.",IIa,C,39,Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease,Ventricular Arrhythmias SCD,2022,77
"Tetralogy of Fallot In patients with repaired TOF who present with SMVT or recurrent, symptomatic appropriate ICD therapy for SMVT, catheter ablation performed in specialized centres is recommended.899–",I,C,39,Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease,Ventricular Arrhythmias SCD,2022,77
"In patients with repaired TOF with SMVT who are undergoing surgical or transcutaneous pulmonary valve replacement, pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention should be considered.",IIa,C,39,Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease,Ventricular Arrhythmias SCD,2022,77
"In patients with repaired TOF with a preserved biventricular function and symptomatic SMVT, catheter ablation or concomitant surgical ablation performed in specialized centres may be considered as an alternative to ICD therapy.",IIb,C,39,Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease,Ventricular Arrhythmias SCD,2022,77
"Diagnostic evaluation It is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an underlying structural, channelopathic, metabolic, or toxicological aetiology.",I,B,40,Recommendations for the management of patients with idiopathic ventricular ﬁbrillation,Ventricular Arrhythmias SCD,2022,77
"Clinical testing (history, ECG and high precordial lead ECG, exercise test, echocardiogram) of ﬁrst-degree family members of idiopathic VF patients may be considered.",IIb,B,40,Recommendations for the management of patients with idiopathic ventricular ﬁbrillation,Ventricular Arrhythmias SCD,2022,77
"In idiopathic VF patients, genetic testing of genes related to channelopathy and cardiomyopathy may be considered.",IIb,B,40,Recommendations for the management of patients with idiopathic ventricular ﬁbrillation,Ventricular Arrhythmias SCD,2022,77
"Secondary prevention of SCD and treatment of VA ICD implantation is recommended in idiopathic VF.352,917–",I,B,40,Recommendations for the management of patients with idiopathic ventricular ﬁbrillation,Ventricular Arrhythmias SCD,2022,77
"Isoproterenol infusion, verapamil, or quinidine for acute treatment of an electrical storm or recurrent ICD discharges should be considered in idiopathic VF.912,913,918,922–",IIa,C,40,Recommendations for the management of patients with idiopathic ventricular ﬁbrillation,Ventricular Arrhythmias SCD,2022,77
Quinidine should be considered for chronic therapy to suppress an electrical storm or recurrent ICD discharges in idiopathic VF.,IIa,B,40,Recommendations for the management of patients with idiopathic ventricular ﬁbrillation,Ventricular Arrhythmias SCD,2022,77
Catheter ablation by experienced electrophysiologists should be considered in idiopathic VF patients with recurrent episodes of VF triggered by a similar PVC non-responsive to medical treatment.927–,IIa,C,40,Recommendations for the management of patients with idiopathic ventricular ﬁbrillation,Ventricular Arrhythmias SCD,2022,77
Diagnosis It is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS diagnostic score .3.,I,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
"In patients with clinically diagnosed LQTS, genetic testing and genetic counselling are recommended.",I,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
"It is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration.",I,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
"The LQTS diagnosis should be considered in the presence of a QTc ≥460 ms and ,480 ms in repeated 12-lead ECGs in patients with an arrhythmic syncope in the absence of secondary causes for QT prolongation.",IIa,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
General recommendations to prevent SCD The following is recommended in LQTS: • Avoid QT-prolonging drugs.c • Avoid and correct electrolyte abnormalities. • Avoid genotype-speciﬁc triggers for arrhythmias.,I,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
"Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.",I,B,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
Mexiletine is indicated in LQT3 patients with a prolonged QT interval.,I,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
Beta-blockers should be considered in patients with a pathogenic mutation and a normal QTc interval.,IIa,B,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
"Risk stratiﬁcation, prevention of SCD and treatment of VA ICD implantation in addition to beta-blockers is recommended in LQTS patients with CA.",I,B,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
ICD implantation is recommended in patients with LQTS who are symptomaticd while receiving beta-blockers and genotype-speciﬁc therapies.,I,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,81
"Either ICD implantation or LCSD should be considered in patients with symptomaticd LQTS, when beta-blockers and genotype-speciﬁc therapies are not tolerated or contraindicated at the therapeutic dose.",IIa,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,82
"In LQTS, it should be considered to calculate the arrhythmic risk before initiation of therapy based on the genotype and the duration of QTc interval.",IIa,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,82
Invasive electrophysiologic study is not recommended in LQTS.,III,C,41,Recommendations for the management of patients with long QT syndrome,Ventricular Arrhythmias SCD,2022,82
Andersen–Tawil syndrome Diagnosis Genetic testing is recommended in patients with suspected Andersen–Tawil syndrome.,I,C,42,Recommendations for management of patients with,Ventricular Arrhythmias SCD,2022,83
Andersen–Tawil syndrome should be considered in patients without SHD who present with at least two of the following: • Prominent U waves with or without prolongation of the QT interval • Bidirectional and/or polymorphic PVCs/VT • Dysmorphic features • Periodic paralysis • KCNJ2 pathogenic loss of function mutation.,IIa,C,42,Recommendations for management of patients with,Ventricular Arrhythmias SCD,2022,83
"Risk stratiﬁcation, prevention of SCD and treatment of VA ICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA or not-tolerated sustained VT.",I,C,42,Recommendations for management of patients with,Ventricular Arrhythmias SCD,2022,83
Beta-blockers and/or ﬂecainide with or without acetazolamide should be considered in patients with Andersen–Tawil syndrome to treat VA.,IIa,C,42,Recommendations for management of patients with,Ventricular Arrhythmias SCD,2022,83
An ILR should be considered in patients with Andersen–Tawil syndrome and unexplained syncope.,IIa,C,42,Recommendations for management of patients with,Ventricular Arrhythmias SCD,2022,83
ICD implantation may be considered in patients with Andersen–Tawil syndrome who have a history of unexplained syncope or suffer from tolerated sustained VT.,IIb,C,42,Recommendations for management of patients with,Ventricular Arrhythmias SCD,2022,83
Diagnosis It is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern.974–,I,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,84
It is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a type 1 Brugada ECG induced by sodium channel blocker challenge or during fever.,I,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,84
Genetic testing for SCN5A gene is recommended for probands with BrS.,I,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,84
"BrS should be considered in patients with no other heart disease and induced type 1 Brugada pattern who have at least one of: • Arrhythmic syncope or nocturnal agonal respiration • A family history of BrS • A family history of SD (,45 years old) with a negative autopsy and circumstance suspicious for BrS.",IIa,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,84
Sodium channel blocker test is not recommended in patients with a prior type I Brugada pattern.,III,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
"General recommendations The following is recommended in all patients with BrS: (a) Avoidance of drugs that may induce ST-segment elevation in right precordial leads (http://www.brugadadrugs.org). (b) Avoidance of cocaine, cannabis, and excessive alcohol intake. (c) Treatment of fever with antipyretic drugs.",I,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
"Risk stratiﬁcation, prevention of SCD and treatment of VA ICD implantation is recommended in patients with BrS who: (a) Are survivors of an aborted CA and/or (b) Have documented spontaneous sustained VT.980,990–",I,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
ICD implantation should be considered in patients with type 1 Brugada pattern and an arrhythmic syncope.,IIa,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
Implantation of a loop recorder should be considered in BrS patients with an unexplained syncope.,IIa,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
"Quinidine should be considered in patients with BrS who qualify for an ICD but have a contraindication, decline, or have recurrent ICD shocks.",IIa,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
Isoproterenol infusion should be considered in BrS patients suffering electrical storm.,IIa,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
Catheter ablation of triggering PVCs and/or RVOT epicardial substrate should be considered in BrS patients with recurrent appropriate ICD shocks refractory to drug therapy.1010–,IIa,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
PES may be considered in asymptomatic patients with a spontaneous type I BrS ECG.,IIb,B,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
ICD implantation may be considered in selected asymptomatic BrS patients with inducible VF during PES using up to 2 extra stimuli.,IIb,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
Catheter ablation in asymptomatic BrS patients is not recommended.,III,C,43,Recommendations for management of patients with Brugada syndrome,Ventricular Arrhythmias SCD,2022,85
Diagnosis It is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.,I,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
It is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP.,I,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
"In an SCD victim with a negative autopsy and medical chart review, and an ante-mortem ECG demonstrating the ERP, the diagnosis of ERS should be considered.",IIa,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
First-degree relatives of ERS patients should be considered for clinical evaluation for ERP with additional high-risk features.c,IIa,B,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
Clinical evaluation is not recommended routinely in asymptomatic subjects with ERP.,III,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
"Risk stratiﬁcation, prevention of SCD and treatment of VA ICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.",I,B,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
"Isoproterenol infusion should be considered for ERS patients with electrical storm.1017,1030–",IIa,B,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
Quinidine in addition to an ICD should be considered for recurrent VF in ERS patients.,IIa,B,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
ILR should be considered in individuals with ERP and at least one risk featured or arrhythmic syncope.,IIa,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
PVC ablation should be considered in ERS patients with recurrent VF episodes triggered by a similar PVC non-responsive to medical treatment.,IIa,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
ICD implantation or quinidine may be considered in individuals with ERP and arrhythmic syncope and additional risk features.d,IIb,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,87
ICD implantation is not recommended in asymptomatic patients with an isolated ERP.,III,C,44,Recommendations for the management of patients with early repolarization pattern/syndrome,Ventricular Arrhythmias SCD,2022,88
"Diagnosis It is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and exercise- or emotion-induced bidirectional, or PVT.",I,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
It is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.,I,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
Genetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.,I,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
Epinephrine or isoproterenol challenge may be considered for the diagnosis of CPVT when an exercise test is not possible.,IIb,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
"General recommendations Avoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with CPVT.",I,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
"Therapeutic interventions Beta-blockers, ideally non-selective (nadolol or propranolol) are recommended in all patients with a clinical diagnosis of CPVT.",I,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
ICD implantation combined with beta-blockers and ﬂecainide is recommended in CPVT patients after aborted CA.,I,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
"LCSD should be considered in patients with diagnosis of CPVT when the combination of beta-blockers and ﬂecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated.",IIa,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
ICD implantation should be considered in patients with CPVT who experience arrhythmogenic syncope and/or documented bidirectional/PVT while on highest tolerated beta-blocker dose and on ﬂecainide.,IIa,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
"Flecainide should be considered in patients with CPVT who experience recurrent syncope, polymorphic/bidirectional VT, or persistent exertional PVCs, while on beta-blockers at the highest tolerated dose.",IIa,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
PES is not recommended for stratiﬁcation of SCD risk.,III,C,45,Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia,Ventricular Arrhythmias SCD,2022,90
"Diagnosis It is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic mutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.",I,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
Genetic testing is indicated in patients diagnosed with SQTS.,I,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
SQTS should be considered in the presence of a QTc ≥320 ms and ≤360 ms and arrhythmic syncope.,IIa,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
"SQTS may be considered in the presence of a QTc ≥320 ms and ≤360 ms and a family history of SD at age ,40 years.",IIb,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
"Risk stratiﬁcation, SCD prevention and treatment of VA ICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA and/or (b) have documented spontaneous sustained VT.",I,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
ILR should be considered in young SQTS patients.,IIa,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
ICD implantation should be considered in SQTS patients with arrhythmic syncope.,IIa,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
"Quinidine may be considered in (a) SQTS patients who qualify for an ICD but present a contraindication to the ICD or refuse it, and (b) asymptomatic SQTS patients and a family history of SCD.1069–",IIb,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
Isoproterenol may be considered in SQTS patients with an electrical storm.,IIb,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
PES is not recommended for SCD risk stratiﬁcation in SQTS patients.,III,C,46,Recommendations for the management of patients with short QT syndrome,Ventricular Arrhythmias SCD,2022,91
"Acute management of VA During pregnancy, electrical cardioversion is recommended for sustained VT.",I,C,47,Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy,Ventricular Arrhythmias SCD,2022,92
"For acute conversion of haemodynamically tolerated SMVT during pregnancy, a beta-blocker, sotalol, ﬂecainide, procainamide, or overdrive ventricular pacing should be considered.",IIa,C,47,Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy,Ventricular Arrhythmias SCD,2022,92
"Long-term management of VA If ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.",I,C,47,Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy,Ventricular Arrhythmias SCD,2022,92
"Continuation of beta-blockers is recommended during pregnancy and post-partum in women with LQTS or CPVT.955,1094–",I,C,47,Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy,Ventricular Arrhythmias SCD,2022,92
Continuation of beta-blockers should be considered during pregnancy in women with ARVC.1097–,IIa,C,47,Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy,Ventricular Arrhythmias SCD,2022,92
"Oral metoprolol, propranolol, or verapamil should be considered for long-term management of idiopathic sustained VT during pregnancy.",IIa,C,47,Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy,Ventricular Arrhythmias SCD,2022,92
"Catheter ablation using non-ﬂuoroscopic mapping systems should be considered, preferably after the ﬁrst trimester, in women with highly symptomatic recurrent SMVT refractory or who are intolerant to AADs.",IIa,C,47,Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy,Ventricular Arrhythmias SCD,2022,92
"Prior to heart transplant In patients awaiting heart transplantation, ICD implantation for primary prevention should be considered.",IIa,C,48,Recommendations for the prevention of sudden cardiac death before and after heart transplantation,Ventricular Arrhythmias SCD,2022,93
"In patients awaiting heart transplantation, WCD may be considered.",IIb,C,48,Recommendations for the prevention of sudden cardiac death before and after heart transplantation,Ventricular Arrhythmias SCD,2022,93
"Post heart transplant In selected transplanted patients with cardiac allograft vasculopathy or treated rejection, ICD implantation may be considered.",IIb,C,48,Recommendations for the prevention of sudden cardiac death before and after heart transplantation,Ventricular Arrhythmias SCD,2022,93
"In athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including echocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.",I,C,49,Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes,Ventricular Arrhythmias SCD,2022,93
It is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current guidelines for sports eligibility.,I,C,49,Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes,Ventricular Arrhythmias SCD,2022,93
It is recommended that staff at sporting facilities are trained in CPR and in the use of AED.,I,C,49,Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes,Ventricular Arrhythmias SCD,2022,93
Pre-participation cardiovascular evaluation of competitive athletes should be considered.,IIa,C,49,Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes,Ventricular Arrhythmias SCD,2022,93
"It should be considered that cardiovascular evaluation of young (,35 years) competitive athletes includes history, physical examination, and 12-lead ECG.",IIa,C,49,Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes,Ventricular Arrhythmias SCD,2022,93
The cardiovascular risk of middle-aged and elderly individuals should be evaluated before engaging in strenuous sports through established scores such as the SCORE2 risk chart.,IIa,C,49,Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes,Ventricular Arrhythmias SCD,2022,93
"In elderly patients in whom a beneﬁt from the deﬁbrillator is not expected due to the patient’s age and comorbidities, omission of ICD implantation for primary prevention may be considered.",IIb,B,50,Recommendations for implantable cardioverter deﬁbrillator implantation in the elderly,Ventricular Arrhythmias SCD,2022,94
"clinical and diagnostic tools for patients with suspected acute coronary syndrome It is recommended to base the diagnosis and initial short-term risk stratification of ACS on a combination of clinical history, symptoms, vital signs, other physical findings, ECG, and hs-cTn.",I,B,1,Recommendations for,Acute Coronary Syndromes,2023,19
"ECG Twelve-lead ECG recording and interpretation is recommended as soon as possible at the point of FMC, with a target of <10 min.",I,B,1,Recommendations for,Acute Coronary Syndromes,2023,19
"Continuous ECG monitoring and the availability of defibrillator capacity is recommended as soon as possible in all patients with suspected STEMI, in suspected ACS with other ECG changes or ongoing chest pain, and once the diagnosis of MI is made.",I,B,1,Recommendations for,Acute Coronary Syndromes,2023,19
"The use of additional ECG leads (V3R, V4R, and V7– V9) is recommended in cases of inferior STEMI or if total vessel occlusion is suspected and standard leads are inconclusive.22–",I,B,1,Recommendations for,Acute Coronary Syndromes,2023,19
An additional 12-lead ECG is recommended in cases with recurrent symptoms or diagnostic uncertainty.,I,C,1,Recommendations for,Acute Coronary Syndromes,2023,19
It is recommended to use an ESC algorithmic approach with serial hs-cTn measurements (0 h/1 h or 0 h/2 h) to rule in and rule out NSTEMI.28–,I,B,1,Recommendations for,Acute Coronary Syndromes,2023,20
Additional testing after 3 h is recommended if the first two hs-cTn measurements of the 0 h/1 h algorithm are inconclusive and no alternative diagnoses explaining the condition have been made.,I,B,1,Recommendations for,Acute Coronary Syndromes,2023,20
The use of established risk scores (e.g. GRACE risk score) for prognosis estimation should be considered.47–,IIa,B,1,Recommendations for,Acute Coronary Syndromes,2023,20
Triage for emergency reperfusion strategy It is recommended that patients with suspected STEMI are immediately triaged for an emergency reperfusion strategy.50–,I,A,1,Recommendations for,Acute Coronary Syndromes,2023,20
non-invasive imaging in the initial assessment of patients with suspected acute coronary syndrome Emergency TTE is recommended in patients with suspected ACS presenting with cardiogenic shock or suspected mechanical complications.,I,C,2,Recommendations for,Acute Coronary Syndromes,2023,23
"In patients with suspected ACS, non-elevated (or uncertain) hs-cTn levels, no ECG changes and no recurrence of pain, incorporating CCTA or a non-invasive stress imaging test as part of the initial workup should be considered.116,122–",IIa,A,2,Recommendations for,Acute Coronary Syndromes,2023,23
Emergency TTE should be considered at triage in cases of diagnostic uncertainty but this should not result in delays in transfer to the cardiac catheterization laboratory if there is suspicion of an acute coronary artery occlusion.,IIa,C,2,Recommendations for,Acute Coronary Syndromes,2023,23
"Routine, early CCTA in patients with suspected ACS is not recommended.",III,B,2,Recommendations for,Acute Coronary Syndromes,2023,23
initial management of patients with acute coronary syndrome Hypoxia Oxygen is recommended in patients with hypoxaemia (SaO2 <90%).,I,C,3,Recommendations for the,Acute Coronary Syndromes,2023,26
Routine oxygen is not recommended in patients without hypoxaemia (SaO2 >90%).,III,A,3,Recommendations for the,Acute Coronary Syndromes,2023,26
Symptoms Intravenous opioids should be considered to relieve pain.,IIa,C,3,Recommendations for the,Acute Coronary Syndromes,2023,26
A mild tranquilizer should be considered in very anxious patients.,IIa,C,3,Recommendations for the,Acute Coronary Syndromes,2023,26
"Intravenous beta-blockers Intravenous beta-blockers (preferably metoprolol) should be considered at the time of presentation in patients undergoing PPCI with no signs of acute heart failure, an SBP >120 mmHg, and no other contraindications.163–",IIa,A,3,Recommendations for the,Acute Coronary Syndromes,2023,26
"Pre-hospital logistics of care It is recommended that the pre-hospital management of patients with a working diagnosis of STEMI is based on regional networks designed to deliver reperfusion therapy expeditiously and effectively, with efforts made to make PPCI available to as many patients as possible.",I,B,3,Recommendations for the,Acute Coronary Syndromes,2023,26
It is recommended that PPCI-capable centres deliver a 24/7 service and are able to perform PPCI without delay.,I,B,3,Recommendations for the,Acute Coronary Syndromes,2023,26
"It is recommended that patients transferred for PPCI bypass the emergency department and CCU/ICU and are transferred directly to the catheterization laboratory.137,175–",I,B,3,Recommendations for the,Acute Coronary Syndromes,2023,26
"It is recommended that EMS transfer patients with suspected STEMI to a PCI-capable centre, bypassing non-PCI centres.",I,C,3,Recommendations for the,Acute Coronary Syndromes,2023,26
It is recommended that all hospitals and EMS participating in the care of patients with suspected STEMI record and audit delay times and work together to achieve and maintain quality targets.,I,C,3,Recommendations for the,Acute Coronary Syndromes,2023,26
perfusion therapy and timing of invasive strategy Recommendations for reperfusion therapy for patients with STEMI Reperfusion therapy is recommended in all patients with a working diagnosis of STEMI (persistent ST-segment elevation or equivalentsc) and symptoms of ischaemia of ≤12 h duration.,I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
A PPCI strategy is recommended over fibrinolysis if the anticipated time from diagnosis to PCI is <120 min.,I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"If timely PPCI (<120 min) cannot be performed in patients with a working diagnosis of STEMI, fibrinolytic therapy is recommended within 12 h of symptom onset in patients without contraindications.",I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"Rescue PCI is recommended for failed fibrinolysis (i.e. ST-segment resolution <50% within 60–90 min of fibrinolytic administration) or in the presence of haemodynamic or electrical instability, worsening ischaemia, or persistent chest pain.",I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"In patients with a working diagnosis of STEMI and a time from symptom onset >12 h, a PPCI strategy is recommended in the presence of ongoing symptoms suggestive of ischaemia, haemodynamic instability, or life-threatening arrhythmias.",I,C,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
A routine PPCI strategy should be considered in STEMI patients presenting late (12–48 h) after symptom onset.189–,IIa,B,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
Routine PCI of an occluded IRA is not recommended in STEMI patients presenting >48 h after symptom onset and without persistent symptoms.,III,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"Transfer/interventions after fibrinolysis Transfer to a PCI-capable centre is recommended in all patients immediately after fibrinolysis.184– 186,212,213,222–",I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"Emergency angiography and PCI of the IRA, if indicated are recommended in patients with new-onset or persistent heart failure/shock after fibrinolysis.",I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"Angiography and PCI of the IRA, if indicated, is recommended between 2 and 24 h after successful fibrinolysis.",I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
A selective invasive approach is recommended in patients without very high- or high-risk NSTE-ACS criteria and with a low index of suspicion for NSTE-ACS.196–,I,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"An immediate invasive strategy is recommended in patients with a working diagnosis of NSTE-ACS and with at least one of the following very high-risk criteria: • Haemodynamic instability or cardiogenic shock • Recurrent or refractory chest pain despite medical treatment • In-hospital life-threatening arrhythmias • Mechanical complications of MI • Acute heart failure presumed secondary to ongoing myocardial ischaemia • Recurrent dynamic ST-segment or T wave changes, particularly intermittent ST-segment elevation.",I,C,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
"An early invasive strategy within 24 h should be considered in patients with at least one of the following high-risk criteria: • Confirmed diagnosis of NSTEMI based on current recommended ESC hs-cTn algorithms • Dynamic ST-segment or T wave changes • Transient ST-segment elevation • GRACE risk score >140202,226–",IIa,A,4,Recommendations for re­,Acute Coronary Syndromes,2023,31
antiplatelet and anticoagulant therapy in acute coronary syndrome Antiplatelet therapy Aspirin is recommended for all patients without contraindications at an initial oral LD of 150–300 mg (or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for long-term treatment.,I,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
"In all ACS patients, a P2Y12 receptor inhibitor is recommended in addition to aspirin, given as an initial oral LD followed by an MD for 12 months unless there is HBRc.",I,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
A proton pump inhibitor in combination with DAPT is recommended in patients at high risk of gastrointestinal bleeding.,I,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
"Prasugrel is recommended in P2Y12 receptor inhibitor-naïve patients proceeding to PCI (60 mg LD, 10 mg o.d. MD, 5 mg o.d. MD for patients aged ≥75 years or with a body weight <60 kg).",I,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
"Ticagrelor is recommended irrespective of the treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d. MD).",I,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
"Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is recommended when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.",I,C,5,Recommendations for,Acute Coronary Syndromes,2023,39
"If patients presenting with ACS stop DAPT to undergo CABG, it is recommended they resume DAPT after surgery for at least 12 months.",I,C,5,Recommendations for,Acute Coronary Syndromes,2023,39
Prasugrel should be considered in preference to ticagrelor for ACS patients who proceed to PCI.,IIa,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
GP IIb/IIIa receptor antagonists should be considered if there is evidence of no-reflow or a thrombotic complication during PCI.,IIa,C,5,Recommendations for,Acute Coronary Syndromes,2023,39
"In P2Y12 receptor inhibitor-naïve patients undergoing PCI, cangrelor may be considered.251–",IIb,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
"In older ACS patients,d especially if HBR,c clopidogrel as the P2Y12 receptor inhibitor may be considered.",IIb,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
Pre-treatment with a P2Y12 receptor inhibitor may be considered in NSTE-ACS patients who are not expected to undergo an early invasive strategy (<24 h) and do not have HBRc.,IIb,C,5,Recommendations for,Acute Coronary Syndromes,2023,39
Pre-treatment with a GP IIb/IIIa receptor antagonist is not recommended.,III,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
"Routine pre-treatment with a P2Y12 receptor inhibitor in NSTE-ACS patients in whom coronary anatomy is not known and early invasive management (<24 h) is planned is not recommended.244,247,248,293–",III,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
Anticoagulant therapy Parenteral anticoagulation is recommended for all patients with ACS at the time of diagnosis.,I,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
Routine use of a UFH bolus (weight-adjusted i.v. bolus during PCI of 70–100 IU/kg) is recommended in patients undergoing PCI.,I,C,5,Recommendations for,Acute Coronary Syndromes,2023,39
Intravenous enoxaparin at the time of PCI should be considered in patients pre-treated with subcutaneous enoxaparin.,IIa,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
Discontinuation of parenteral anticoagulation should be considered immediately after an invasive procedure.,IIa,C,5,Recommendations for,Acute Coronary Syndromes,2023,39
Patients with STEMI Enoxaparin should be considered as an alternative to UFH in patients with STEMI undergoing PPCI.,IIa,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
"Bivalirudin with a full-dose post PCI infusion should be considered as an alternative to UFH in patients with STEMI undergoing PPCI.259,299,300–",IIa,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
Fondaparinux is not recommended in patients with STEMI undergoing PPCI.,III,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
"Patients with NSTE-ACS For patients with NSTE-ACS in whom early invasive angiography (i.e. within 24 h) is not anticipated, fondaparinux is recommended.",I,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
"For patients with NSTE-ACS in whom early invasive angiography (i.e. within 24 h) is anticipated, enoxaparin should be considered as an alternative to UFH.",IIa,B,5,Recommendations for,Acute Coronary Syndromes,2023,39
"Combining antiplatelets and OAC As the default strategy for patients with atrial fibrillation and CHA2DS2-VASc score ≥1 in men and ≥2 in women, after up to 1 week of triple antithrombotic therapy following the ACS event, dual antithrombotic therapy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel) for up to 12 months is recommended.305–",I,A,5,Recommendations for,Acute Coronary Syndromes,2023,39
"During PCI, a UFH bolus is recommended in any of the following circumstances: • if the patient is on a NOAC • if the INR is <2.5 in VKA-treated patients.",I,C,5,Recommendations for,Acute Coronary Syndromes,2023,39
"When rivaroxaban is used and concerns about HBR prevail over ischaemic stroke, rivaroxaban 15 mg o.d. should be considered in preference to rivaroxaban 20 mg o.d. for the duration of concomitant SAPT or DAPT.",IIa,B,5,Recommendations for,Acute Coronary Syndromes,2023,40
"In patients at HBR,c dabigatran 110 mg b.i.d. should be considered in preference to dabigatran 150 mg b.i.d. for the duration of concomitant SAPT or DAPT, to mitigate bleeding risk.",IIa,B,5,Recommendations for,Acute Coronary Syndromes,2023,40
"In patients requiring anticoagulation and treated medically, a single antiplatelet agent in addition to an OAC should be considered for up to 1 year.",IIa,B,5,Recommendations for,Acute Coronary Syndromes,2023,40
"In patients treated with an OAC, aspirin plus clopidogrel for longer than 1 week and up to 1 month should be considered in those with high ischaemic risk or with other anatomical/procedural characteristics that are judged to outweigh the bleeding risk.e",IIa,C,5,Recommendations for,Acute Coronary Syndromes,2023,40
"In patients requiring OAC, withdrawing antiplatelet therapy at 6 months while continuing OAC may be considered.",IIb,B,5,Recommendations for,Acute Coronary Syndromes,2023,40
The use of ticagrelor or prasugrel as part of triple antithrombotic therapy is not recommended.,III,C,5,Recommendations for,Acute Coronary Syndromes,2023,40
"alternative antithrombotic therapy regimens Shortening/de-escalation of antithrombotic therapy In patients who are event-free after 3–6 months of DAPT and who are not high ischaemic risk, single antiplatelet therapy (preferably with a P2Y12 receptor inhibitor) should be considered.264,268–",IIa,A,6,Recommendations for,Acute Coronary Syndromes,2023,40
De-escalation of P2Y12 receptor inhibitor treatment (e.g. with a switch from prasugrel/ticagrelor to clopidogrel) may be considered as an alternative DAPT strategy to reduce bleeding risk.279–,IIb,A,6,Recommendations for,Acute Coronary Syndromes,2023,40
"In HBR patients, aspirin or P2Y12 receptor inhibitor monotherapy after 1 month of DAPT may be considered.",IIb,B,6,Recommendations for,Acute Coronary Syndromes,2023,40
De-escalation of antiplatelet therapy in the first 30 days after an ACS event is not recommended.,III,B,6,Recommendations for,Acute Coronary Syndromes,2023,40
Prolonging antithrombotic therapy Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.,I,B,6,Recommendations for,Acute Coronary Syndromes,2023,40
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be considered in patients with high ischaemic risk and without HBRc.314–,IIa,A,6,Recommendations for,Acute Coronary Syndromes,2023,40
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention may be considered in patients with moderate ischaemic risk and without HBRc.314–,IIb,A,6,Recommendations for,Acute Coronary Syndromes,2023,40
P2Y12 inhibitor monotherapy may be considered as an alternative to aspirin monotherapy for long-term treatment.,IIb,A,6,Recommendations for,Acute Coronary Syndromes,2023,40
"fibrinolytic therapy Fibrinolytic therapy When fibrinolysis is the reperfusion strategy, it is recommended to initiate this treatment as soon as possible after diagnosis in the pre-hospital setting (aim for target of <10 min to lytic bolus).206,353–",I,A,7,Recommendations for,Acute Coronary Syndromes,2023,43
"A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended.",I,B,7,Recommendations for,Acute Coronary Syndromes,2023,43
A half-dose of tenecteplase should be considered in patients >75 years of age.,IIa,B,7,Recommendations for,Acute Coronary Syndromes,2023,43
Antiplatelet co-therapy with fibrinolysis Aspirin and clopidogrel are recommended.340–,I,A,7,Recommendations for,Acute Coronary Syndromes,2023,43
"Anticoagulation co-therapy with fibrinolysis Anticoagulation is recommended in patients treated with fibrinolysis until revascularization (if performed) or for the duration of hospital stay (up to 8 days).260,347,348,350,357–",I,A,7,Recommendations for,Acute Coronary Syndromes,2023,43
"Enoxaparin i.v. followed by s.c. is recommended as the preferred anticoagulant.347,348,357–",I,A,7,Recommendations for,Acute Coronary Syndromes,2023,43
"When enoxaparin is not available, UFH is recommended as a weight-adjusted i.v. bolus, followed by infusion.",I,B,7,Recommendations for,Acute Coronary Syndromes,2023,43
"In patients treated with streptokinase, an i.v. bolus of fondaparinux followed by an s.c. dose 24 h later should be considered.",IIa,B,7,Recommendations for,Acute Coronary Syndromes,2023,43
cardiac arrest and out-of-hospital cardiac arrest Cardiac arrest and OHCA A PPCI strategy is recommended in patients with resuscitated cardiac arrest and an ECG with persistent ST-segment elevation (or equivalents).,I,B,8,Recommendations for,Acute Coronary Syndromes,2023,44
Routine immediate angiography after resuscitated cardiac arrest is not recommended in haemodynamically stable patients without persistent ST-segment elevation (or equivalents).373–,III,A,8,Recommendations for,Acute Coronary Syndromes,2023,44
Temperature control Temperature control (i.e. continuous monitoring of core temperature and active prevention of fever [i.e. >37.7°C]) is recommended after either out-of-hospital or in-hospital cardiac arrest for adults who remain unresponsive after return of spontaneous circulation.378–,I,B,8,Recommendations for,Acute Coronary Syndromes,2023,44
Systems of care It is recommended that healthcare systems implement strategies to facilitate transfer of all patients in whom ACS is suspected after resuscitated cardiac arrest directly to a hospital offering 24/7 PPCI via one specialized EMS.390–,I,C,8,Recommendations for,Acute Coronary Syndromes,2023,44
Transport of patients with OHCA to a cardiac arrest centre according to local protocols should be considered.,IIa,C,8,Recommendations for,Acute Coronary Syndromes,2023,44
Evaluation of neurological prognosis Evaluation of neurological prognosis (no earlier than 72 h after admission) is recommended in all comatose survivors after cardiac arrest.,I,C,8,Recommendations for,Acute Coronary Syndromes,2023,44
cardiogenic shock Immediate coronary angiography and PCI of the IRA (if indicated) is recommended in patients with CS complicating ACS.,I,B,9,Recommendations for,Acute Coronary Syndromes,2023,45
Emergency CABG is recommended for ACS-related CS if PCI of the IRA is not feasible/unsuccessful.,I,B,9,Recommendations for,Acute Coronary Syndromes,2023,45
"In cases of haemodynamic instability, emergency surgical/catheter-based repair of mechanical complications of ACS is recommended, based on Heart Team discussion.",I,C,9,Recommendations for,Acute Coronary Syndromes,2023,45
Fibrinolysis should be considered in STEMI patients presenting with CS if a PPCI strategy is not available within 120 min from the time of STEMI diagnosis and mechanical complications have been ruled out.,IIa,C,9,Recommendations for,Acute Coronary Syndromes,2023,45
"The routine use of an IABP in ACS patients with CS and without mechanical complications is not recommended.399,405–",III,B,9,Recommendations for,Acute Coronary Syndromes,2023,45
"in-hospital management Logistical issues for hospital stay It is recommended that all hospitals participating in the care of high-risk patients have an ICCU/CCU equipped to provide all required aspects of care, including treatment of ischaemia, severe heart failure, arrhythmias, and common comorbidities.",I,C,10,Recommendations for,Acute Coronary Syndromes,2023,47
It is recommended that high-risk patients (including all STEMI patients and very high-risk NSTE-ACS patients) have ECG monitoring for a minimum of 24 h.,I,C,10,Recommendations for,Acute Coronary Syndromes,2023,47
"It is recommended that high-risk patients with successful reperfusion therapy and an uncomplicated clinical course (including all STEMI patients and very high-risk NSTE-ACS patients) are kept in the CCU/ ICCU for a minimum of 24 h whenever possible, after which they may be moved to a step-down monitored bed for an additional 24–48 h.",I,C,10,Recommendations for,Acute Coronary Syndromes,2023,47
Discharge of selected high-risk patients within 48– 72 h should be considered if early rehabilitation and adequate follow-up are arranged.,IIa,A,10,Recommendations for,Acute Coronary Syndromes,2023,47
Same-day transfer in selected stable patients after successful and uneventful PCI should be considered.,IIa,C,10,Recommendations for,Acute Coronary Syndromes,2023,47
"Imaging Routine echocardiography is recommended during hospitalization to assess regional and global LV function, detect mechanical complications, and exclude LV thrombus.",I,C,10,Recommendations for,Acute Coronary Syndromes,2023,47
"When echocardiography is suboptimal/inconclusive, CMR imaging may be considered.",IIb,C,10,Recommendations for,Acute Coronary Syndromes,2023,47
"technical aspects of invasive strategies Radial access is recommended as the standard approach, unless there are overriding procedural considerations.",I,A,11,Recommendations for,Acute Coronary Syndromes,2023,50
PCI with stent deployment in the IRA during the index procedure is recommended in patients undergoing PPCI.490–,I,A,11,Recommendations for,Acute Coronary Syndromes,2023,50
"In patients with spontaneous coronary artery dissection, PCI is recommended only for patients with symptoms and signs of ongoing myocardial ischaemia, a large area of myocardium in jeopardy, and reduced antegrade flow.",I,C,11,Recommendations for,Acute Coronary Syndromes,2023,50
Intravascular imaging should be considered to guide PCI.495–,IIa,A,11,Recommendations for,Acute Coronary Syndromes,2023,50
Coronary artery bypass grafting should be considered in patients with an occluded IRA when PPCI is not feasible/unsuccessful and there is a large area of myocardium in jeopardy.,IIa,C,11,Recommendations for,Acute Coronary Syndromes,2023,50
Intravascular imaging (preferably optical coherence tomography) may be considered in patients with ambiguous culprit lesions.,IIb,C,11,Recommendations for,Acute Coronary Syndromes,2023,50
The routine use of thrombus aspiration is not recommended.472–,III,A,11,Recommendations for,Acute Coronary Syndromes,2023,50
"management of patients with multivessel disease It is recommended to base the revascularization strategy (IRA PCI, multivessel PCI/CABG) on the patient’s clinical status and comorbidities, as well as their disease complexity, according to the principles of management of myocardial revascularization.",I,B,12,Recommendations for,Acute Coronary Syndromes,2023,53
Multivessel disease in ACS patients presenting in cardiogenic shock IRA-only PCI during the index procedure is recommended.,I,B,12,Recommendations for,Acute Coronary Syndromes,2023,53
Staged PCI of non-IRA should be considered.c,IIa,C,12,Recommendations for,Acute Coronary Syndromes,2023,53
It is recommended that PCI of the non-IRA is based on angiographic severity.,I,B,12,Recommendations for,Acute Coronary Syndromes,2023,53
Invasive epicardial functional assessment of non-culprit segments of the IRA is not recommended during the index procedure.,III,C,12,Recommendations for,Acute Coronary Syndromes,2023,53
"Multivessel disease in haemodynamically stable NSTE-ACS patients undergoing PCI In patients presenting with NSTE-ACS and MVD, complete revascularization should be considered, preferably during the index procedure.",IIa,C,12,Recommendations for,Acute Coronary Syndromes,2023,53
Functional invasive evaluation of non-IRA severity during the index procedure may be considered.,IIb,B,12,Recommendations for,Acute Coronary Syndromes,2023,53
"myocardial infarction with non-obstructive coronary arteries In patients with a working diagnosis of MINOCA, CMR imaging is recommended after invasive angiography if the final diagnosis is not clear.",I,B,13,Recommendations for,Acute Coronary Syndromes,2023,56
"Management of MINOCA according to the final established underlying diagnosis is recommended, consistent with the appropriate disease-specific guidelines.",I,B,13,Recommendations for,Acute Coronary Syndromes,2023,56
"In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to determine the underlying final diagnosis.",I,C,13,Recommendations for,Acute Coronary Syndromes,2023,56
acute coronary syndrome complications Heart failure IABP should be considered in patients with haemodynamic instability/cardiogenic shock due to ACS-related mechanical complications.,IIa,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
LV thrombus CMR imaging should be considered in patients with equivocal echocardiographic images or in cases of high clinical suspicion of LV thrombus.,IIa,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
Oral anticoagulant therapy (VKA or NOAC) should be considered for 3–6 months in patients with confirmed LV thrombus.,IIa,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
"Following an acute anterior MI, a contrast echocardiogram may be considered for the detection of LV thrombus if the apex is not well visualized on echocardiography.",IIb,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
Atrial fibrillation Intravenous beta-blockers are recommended when rate control is needed in the absence of acute HF or hypotension.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
Intravenous amiodarone is recommended when rate control is needed in the presence of acute HF and no hypotension.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
Immediate electrical cardioversion is recommended in patients with ACS and haemodynamic instability and when adequate rate control cannot be achieved promptly with pharmacological agents.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
Intravenous amiodarone is recommended to facilitate electrical cardioversion and/or decrease risk for early recurrence of AF after electrical cardioversion in unstable patients with recent-onset AF.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
"In patients with documented de novo AF during the acute phase of ACS, long-term oral anticoagulation should be considered depending on the CHA2DS2- VASc score, after taking the HAS-BLED score and the need for concomitant antiplatelet therapy into consideration. NOACs are the preferred drugs.",IIa,C,14,Recommendations for,Acute Coronary Syndromes,2023,58
Ventricular arrythmias ICD therapy is recommended to reduce sudden cardiac death in patients with symptomatic HF (NYHA Class II–III) and LVEF ≤35% despite optimal medical therapy for >3 months and at least 6 weeks after MI who are expected to survive for at least 1 year with good functional status.,I,A,14,Recommendations for,Acute Coronary Syndromes,2023,58
Prompt and complete revascularization is recommended to treat myocardial ischaemia that may be present in patients with recurrent VT and/or VF.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
Transvenous catheter pacing termination and/or overdrive pacing should be considered if VT cannot be controlled by repeated electrical cardioversion.,IIa,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
"Radiofrequency catheter ablation at a specialized ablation centre followed by ICD implantation should be considered in patients with recurrent VT, VF, or electrical storm despite complete revascularization and optimal medical therapy.",IIa,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
"Treatment of recurrent VT with haemodynamic relevance (despite repeated electrical cardioversion) with lidocaine may be considered if beta-blockers, amiodarone, and overdrive stimulation are not effective/applicable.",IIb,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
"In patients with recurrent life-threatening ventricular arrhythmias, sedation or general anaesthesia to reduce sympathetic drive may be considered.",IIb,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
"ICD implantation or the temporary use of a wearable cardioverter defibrillator may be considered <40 days after MI in selected patients (incomplete revascularization, pre-existing LVEF dysfunction, occurrence of arrhythmias >48 h after STEMI onset, polymorphic VT or VF).",IIb,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
Treatment of asymptomatic and haemodynamically irrelevant ventricular arrhythmias with anti-arrhythmic drugs is not recommended.,III,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
"Bradyarrhythmias In cases of sinus bradycardia with haemodynamic intolerance or high-degree AV block without stable escape rhythm: • i.v. positive chronotropic medication (adrenaline, vasopressin, and/or atropine) is recommended.",I,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
• temporary pacing is recommended in cases of failure to respond to atropine.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
• urgent angiography with a view to revascularization is recommended if the patient has not received previous reperfusion therapy.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
Implantation of a permanent pacemaker is recommended when high-degree AV block does not resolve within a waiting period of at least 5 days after MI.,I,C,14,Recommendations for,Acute Coronary Syndromes,2023,59
Pacing is not recommended if high-degree AV block resolves after revascularization or spontaneously.620–,III,B,14,Recommendations for,Acute Coronary Syndromes,2023,59
acute coronary syndrome comorbid conditions Chronic kidney disease The use of low- or iso-osmolar contrast media (at the lowest possible volume) is recommended for invasive strategies.691–,I,A,15,Recommendations for,Acute Coronary Syndromes,2023,62
It is recommended to assess kidney function using eGFR in all patients with ACS.,I,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD (dose adjustment may be necessary) as in patients with normal kidney function.,I,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
"Hydration during and after angiography should be considered in patients at risk of contrast-induced nephropathy, especially in patients with acute kidney injury and/or CKD with eGFR <30 mL/min/ 1.73 m2.694–",IIa,B,15,Recommendations for,Acute Coronary Syndromes,2023,62
"Diabetes It is recommended to base the choice of long-term glucose-lowering treatment on the presence of comorbidities, including heart failure, CKD, and obesity.698–",I,A,15,Recommendations for,Acute Coronary Syndromes,2023,62
It is recommended to assess glycaemic status at initial evaluation in all patients with ACS.705–,I,B,15,Recommendations for,Acute Coronary Syndromes,2023,62
It is recommended to frequently monitor blood glucose levels in patients with known diabetes mellitus or hyperglycaemia (defined as glucose levels ≥11.1 mmol/L or ≥200 mg/dL).,I,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
"Glucose-lowering therapy should be considered in patients with ACS with persistent hyperglycaemia, while episodes of hypoglycaemia should be avoided.",IIa,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
Older adults It is recommended to apply the same diagnostic and treatment strategies in older patients as in younger patients.,I,B,15,Recommendations for,Acute Coronary Syndromes,2023,62
"It is recommended to adapt the choice and dosage of antithrombotic agent, as well as of secondary prevention medications, to renal function, co-medications, comorbidities, frailty, cognitive function, and specific contraindications.",I,B,15,Recommendations for,Acute Coronary Syndromes,2023,62
"For frail older patients with comorbidities, a holistic approach is recommended to individualize interventional and pharmacological treatments after careful evaluation of the risks and benefits.",I,B,15,Recommendations for,Acute Coronary Syndromes,2023,62
A temporary interruption of cancer therapy is recommended in patients in whom the cancer therapy is suspected to be a contributing cause of ACSc.,I,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
A conservative non-invasive strategy should be considered in ACS patients with poor cancer prognosisd (i.e. with expected survival <6 months) and/or very high bleeding risk.,IIa,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
Aspirin is not recommended in cancer patients with a platelet count <10 000/μL.,III,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
Clopidogrel is not recommended in cancer patients with a platelet count <30 000/μL.,III,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
"In ACS patients with cancer and <50 000/μL platelet count, prasugrel or ticagrelor are not recommended.",III,C,15,Recommendations for,Acute Coronary Syndromes,2023,62
"long-term management Cardiac rehabilitation It is recommended that all ACS patients participate in a medically supervised, structured, comprehensive, multidisciplinary exercise-based cardiac rehabilitation and prevention programme.721–",I,A,16,Recommendations for,Acute Coronary Syndromes,2023,68
"Lifestyle management It is recommended that ACS patients adopt a healthy lifestyle, including: • stopping all smoking of tobacco • healthy diet (Mediterranean style) • alcohol restriction • regular aerobic physical activity and resistance exercise • reduced sedentary time724,761,763,772,773,776,777,855–",I,B,16,Recommendations for,Acute Coronary Syndromes,2023,68
"In smokers, offering follow-up support, nicotine replacement therapy, varenicline or bupropion, individually or in combination, should be considered.859–",IIa,A,16,Recommendations for,Acute Coronary Syndromes,2023,68
Pharmacological treatment Lipid-lowering therapy It is recommended that high-dose statin therapy is initiated or,I,A,16,Recommendations for,Acute Coronary Syndromes,2023,68
It is recommended to aim to achieve an LDL-C level of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C by ≥50% from baseline.,I,A,16,Recommendations for,Acute Coronary Syndromes,2023,68
"If the LDL-C goal is not achieved despite maximally tolerated statin therapy after 4–6 weeks, the addition of ezetimibe is recommended.",I,B,16,Recommendations for,Acute Coronary Syndromes,2023,68
"If the LDL-C goal is not achieved despite maximally tolerated statin therapy and ezetimibe after 4–6 weeks, the addition of a PCSK9 inhibitor is recommended.",I,A,16,Recommendations for,Acute Coronary Syndromes,2023,68
It is recommended to intensify lipid-lowering therapyc during the index ACS hospitalization for patients who were on lipid-lowering therapy before admission.,I,C,16,Recommendations for,Acute Coronary Syndromes,2023,68
"For patients with a recurrent atherothrombotic event (recurrence within 2 years of first ACS episode) while taking maximally tolerated statin-based therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) may be considered.",IIb,B,16,Recommendations for,Acute Coronary Syndromes,2023,68
Combination therapy with high-dose statin plus ezetimibe may be considered during index hospitalization.,IIb,B,16,Recommendations for,Acute Coronary Syndromes,2023,68
"Routine beta-blockers for all ACS patients regardless of LVEF should be considered.798,873–",IIa,B,16,Recommendations for,Acute Coronary Syndromes,2023,69
"RAAS system inhibitors Angiotensin-converting enzyme (ACE) inhibitorsd are recommended in ACS patients with HF symptoms, LVEF ≤40%, diabetes, hypertension, and/ or CKD.195,813–",I,A,16,Recommendations for,Acute Coronary Syndromes,2023,69
Mineralocorticoid receptor antagonists are recommended in ACS patients with an LVEF ≤40% and HF or diabetes.,I,A,16,Recommendations for,Acute Coronary Syndromes,2023,69
Routine ACE inhibitors for all ACS patients regardless of LVEF should be considered.,IIa,A,16,Recommendations for,Acute Coronary Syndromes,2023,69
Adherence to medication A polypill should be considered as an option to improve adherence and outcomes in secondary prevention after ACS.,IIa,B,16,Recommendations for,Acute Coronary Syndromes,2023,69
"Imaging In patients with pre-discharge LVEF ≤40%, repeat evaluation of the LVEF 6–12 weeks after an ACS (and after complete revascularization and the institution of optimal medical therapy) is recommended to assess the potential need for sudden cardiac death primary prevention ICD implantation.",I,C,16,Recommendations for,Acute Coronary Syndromes,2023,69
Cardiac magnetic resonance imaging should be considered as an adjunctive imaging modality in order to assess the potential need for primary prevention ICD implantation.,IIa,C,16,Recommendations for,Acute Coronary Syndromes,2023,69
"Vaccination Influenza vaccination is recommended for all ACS patients.843,845–",I,A,16,Recommendations for,Acute Coronary Syndromes,2023,69
"patient perspectives in acute coronary syndrome care Patient-centred care is recommended by assessing and adhering to individual patient preferences, needs and beliefs, ensuring that patient values are used to inform all clinical decisions.",I,B,17,Recommendations for,Acute Coronary Syndromes,2023,72
"It is recommended to include ACS patients in decision-making (as much as their condition allows) and to inform them about the risk of adverse events, radiation exposure, and alternative options. Decision aids can be used to facilitate the discussion.",I,B,17,Recommendations for,Acute Coronary Syndromes,2023,72
It is recommended to assess symptoms using methods that help patients to describe their experience.,I,C,17,Recommendations for,Acute Coronary Syndromes,2023,72
"Use of the ‘teach back’ technique for decision support during the securing of informed consent should be considered.885,889–",IIa,B,17,Recommendations for,Acute Coronary Syndromes,2023,72
Assessment of mental well-being using a validated tool and onward psychological referral when appropriate should be considered.,IIa,B,17,Recommendations for,Acute Coronary Syndromes,2023,72
diagnostic tools for patients with suspected acute coronary syndrome It is recommended that patients with suspected STEMI are immediately triaged for an emergency reperfusion strategy.,I,A,1,clinical and,Acute Coronary Syndromes,2023,77
"It is recommended to base the diagnosis and initial short-term risk stratification of ACS on a combination of clinical history, symptoms, vital signs, other physical findings, ECG, and hs-cTn.",I,B,1,clinical and,Acute Coronary Syndromes,2023,77
"Twelve-lead ECG recording and interpretation is recommended as soon as possible at the point of first medical contact, with a target of <10 min.",I,B,1,clinical and,Acute Coronary Syndromes,2023,77
"Continuous ECG monitoring and the availability of defibrillator capacity is recommended as soon as possible in all patients with suspected STEMI, in suspected ACS with other ECG changes or ongoing chest pain, and once the diagnosis of MI is made.",I,B,1,clinical and,Acute Coronary Syndromes,2023,77
"The use of additional ECG leads (V3R, V4R, and V7– V9) is recommended in cases of inferior STEMI or if total vessel occlusion is suspected and standard leads are inconclusive.",I,B,1,clinical and,Acute Coronary Syndromes,2023,77
An additional 12-lead ECG is recommended in cases with recurrent symptoms or diagnostic uncertainty.,I,C,1,clinical and,Acute Coronary Syndromes,2023,77
It is recommended to measure cardiac troponins with high-sensitivity assays immediately after presentation and to obtain the results within 60 min of blood sampling.,I,B,1,clinical and,Acute Coronary Syndromes,2023,77
It is recommended to use an ESC algorithmic approach with serial hs-cTn measurements (0 h/1 h or 0 h/2 h) to rule in and rule out NSTEMI.,I,B,1,clinical and,Acute Coronary Syndromes,2023,77
Additional testing after 3 h is recommended if the first two hs-cTn measurements of the 0 h/1 h algorithm are inconclusive and no alternative diagnoses explaining the condition have been made.,I,B,1,clinical and,Acute Coronary Syndromes,2023,77
Recommendations for non-invasive imaging in the initial assessment of patients with suspected acute coronary syndrome Emergency TTE is recommended in patients with suspected ACS presenting with cardiogenic shock or suspected mechanical complications.,I,C,1,clinical and,Acute Coronary Syndromes,2023,77
"Routine, early coronary computed tomography angiography in patients with suspected ACS is not recommended.",III,B,1,clinical and,Acute Coronary Syndromes,2023,77
It is recommended that PPCI-capable centres deliver a 24/7 service and are able to perform PPCI without delay.,I,B,1,clinical and,Acute Coronary Syndromes,2023,77
It is recommended that patients transferred for PPCI bypass the emergency department and CCU/ICU and are transferred directly to the catheterization laboratory.,I,B,1,clinical and,Acute Coronary Syndromes,2023,77
Oxygen is recommended in patients with hypoxaemia (SaO2 <90%).,I,C,1,clinical and,Acute Coronary Syndromes,2023,77
"It is recommended that EMS transfer patients with suspected STEMI to a PCI-capable centre, bypassing non-PCI centres.",I,C,1,clinical and,Acute Coronary Syndromes,2023,77
"It is recommended that ambulance teams are trained and equipped to identify ECG patterns suggestive of acute coronary occlusion and to administer initial therapy, including defibrillation, and fibrinolysis when applicable.",I,C,1,clinical and,Acute Coronary Syndromes,2023,77
It is recommended that all hospitals and EMS participating in the care of patients with suspected STEMI record and audit delay times and work together to achieve and maintain quality targets.,I,C,1,clinical and,Acute Coronary Syndromes,2023,77
Routine oxygen is not recommended in patients with oxygen saturation >90%.,III,A,1,clinical and,Acute Coronary Syndromes,2023,77
Recommendations for reperfusion therapy and timing of invasive strategy Recommendations for reperfusion therapy for patients with STEMI Reperfusion therapy is recommended in all patients with a working diagnosis of STEMI (persistent ST-segment elevation or equivalents) and symptoms of ischaemia of ≤12 h duration.,I,A,1,clinical and,Acute Coronary Syndromes,2023,77
A PPCI strategy is recommended over fibrinolysis if the anticipated time from diagnosis to PCI is <120 min.,I,A,1,clinical and,Acute Coronary Syndromes,2023,77
"If timely PPCI (<120 min) cannot be performed in patients with a working diagnosis of STEMI, fibrinolytic therapy is recommended within 12 h of symptom onset in patients without contraindications.",I,A,1,clinical and,Acute Coronary Syndromes,2023,77
"Rescue PCI is recommended for failed fibrinolysis (i.e. ST-segment resolution <50% within 60–90 min of fibrinolytic administration) or in the presence of haemodynamic or electrical instability, worsening ischaemia, or persistent chest pain.",I,A,1,clinical and,Acute Coronary Syndromes,2023,77
Routine PCI of an occluded IRA is not recommended in STEMI patients presenting >48 h after symptom onset and without persistent symptoms.,III,A,1,clinical and,Acute Coronary Syndromes,2023,78
Transfer/interventions after fibrinolysis Transfer to a PCI-capable centre is recommended in all patients immediately after fibrinolysis.,I,A,1,clinical and,Acute Coronary Syndromes,2023,78
"Emergency angiography and PCI of the IRA, if indicated is recommended in patients with new-onset or persistent heart failure/shock after fibrinolysis.",I,A,1,clinical and,Acute Coronary Syndromes,2023,78
"Angiography and PCI of the IRA, if indicated, is recommended between 2 and 24 h after successful fibrinolysis.",I,A,1,clinical and,Acute Coronary Syndromes,2023,78
Invasive strategy in NSTE-ACS An invasive strategy during hospital admission is recommended in NSTE-ACS patients with high-risk criteria or with a high index of suspicion for unstable angina.,I,A,1,clinical and,Acute Coronary Syndromes,2023,78
A selective invasive approach is recommended in patients without very high- or high-risk features and a low index of suspicion for NSTE-ACS.,I,A,1,clinical and,Acute Coronary Syndromes,2023,78
"An immediate invasive strategy is recommended in patients with a working diagnosis of NSTE-ACS and with at least one of the following very high-risk criteria: • Haemodynamic instability or cardiogenic shock • Recurrent or refractory chest pain despite medical treatment • In-hospital life-threatening arrhythmias • Mechanical complications of MI • Acute heart failure presumed secondary to ongoing myocardial ischaemia Recurrent dynamic ST-segment or T wave changes, particularly intermittent ST-segment elevation.",I,C,1,clinical and,Acute Coronary Syndromes,2023,78
Recommendations for antiplatelet and anticoagulant therapy in acute coronary syndrome Antiplatelet therapy Aspirin is recommended for all patients without contraindications at an initial oral LD of 150–300 mg (or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for long-term treatment.,I,A,1,clinical and,Acute Coronary Syndromes,2023,78
"In all ACS patients, a P2Y12 receptor inhibitor is recommended in addition to aspirin, given as an initial oral LD followed by an MD for 12 months unless there is high bleeding risk.",I,A,1,clinical and,Acute Coronary Syndromes,2023,78
A proton pump inhibitor in combination with dual antiplatelet therapy is recommended in patients at high risk of gastrointestinal bleeding.,I,A,1,clinical and,Acute Coronary Syndromes,2023,78
"Ticagrelor is recommended irrespective of the treatment strategy (invasive or conservative) (180 mg LD, 90 mg twice a day MD).",I,B,1,clinical and,Acute Coronary Syndromes,2023,78
"Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is recommended when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.",I,C,1,clinical and,Acute Coronary Syndromes,2023,78
"If patients presenting with ACS stop DAPT to undergo CABG, it is recommended they resume DAPT after surgery for at least 12 months.",I,C,1,clinical and,Acute Coronary Syndromes,2023,78
Pre-treatment with a glycoprotein IIb/IIIa antagonist is not recommended.,III,A,1,clinical and,Acute Coronary Syndromes,2023,78
Routine pre-treatment with a P2Y12 receptor inhibitor in NSTE-ACS patients in whom coronary anatomy is not known and early invasive management (<24 h) is planned is not recommended.,III,A,1,clinical and,Acute Coronary Syndromes,2023,78
Anticoagulant therapy Parenteral anticoagulation is recommended for all patients with ACS at the time of diagnosis.,I,A,1,clinical and,Acute Coronary Syndromes,2023,78
Routine use of a UFH bolus (weight-adjusted i.v. bolus during PCI of 70–100 IU/kg) is recommended in patients undergoing PCI.,I,C,1,clinical and,Acute Coronary Syndromes,2023,78
Patients with STEMI Fondaparinux is not recommended in patients with STEMI undergoing PPCI.,III,B,1,clinical and,Acute Coronary Syndromes,2023,78
"Patients with NSTE-ACS For patients with NSTE-ACS in whom early invasive angiography (i.e. within 24 h) is not anticipated, fondaparinux is recommended.",I,B,1,clinical and,Acute Coronary Syndromes,2023,78
"Combining antiplatelets and OAC As the default strategy for patients with atrial fibrillation and CHA2DS2-VASc score ≥1 in men and ≥2 in women, after up to 1 week of triple antithrombotic therapy following the ACS event, dual antithrombotic therapy using a non-vitamin K antagonist oral anticoagulant at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel) for up to 12 months is recommended.",I,A,1,clinical and,Acute Coronary Syndromes,2023,78
"During PCI, a UFH bolus is recommended in any of the following circumstances: • if the patient is on a NOAC • if the INR is <2.5 in VKA-treated patients.",I,C,1,clinical and,Acute Coronary Syndromes,2023,78
The use of ticagrelor or prasugrel as part of triple antithrombotic therapy is not recommended.,III,C,1,clinical and,Acute Coronary Syndromes,2023,78
De-escalation of antiplatelet therapy in the first 30 days after ACS is not recommended.,III,B,1,clinical and,Acute Coronary Syndromes,2023,79
"Recommendations for fibrinolytic therapy When fibrinolysis is the reperfusion strategy, it is recommended to initiate this treatment as soon as possible after diagnosis in the pre-hospital setting (aim for target of <10 min to lytic bolus).",I,A,1,clinical and,Acute Coronary Syndromes,2023,79
"A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended.",I,B,1,clinical and,Acute Coronary Syndromes,2023,79
Antiplatelet co-therapy with fibrinolysis Aspirin and clopidogrel are recommended.,I,A,1,clinical and,Acute Coronary Syndromes,2023,79
Anticoagulation co-therapy with fibrinolysis Anticoagulation is recommended in patients treated with fibrinolysis until revascularization (if performed) or for the duration of hospital stay (up to 8 days).,I,A,1,clinical and,Acute Coronary Syndromes,2023,79
Enoxaparin i.v. followed by subcutaneous is recommended as the preferred anticoagulant.,I,A,1,clinical and,Acute Coronary Syndromes,2023,79
"When enoxaparin is not available, unfractionated heparin is recommended as a weight-adjusted i.v. bolus, followed by infusion.",I,B,1,clinical and,Acute Coronary Syndromes,2023,79
Recommendations for cardiac arrest and out-of-hospital cardiac arrest A PPCI strategy is recommended in patients with resuscitated cardiac arrest and an ECG with persistent ST-segment elevation (or equivalents).,I,B,1,clinical and,Acute Coronary Syndromes,2023,79
Temperature control (i.e. continuous monitoring of core temperature and active prevention of fever [i.e. >37.7°C]) is recommended after either out-of-hospital or in-hospital cardiac arrest for adults who remain unresponsive after return of spontaneous circulation.,I,B,1,clinical and,Acute Coronary Syndromes,2023,79
Routine immediate angiography after resuscitated cardiac arrest is not recommended in haemodynamically stable patients without persistent ST-segment elevation (or equivalents).,III,A,1,clinical and,Acute Coronary Syndromes,2023,79
Systems of care It is recommended that healthcare systems implement strategies to facilitate transfer of all patients in whom ACS is suspected after resuscitated cardiac arrest directly to a hospital offering 24/7 PPCI via one specialized EMS.,I,C,1,clinical and,Acute Coronary Syndromes,2023,79
Evaluation of neurological prognosis Evaluation of neurological prognosis (no earlier than 72 h after admission) is recommended in all comatose survivors after cardiac arrest.,I,C,1,clinical and,Acute Coronary Syndromes,2023,79
Emergency CABG is recommended for ACS-related CS if PCI of the IRA is not feasible/ unsuccessful.,I,B,1,clinical and,Acute Coronary Syndromes,2023,79
"In cases of haemodynamic instability, emergency surgical/catheter-based repair of mechanical complications of ACS is recommended, based on Heart Team discussion.",I,C,1,clinical and,Acute Coronary Syndromes,2023,79
The routine use of an intra-aortic balloon pump in ACS patients with CS and without mechanical complications is not recommended.,III,B,1,clinical and,Acute Coronary Syndromes,2023,79
"Recommendations for in-hospital management It is recommended that all hospitals participating in the care of high-risk patients have an ICCU/CCU equipped to provide all required aspects of care, including treatment of ischaemia, severe heart failure, arrhythmias, and common comorbidities.",I,C,1,clinical and,Acute Coronary Syndromes,2023,79
It is recommended that high-risk patients (including all STEMI patients and very high-risk NSTE-ACS patients) have ECG monitoring for a minimum of 24 h.,I,C,1,clinical and,Acute Coronary Syndromes,2023,79
"It is recommended that high-risk patients with successful reperfusion therapy and an uncomplicated clinical course (including all STEMI patients and very high-risk NSTE-ACS patients) are kept in the CCU/ ICCU for a minimum of 24 h whenever possible, after which they may be moved to a step-down monitored bed for an additional 24–48 h.",I,C,1,clinical and,Acute Coronary Syndromes,2023,79
"Recommendations for technical aspects of invasive strategies Radial access is recommended as the standard approach, unless there are over-riding procedural considerations.",I,A,1,clinical and,Acute Coronary Syndromes,2023,79
PCI with stent deployment in the IRA during the index procedure is recommended for patients undergoing PPCI.,I,A,1,clinical and,Acute Coronary Syndromes,2023,79
Drug-eluting stents are recommended in preference to bare metal stents in all cases.,I,A,1,clinical and,Acute Coronary Syndromes,2023,79
"In patients with spontaneous coronary artery dissection, PCI is recommended only for patients with symptoms and signs of ongoing myocardial ischaemia, a large area of myocardium in jeopardy, and reduced antegrade flow.",I,C,1,clinical and,Acute Coronary Syndromes,2023,79
The routine use of thrombus aspiration is not recommended.,III,A,1,clinical and,Acute Coronary Syndromes,2023,79
"Recommendations for management of patients with multivessel disease It is recommended to base the revascularization strategy (IRA PCI, multivessel PCI/CABG) on the patient’s clinical status and comorbidities, as well as their disease complexity, according to the principles of management of myocardial revascularization.",I,B,1,clinical and,Acute Coronary Syndromes,2023,79
Multivessel disease in haemodynamically stable STEMI patients undergoing PPCI Complete revascularization is recommended either during the index PCI procedure or within 45 days.,I,A,1,clinical and,Acute Coronary Syndromes,2023,80
It is recommended that PCI of the non-IRA is based on angiographic severity.,I,B,1,clinical and,Acute Coronary Syndromes,2023,80
Invasive epicardial functional assessment of non-culprit segments of the IRA is not recommended during the index procedure.,III,C,1,clinical and,Acute Coronary Syndromes,2023,80
Recommendations for myocardial infarction with non-obstructive coronary arteries In patients with a working diagnosis of MINOCA CMR imaging is recommended after invasive angiography if the final diagnosis is not clear,I,B,1,clinical and,Acute Coronary Syndromes,2023,80
"Management of MINOCA according to the final established underlying diagnosis is recommended, consistent with the appropriate disease-specific guidelines.",I,B,1,clinical and,Acute Coronary Syndromes,2023,80
"In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to determine the underlying final diagnosis.",I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Recommendations for acute coronary syndrome complications Atrial fibrillation Intravenous beta-blockers are recommended when rate control is needed in the absence of acute HF or hypotension.,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Intravenous amiodarone is recommended when rate control is needed in the presence of acute HF and no hypotension.,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Immediate electrical cardioversion is recommended in patients with ACS and haemodynamic instability and when adequate rate control cannot be achieved promptly with pharmacological agents.,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Intravenous amiodarone is recommended to facilitate electrical cardioversion and/or decrease risk of early recurrence of AF after electrical cardioversion in unstable patients with recent-onset AF.,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Ventricular arrythmias Implantable cardioverter defibrillator use is recommended to reduce sudden cardiac death in patients with symptomatic HF (NYHA Class II–III) and LVEF ≤35% despite optimal medical therapy for >3 months and at least 6 weeks after MI who are expected to survive for at least 1 year with good functional status.,I,A,1,clinical and,Acute Coronary Syndromes,2023,80
Intravenous beta-blocker and/or amiodarone treatment is recommended for patients with polymorphic VT and/or VF unless contraindicated.,I,B,1,clinical and,Acute Coronary Syndromes,2023,80
"Bradyarrhythmias In cases of sinus bradycardia with haemodynamic intolerance or high-degree AV block without stable escape rhythm: • i.v. positive chronotropic medication (adrenaline, vasopressin, and/or atropine) is recommended. • temporary pacing is recommended in cases of failure to respond to atropine. • urgent angiography with a view to revascularization is recommended if the patient has not received previous reperfusion therapy.",I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Implantation of a permanent pacemaker is recommended when high-degree AV block does not resolve within a waiting period of at least 5 days after MI.,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Pacing is not recommended if high-degree AV block resolves after revascularization or spontaneously.,III,B,1,clinical and,Acute Coronary Syndromes,2023,80
Treatment of asymptomatic and haemodynamically irrelevant ventricular arrhythmias with anti-arrhythmic drugs is not recommended.,III,C,1,clinical and,Acute Coronary Syndromes,2023,80
Recommendations for acute coronary syndrome comorbid conditions Chronic kidney disease The use of low- or iso-osmolar contrast media (at the lowest possible volume) is recommended for invasive strategies.,I,A,1,clinical and,Acute Coronary Syndromes,2023,80
It is recommended to assess kidney function using eGFR in all patients with ACS.,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD (dose adjustment may be necessary) as in patients with normal kidney function.,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
"Diabetes It is recommended to base the choice of long-term glucose-lowering treatment on the presence of comorbidities, including heart failure, CKD, and obesity.",I,A,1,clinical and,Acute Coronary Syndromes,2023,80
It is recommended to assess glycaemic status at initial evaluation in all patients with ACS.,I,B,1,clinical and,Acute Coronary Syndromes,2023,80
It is recommended to frequently monitor blood glucose levels in patients with known diabetes mellitus or hyperglycaemia (defined as glucose levels ≥11.1 mmol/L or ≥200 mg/dL).,I,C,1,clinical and,Acute Coronary Syndromes,2023,80
Older adults It is recommended to apply the same diagnostic and treatment strategies in older patients as in younger patients.,I,B,1,clinical and,Acute Coronary Syndromes,2023,80
"For frail older patients with comorbidities, a holistic approach is recommended to individualize interventional and pharmacological treatments after careful evaluation of the risks and benefits.",I,B,1,clinical and,Acute Coronary Syndromes,2023,81
An invasive strategy is recommended in cancer patients presenting with high-risk ACS with expected life survival ≥6 months.,I,B,1,clinical and,Acute Coronary Syndromes,2023,81
A temporary interruption of cancer therapy is recommended in patients in whom the cancer therapy is suspected to be a contributing cause of ACS.,I,C,1,clinical and,Acute Coronary Syndromes,2023,81
Aspirin is not recommended in cancer patients with a platelet count <10 000/μL.,III,C,1,clinical and,Acute Coronary Syndromes,2023,81
Clopidogrel is not recommended in cancer patients with a platelet count <30 000/μL.,III,C,1,clinical and,Acute Coronary Syndromes,2023,81
"In ACS patients with cancer and <50 000/μL platelet count, prasugrel or ticagrelor are not recommended.",III,C,1,clinical and,Acute Coronary Syndromes,2023,81
"Recommendations for long-term management It is recommended that all ACS patients participate in a medically supervised, structured, comprehensive, multidisciplinary exercise-based cardiac rehabilitation and prevention programme.",I,A,1,clinical and,Acute Coronary Syndromes,2023,81
"It is recommended that ACS patients adopt a healthy lifestyle, including: • stopping all smoking of tobacco • healthy diet (Mediterranean style) • alcohol restriction • regular aerobic physical activity and resistance exercise • reduced sedentary time",I,B,1,clinical and,Acute Coronary Syndromes,2023,81
Pharmacological treatment Lipid-lowering therapy It is recommended that high-dose statin therapy is initiated or,I,A,1,clinical and,Acute Coronary Syndromes,2023,81
It is recommended to aim to achieve an LDL-C level of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C by ≥50% from baseline.,I,A,1,clinical and,Acute Coronary Syndromes,2023,81
"If the LDL-C goal is not achieved despite maximally tolerated statin therapy and ezetimibe after 4–6 weeks, the addition of a PCSK9 inhibitor is recommended",I,A,1,clinical and,Acute Coronary Syndromes,2023,81
"If the LDL-C goal is not achieved despite maximally tolerated statin therapy after 4–6 weeks, the addition of ezetimibe is recommended.",I,B,1,clinical and,Acute Coronary Syndromes,2023,81
It is recommended to intensify lipid-lowering therapy during the index ACS hospitalization for patients who were on lipid-lowering therapy before admission.,I,C,1,clinical and,Acute Coronary Syndromes,2023,81
"RAAS system inhibitors Angiotensin-converting enzyme inhibitors are recommended in ACS patients with HF symptoms, LVEF ≤40%, diabetes, hypertension, and/or CKD.",I,A,1,clinical and,Acute Coronary Syndromes,2023,81
Mineralocorticoid receptor antagonists are recommended in ACS patients with an LVEF ≤40% and HF or diabetes.,I,A,1,clinical and,Acute Coronary Syndromes,2023,81
"Imaging In patients with pre-discharge LVEF ≤40%, repeat evaluation of the LVEF 6–12 weeks after an ACS (and after complete revascularization and the institution of optimal medical therapy) is recommended to assess the potential need for sudden cardiac death primary prevention ICD implantation.",I,C,1,clinical and,Acute Coronary Syndromes,2023,81
Vaccination Influenza vaccination is recommended for all ACS patients.,I,A,1,clinical and,Acute Coronary Syndromes,2023,81
"Recommendations for patient perspectives in acute coronary syndrome care Patient-centred care is recommended by assessing and adhering to individual patient preferences, needs and beliefs, ensuring that patient values are used to inform all clinical decisions.",I,B,1,clinical and,Acute Coronary Syndromes,2023,81
"It is recommended to include ACS patients in decision-making (as much as their condition allows) and to inform them about the risk of adverse events, radiation exposure, and alternative options. Decision aids should be used to facilitate the discussion.",I,B,1,clinical and,Acute Coronary Syndromes,2023,81
It is recommended to assess symptoms using methods that help patients to describe their experience.,I,C,1,clinical and,Acute Coronary Syndromes,2023,81
"diagnosing diabetes Screening for diabetes is recommended in all individuals with CVD,c using fasting glucose and/or HbA1c.5–",I,A,1,Recommendations for,CVD Diabetes,2023,18
"It is recommended that the diagnosis of diabetes is based on HbA1c and/or fasting plasma glucose, or on an OGTT if still in doubt.d,5–",I,B,1,Recommendations for,CVD Diabetes,2023,18
assessing cardiovascular risk in patients with type 2 diabetes Recommendations to assess cardiovascular risk in patients with diabetes It is recommended to screen patients with diabetes for the presence of severe TOD.c,I,A,2,Recommendations for,CVD Diabetes,2023,19
It is recommended to assess medical history and the presence of symptoms suggestive of ASCVD in patients with diabetes.53–,I,B,2,Recommendations for,CVD Diabetes,2023,19
reducing weight in patients with type 2 diabetes with or without cardiovascular disease It is recommended that individuals living with overweight or obesity aim to reduce weight and increase physical exercise to improve metabolic control and overall CVD risk profile.,I,A,3,Recommendations for,CVD Diabetes,2023,20
Glucose-lowering medications with effects on weight loss (e.g. GLP-1 RAs) should be considered in patients with overweight or obesity to reduce weight.,IIa,B,3,Recommendations for,CVD Diabetes,2023,20
Bariatric surgery should be considered for high and very high risk patients with BMI ≥35 kg/m2 (≥Class IIc) when repetitive and structured efforts of lifestyle changes combined with weight-reducing medications do not result in maintained weight loss.73–,IIa,B,3,Recommendations for,CVD Diabetes,2023,20
physical activity/exercise in patients with type 2 diabetes with or without cardiovascular disease Recommendation It is recommended to increase any physical activity (e.g. 10 min daily walking) in all patients with T2DM with and without CVD. Optimal is a weekly activity of 150 min of moderate intensity or 75 min of vigorous endurance intensity.,I,A,5,Recommendations for,CVD Diabetes,2023,21
"It is recommended to adapt exercise interventions to T2DM-associated comorbidities, e.g. frailty, neuropathy, or retinopathy.",I,B,5,Recommendations for,CVD Diabetes,2023,21
"It is recommended to introduce structured exercise training in patients with T2DM and established CVD, e.g. CAD, HFpEF, HFmrEF, HFrEF, or AF to improve metabolic control, exercise capacity and quality of life, and to reduce CV events.",I,B,5,Recommendations for,CVD Diabetes,2023,21
It is recommended to perform resistance exercise in addition to endurance exercise at least twice a week.,I,B,5,Recommendations for,CVD Diabetes,2023,21
"The use of behavioural theory-based interventions, such as goal-setting, re-evaluation of goals, self-monitoring, and feedback, should be considered to promote physical activity behaviour.",IIa,B,5,Recommendations for,CVD Diabetes,2023,21
It should be considered to perform a maximally tolerated exercise stress test in patients with T2DM and established CVD before starting a structured exercise programme.,IIa,C,5,Recommendations for,CVD Diabetes,2023,21
It may be considered to use wearable activity trackers to increase physical activity behaviour.,IIb,B,5,Recommendations for,CVD Diabetes,2023,21
nutrition in patients with type 2 diabetes with or without cardiovascular disease It is recommended to adopt a Mediterranean or plant-based diet with high unsaturated fat content to lower cardiovascular risk.,I,A,4,Recommendations for,CVD Diabetes,2023,21
smoking cessation in patients with type 2 diabetes with or without cardiovascular disease It is recommended to stop smoking to reduce cardiovascular risk.118–,I,A,6,Recommendations for,CVD Diabetes,2023,22
"Nicotine replacement therapy, varenicline, and bupropion, as well as individual or telephone counselling, should be considered to improve smoking cessation success rate.",IIa,B,6,Recommendations for,CVD Diabetes,2023,22
glycaemic targets in patients with diabetes It is recommended to apply tight glycaemic control (HbA1c <7%) to reduce microvascular complications.126–,I,A,7,Recommendations for,CVD Diabetes,2023,22
"It is recommended to avoid hypoglycaemia, particularly in patients with CVD.134–",I,B,7,Recommendations for,CVD Diabetes,2023,22
"It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy.",I,C,7,Recommendations for,CVD Diabetes,2023,22
"Tight glycaemic control should be considered for reducing CAD in the long term, preferably using agents with proven CV benefit.c,129–",IIa,B,7,Recommendations for,CVD Diabetes,2023,22
"glucose-lowering treatment for patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce cardiovascular risk It is recommended to prioritize the use of glucose-lowering agents with proven CV benefitsc,d followed by agents with proven CV safetye over agents without proven CV benefit or proven CV safety.",I,C,8,Recommendations for,CVD Diabetes,2023,30
"Sodium–glucose co-transporter-2 inhibitors SGLT2 inhibitors with proven CV benefitc are recommended in patients with T2DM and ASCVD to reduce CV events, independent of baseline or target HbA1c and independent of concomitant glucose-lowering medication.71,150–",I,A,8,Recommendations for,CVD Diabetes,2023,30
"Glucagon-like peptide-1 receptor agonists GLP-1 RAs with proven CV benefitd are recommended in patients with T2DM and ASCVD to reduce CV events, independent of baseline or target HbA1c and independent of concomitant glucose-lowering medication.",I,A,8,Recommendations for,CVD Diabetes,2023,30
"Other glucose-lowering medications to reduce cardiovascular risk If additional glucose control is needed, metformin should be considered in patients with T2DM and ASCVD.",IIa,C,8,Recommendations for,CVD Diabetes,2023,30
"If additional glucose control is needed, pioglitazone may be considered in patients with T2DM and ASCVD without HF.",IIb,B,8,Recommendations for,CVD Diabetes,2023,30
"glucose-lowering treatment for patients with type 2 dia­ betes without atherosclerotic cardiovascular disease or severe target-organ damage to reduce cardiovascular risk In patients with T2DM without ASCVD or severe TODc at low or moderate risk, treatment with metformin should be considered to reduce CV risk.",IIa,C,9,Recommendation for,CVD Diabetes,2023,30
"In patients with T2DM without ASCVD or severe TODc but with a calculated 10-year CVD riskd ≥10%, treatment with a SGLT2 inhibitor or GLP-1 RA may be considered to reduce CV risk.",IIb,C,9,Recommendation for,CVD Diabetes,2023,30
blood pressure management in patients with diabetes Screening for hypertension Regular BP measurementsc are recommended in all patients with diabetes to detect and treat hypertension to reduce CV risk.,I,A,10,Recommendations for,CVD Diabetes,2023,32
Treatment targets Anti-hypertensive drug treatment is recommended for people with diabetes when office BP is ≥140/ 90 mmHg.,I,A,10,Recommendations for,CVD Diabetes,2023,32
"It is recommended to treat hypertension in patients with diabetes in an individualized manner. The BP goal is to target SBP to 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg. In older people (age >65 years), it is recommended to target SBP to 130– 139 mmHg.196,236–",I,A,10,Recommendations for,CVD Diabetes,2023,32
An on-treatment SBP target of <130 mmHg may be considered in patients with diabetes at particularly high risk of a cerebrovascular event to further reduce their risk of stroke.194–,IIb,B,10,Recommendations for,CVD Diabetes,2023,32
"Treatment and evaluation Lifestyle changes (weight loss if overweight, physical activity, alcohol restriction, sodium restriction, increased consumption of vegetables, using low-fat dairy products) are recommended in patients with diabetes and hypertension.205–",I,A,10,Recommendations for,CVD Diabetes,2023,32
"It is recommended to initiate treatment with a combination of a RAS inhibitor and a CCB or thiazide/thiazide-like diuretic.196,213–",I,A,10,Recommendations for,CVD Diabetes,2023,32
Home BP self-monitoring should be considered in patients with diabetes on anti-hypertensive treatments to check that BP is appropriately controlled.,IIa,B,10,Recommendations for,CVD Diabetes,2023,32
"24 h ambulatory blood pressure monitoring should be considered to assess abnormal 24 h BP patterns, including nocturnal hypertension and reduced or reversed nocturnal BP dipping, and to adjust anti-hypertensive treatment.",IIa,B,10,Recommendations for,CVD Diabetes,2023,32
"the management of dyslipidaemia in patients with diabetes Lipid targets In patients with T2DM at moderate CV risk, an LDL-C target of <2.6 mmol/L (<100 mg/dL) is recommended.",I,A,11,Recommendations for,CVD Diabetes,2023,34
"In patients with T2DM at high CV risk, an LDL-C target of <1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least 50% is recommended.",I,A,11,Recommendations for,CVD Diabetes,2023,34
"In patients with T2DM, a secondary goal of a non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in very high CV risk patients and <2.6 mmol/L (<100 mg/dL) in high CV risk patients is recommended.283–",I,B,11,Recommendations for,CVD Diabetes,2023,35
Lipid-lowering treatment Statins are recommended as the first-choice LDL-C-lowering treatment in patients with diabetes and above-target LDL-C levels. Administration of statins is defined based on the CV risk profile of the patients and the recommended LDL-C (or non-HDL-C) target levels.247–,I,A,11,Recommendations for,CVD Diabetes,2023,35
"A PCSK9 inhibitor is recommended in patients at very high CV risk, with persistently high LDL-C levels above target despite treatment with a maximum tolerated statin dose, in combination with ezetimibe, or in patients with statin intolerance.",I,A,11,Recommendations for,CVD Diabetes,2023,35
"If the target LDL-C is not reached with statins, combination therapy with ezetimibe is recommended.",I,B,11,Recommendations for,CVD Diabetes,2023,35
"If a statin-based regimen is not tolerated at any dosage (even after re-challenge), a PCSK9 inhibitor added to ezetimibe should be considered.",IIa,B,11,Recommendations for,CVD Diabetes,2023,35
"If a statin-based regimen is not tolerated at any dosage (even after re-challenge), ezetimibe should be considered.",IIa,C,11,Recommendations for,CVD Diabetes,2023,35
High-dose icosapent ethyl (2 g b.i.d.) may be considered in combination with a statin in patients with hypertriglyceridaemiac.,IIb,B,11,Recommendations for,CVD Diabetes,2023,35
"patients with diabetes without a history of symptomatic atherosclerotic cardiovascular disease or revascularization Recommendation In adults with T2DM without a history of symptomatic ASCVD or revascularization, ASA (75– 100 mg o.d.) may be considered to prevent the first severe vascular event, in the absence of clear contraindications.c",IIb,A,12,Recommendations for,CVD Diabetes,2023,35
antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome without indications for long-term oral anticoagulation ASA at a dose of 75–100 mg o.d. is recommended in patients with diabetes and previous MI or revascularization (CABG or stenting).,I,A,13,Recommendations for,CVD Diabetes,2023,38
"In patients with ACS and diabetes who undergo PCI, a P2Y12 receptor inhibitor (ticagrelor or prasugrel) is recommended in addition to ASA (75–100 mg o.d.), maintained over 12 months. 310–",I,A,13,Recommendations for,CVD Diabetes,2023,38
"Clopidogrel 75 mg o.d. following appropriate loading (e.g. 600 mg or at least 5 days already on maintenance therapy) is recommended in addition to ASA for 6 months following coronary stenting in patients with CCS, irrespective of stent type, unless a shorter duration is indicated due to the risk or occurrence of life-threatening bleeding.327–",I,A,13,Recommendations for,CVD Diabetes,2023,38
Clopidogrel is recommended as an alternative in case of ASA intolerance.,I,B,13,Recommendations for,CVD Diabetes,2023,38
Prolonging DAPT beyond 12 months after ACS should be considered for up to 3 years in patients with diabetes who have tolerated DAPT without major bleeding complications.c,IIa,A,13,Recommendations for,CVD Diabetes,2023,38
Adding very low-dose rivaroxaband to low-dose ASA for long-term prevention of serious vascular events should be considered in patients with diabetes and CCS or symptomatic PAD without high bleeding risk.,IIa,B,13,Recommendations for,CVD Diabetes,2023,38
"antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome and/or post- percutaneous coronary intervention requiring long- term oral anticoagulation In patients with AF and receiving antiplatelet therapy, eligible for anticoagulation, and without a contraindication,c NOACs are recommended in preference to a VKA.",I,A,14,Recommendations for,CVD Diabetes,2023,39
"In patients with ACS or CCS and diabetes undergoing coronary stent implantation and having an indication for anticoagulation, triple therapy with low-dose ASA, clopidogrel, and an OAC is recommended for at least 1 week, followed by dual therapy with an OAC and a single, oral, antiplatelet agent.339–",I,A,14,Recommendations for,CVD Diabetes,2023,39
"In patients with ACS or CCS and diabetes undergoing coronary stent implantation and having an indication for anticoagulation, prolonging triple therapy with low-dose ASA, clopidogrel, and an OAC should be considered up to 1 month if the thrombotic risk outweighs the bleeding risk in the individual patient.341–",IIa,C,14,Recommendations for,CVD Diabetes,2023,39
"gastric protection in patients with diabetes taking an­ tithrombotic drugs When antithrombotic drugs are used in combination, proton pump inhibitors are recommended to prevent gastrointestinal bleeding.337,347,348,351–",I,A,15,Recommendations for,CVD Diabetes,2023,39
"When a single antiplatelet or anticoagulant drug is used, proton pump inhibitors should be considered to prevent gastrointestinal bleeding, considering the bleeding risk of the individual patient.",IIa,A,15,Recommendations for,CVD Diabetes,2023,39
"When clopidogrel is used, omeprazole and esomeprazole are not recommended for gastric protection.",III,B,15,Recommendations for,CVD Diabetes,2023,39
multifactorial approach in patients with type 2 diabetes with and without cardiovascular disease Identifying and treating risk factors and comorbidities early is recommended.,I,A,16,Recommendations for a,CVD Diabetes,2023,40
A multifactorial approach to managing T2DM with treatment targets is recommended.,I,B,16,Recommendations for a,CVD Diabetes,2023,40
Multidisciplinary behavioural approaches that combine the knowledge and skills of different caregivers are recommended.,I,C,16,Recommendations for a,CVD Diabetes,2023,40
Principles of motivational interviewing should be considered to induce behavioural changes.372–,IIa,C,16,Recommendations for a,CVD Diabetes,2023,40
Telehealth may be considered to improve risk profile.,IIb,B,16,Recommendations for a,CVD Diabetes,2023,40
"revascularization in patients with diabetes It is recommended that similar revascularization techniques are implemented (e.g. the use of DES and the radial approach for PCI, and the use of the left internal mammary artery as the graft for CABG) in patients with and without diabetes.",I,A,17,Recommendations for,CVD Diabetes,2023,42
"Myocardial revascularization in CCS is recommended when angina persists despite treatment with anti-anginal drugs or in patients with a documented large area of ischaemia (>10% LV).382,401,402,402a",I,A,17,Recommendations for,CVD Diabetes,2023,42
Complete revascularization is recommended in patients with STEMI without cardiogenic shock and with multivessel CAD.403–,I,A,17,Recommendations for,CVD Diabetes,2023,42
Complete revascularization should be considered in patients with NSTE-ACS without cardiogenic shock and with multivessel CAD.,IIa,C,17,Recommendations for,CVD Diabetes,2023,42
Routine immediate revascularization of non-culprit lesions in patients with MI and multivessel disease presenting with cardiogenic shock is not recommended.,III,B,17,Recommendations for,CVD Diabetes,2023,42
glycaemic control in patients with diabetes and acute coronary syndrome It is recommended to assess glycaemic status at initial evaluation in all patients with ACS.,I,B,18,Recommendations for,CVD Diabetes,2023,43
It is recommended to frequently monitor blood glucose levels in patients with known diabetes or hyperglycaemia (defined as glucose levels ≥11.1 mmol/L or ≥200 mg/dL).,I,C,18,Recommendations for,CVD Diabetes,2023,43
"Glucose-lowering therapy should be considered in patients with ACS with persistent hyperglycaemia, while episodes of hypoglycaemia should be avoided.",IIa,C,18,Recommendations for,CVD Diabetes,2023,43
"heart failure screening and diagnosis in patients with diabetes Evaluating for heart failure If HF is suspected, it is recommended to measure BNP/NT-proBNP.",I,B,19,Recommendations for,CVD Diabetes,2023,46
Systematic survey for HF symptoms and/or signs of HF is recommended at each clinical encounter in all patients with diabetes.,I,C,19,Recommendations for,CVD Diabetes,2023,46
Diagnostic tests in all patients with suspected heart failure 12-lead ECG is recommended.,I,C,19,Recommendations for,CVD Diabetes,2023,46
Transthoracic echocardiography is recommended.,I,C,19,Recommendations for,CVD Diabetes,2023,46
Chest radiography (X-ray) is recommended.,I,C,19,Recommendations for,CVD Diabetes,2023,46
"heart failure treatments in patients with heart failure with reduced ejection fraction and diabetes Recommendations for the pharmacological treatment indicated in patients with HFrEF (NYHA class II–IV) and diabetes SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozinc) are recommended in all patients with HFrEF and T2DM to reduce the risk of HF hospitalization and CV death.",I,A,20,Recommendations for,CVD Diabetes,2023,48
Sacubitril/valsartan or an ACE-I is recommended in all patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.,I,A,20,Recommendations for,CVD Diabetes,2023,48
Beta-blockersd are recommended in patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.509–,I,A,20,Recommendations for,CVD Diabetes,2023,48
"An intensive strategy of early initiation of evidence-based treatment (SGLT2 inhibitors, ARNI/ ACE-Is, beta-blockers, and MRAs), with rapid up-titration to trial-defined target doses starting before discharge and with frequent follow-up visits in the first 6 weeks following a HF hospitalization is recommended to reduce re-admissions or mortality.",I,B,20,Recommendations for,CVD Diabetes,2023,48
"Recommendations for other treatments indicated in selected patients with HFrEF (NYHA class II–IV) and diabetes Device therapy with an ICD, CRT-P, or CRT-D is recommended in patients with diabetes, as in the general population with HFrEF.522–",I,A,20,Recommendations for,CVD Diabetes,2023,48
"ARBs are recommended in symptomatic patients with HFrEF and diabetes who do not tolerate sacubitril/valsartan or ACE-Is, to reduce the risk of HF hospitalization and CV death.513–",I,A,20,Recommendations for,CVD Diabetes,2023,48
"Diuretics are recommended in patients with HFrEF and diabetes with signs and/or symptoms of fluid congestion to improve symptoms, exercise capacity, and HF hospitalization.",I,C,20,Recommendations for,CVD Diabetes,2023,48
"Ivabradine should be considered to reduce the risk of HF hospitalization and CV death in patients with HFrEF and diabetes in sinus rhythm, with a resting heart rate ≥70 b.p.m., who remain symptomatic despite treatment with beta-blockers (maximum tolerated dose), ACE-Is/ARBs, and MRAs.",IIa,B,20,Recommendations for,CVD Diabetes,2023,48
"Hydralazine and isosorbide dinitrate should be considered in self-identified Black patients with diabetes and LVEF ≤ 35% or with LVEF <45% combined with a dilated left ventricle in NYHA class III–IV despite treatment with an ACE-I (or ARNI), a beta-blocker, and an MRA, to reduce the risk of HF hospitalization and death.",IIa,B,20,Recommendations for,CVD Diabetes,2023,48
"Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treatment with sacubitril/valsartan or an ACE-I, a beta-blocker, and an MRA, to reduce the risk of hospitalization.",IIb,B,20,Recommendations for,CVD Diabetes,2023,48
heart failure treatments in patients with diabetes and left ventricular ejection fraction over 40% Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF hospitalization or CV death.530–,I,A,21,Recommendations for,CVD Diabetes,2023,49
"Diuretics are recommended in patients with HFpEF or HFmrEF and diabetes with signs and/or symptoms of fluid congestion to improve symptoms, exercise capacity, and HF hospitalization.",I,C,21,Recommendations for,CVD Diabetes,2023,49
"with and without heart failure Recommendations for glucose-lowering medications to reduce heart failure hospitalization in patients with type 2 diabetes with or without existing heart failure SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozinc) are recommended in patients with T2DM with multiple ASCVD risk factors or established ASCVD to reduce the risk of HF hospitalization.71,150–",I,A,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
"SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozinc) are recommended in patients with T2DM and HFrEF to reduce the risk of HF hospitalization and CV death.",I,A,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF hospitalization or CV death.,I,A,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
"Recommendations for additional glucose-lowering agents with safety demonstrated for heart failure hospitalization in patients with type 2 diabetes if additional glucose control is needed GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF.70,158–",IIa,A,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
"DPP-4 inhibitors (sitagliptin and linagliptin) have a neutral effect on the risk of HF hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF.",IIa,A,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
Basal insulins (glargine and degludec) have a neutral effect on the risk of HF hospitalization and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF.,IIa,B,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
Metformin should be considered for glucose-lowering treatment in patients with T2DM and HF.d,IIa,B,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
Recommendations for glucose-lowering medications with an increased risk of heart failure hospitalization in patients with type 2 diabetes Pioglitazone is associated with an increased risk of incident HF in patients with diabetes and is not recommended for glucose-lowering treatment in patients at risk of HF (or with previous HF).,III,A,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
The DPP-4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization in patients with diabetes and is not recommended for glucose-lowering treatment in patients at risk of HF (or with previous HF).,III,B,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
Recommendations for special consideration It is recommended to switch glucose-lowering treatment from agents without proven CV benefit or proven safety to agents with proven CV benefit.e,I,C,22,Recommendations for glucose-lowering medications in patients with type 2 diabetes,CVD Diabetes,2023,52
atrial fibrillation in patients with diabetes Screening Opportunistic screening for AF by pulse taking or ECG is recommended in patients ≥65 years of age.,I,B,23,Recommendations for,CVD Diabetes,2023,56
Opportunistic screening for AF by pulse taking or ECG is recommended in patients with diabetes <65 years of age (particularly when other risk factors are present) because patients with diabetes exhibit a higher AF frequency at a younger age.,I,C,23,Recommendations for,CVD Diabetes,2023,56
"Systematic ECG screening should be considered to detect AF in patients aged ≥75 years, or those at high risk of stroke.577,633–",IIa,B,23,Recommendations for,CVD Diabetes,2023,56
Anticoagulation Oral anticoagulation is recommended for preventing stroke in patients with AF and diabetes and with at least one additional (CHA2DS2-VASc) risk factor for stroke.,I,A,23,Recommendations for,CVD Diabetes,2023,56
"For preventing stroke in AF, NOACs are recommended in preference to VKAs, with the exception of patients with mechanical valve prostheses or moderate to severe mitral stenosis.",I,A,23,Recommendations for,CVD Diabetes,2023,56
Oral anticoagulation should be considered for preventing stroke in patients with AF and diabetes but no other CHA2DS2-VASc risk factor for stroke. This includes patients with T1DM or T2DM <65 years old.638–,IIa,B,23,Recommendations for,CVD Diabetes,2023,56
"Use of a formal, structured, bleeding risk score (HAS-BLED score) should be considered to identify modifiable and non-modifiable risk factors for bleeding in patients with diabetes and AF, and to identify patients in need of closer follow-up.641–",IIa,B,23,Recommendations for,CVD Diabetes,2023,56
patients with chronic kidney disease and diabetes Intensive LDL-C lowering with statins or a statin/ ezetimibe combination is recommended.c,I,A,24,Recommendations for,CVD Diabetes,2023,61
A BP target of ≤130/80 mmHg is recommended to reduce risk of CVD and albuminuria.,I,A,24,Recommendations for,CVD Diabetes,2023,61
"Personalized HbA1c targets 6.5–8.0% (48–64 mmol/ mol) are recommended, with a target <7.0% (<53 mmol/mol) to reduce microvascular complications, wherever possible.",I,A,24,Recommendations for,CVD Diabetes,2023,61
The maximum tolerated dose of an ACE-I or ARB is recommended.705–,I,A,24,Recommendations for,CVD Diabetes,2023,61
"A SGLT2 inhibitor (canagliflozin, empagliflozin, or dapagliflozin)d is recommended in patients with T2DM and CKD with an eGFR ≥20 mL/min/1.73 m2 to reduce the risk of CVD and kidney failure.",I,A,24,Recommendations for,CVD Diabetes,2023,61
"A GLP-1 RA is recommended at eGFR >15 mL/min/ 1.73 m2 to achieve adequate glycaemic control, due to low risk of hypoglycaemia and beneficial effects on weight, CV risk, and albuminuria.",I,A,24,Recommendations for,CVD Diabetes,2023,62
Low-dose ASA (75–100 mg o.d.) is recommended in patients with CKD and ASCVD.,I,A,24,Recommendations for,CVD Diabetes,2023,62
It is recommended that patients with diabetes are routinely screened for kidney disease by assessing eGFR defined by CKD-EPI and UACR.,I,B,24,Recommendations for,CVD Diabetes,2023,62
"Treatment with intensive medical or an initial invasive strategy is recommended in people with CKD, diabetes, and stable moderate or severe CAD, due to similar outcomes.e",I,B,24,Recommendations for,CVD Diabetes,2023,62
"Kidney specialist advice may be considered for managing a raised serum phosphate, other evidence of CKD-MBD, and renal anaemia.",IIb,C,24,Recommendations for,CVD Diabetes,2023,62
Combined use of an ARB with an ACE-I is not recommended.,III,B,24,Recommendations for,CVD Diabetes,2023,62
"peripheral arterial and aortic diseases in patients with diabetes Recommendation Lower-extremity arterial disease In patients with diabetes and symptomatic LEAD, antiplatelet therapy is recommended.",I,A,25,Recommendations for,CVD Diabetes,2023,64
"In patients with diabetes and CLTI, it is recommended to assess the risk of amputation; the WIfI score is useful for this purpose.",I,B,25,Recommendations for,CVD Diabetes,2023,64
"As patients with diabetes and LEAD are at very high CV risk, a LDL-C target of <1.4 mmol/L (<55 mg/dL) and a LDL-C reduction of at least 50% is recommended.",I,B,25,Recommendations for,CVD Diabetes,2023,64
"Screening for LEAD is recommended on a regular basis, with clinical assessment and/or ABI measurement.",I,C,25,Recommendations for,CVD Diabetes,2023,64
"Patient education about foot care is recommended in patients with diabetes, and especially those with LEAD, even if asymptomatic. Early recognition of tissue loss and/or infection, and referral to a multidisciplinary team, is mandatory to improve limb salvage.",I,C,25,Recommendations for,CVD Diabetes,2023,64
"An ABI ≤0.90 is diagnostic of LEAD, irrespective of symptoms. In symptomatic cases, further assessment including duplex ultrasound is recommended.",I,C,25,Recommendations for,CVD Diabetes,2023,64
"When ABI is elevated (>1.40), other non-invasive tests, including TBI or duplex ultrasound, are recommended.",I,C,25,Recommendations for,CVD Diabetes,2023,64
"In case of CLTI, revascularization is recommended whenever feasible for limb salvage.",I,C,25,Recommendations for,CVD Diabetes,2023,65
"In patients with chronic, symptomatic LEAD without high bleeding risk, a combination of low-dose rivaroxaban (2.5 mg b.i.d.) and ASA (100 mg o.d.) should be considered.",IIa,B,25,Recommendations for,CVD Diabetes,2023,65
"Carotid artery disease In patients with diabetes and carotid artery disease, it is recommended to implement the same diagnostic work-up and therapeutic strategies (medical, surgical, or endovascular) as in patients without diabetes.",I,C,25,Recommendations for,CVD Diabetes,2023,65
"Aortic aneurysm In patients with diabetes and aortic aneurysm, it is recommended to implement the same diagnostic work-up and therapeutic strategies (medical, surgical, or endovascular) as in patients without diabetes.",I,C,25,Recommendations for,CVD Diabetes,2023,65
"patients with type 1 diabetes Recommendation In patients with T1DM, it is recommended that adjustment of glucose-lowering medication follows principles of patient self-management under the guidance of the diabetes healthcare multidisciplinary team.",I,C,26,Recommendations for,CVD Diabetes,2023,66
"Avoiding hypoglycaemic episodes is recommended, particularly in those with established CVD.780–",I,C,26,Recommendations for,CVD Diabetes,2023,66
Statins should be considered for LDL-C lowering in adults older than 40 years with T1DM without a history of CVD to reduce CV risk.,IIa,B,26,Recommendations for,CVD Diabetes,2023,66
Statins should be considered for use in adults younger than 40 years with T1DM and other risk factors of CVD or microvascular end-organ damage or 10-year CVD risk ≥10% to reduce CVD risk.,IIa,B,26,Recommendations for,CVD Diabetes,2023,66
The use of the Scottish/Swedish risk prediction model may be considered to estimate 10-year CVD risk in patients with T1DM.,IIb,B,26,Recommendations for,CVD Diabetes,2023,66
"person-centred care in diabetes Structured education programmes are recommended in patients with diabetes to improve diabetes knowledge, glycaemic control, disease management, and patient empowerment.",I,A,27,Recommendations for,CVD Diabetes,2023,68
Person-centred care is recommended to facilitate shared control and decision-making within the context of person priorities and goals.822–,I,C,27,Recommendations for,CVD Diabetes,2023,68
"Providing individual empowerment strategies should be considered to enhance self-efficacy, self-care, and motivation in patients with diabetes.825,826,831–",IIa,B,27,Recommendations for,CVD Diabetes,2023,68
provision of service of multidisciplinary cardiomyopathy teams It is recommended that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the diagnosis and management of cardiomyopathies.,I,C,1,Recommendations for the,Cardiomyopathies,2023,17
"Timely and adequate preparation for transition of care from paediatric to adult services, including joint consultations, is recommended in all adolescents with cardiomyopathy.",I,C,1,Recommendations for the,Cardiomyopathies,2023,17
"diagnostic work-up in cardiomyopathies It is recommended that all patients with suspected or established cardiomyopathy undergo systematic evaluation using a multiparametric approach that includes clinical evaluation, pedigree analysis, ECG, Holter monitoring, laboratory tests, and multimodality imaging.",I,C,2,Recommendations for,Cardiomyopathies,2023,18
"It is recommended that all patients with suspected cardiomyopathy undergo evaluation of family history and that a three- to four-generation family tree is created to aid in diagnosis, provide clues to underlying aetiology, determine inheritance pattern, and identify at-risk relatives.64–",I,C,2,Recommendations for,Cardiomyopathies,2023,18
"laboratory tests in the diagnosis of cardiomyopathies Routine (first-level) laboratory testsc are recommended in all patients with suspected or confirmed cardiomyopathy to evaluate aetiology, assess disease severity, and aid in detection of extracardiac manifestations and assessment of secondary organ dysfunction.",I,C,3,Recommendations for,Cardiomyopathies,2023,22
"Additional (second-level) testsc should be considered in patients with cardiomyopathy and extracardiac features to aid in detection of metabolic and syndromic causes, following specialist evaluation.",IIa,C,3,Recommendations for,Cardiomyopathies,2023,22
"echocardiographic evaluation in patients with cardiomyopathy Recommendation A comprehensive evaluation of cardiac dimensions and LV and RV systolic (global and regional) and LV diastolic function is recommended in all patients with cardiomyopathy at initial evaluation, and during follow-up, to monitor disease progression and aid risk stratification and management.78,83–",I,B,4,Recommendation for,Cardiomyopathies,2023,22
"cardiac magnetic resonance indication in patients with cardiomyopathy Contrast-enhanced CMR is recommended in patients with cardiomyopathy at initial evaluation.10,90,116,119–",I,B,5,Recommendations for,Cardiomyopathies,2023,24
"Contrast-enhanced CMR should be considered for the serial follow-up and assessment of therapeutic response in patients with cardiac amyloidosis, Anderson–Fabry disease, sarcoidosis, inflammatory cardiomyopathies, and haemochromatosis with cardiac involvement.148–",IIa,C,5,Recommendations for,Cardiomyopathies,2023,24
"In families with cardiomyopathy in which a disease-causing variant has been identified, contrast-enhanced CMR should be considered in genotype-positive/phenotype-negative family members to aid diagnosis and detect early disease.10,122,126,128,129,135–143,145,153–",IIa,B,5,Recommendations for,Cardiomyopathies,2023,24
"In cases of familial cardiomyopathy without a genetic diagnosis, contrast-enhanced CMR may be considered in phenotype-negative family members to aid diagnosis and detect early disease.",IIb,C,5,Recommendations for,Cardiomyopathies,2023,24
computed tomography and nuclear imaging DPD/PYP/HMDP bone-tracer scintigraphy is recommended in patients with suspected ATTR-related cardiac amyloidosis to aid diagnosis.166–,I,B,6,Recommendations for,Cardiomyopathies,2023,26
Contrast-enhanced cardiac CT should be considered in patients with suspected cardiomyopathy who have inadequate echocardiographic imaging and contraindications to CMR.,IIa,C,6,Recommendations for,Cardiomyopathies,2023,26
"In patients with suspected cardiomyopathy, CT-based imaging should be considered to exclude congenital or acquired coronary artery disease as a cause of the observed myocardial abnormality.",IIa,C,6,Recommendations for,Cardiomyopathies,2023,26
18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.,IIa,C,6,Recommendations for,Cardiomyopathies,2023,26
"endomyocardial biopsy in patients with cardiomyopathy Recommendation In patients with suspected cardiomyopathy, EMB should be considered to aid in diagnosis and management when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means.174–",IIa,C,7,Recommendation for,Cardiomyopathies,2023,26
"genetic counselling and testing in cardiomyopathies Genetic counselling Genetic counselling, provided by an appropriately trained healthcare professional and including genetic education to inform decision-making and psychosocial support, is recommended for families with an inherited or suspected inherited cardiomyopathy, regardless of whether genetic testing is being considered.204,206,208,209,221–",I,B,8,Recommendations for,Cardiomyopathies,2023,35
"It is recommended that genetic testing for cardiomyopathy is performed with access to a multidisciplinary team, including those with expertise in genetic testing methodology, sequence variant interpretation, and clinical application of genetic testing, typically in a specialized cardiomyopathy service or in a network model with access to equivalent expertise.222,224–",I,B,8,Recommendations for,Cardiomyopathies,2023,35
"Pre- and post-test genetic counselling is recommended in all individuals undergoing genetic testing for cardiomyopathy.204,208,227–",I,B,8,Recommendations for,Cardiomyopathies,2023,35
"If pre-natal diagnostic testing is to be pursued by the family, it is recommended that this is performed early in pregnancy, to allow decisions regarding continuation or co-ordination of pregnancy to be made.",I,C,8,Recommendations for,Cardiomyopathies,2023,35
A discussion about reproductive genetic testing options with an appropriately trained healthcare professional should be considered for all families with a genetic diagnosis.,IIa,C,8,Recommendations for,Cardiomyopathies,2023,35
"Index patients Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.227–",I,B,8,Recommendations for,Cardiomyopathies,2023,35
Genetic testing is recommended for a deceased individual identified to have cardiomyopathy at post-mortem if a genetic diagnosis would facilitate management of surviving relatives.239–,I,C,8,Recommendations for,Cardiomyopathies,2023,35
"Genetic testing may be considered in patients fulfilling diagnostic criteria for cardiomyopathy when it will have a net benefit to the patient, considering the psychological impact and preference, even if it does not enable diagnosis, prognostication, or therapeutic stratification, or cascade genetic screening of their relatives.",IIb,C,8,Recommendations for,Cardiomyopathies,2023,35
Genetic testing in patients with a borderline phenotype not fulfilling diagnostic criteria for a cardiomyopathy may be considered only after detailed assessment by specialist teams.,IIb,C,8,Recommendations for,Cardiomyopathies,2023,35
"Cascade genetic testing with pre- and post-test counselling should be considered in paediatric at-risk relatives if a confident genetic diagnosis (i.e. a P/LP variant) has been established in an individual with cardiomyopathy in the family (starting with first-degree relatives, if available, and cascading out sequentially), considering the underlying cardiomyopathy, expected age of onset, presentation in the family, and clinical/legal consequences.233–",IIa,B,8,Recommendations for,Cardiomyopathies,2023,35
"Testing for the presence of a familial variant of unknown significance, typically in parents and/or affected relatives, to determine if the variant segregates with the cardiomyopathy phenotype should be considered if this might allow the variant to be interpreted with confidence.",IIa,C,8,Recommendations for,Cardiomyopathies,2023,35
Diagnostic genetic testing is not recommended in a phenotype-negative relative of a patient with cardiomyopathy in the absence of a confident genetic diagnosis (i.e. a P/LP variant) in the family.,III,C,8,Recommendations for,Cardiomyopathies,2023,35
"cardiac transplantation in patients with cardiomyopathy Orthotopic cardiac transplantation is recommended for eligible cardiomyopathy patients with advanced heart failure (NYHA class III–IV) or intractable ventricular arrhythmia refractory to medical/invasive/ device therapy, and who do not have absolute contraindications.317–",I,C,9,Recommendations for,Cardiomyopathies,2023,38
"left ventricular assist device therapy in patients with cardiomyopathy Recommendation Mechanical circulatory support therapy should be considered in selected cardiomyopathy patients with advanced heart failure (NYHA class III–IV) despite optimal pharmacological and device treatment, who are otherwise suitable for heart transplantation, to improve symptoms and reduce the risk of heart failure hospitalization from worsening heart failure and premature death while awaiting a transplant.320–",IIa,B,10,Recommendation for,Cardiomyopathies,2023,38
"Mechanical circulatory support therapy should be considered in selected cardiomyopathy patients with advanced heart failure (NYHA class III–IV) despite optimal pharmacological and device therapy, who are not eligible for cardiac transplantation or other surgical options, and without severe right ventricular dysfunction, to reduce the risk of death and improve symptoms.321,325–",IIa,B,10,Recommendation for,Cardiomyopathies,2023,38
"management of atrial fibrillation and atrial flutter in patients with cardiomyopathy Anticoagulation Oral anticoagulation in order to reduce the risk of stroke and thrombo-embolic events is recommended in all patients with HCM or cardiac amyloidosis and AF or atrial flutter (unless contraindicated).332,365,369,371,373,378,413,427,428,456–",I,B,11,Recommendations for,Cardiomyopathies,2023,41
"Oral anticoagulation to reduce the risk of stroke and thrombo-embolic events is recommended in patients with DCM, NDLVC, or ARVC, and AF or atrial flutter with a CHA2DS2-VASc score ≥2 in men or ≥3 in women.465–",I,B,11,Recommendations for,Cardiomyopathies,2023,41
"Oral anticoagulation to reduce the risk of stroke and thrombo-embolic events should be considered in patients with DCM, NDLVC, or ARVC, and AF or atrial flutter with a CHA2DS2-VASc score of 1 in men or of 2 in women.470–",IIa,B,11,Recommendations for,Cardiomyopathies,2023,42
"Control of symptoms and heart failure Atrial fibrillation catheter ablation is recommended for rhythm control after one failed or intolerant class I or III AAD to improve symptoms of AF recurrences in patients with paroxysmal or persistent AF and cardiomyopathy.335,397–399,412,415–420,430– 435,447,451,473–",I,B,11,Recommendations for,Cardiomyopathies,2023,42
"Atrial fibrillation catheter ablation is recommended to reverse LV dysfunction in AF patients with cardiomyopathy when tachycardia-induced component is highly probable, independent of their symptom status.405,407,408,499–",I,B,11,Recommendations for,Cardiomyopathies,2023,42
"Maintenance of sinus rhythm rather than rate control should be considered at an early stage for patients with a cardiomyopathy and AF without major risk factors for recurrence, regardless of symptoms.",IIa,C,11,Recommendations for,Cardiomyopathies,2023,42
"Atrial fibrillation catheter ablation should be considered as first-line rhythm control therapy to improve symptoms in selected patients with cardiomyopathy and paroxysmal or persistent AF without major risk factors for recurrences as an alternative to class I or III AADs, considering patient choice, benefit, and risk.392,393,480,502–",IIa,C,11,Recommendations for,Cardiomyopathies,2023,42
"Atrial fibrillation catheter ablation should be considered in selected patients with cardiomyopathy, AF, and heart failure and/or reduced LVEF to prevent AF recurrences and improve QoL, LVEF, and survival and reduce heart failure hospitalization.399–401,403– 408,499–",IIa,B,11,Recommendations for,Cardiomyopathies,2023,42
"Comorbidities and associated risk factors management Modification of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity in patients with cardiomyopathy.347,508–",I,B,11,Recommendations for,Cardiomyopathies,2023,42
implantable cardioverter defibrillator in patients with cardiomyopathy General recommendations Implantation of a cardioverter defibrillator is only recommended in patients who have an expectation of good quality survival >1 year.,I,C,12,Recommendations for,Cardiomyopathies,2023,43
"It is recommended that ICD implantation be guided by shared decision-making that: • is evidence-based; • considers a person’s individual preferences, beliefs, circumstances, and values; and • ensures that the person understands the benefits, harms, and possible consequences of different treatment options.c",I,C,12,Recommendations for,Cardiomyopathies,2023,43
"It is recommended that prior to ICD implantation, patients are counselled on the risk of inappropriate shocks, implant complications, and the social, occupational, and driving implications of the device.",I,C,12,Recommendations for,Cardiomyopathies,2023,43
It is not recommended to implant an ICD in patients with incessant ventricular arrhythmias until the ventricular arrhythmia is controlled.,III,C,12,Recommendations for,Cardiomyopathies,2023,43
"• in patients with NDLVC and RCM who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained ventricular arrhythmia causing syncope or haemodynamic compromise in the absence of reversible causes.",I,C,12,Recommendations for,Cardiomyopathies,2023,43
"ICD implantation should be considered in patients with cardiomyopathy presenting with haemodynamically tolerated VT, in the absence of reversible causes.",IIa,C,12,Recommendations for,Cardiomyopathies,2023,43
"Primary prevention Comprehensive SCD risk stratification is recommended in all cardiomyopathy patients who have not suffered a previous cardiac arrest/sustained ventricular arrhythmia at initial evaluation and at 1–2 year intervals, or whenever there is a change in clinical status.",I,C,12,Recommendations for,Cardiomyopathies,2023,43
"The use of validated SCD algorithms/scores as aids to the shared decision-making when offering ICD implantation, where available:e • is recommended in patients with HCM.",I,B,12,Recommendations for,Cardiomyopathies,2023,43
"• should be considered in patients with DCM, NDLVC, and ARVC.185,186,524,526,536–",IIa,B,12,Recommendations for,Cardiomyopathies,2023,43
"If a patient with cardiomyopathy requires pacemaker implantation, comprehensive SCD risk stratification to evaluate the need for ICD implantation should be considered.",IIa,C,12,Recommendations for,Cardiomyopathies,2023,43
"Choice of ICD When an ICD is indicated, it is recommended to evaluate whether the patient could benefit from CRT.",I,A,12,Recommendations for,Cardiomyopathies,2023,43
"Subcutaneous defibrillators should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia, cardiac resynchronization, or antitachycardia pacing is not anticipated.",IIa,B,12,Recommendations for,Cardiomyopathies,2023,43
The wearable cardioverter defibrillator should be considered for adult patients with a secondary prevention ICD indication who are temporarily not candidates for ICD implantation.,IIa,C,12,Recommendations for,Cardiomyopathies,2023,43
routine follow-up of patients with cardiomyopathy It is recommended that all clinically stable patients with cardiomyopathy undergo routine follow-up using a multiparametric approach that includes ECG and echocardiography every 1 to 2 years.,I,C,13,Recommendations for,Cardiomyopathies,2023,44
Clinical evaluation with ECG and multimodality imaging is recommended in patients with cardiomyopathy whenever there is a substantial or unexpected change in symptoms.,I,C,13,Recommendations for,Cardiomyopathies,2023,44
"family screening and follow-up evaluation of relatives Following cascade genetic testing, clinical evaluation using a multiparametric approach that includes ECG and cardiac imaging and long-term follow-up is recommended in first-degree relatives who have the same disease-causing variant as the proband.",I,B,14,Recommendations for,Cardiomyopathies,2023,44
"Following cascade genetic testing, it is recommended that first-degree relatives without a phenotype who do not have the same disease-causing variant as the proband are discharged from further follow-up but advised to seek re-assessment if they develop symptoms or when new clinically relevant data emerge in the family.",I,C,14,Recommendations for,Cardiomyopathies,2023,44
"It is recommended that when no P/LP variant is identified in the proband or genetic testing is not performed, an initial clinical evaluation using a multiparametric approach that includes ECG and cardiac imaging is performed in first-degree relatives.",I,C,14,Recommendations for,Cardiomyopathies,2023,44
"When no P/LP variant is identified in the proband or genetic testing is not performed, regular, long-term clinical evaluation using a multiparametric approach that includes ECG and cardiac imaging should be considered in first-degree relatives.",IIa,C,14,Recommendations for,Cardiomyopathies,2023,44
"During cascade screening, where a first-degree relative has died, clinical evaluation of close relatives of the deceased individual (i.e. second-degree relatives of the index patient) should be considered.",IIa,C,14,Recommendations for,Cardiomyopathies,2023,44
psychological support in patients and family members with cardiomyopathies It is recommended that psychological support by an appropriately trained health professional be offered to all individuals who have experienced the premature sudden cardiac death of a family member with cardiomyopathy.,I,B,15,Recommendations for,Cardiomyopathies,2023,47
It is recommended that psychological support by an appropriately trained health professional be offered to all individuals with an inherited cardiomyopathy who receive an implantable cardioverter defibrillator.552–,I,B,15,Recommendations for,Cardiomyopathies,2023,47
Psychological support by an appropriately trained health professional should be considered in all patients and families with an inherited cardiomyopathy and in particular for those issues described in the text.c,IIa,C,15,Recommendations for,Cardiomyopathies,2023,47
"evaluation of left ventricular outflow tract obstruction In all patients with HCM, at initial evaluation, transthoracic 2D and Doppler echocardiography are recommended, at rest and during Valsalva manoeuvre in the sitting and semi-supine positions— and then on standing if no gradient is provoked—to detect LVOTO.84,86,365,525,584,587,589–",I,B,16,Recommendation for,Cardiomyopathies,2023,47
"In symptomatic patients with HCM and a resting or provokedc peak instantaneous LV outflow tract gradient <50 mmHg, 2D and Doppler echocardiography during exercise in the standing, sitting (when possible), or semi-supine position are recommended to detect provocable LVOTO and exercise-induced mitral regurgitation.588,595–",I,B,16,Recommendation for,Cardiomyopathies,2023,47
"Transoesophageal echocardiography should be considered in patients with HCM and LVOTO if the mechanism of obstruction is unclear or when assessing the mitral valve apparatus before a septal reduction procedure, or when severe mitral regurgitation caused by intrinsic valve abnormalities is suspected.599–",IIa,C,16,Recommendation for,Cardiomyopathies,2023,47
dation for cardiovascular magnetic resonance evaluation in hypertrophic cardiomyopathy Recommendation Contrast-enhanced CMR may be considered before ASA or myectomy to assess the extent and distribution of hypertrophy and myocardial fibrosis.,IIb,C,17,Additional recommen­,Cardiomyopathies,2023,48
"treatment of left ventricular outflow tract obstruction (general measures) Avoidance of digoxin and arterial and venous dilators, including nitrates and phosphodiesterase inhibitors, should be considered, if possible, in patients with resting or provocable LVOTO.",IIa,C,18,Recommendations for,Cardiomyopathies,2023,51
Restoration of sinus rhythm or appropriate rate control should be considered before invasive management of LVOTO in patients with new-onset or poorly controlled AF.,IIa,C,18,Recommendations for,Cardiomyopathies,2023,51
"medical treatment of left ventricular outflow tract obstruction Non-vasodilating beta-blockers, titrated to maximum tolerated dose, are recommended as first-line therapy to improve symptoms in patients with resting or provokedc LVOTO.631–633,648–",I,B,19,Recommendations for,Cardiomyopathies,2023,52
"Verapamil or diltiazem, titrated to maximum tolerated dose, are recommended to improve symptoms in symptomatic patients with resting or provokedc LVOTO who are intolerant or have contraindications to beta-blockers.633,637–",I,B,19,Recommendations for,Cardiomyopathies,2023,52
"Disopyramide,d titrated to maximum tolerated dose, is recommended in addition to a beta-blocker (or, if this is not possible, with verapamil or diltiazem) to improve symptoms in patients with resting or provokedc LVOTO.632–",I,B,19,Recommendations for,Cardiomyopathies,2023,52
"Cardiac myosin ATPase inhibitor (mavacamten), titrated to maximum tolerated dose with echocardiographic surveillance of LVEF, should be considered in addition to a beta-blocker (or, if this is not possible, with verapamil or diltiazem) to improve symptoms in adult patients with resting or provokedc LVOTO.622,642–",IIa,A,19,Recommendations for,Cardiomyopathies,2023,52
Oral or i.v. beta-blockers and vasoconstrictors should be considered in patients with severe provocablec LVOTO presenting with hypotension and acute pulmonary oedema who do not respond to fluid administration.,IIa,C,19,Recommendations for,Cardiomyopathies,2023,52
"Disopyramide, titrated to maximum tolerated dose, may be considered as monotherapy in patients who are intolerant to or have contraindications to beta-blockers and verapamil/diltiazem to improve symptoms in patients with resting or provokedc LVOTO.",IIb,C,19,Recommendations for,Cardiomyopathies,2023,52
Beta-blockers or verapamil may be considered in selected cases in asymptomatic patients with resting or provokedc LVOTO to reduce LV pressures.,IIb,C,19,Recommendations for,Cardiomyopathies,2023,52
The cautious use of low-dose diuretics may be considered in symptomatic LVOTO to improve exertional dyspnoea.,IIb,C,19,Recommendations for,Cardiomyopathies,2023,52
"septal reduction therapy It is recommended that SRT be performed by experienced operators working as part of a multidisciplinary team expert in the management of HCM.664,665,687,695,696,708–",I,C,20,Recommendations for,Cardiomyopathies,2023,54
"SRT to improve symptoms is recommended in patients with a resting or maximum provoked LVOT gradient of ≥50 mmHg who are in NYHA/Ross functional class III–IV, despite maximum tolerated medical therapy.697–",I,B,20,Recommendations for,Cardiomyopathies,2023,54
"Septal myectomy, rather than ASA, is recommended in children with an indication for SRT, as well as in adult patients with an indication for SRT and other lesions requiring surgical intervention (e.g. mitral valve abnormalities).",I,C,20,Recommendations for,Cardiomyopathies,2023,54
"SRT should be considered in patients with recurrent exertional syncope caused by a resting or maximum provoked LVOTO gradient ≥50 mmHg despite optimal medical therapy.686,711–",IIa,C,20,Recommendations for,Cardiomyopathies,2023,54
"Mitral valve repair or replacement should be considered in symptomatic patients with a resting or maximum provoked LVOTO gradient ≥50 mmHg and moderate-to-severe mitral regurgitation that cannot be corrected by SRT alone.661,669–",IIa,C,20,Recommendations for,Cardiomyopathies,2023,54
Mitral valve repair should be considered in patients with a resting or maximum provoked LVOTO gradient ≥50 mmHg when there is moderate-to-severe mitral regurgitation following isolated myectomy.,IIa,C,20,Recommendations for,Cardiomyopathies,2023,54
SRT may be considered in expert centres with demonstrable low procedural complication rates in patients with mild symptoms (NYHA class II) refractory to medical therapy who have a resting or maximum provoked (exercise or Valsalva) gradient of ≥50 mmHg and: • moderate-to-severe SAM-related mitral regurgitation; or • AF; or • moderate-to-severe left atrial dilatation.,IIb,C,20,Recommendations for,Cardiomyopathies,2023,54
"indications for cardiac pacing in patients with obstruction Sequential AV pacing, with optimal AV interval to reduce the LV outflow tract gradient or to facilitate medical treatment with beta-blockers and/or verapamil, may be considered in selected patients with resting or provocable LVOTO ≥50 mmHg, sinus rhythm, and drug-refractory symptoms, who have contraindications for ASA or septal myectomy or are at high risk of developing heart block following ASA or septal myectomy.633,719–",IIb,C,21,Recommendations for,Cardiomyopathies,2023,55
"In patients with resting or provocable LVOTO ≥50 mmHg, sinus rhythm, and drug-refractory symptoms, in whom there is an indication for an ICD, a dual-chamber ICD (instead of a single-lead device) may be considered, to reduce the LV outflow tract gradient or to facilitate medical treatment with beta-blockers and/or verapamil.633,719–",IIb,C,21,Recommendations for,Cardiomyopathies,2023,55
chest pain on exertion in patients without left ventricu­ lar outflow tract obstruction Beta-blockers and calcium antagonists (verapamil or diltiazem) should be considered to improve symptoms in patients with angina-like chest pain even in the absence of LVOTO or obstructive CAD.740–,IIa,C,22,Recommendations for,Cardiomyopathies,2023,55
"Oral nitrates may be considered to improve symptoms in patients with angina-like chest pain, even in the absence of obstructive CAD, if there is no LVOTO.",IIb,C,22,Recommendations for,Cardiomyopathies,2023,55
Ranolazine may be considered to improve symptoms in patients with angina-like chest pain even in the absence of LVOTO or obstructive CAD.,IIb,C,22,Recommendations for,Cardiomyopathies,2023,55
"dations for prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy Secondary prevention Implantation of an ICD is recommended in patients who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained VT with haemodynamic compromise.",I,B,23,Additional recommen­,Cardiomyopathies,2023,59
Validated paediatric-specific risk prediction models (e.g. HCM Risk-Kids) are recommended as a method of estimating risk of sudden death at 5 years in patients aged <16 years for primary prevention.,I,B,23,Additional recommen­,Cardiomyopathies,2023,59
"Implantation of an ICD should be considered in patients with an estimated 5-year risk of sudden death of ≥6%, following detailed clinical assessment that considers: (i) the lifelong risk of complications; (ii) competing mortality risk from the disease and comorbidities; AND (iii) the impact of an ICD on lifestyle, socio-economic status, and psychological health.",IIa,B,23,Additional recommen­,Cardiomyopathies,2023,60
"In patients with LV apical aneurysms, decisions about primary prevention ICD based on an assessment of risk using the HCM Risk-SCD or a validated paediatric risk-prediction (e.g. HCM Risk-Kids) tool and not solely on the presence of the aneurysm should be considered.",IIa,B,23,Additional recommen­,Cardiomyopathies,2023,60
"Implantation of an ICD may be considered in individual patients with an estimated 5-year risk of SCD of between ≥4% and <6%, following detailed clinical assessment that takes into account the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status, and psychological health.",IIb,B,23,Additional recommen­,Cardiomyopathies,2023,60
"For patients who are in the low-risk category (<4% estimated 5-year risk of SCD), the presence of extensive LGE (≥15%) on CMR may be considered in shared decision-making with patients about prophylactic ICD implantation, acknowledging the lack of robust data on the impact of scar quantification on the personalized risk estimates generated by HCM Risk-SCD or a validated paediatric model (e.g. HCM Risk-Kids).141,796,797,834–",IIb,B,23,Additional recommen­,Cardiomyopathies,2023,60
"For patients who are in the low-risk category (<4% estimated 5-year risk of SCD), the presence of LVEF <50% may be considered in shared decision-making with patients about prophylactic ICD implantation, acknowledging the lack of robust data on the impact of systolic dysfunction on the personalized risk estimates generated by HCM Risk-SCD or a validated paediatric model (e.g. HCM Risk-Kids).89,315,841–",IIb,B,23,Additional recommen­,Cardiomyopathies,2023,60
an implantable cardioverter defibrillator in patients with dilated cardiomyopathy Secondary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with DCM who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.,I,B,24,Recommendations for,Cardiomyopathies,2023,64
"Primary prevention An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with DCM, symptomatic heart failure, and LVEF ≤35% despite >3 months of OMT.",IIa,A,24,Recommendations for,Cardiomyopathies,2023,64
The patient’s genotype should be considered in the estimation of SCD risk in DCM.,IIa,B,24,Recommendations for,Cardiomyopathies,2023,64
An ICD should be considered in patients with DCM with a genotype associated with high SCD risk and LVEF >35% in the presence of additional risk factors (see Table 21).,IIa,C,24,Recommendations for,Cardiomyopathies,2023,64
"resting and ambulatory electrocardiogram monitoring in patients with non-dilated left ventricular cardiomyopathy Recommendation Ambulatory ECG monitoring is recommended in patients with NDLVC annually or when there is a change in clinical status, to aid in management and risk stratification.",I,C,25,Recommendation for,Cardiomyopathies,2023,65
an implantable cardioverter defibrillator in patients with non-dilated left ventricular cardiomyopathy Secondary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with NDLVC who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.,I,C,26,Recommendations for,Cardiomyopathies,2023,66
"Primary prevention An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with NDLVC, heart failure symptoms, and LVEF ≤35% despite >3 months of OMT.",IIa,A,26,Recommendations for,Cardiomyopathies,2023,66
The patient’s genotype should be considered in the estimation of SCD risk in NDLVC.,IIa,C,26,Recommendations for,Cardiomyopathies,2023,66
"An ICD should be considered in patients with NDLVC with a genotype associated with high SCD risk and LVEF >35% in the presence of additional risk factors (see Table 21).185,186,438,541,542,865–869,878–",IIa,C,26,Recommendations for,Cardiomyopathies,2023,66
An ICD may be considered in selected patients with NDLVC with a genotype associated with high SCD risk and LVEF >35% without additional risk factors (see Table 21).,IIb,C,26,Recommendations for,Cardiomyopathies,2023,66
An ICD may be considered in patients with NDLVC without a genotype associated with high SCD risk and LVEF >35% in the presence of additional risk factors.c,IIb,C,26,Recommendations for,Cardiomyopathies,2023,66
"resting and ambulatory electrocardiogram monitoring in patients with arrhythmogenic right ventricular cardiomyopathy Recommendation Annual ambulatory ECG monitoring is recommended in patients with ARVC to aid in diagnosis, management, and risk stratification.",I,C,27,Recommendation for,Cardiomyopathies,2023,67
"the antiarrhythmic management of patients with arrhythmogenic right ventricular cardiomyopathy Beta-blocker therapy is recommended in ARVC patients with VE, NSVT, and VT.920–",I,C,28,Recommendations for,Cardiomyopathies,2023,68
Amiodarone should be considered when regular beta-blocker therapy fails to control arrhythmia-related symptoms in patients with ARVC.,IIa,C,28,Recommendations for,Cardiomyopathies,2023,68
Flecainide in addition to beta-blockers should be considered when single agent treatment has failed to control arrhythmia-related symptoms in patients with ARVC.,IIa,C,28,Recommendations for,Cardiomyopathies,2023,68
"Catheter ablation with availability for epicardial approach guided by 3D electroanatomical mapping of VT should be considered in ARVC patients with incessant VT or frequent appropriate ICD interventions for VT despite pharmacological therapy with beta-blockers.925,929–",IIa,C,28,Recommendations for,Cardiomyopathies,2023,68
sudden cardiac death prevention in patients with arrhythmogenic right ventricular cardiomyopathy Secondary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with ARVC who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.,I,A,29,Recommendations for,Cardiomyopathies,2023,69
"An ICD should be considered in ARVC patients who have suffered a haemodynamically tolerated VT.522,939,943–945,948–",IIa,B,29,Recommendations for,Cardiomyopathies,2023,69
Primary prevention High-risk featuresc should be considered to aid individualized decision-making for ICD implantation in patients with ARVC.,IIa,B,29,Recommendations for,Cardiomyopathies,2023,69
"The updated 2019 ARVC risk calculator should be considered to aid individualized decision-making for ICD implantation in patients with ARVC.d,524,526,536–",IIa,B,29,Recommendations for,Cardiomyopathies,2023,69
the management of patients with restrictive cardiomyopathy It is recommended that multimodality imaging be used to differentiate RCM from HCM or DCM with restrictive physiology.,I,C,30,Recommendations for,Cardiomyopathies,2023,72
It is recommended that baseline cardiac and non-cardiac investigations are performed to assess involvement of the neuromuscular system or other syndromic disorders.,I,C,30,Recommendations for,Cardiomyopathies,2023,72
Cardiac catheterization is recommended in all children with RCM to measure pulmonary artery pressures and PVR at diagnosis and at 6–12 monthly intervals to assess change in PVR.,I,B,30,Recommendations for,Cardiomyopathies,2023,72
ICD implantation is recommended to reduce the risk of sudden death and all-cause mortality in patients with RCM who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.,I,C,30,Recommendations for,Cardiomyopathies,2023,72
"Endomyocardial biopsy should be considered in patients with RCM to exclude specific diagnoses (including iron overload, storage disorders, mitochondrial cytopathies, amyloidosis, and granulomatous myocardial diseases) and to diagnose restrictive myofibrillar disease caused by desmin variants.",IIa,C,30,Recommendations for,Cardiomyopathies,2023,72
ICD implantation may be considered in children with RCM who have evidence of myocardial ischaemia and syncope.,IIb,C,30,Recommendations for,Cardiomyopathies,2023,72
tions for patients with cardiomyopathy All cardiomyopathies Regular low- to moderate-intensity exercise is recommended in all able individuals with cardiomyopathy.,I,C,31,Exercise recommenda­,Cardiomyopathies,2023,80
HCM High-intensity exercise and competitive sport should be considered in genotype-positive/ phenotype-negative individuals who seek to do so.,IIa,C,31,Exercise recommenda­,Cardiomyopathies,2023,81
High-intensity exercise and competitive sport may be considered in asymptomatic low-riskc individuals with morphologically mild hypertrophic cardiomyopathy in the absence of resting or inducible left ventricular outflow obstruction and exercise-induced complex ventricular arrhythmias.,IIb,B,31,Exercise recommenda­,Cardiomyopathies,2023,81
"High-intensity exercise, including competitive sport, is not recommended in high-risk individuals and in individuals with left ventricular outflow tract obstruction and exercise-induced complex ventricular arrhythmias.",III,C,31,Exercise recommenda­,Cardiomyopathies,2023,81
"ARVC Avoidance of high-intensity exercise, including competitive sport, may be considered in genotype-positive/phenotype-negative individuals in families with ARVC.",IIb,C,31,Exercise recommenda­,Cardiomyopathies,2023,81
"Moderate- and/or high-intensity exercise, including competitive sport, is not recommended in individuals with ARVC.181,1111–",III,B,31,Exercise recommenda­,Cardiomyopathies,2023,81
DCM and NDLVC Moderate- and high-intensity exercise should be considered in individuals who are gene positive and phenotype negative (with the exception of pathogenic variants in LMNA and TMEM43) who seek to do so.,IIa,C,31,Exercise recommenda­,Cardiomyopathies,2023,81
High-intensity exercise and competitive sport may be considered in a select group of asymptomatic and optimally treated individuals with a left ventricular ejection fraction ≥50% in the absence of exercise-induced complex arrhythmias.,IIb,C,31,Exercise recommenda­,Cardiomyopathies,2023,81
Moderate-intensity exercise may be considered in asymptomatic and optimally treated individuals with a left ventricular ejection fraction of 40–49% in the absence of exercise-induced complex arrhythmias.,IIb,C,31,Exercise recommenda­,Cardiomyopathies,2023,81
"High-intensity exercise, including competitive sport, is not recommended in symptomatic individuals, those with a left ventricular ejection fraction ≤40%, exercise-induced arrhythmias or pathogenic variants in LMNA or TMEM43.",III,C,31,Exercise recommenda­,Cardiomyopathies,2023,81
reproductive issues in patients with cardiomyopathy Pre-pregnancy risk assessment and counselling are recommended in all women using the mWHO classification of maternal risk.,I,C,32,Recommendations for,Cardiomyopathies,2023,83
Counselling on safe and effective contraception is recommended in all women of fertile age and their partners.,I,C,32,Recommendations for,Cardiomyopathies,2023,83
Counselling on the risk of disease inheritance is recommended for all men and women before conception.,I,C,32,Recommendations for,Cardiomyopathies,2023,83
"Vaginal delivery is recommended in most women with cardiomyopathies, unless there are obstetric indications for caesarean section, severe heart failure (EF <30% or NYHA class III–IV), or severe outflow tract obstructions, or in women presenting in labour on oral anticoagulants.",I,C,32,Recommendations for,Cardiomyopathies,2023,83
It is recommended that medication be carefully reviewed for safety in advance of pregnancy and adjusted according to tolerability in pregnancy.,I,C,32,Recommendations for,Cardiomyopathies,2023,83
Therapeutic anticoagulation with LMWH or VKAs according to the stage of pregnancy is recommended for patients with AF.,I,C,32,Recommendations for,Cardiomyopathies,2023,83
"Continuation of beta-blockers should be considered during pregnancy in women with cardiomyopathies, with close follow-up of foetal growth and of the condition of the neonate, and if benefits outweigh risks.",IIa,C,32,Recommendations for,Cardiomyopathies,2023,83
Genetic counselling and testing should be considered in patients with peripartum cardiomyopathy.,IIa,C,32,Recommendations for,Cardiomyopathies,2023,83
non-cardiac surgery in patients with cardiomyopathy Peri-operative ECG monitoring is recommended for all patients with cardiomyopathy undergoing surgery.,I,C,33,Recommendations for,Cardiomyopathies,2023,83
"In patients with cardiomyopathy and suspected or known HF scheduled for intermediate or high-risk NCS, it is recommended to re-evaluate LV function with echocardiography (assessing LVOTO in HCM patients) and measurement of NT-proBNP/BNP levels, unless this has recently been performed.1151,1153–1156,1158–",I,B,33,Recommendations for,Cardiomyopathies,2023,83
It is recommended that cardiomyopathy patients with high-risk genotypes or associated factors for arrhythmic or heart failure complications or severe LVOTO be referred for additional specialized investigations to a cardiomyopathy unit before undergoing elective NCS.,I,C,33,Recommendations for,Cardiomyopathies,2023,83
"In patients aged <65 years with a first-degree relative with a cardiomyopathy, it is recommended to perform an ECG and TTE before NCS, regardless of symptoms.",I,C,33,Recommendations for,Cardiomyopathies,2023,83
management of cardiovascular risk factors in patients with cardiomyopathy Recommendation Identification and management of risk factors and concomitant diseases is recommended as an integral part of the management of cardiomyopathy patients.,I,C,34,Recommendation for,Cardiomyopathies,2023,86
antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk for infective endocarditis General prevention measures are recommended in individuals at high and intermediate risk for IE.,I,C,1,Recommendations for,Endocarditis,2023,14
Antibiotic prophylaxis is recommended in patients with previous IE.,I,B,1,Recommendations for,Endocarditis,2023,14
"Antibiotic prophylaxis is recommended in patients with surgically implanted prosthetic valves and with any material used for surgical cardiac valve repair.47,87–",I,C,1,Recommendations for,Endocarditis,2023,14
Antibiotic prophylaxis is recommended in patients with transcatheter implanted aortic and pulmonary valvular prostheses.91–,I,C,1,Recommendations for,Endocarditis,2023,14
"Antibiotic prophylaxis is recommended in patients with untreated cyanotic CHD, and patients treated with surgery or transcatheter procedures with post-operative palliative shunts, conduits, or other prostheses. After surgical repair, in the absence of residual defects or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure.",I,C,1,Recommendations for,Endocarditis,2023,14
Antibiotic prophylaxis is recommended in patients with ventricular assist devices.,I,C,1,Recommendations for,Endocarditis,2023,14
Antibiotic prophylaxis should be considered in patients with transcatheter mitral and tricuspid valve repair.,IIa,C,1,Recommendations for,Endocarditis,2023,14
Antibiotic prophylaxis may be considered in recipients of heart transplant.105–,IIb,C,1,Recommendations for,Endocarditis,2023,14
Antibiotic prophylaxis is not recommended in other patients at low risk for IE.,III,C,1,Recommendations for,Endocarditis,2023,14
"infective endocarditis prevention in high-risk patients Antibiotic prophylaxis is recommended in dental extractions, oral surgery procedures, and procedures requiring manipulation of the gingival or periapical region of the teeth.",I,B,2,Recommendations for,Endocarditis,2023,16
"Systemic antibiotic prophylaxis may be considered for high-riskc patients undergoing an invasive diagnostic or therapeutic procedure of the respiratory, gastrointestinal, genitourinary tract, skin, or musculoskeletal systems.",IIb,C,2,Recommendations for,Endocarditis,2023,16
infective endocarditis prevention in cardiac procedures Pre-operative screening for nasal carriage of S. aureus is recommended before elective cardiac surgery or transcatheter valve implantation to treat carriers.,I,A,3,Recommendations for,Endocarditis,2023,16
Peri-operative antibiotic prophylaxis is recommended before placement of a CIED.116–,I,A,3,Recommendations for,Endocarditis,2023,16
Optimal pre-procedural aseptic measures of the site of implantation is recommended to prevent CIED infections.,I,B,3,Recommendations for,Endocarditis,2023,16
"Periprocedural antibiotic prophylaxis is recommended in patients undergoing surgical or transcatheter implantation of a prosthetic valve, intravascular prosthetic, or other foreign material.",I,B,3,Recommendations for,Endocarditis,2023,16
Surgical standard aseptic measures are recommended during the insertion and manipulation of catheters in the catheterization laboratory environment.,I,C,3,Recommendations for,Endocarditis,2023,16
"Elimination of potential sources of sepsis (including of dental origin) should be considered ≥2 weeks before implantation of a prosthetic valve or other intracardiac or intravascular foreign material, except in urgent procedures.",IIa,C,3,Recommendations for,Endocarditis,2023,16
Systematic skin or nasal decolonization without screening for S. aureus is not recommended.,III,C,3,Recommendations for,Endocarditis,2023,16
"Endocarditis Team Diagnosis and management of patients with complicated IE are recommended to be performed at an early stage in a Heart Valve Centre, with immediate surgical facilities and an ‘Endocarditis Team’ to improve the outcomes.36–",I,B,4,Recommendations for the,Endocarditis,2023,18
"For patients with uncomplicated IE managed in a Referring Centre, early and regular communication between the local and the Heart Valve Centre endocarditis teams is recommended to improve the outcomes of the patients.36–",I,B,4,Recommendations for the,Endocarditis,2023,18
role of echocardiography in infective endocarditis A. Diagnosis TTE is recommended as the first-line imaging modality in suspected IE.,I,B,5,Recommendations for the,Endocarditis,2023,22
TOE is recommended in all patients with clinical suspicion of IE and a negative or non-diagnostic TTE.,I,B,5,Recommendations for the,Endocarditis,2023,22
"TOE is recommended in patients with clinical suspicion of IE, when a prosthetic heart valve or an intracardiac device is present.",I,B,5,Recommendations for the,Endocarditis,2023,22
Repeating TTE and/or TOE within 5–7 days is recommended in cases of initially negative or inconclusive examination when clinical suspicion of IE remains high.,I,C,5,Recommendations for the,Endocarditis,2023,22
"TOE is recommended in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with good quality TTE examination and unequivocal echocardiographic findings.",I,C,5,Recommendations for the,Endocarditis,2023,22
"Performing an echocardiography should be considered in S. aureus, E. faecalis, and some Streptococcus spp. bacteraemia.",IIa,B,5,Recommendations for the,Endocarditis,2023,22
"B. Follow-up under medical therapy Repeating TTE and/or TOE is recommended as soon as a new complication of IE is suspected (new murmur, embolism, persisting fever and bacteraemia, HF, abscess, AVB).",I,B,5,Recommendations for the,Endocarditis,2023,22
TOE is recommended when patient is stable before switching from intravenous to oral antibiotic therapy.,I,B,5,Recommendations for the,Endocarditis,2023,22
"During follow-up of uncomplicated IE, repeat TTE and/ or TOE should be considered to detect new silent complications. The timing of repeat TTE and/or TOE depends on the initial findings, type of microorganism, and initial response to therapy.",IIa,B,5,Recommendations for the,Endocarditis,2023,22
C. Intra-operative echocardiography Intra-operative echocardiography is recommended in all cases of IE requiring surgery.,I,C,5,Recommendations for the,Endocarditis,2023,22
D. Following completion of therapy TTE and/or TOE are recommended at completion of antibiotic therapy for evaluation of cardiac and valve morphology and function in patients with IE who did not undergo heart valve surgery.182–,I,C,5,Recommendations for the,Endocarditis,2023,22
"role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis Cardiac CTA is recommended in patients with possible NVE to detect valvular lesions and confirm the diagnosis of IE.",I,B,6,Recommendations for the,Endocarditis,2023,23
"[18F]FDG-PET/CT(A) and cardiac CTA are recommended in possible PVE to detect valvular lesions and confirm the diagnosis of IE.22,129,209,210,237–",I,B,6,Recommendations for the,Endocarditis,2023,23
Cardiac CTA is recommended in NVE and PVE to diagnose paravalvular or periprosthetic complications if echocardiography is inconclusive.,I,B,6,Recommendations for the,Endocarditis,2023,23
"Brain and whole-body imaging (CT, [18F]FDG-PET/ CT, and/or MRI) are recommended in symptomaticc patients with NVE and PVE to detect peripheral lesions or add minor diagnostic criteria.22,197–",I,B,6,Recommendations for the,Endocarditis,2023,23
WBC SPECT/CT should be considered in patients with high clinical suspicion of PVE when echocardiography is negative or inconclusive and when PET/CT is unavailable.213–,IIa,C,6,Recommendations for the,Endocarditis,2023,23
[18F]FDG-PET/CT(A) may be considered in possible CIED-related IE to confirm the diagnosis of IE.,IIb,B,6,Recommendations for the,Endocarditis,2023,23
"Brain and whole-body imaging (CT, [18F]FDG-PET/ CT, and MRI) in NVE and PVE may be considered for screening of peripheral lesions in asymptomatic patients.188,197–",IIb,B,6,Recommendations for the,Endocarditis,2023,23
"cocci and Streptococcus gallolyticus group Penicillin-susceptible oral streptococci and Streptococcus gallolyticus group Standard treatment: 4-week duration in NVE or 6-week duration in PVE In patients with IE due to oral streptococci and S. gallolyticus group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 (in NVE) or 6 weeks (in PVE), using the following doses:",I,B,7,Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­,Endocarditis,2023,30
"Adult antibiotic dosage and route Penicillin G 12–18 millionc U/day i.v. either in 4–6 doses or continuously Amoxicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 2 g/day i.v. in 1 dose Paediatric antibiotic dosage and route Penicillin G 200 000 U/kg/day i.v. in 4–6 divided doses Amoxicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Ceftriaxone 100 mg/kg/day i.v. in 1 dose Standard treatment: 2-week duration (not applicable to PVE) 2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of non-complicated NVE due to oral streptococci and S. gallolyticus in patients with normal renal function using the following doses:",I,B,7,Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­,Endocarditis,2023,30
Adult antibiotic dosage and route Penicillin G 12–18 millionc U/day i.v. either in 4–6 doses or continuously Amoxicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 2 g/day i.v. in 1 dose Gentamicind 3 mg/kg/day i.v. or i.m. in 1 dosed,I,C,7,Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­,Endocarditis,2023,31
"Adult antibiotic dosage and route Vancomycine 30 mg/kg/day i.v. in 2 dosese Paediatric antibiotic dosage and route Vancomycine 30 mg/kg/day i.v. in 2 or 3 equally divided dosese Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin In patients with NVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 4 weeks in combination with gentamicin for 2 weeks is recommended using the following doses:285–",I,B,7,Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­,Endocarditis,2023,31
"Adult antibiotic dosage and route Penicillin G 24 million U/day i.v. either in 4–6 doses or continuously Amoxicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 2 g/day i.v. in 1 dose Gentamicin 3 mg/kg/day i.v. or i.m. in 1 dosed In patients with PVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses:285–",I,B,7,Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­,Endocarditis,2023,31
"Adult antibiotic dosage and route Penicillin G 24 million U/day i.v. either in 4–6 doses or continuously Amoxicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 2 g/day i.v. in 1 dose Gentamicind 3 mg/kg/day i.v. or i.m. in 1 dosed Allergy to beta-lactams In patients with NVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 4 weeks is recommended using the following doses:",I,C,7,Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­,Endocarditis,2023,31
"Adult antibiotic dosage and route Vancomycine 30 mg/kg/day i.v. in 2 dosese Paediatric antibiotic dosage and route Vancomycine 30 mg/kg/day i.v. in 2 dosese In patients with PVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses:",I,C,7,Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­,Endocarditis,2023,31
"spp. IE caused by methicillin-susceptible staphylococci In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using the following doses:264,314,316–",I,B,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,33
"Adult antibiotic dosage and route (Flu)cloxacillinc 12 g/day i.v. in 4–6 doses Cefazoline 6 g/day i.v. in 3 doses Paediatric antibiotic dosage and route (Flu)cloxacillinc 200–300 mg/kg/day i.v. in 4–6 equally divided doses Cefazoline 100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:264,314,316–",I,B,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,33
"Adult antibiotic dosage and route (Flu)cloxacillinc 12 g/day i.v. in 4–6 doses Cefazolin 6 g/day i.v. in 3 doses Rifampin 900 mg/day i.v. or orally in 3 equally divided doses Gentamicind 3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses Paediatric antibiotic dosage and route (Flu)cloxacillinc 200–300 mg/kg/day i.v. in 4–6 equally divided doses Cefazolin 100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day Rifampin 20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day Gentamicind 3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses Allergy to beta-lactams In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin for 4–6 weeks is recommended using the following doses:322–",I,B,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,33
"Adult antibiotic dosage and route Cefazoline 6 g/day i.v. in 3 doses Paediatric antibiotic dosage and route Cefazoline 100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin combined with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:",I,B,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,33
"Adult antibiotic dosage and route Cefazoline 6 g/day i.v. in 3 doses Rifampin 900 mg/day i.v. or orally in 3 equally divided doses Gentamicind 3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses Paediatric antibiotic dosage and route Cefazoline 100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day Rifampin 20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day Gentamicind 3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses",IIb,C,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,34
"Adult antibiotic dosage and route Daptomycin 10 mg/kg/day i.v. in 1 dose Ceftarolinef OR Fosfomycing 1800 mg/day i.v. in 3 doses OR 8–12 g/day i.v. in 4 doses In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, daptomycin combined with ceftaroline or fosfomycin or gentamicin with rifampin for at least 6 weeks and gentamicin for 2 weeks may be considered using the following doses:",IIb,C,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,34
"Adult antibiotic dosage and route Daptomycin 10 mg/kg/day i.v. in 1 dose Ceftarolinef OR Fosfomycing 1800 mg/day i.v. in 3 doses OR 8–12 g/day i.v. in 4 doses Rifampin 900 mg/day i.v. or orally in 3 equally divided doses Gentamicind 3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses IE caused by methicillin-resistant staphylococci In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following doses:",I,B,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,34
"Adult antibiotic dosage and route Vancomycinh 30–60 mg/kg/day i.v. in 2–3 doses Paediatric antibiotic dosage and route Vancomycinh 30 mg/kg/day i.v. in 2–3 equally divided doses In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:",I,B,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,34
"Adult antibiotic dosage and route Vancomycinh 30–60 mg/kg/day i.v. in 2–3 doses Rifampin 900–1200 mg/day i.v. or orally in 2 or 3 divided doses Gentamicind 3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses Paediatric antibiotic dosage and route Vancomycinh 30 mg/kg/day i.v. in 2–3 equally divided doses Rifampin 20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day Gentamicind 3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses In patients with NVE due to methicillin-resistant staphylococci, daptomycin combined with cloxacillin, ceftaroline or fosfomycin may be considered using the following doses:335,345–",IIb,C,8,Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus,Endocarditis,2023,34
"Beta-lactam and gentamicin-susceptible strains In patients with NVE due to non-HLAR Enterococcus spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses:",I,B,9,Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.,Endocarditis,2023,35
"Adult antibiotic dosage and route Amoxicillin 12 g/day i.v. in 4–6 doses Ampicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 4 g/day i.v. in 2 doses Gentamicinc 3 mg/kg/day i.v. or i.m. in 1 dose Paediatric antibiotic dosage and route Amoxicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Ampicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Ceftriaxone 100 mg/kg i.v. in 2 doses Gentamicinc 3 mg/kg/day i.v. or i.m. in 3 equally divided doses In patients with PVE and patients with complicated NVE or >3 months of symptoms due to non-HLAR Enterococcus spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses:",I,B,9,Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.,Endocarditis,2023,35
"Adult antibiotic dosage and route Amoxicillin 12 g/day i.v. in 4–6 doses Ampicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 4 g/day i.v. in 2 doses Gentamicinc 3 mg/kg/day i.v. or i.m. in 1 dose Paediatric antibiotic dosage and route Ampicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Amoxicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Ceftriaxone 100 mg/kg/day i.v. in 2 doses Gentamicinc 3 mg/kg/day i.v. or i.m. in 3 equally divided doses",I,B,9,Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.,Endocarditis,2023,36
"Adult antibiotic dosage and route Ampicillin 12 g/day i.v. in 4–6 doses Amoxicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 4 g/day i.v. or i.m. in 2 doses Paediatric antibiotic dosage and route Ampicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Amoxicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Ceftriaxone 100 mg/kg i.v. or i.m. in 2 doses Beta-lactam resistant Enterococcus spp. (E. faecium)e In patients with IE due to beta-lactam resistant Enterococcus spp. (E. faecium), vancomycin for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses:",I,C,9,Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.,Endocarditis,2023,36
"Adult antibiotic dosage and route Vancomycin 30 mg/kg/day i.v. in 2 doses Gentamicin 3 mg/kg/day i.v. or i.m. in 1 dose Paediatric antibiotic dosage and route Vancomycin 30 mg/kg/day i.v. in 2–3 equally divided doses Gentamicin 3 mg/kg/day i.v. or i.m. in 1 dose Vancomycin-resistant Enterococcus spp.f In patients with IE due to vancomycin-resistant Enterococcus spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or ceftaroline) or fosfomycin is recommended using the following doses:",I,C,9,Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.,Endocarditis,2023,36
"antibiotic regimens for initial empirical treatment of infective endocarditis (before pathogen identification)a Classb Levelc In patients with community-acquired NVE or late PVE (≥12 months post-surgery), ampicillin in combination with ceftriaxone or with (flu)cloxacillin and gentamicin should be considered using the following doses:",IIa,C,10,Recommendations for,Endocarditis,2023,38
"Adult antibiotic dosage and route Ampicillin 12 g/day i.v. in 4–6 doses Ceftriaxone 4 g/day i.v. or i.m. in 2 doses (Flu)cloxacillin 12 g/day i.v. in 4–6 doses Gentamicind 3 mg/kg/day i.v. or i.m. in 1 dose Paediatric antibiotic dosage and route Ampicillin 200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day Ceftriaxone 100 mg/kg i.v. or i.m. in 1 dose (Flu)cloxacillin 200–300 mg/kg/day i.v. in 4–6 equally divided doses Gentamicind 3 mg/kg/day i.v. or i.m. in 3 equally divided doses In patients with early PVE (<12 months post-surgery) or nosocomial and non-nosocomial healthcare-associated IE, vancomycin or daptomycin combined with gentamicin and rifampin may be considered using the following doses:",IIb,C,10,Recommendations for,Endocarditis,2023,38
"Adult antibiotic dosage and route Vancomycine 30 mg/kg/day i.v. in 2 doses Daptomycin 10 mg/kg/day i.v. in 1 dose Gentamicind 3 mg/kg/day i.v. or i.m. in 1 dose Rifampin 900–1200 mg i.v. or orally in 2 or 3 doses Paediatric antibiotic dosage and route Vancomycine 40 mg/kg/day i.v. in 2–3 equally divided doses Gentamicind 3 mg/kg/day i.v. or i.m. in 3 equally divided doses Rifampin 20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day Allergy to beta-lactams In patients with community-acquired NVE or late PVE (≥12 months post-surgery) who are allergic to penicillin, cefazolin, or vancomycin in combination with gentamicin may be considered using the following doses:",IIb,C,10,Recommendations for,Endocarditis,2023,38
"outpatient antibiotic treatment of infective endocarditis Outpatient parenteral or oral antibiotic treatment should be considered in patients with left-sided IE caused by Streptococcus spp., E. faecalis, S. aureus, or CoNS who were receiving appropriate i.v. antibiotic treatment for at least 10 days (or at least 7 days after cardiac surgery), are clinically stable, and who do not show signs of abscess formation or valve abnormalities requiring surgery on TOE.",IIa,A,11,Recommendations for,Endocarditis,2023,40
"Outpatient parenteral antibiotic treatment is not recommended in patients with IE caused by highly difficult-to-treat microorganisms,c liver cirrhosis (Child-Pugh B or C), severe cerebral nervous system emboli, untreated large extracardiac abscesses, heart valve complications, or other severe conditions requiring surgery, severe post-surgical complications, and PWID-related IE.",III,C,11,Recommendations for,Endocarditis,2023,40
"the main indications of surgery in infective endocarditis (native valve endocarditis and prosthetic valve endocarditis)a Classb Levelc (i) Heart failure Emergencyd surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation, obstruction, or fistula causing refractory pulmonary oedema or cardiogenic shock.",I,B,12,Recommendations for,Endocarditis,2023,44
"Urgentd surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation or obstruction causing symptoms of HF or echocardiographic signs of poor haemodynamic tolerance.5,420–",I,B,12,Recommendations for,Endocarditis,2023,44
"(ii) Uncontrolled infection Urgentd surgery is recommended in locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation, prosthetic dehiscence, new AVB).",I,B,12,Recommendations for,Endocarditis,2023,44
Urgentd or non-urgent surgery is recommended in IE caused by fungi or multiresistant organisms according to the haemodynamic condition of the patient.,I,C,12,Recommendations for,Endocarditis,2023,44
Urgentd surgery should be considered in IE with persistently positive blood cultures >1 week or persistent sepsis despite appropriate antibiotic therapy and adequate control of metastatic foci.,IIa,B,12,Recommendations for,Endocarditis,2023,44
Urgentd surgery should be considered in PVE caused by S. aureus or non-HACEK Gram-negative bacteria,IIa,C,12,Recommendations for,Endocarditis,2023,44
(iii) Prevention of embolism Urgentd surgery is recommended in aortic or mitral NVE or PVE with persistent vegetations ≥10 mm after one or more embolic episodes despite appropriate antibiotic therapy.,I,B,12,Recommendations for,Endocarditis,2023,44
Urgentd surgery is recommended in IE with vegetation ≥10 mm and other indications for surgery.,I,C,12,Recommendations for,Endocarditis,2023,44
Urgentd surgery may be considered in aortic or mitral IE with vegetation ≥10 mm and without severe valve dysfunction or without clinical evidence of embolism and low surgical risk.,IIb,B,12,Recommendations for,Endocarditis,2023,44
the treatment of neurological complications of infective endocarditis Brain CT or MRA is recommended in patients with IE and suspected infective cerebral aneurysms.,I,B,13,Recommendations for,Endocarditis,2023,45
"Neurosurgery or endovascular therapy is recommended for large aneurysms, those with continuous growth despite optimal antibiotic therapy, and ruptured intracranial infective cerebral aneurysms.",I,C,13,Recommendations for,Endocarditis,2023,45
"If non-invasive techniques are negative and the suspicion of infective aneurysm remains, invasive angiography should be considered.",IIa,B,13,Recommendations for,Endocarditis,2023,45
"In embolic stroke, mechanical thrombectomy may be considered if the expertise is available in a timely manner.",IIb,C,13,Recommendations for,Endocarditis,2023,45
Thrombolytic therapy is not recommended in embolic stroke due to IE.,III,C,13,Recommendations for,Endocarditis,2023,45
"pacemaker implantation in patients with complete atrioventricular block and infective endocarditis Immediate epicardial pacemaker implantation should be considered in patients undergoing surgery for valvular IE and complete AVB if one of the following predictors of persistent AVB is present: pre-operative conduction abnormality, S. aureus infection, aortic root abscess, tricuspid valve involvement, or previous valvular surgery.",IIa,C,14,Recommendations for,Endocarditis,2023,46
patients with musculoskeletal manifestations of infect­ ive endocarditis MRI or PET/CT is recommended in patients with suspected spondylodiscitis and vertebral osteomyelitis complicating IE.,I,C,15,Recommendations for,Endocarditis,2023,47
"TTE/TOE is recommended to rule out IE in patients with spondylodiscitis and/or septic arthritis with positive blood cultures for typical IE microorganisms.247,248,517–",I,C,15,Recommendations for,Endocarditis,2023,47
"More than 6-week antibiotic therapy should be considered in patients with osteoarticular IE-related lesions caused by difficult-to-treat microorganisms, such as S. aureus or Candida spp., and/or complicated with severe vertebral destruction or abscesses.",IIa,C,15,Recommendations for,Endocarditis,2023,47
"pre-operative coronary anatomy assessment in patients requiring surgery for infective endocarditis In haemodynamically stable patients with aortic valve vegetations who require cardiac surgery and are high risk for CAD, a high-resolution multislice coronary CTA is recommended.",I,B,16,Recommendations for,Endocarditis,2023,48
"Invasive coronary angiography is recommended in patients requiring heart surgery who are high risk for CAD, in the absence of aortic valve vegetations.",I,C,16,Recommendations for,Endocarditis,2023,48
"In emergency situations, valvular surgery without pre-operative coronary anatomy assessment regardless of CAD risk should be considered.",IIa,C,16,Recommendations for,Endocarditis,2023,48
Invasive coronary angiography may be considered despite the presence of aortic valve vegetations in selected patients with known CAD or at high risk of significant obstructive CAD.,IIb,C,16,Recommendations for,Endocarditis,2023,48
"cardiac surgery after neurological complications in active infective endocarditis After a transient ischaemic attack, cardiac surgery, if indicated, is recommended without delay.",I,B,17,Indications and timing of,Endocarditis,2023,50
"After a stroke, surgery is recommended without any delay in the presence of HF, uncontrolled infection, abscess, or persistent high embolic risk, as long as coma is absent and the presence of cerebral haemorrhage has been excluded by cranial CT or MRI.451,468,473,567,568,570–",I,B,17,Indications and timing of,Endocarditis,2023,50
"Following intracranial haemorrhage, delaying cardiac surgery >1 month, if possible, with frequent re-assessment of the patient’s clinical condition and imaging should be considered.",IIa,C,17,Indications and timing of,Endocarditis,2023,50
"In patients with intracranial haemorrhage and unstable clinical status due to HF, uncontrolled infection or persistent high embolic risk, urgent or emergency surgery should be considered weighing the likelihood of a meaningful neurological outcome.199,581–",IIa,C,17,Indications and timing of,Endocarditis,2023,50
"post-discharge follow-up Patient education on the risk of recurrence and preventive measures, with emphasis on dental health, and based on the individual risk profile, is recommended during follow-up.",I,C,18,Recommendations for,Endocarditis,2023,52
Addiction treatment for patients following PWID-related IE is recommended.,I,C,18,Recommendations for,Endocarditis,2023,52
Cardiac rehabilitation including physical exercise training should be considered in clinically stable patients based on an individual assessment.,IIa,C,18,Recommendations for,Endocarditis,2023,52
"Psychosocial support may be considered to be integrated in follow-up care, including screening for anxiety and depression, and referral to relevant psychological treatment.",IIb,C,18,Recommendations for,Endocarditis,2023,52
prosthetic valve endocarditis Surgery is recommended for early PVE (within 6 months of valve surgery) with new valve replacement and complete debridement.,I,C,19,Recommendations for,Endocarditis,2023,53
cardiovascular implanted electronic device-related in­ fective endocarditis Antibiotic prophylaxis covering S. aureus is recommended for CIED implantation.,I,A,20,Recommendations for,Endocarditis,2023,57
TTE and TOE are both recommended in case of suspected CIED-related IE to identify vegetations.692–,I,B,20,Recommendations for,Endocarditis,2023,57
Complete system extraction without delay is recommended in patients with definite CIED-related IE under initial empirical antibiotic therapy.,I,B,20,Recommendations for,Endocarditis,2023,57
"Obtaining at least three sets of blood cultures is recommended before prompt initiation of empirical antibiotic therapy for CIED infection,710 covering methicillin-resistant staphylococci and Gram-negative bacteria.",I,C,20,Recommendations for,Endocarditis,2023,57
"If CIED reimplantation is indicated after extraction for CIED-related IE, it is recommended to be performed at a site distant from the previous generator, as late as possible, once signs and symptoms of infection have abated and until blood cultures are negative for at least 72 h in the absence of vegetations, and negative for at least 2 weeks if vegetations were visualized.",I,C,20,Recommendations for,Endocarditis,2023,57
"In cases of possible CIED-related IE with occult Gram-positive bacteraemia or fungaemia, complete system removal should be considered in case bacteraemia/fungaemia persists after a course of antimicrobial therapy.673–",IIa,C,20,Recommendations for,Endocarditis,2023,58
Extension of antibiotic treatment of CIED-related endocarditis to (4–6) weeks following device extraction should be considered in the presence of septic emboli or prosthetic valves.,IIa,C,20,Recommendations for,Endocarditis,2023,58
Use of an antibiotic envelope may be considered in select high-risk patients undergoing CIED reimplantation to reduce risk of infection.,IIb,B,20,Recommendations for,Endocarditis,2023,58
"In cases of possible CIED-related IE with occult Gram-negative bacteraemia, complete system removal may be considered in case of persistent/ relapsing bacteraemia after a course of antimicrobial therapy.",IIb,C,20,Recommendations for,Endocarditis,2023,58
"In non-S. aureus CIED-related endocarditis without valve involvement or lead vegetations, and if follow-up blood cultures are negative without septic emboli, 2 weeks of antibiotic treatment may be considered following device extraction.",IIb,C,20,Recommendations for,Endocarditis,2023,58
"Removal of CIED after a single positive blood culture, with no other clinical evidence of infection, is not recommended.",III,C,20,Recommendations for,Endocarditis,2023,58
the surgical treatment of right-sided infective endocarditis Surgery is recommended in patients with right-sided IE who are receiving appropriate antibiotic therapy for the following scenarios: Right ventricular dysfunction secondary to acute severe tricuspid regurgitation non-responsive to diuretics.,I,B,21,Recommendations for,Endocarditis,2023,60
Persistent vegetation with respiratory insufficiency requiring ventilatory support after recurrent pulmonary emboli.,I,B,21,Recommendations for,Endocarditis,2023,60
Large residual tricuspid vegetations (>20 mm) after recurrent septic pulmonary emboli.,I,C,21,Recommendations for,Endocarditis,2023,60
Patients with simultaneous involvement of left-heart structures.,I,C,21,Recommendations for,Endocarditis,2023,60
"Tricuspid valve repair should be considered instead of valve replacement, when possible.",IIa,B,21,Recommendations for,Endocarditis,2023,60
Surgery should be considered in patients with right-sided IE who are receiving appropriate antibiotic therapy and present persistent bacteraemia/sepsis after at least 1 week of appropriate antibiotic therapy.,IIa,C,21,Recommendations for,Endocarditis,2023,60
Prophylactic placement of an epicardial pacing lead should be considered at the time of tricuspid valve surgical procedures.,IIa,C,21,Recommendations for,Endocarditis,2023,60
Debulking of right intra-atrial septic masses by aspiration may be considered in selected patients who are high risk for surgery.,IIb,C,21,Recommendations for,Endocarditis,2023,60
the use of antithrombotic therapy in infective endocarditis Recommendation Interruption of antiplatelet or anticoagulant therapy is recommended in the presence of major bleeding (including intracranial haemorrhage).,I,C,22,Recommendations for,Endocarditis,2023,62
"In patients with intracranial haemorrhage and a mechanical valve, reinitiating unfractionated heparin should be considered as soon as possible following multidisciplinary discussion.",IIa,C,22,Recommendations for,Endocarditis,2023,62
Thrombolytic therapy is not recommended in patients with IE.,III,C,22,Recommendations for,Endocarditis,2023,62
treatment of patients with symptomatic heart failure with mildly reduced ejection fraction Recommendation An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HFmrEF to reduce the risk of HF hospitalization or CV death.c,I,A,1,Recommendation for the,Heart Failure Update,2023,7
treatment of patients with symptomatic heart failure with preserved ejection fraction Recommendation An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HFpEF to reduce the risk of HF hospitalization or CV death.c,I,A,2,Recommendation for the,Heart Failure Update,2023,7
"pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure Recommendation An intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge and during frequent and careful follow-up visits in the first 6 weeks following a HF hospitalization is recommended to reduce the risk of HF rehospitalization or death.c,d,e",I,B,3,Recommendation for,Heart Failure Update,2023,9
"prevention of heart failure in patients with type 2 diabetes mellitus and chronic kidney disease In patients with T2DM and CKD,c SGLT2 inhibitors are recommended to reduce the risk of HF hospitalization or CV death.",I,A,4,Recommendations for the,Heart Failure Update,2023,10
"In patients with T2DM and CKD,c finerenone is recommended to reduce the risk of HF hospitalization.",I,A,4,Recommendations for the,Heart Failure Update,2023,10
"management of iron deficiency in patients with heart failure Intravenous iron supplementation is recommended in symptomatic patients with HFrEF and HFmrEF, and iron deficiency, to alleviate HF symptoms and improve quality of life.c 12,41,47–",I,A,5,Recommendations for the,Heart Failure Update,2023,11
"Intravenous iron supplementation with ferric carboxymaltose or ferric derisomaltose should be considered in symptomatic patients with HFrEF and HFmrEF, and iron deficiency, to reduce the risk of HF hospitalization.c 12,41,43–",IIa,A,5,Recommendations for the,Heart Failure Update,2023,11
"diagnosis of AF (see also Evidence Table 1) Confirmation by an electrocardiogram (12-lead, multiple, or single leads) is recommended to establish the diagnosis of clinical AF and commence risk stratification and treatment.25–",I,A,1,Recommendations for the,Atrial Fibrillation,2024,15
"symptom evaluation in patients with AF (see also Evidence Table 2) Evaluating the impact of AF-related symptoms is recommended before and after major changes in treatment to inform shared decision-making and guide treatment choices.17,36,46–",I,B,2,Recommendations for,Atrial Fibrillation,2024,15
diagnostic evaluation in patients with new AF (see also Evidence Table 3) A transthoracic echocardiogram is recommended in patients with an AF diagnosis where this will guide treatment decisions.,I,C,3,Recommendations for,Atrial Fibrillation,2024,15
"comorbidity and risk factor management in AF (see also Evidence Table 5) Recommendation Identification and management of risk factors and comorbidities is recommended as an integral part of AF care.39,125–",I,B,5,Recommendations for,Atrial Fibrillation,2024,26
Blood pressure lowering treatment is recommended in patients with AF and hypertension to reduce recurrence and progression of AF and prevent adverse cardiovascular events.126–,I,B,5,Recommendations for,Atrial Fibrillation,2024,26
"Diuretics are recommended in patients with AF, HF, and congestion to alleviate symptoms and facilitate better AF management.",I,C,5,Recommendations for,Atrial Fibrillation,2024,26
Appropriate medical therapy for HF is recommended in AF patients with HF and impaired LVEF to reduce symptoms and/or HF hospitalization and prevent AF recurrence.131–,I,B,5,Recommendations for,Atrial Fibrillation,2024,26
"Sodium-glucose cotransporter-2 inhibitors are recommended for patients with HF and AF regardless of left ventricular ejection fraction to reduce the risk of HF hospitalization and cardiovascular death.136,138–",I,A,5,Recommendations for,Atrial Fibrillation,2024,26
"Effective glycaemic control is recommended as part of comprehensive risk factor management in individuals with diabetes mellitus and AF, to reduce burden, recurrence, and progression of AF.",I,C,5,Recommendations for,Atrial Fibrillation,2024,26
"Weight loss is recommended as part of comprehensive risk factor management in overweight and obese individuals with AF to reduce symptoms and AF burden, with a target of 10% or more reduction in body weight.125–",I,B,5,Recommendations for,Atrial Fibrillation,2024,26
A tailored exercise programme is recommended in individuals with paroxysmal or persistent AF to improve cardiorespiratory fitness and reduce AF recurrence.141–,I,B,5,Recommendations for,Atrial Fibrillation,2024,26
Reducing alcohol consumption to ≤3 standard drinks (≤30 grams of alcohol) per week is recommended as part of comprehensive risk factor management to reduce AF recurrence.,I,B,5,Recommendations for,Atrial Fibrillation,2024,26
"Bariatric surgery may be considered in conjunction with lifestyle changes and medical management in individuals with AF and body mass index ≥40 kg/m2 c where a rhythm control strategy is planned, to reduce recurrence and progression of AF.",IIb,C,5,Recommendations for,Atrial Fibrillation,2024,26
"Management of obstructive sleep apnoea may be considered as part of a comprehensive management of risk factors in individuals with AF to reduce recurrence and progression.126–128,148–",IIb,B,5,Recommendations for,Atrial Fibrillation,2024,26
"When screening for obstructive sleep apnoea in individuals with AF, using only symptom-based questionnaires is not recommended.155–",III,B,5,Recommendations for,Atrial Fibrillation,2024,26
assess and manage thromboembolic risk in AF (see also Evidence Table 6) Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk to prevent ischaemic stroke and thromboembolism.,I,A,6,Recommendations to,Atrial Fibrillation,2024,29
A CHA2DS2-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral anticoagulation.,I,C,6,Recommendations to,Atrial Fibrillation,2024,29
"Oral anticoagulation is recommended in all patients with AF and hypertrophic cardiomyopathy or cardiac amyloidosis, regardless of CHA2DS2-VA score, to prevent ischaemic stroke and thromboembolism.270–",I,B,6,Recommendations to,Atrial Fibrillation,2024,29
Individualized reassessment of thromboembolic risk is recommended at periodic intervals in patients with AF to ensure anticoagulation is started in appropriate patients.277–,I,B,6,Recommendations to,Atrial Fibrillation,2024,29
"Direct oral anticoagulant therapy may be considered in patients with asymptomatic device-detected subclinical AF and elevated thromboembolic risk to prevent ischaemic stroke and thromboembolism, excluding patients at high risk of bleeding.",IIb,B,6,Recommendations to,Atrial Fibrillation,2024,29
Antiplatelet therapy is not recommended as an alternative to anticoagulation in patients with AF to prevent ischaemic stroke and thromboembolism.,III,A,6,Recommendations to,Atrial Fibrillation,2024,29
"Using the temporal pattern of clinical AF (paroxysmal, persistent, or permanent) is not recommended to determine the need for oral anticoagulation.",III,B,6,Recommendations to,Atrial Fibrillation,2024,29
"oral anticoagulation in AF (see also Evidence Table 7) Direct oral anticoagulants are recommended in preference to VKAs to prevent ischaemic stroke and thromboembolism, except in patients with mechanical heart valves or moderate-to-severe mitral stenosis.25–28,292–",I,A,7,Recommendations for,Atrial Fibrillation,2024,31
A target INR of 2.0–3.0 is recommended for patients with AF prescribed a VKA for stroke prevention to ensure safety and effectiveness.295–,I,B,7,Recommendations for,Atrial Fibrillation,2024,31
Switching to a DOAC is recommended for eligible patients that have failed to maintain an adequate time in therapeutic range on a VKA (TTR <70%) to prevent thromboembolism and intracranial haemorrhage.299–,I,B,7,Recommendations for,Atrial Fibrillation,2024,31
"Keeping the time in therapeutic range above 70% should be considered in patients taking a VKA to ensure safety and effectiveness, with INR checks at appropriate frequency and patient-directed education and counselling.304–",IIa,A,7,Recommendations for,Atrial Fibrillation,2024,31
Maintaining VKA treatment rather than switching to a DOAC may be considered in patients aged ≥75 years on clinically stable therapeutic VKA with polypharmacy to prevent excess bleeding risk.,IIb,B,7,Recommendations for,Atrial Fibrillation,2024,31
"A reduced dose of DOAC therapy is not recommended, unless patients meet DOAC-specific criteria,c to prevent underdosing and avoidable thromboembolic events.310–",III,B,7,Recommendations for,Atrial Fibrillation,2024,31
"thromboembolism despite anticoagulation (see also Evidence Table 9) Recommendation A thorough diagnostic work-up should be considered in patients taking an oral anticoagulant and presenting with ischaemic stroke or thromboembolism to prevent recurrent events, including assessment of non-cardioembolic causes, vascular risk factors, dosage, and adherence.",IIa,B,9,Recommendations for,Atrial Fibrillation,2024,33
Adding antiplatelet treatment to anticoagulation is not recommended in patients with AF to prevent recurrent embolic stroke.,III,B,9,Recommendations for,Atrial Fibrillation,2024,33
"Switching from one DOAC to another, or from a DOAC to a VKA, without a clear indication is not recommended in patients with AF to prevent recurrent embolic stroke.",III,B,9,Recommendations for,Atrial Fibrillation,2024,33
combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8) Recommendation Adding antiplatelet treatment to oral anticoagulation is not recommended in AF patients for the goal of preventing ischaemic stroke or thromboembolism.,III,B,8,Recommendations for,Atrial Fibrillation,2024,33
percutaneous left atrial appendage occlusion (see also Evidence Table 10) Recommendation Percutaneous LAA occlusion may be considered in patients with AF and contraindications for long-term anticoagulant treatment to prevent ischaemic stroke and thromboembolism.,IIb,C,10,Recommendations for,Atrial Fibrillation,2024,34
"assessment of bleeding risk (see also Evidence Table 12) Assessment and management of modifiable bleeding risk factors is recommended in all patients eligible for oral anticoagulation, as part of shared decision-making to ensure safety and prevent bleeding.439–",I,B,12,Recommendations for,Atrial Fibrillation,2024,35
Use of bleeding risk scores to decide on starting or withdrawing oral anticoagulation is not recommended in patients with AF to avoid under-use of anticoagulation.,III,B,12,Recommendations for,Atrial Fibrillation,2024,35
"surgical left atrial appendage occlusion (see also Evidence Table 11) Surgical closure of the left atrial appendage is recommended as an adjunct to oral anticoagulation in patients with AF undergoing cardiac surgery to prevent ischaemic stroke and thromboembolism.400,401,408–",I,B,11,Recommendations for,Atrial Fibrillation,2024,35
Surgical closure of the left atrial appendage should be considered as an adjunct to oral anticoagulation in patients with AF undergoing endoscopic or hybrid AF ablation to prevent ischaemic stroke and thromboembolism.,IIa,C,11,Recommendations for,Atrial Fibrillation,2024,35
Stand-alone endoscopic surgical closure of the left atrial appendage may be considered in patients with AF and contraindications for long-term anticoagulant treatment to prevent ischaemic stroke and thromboembolism.,IIb,C,11,Recommendations for,Atrial Fibrillation,2024,35
"heart rate control in patients with AF (see also Evidence Table 14) Rate control therapy is recommended in patients with AF, as initial therapy in the acute setting, an adjunct to rhythm control therapies, or as a sole treatment strategy to control heart rate and reduce symptoms.458–",I,B,14,Recommendations for,Atrial Fibrillation,2024,38
"Beta-blockers, diltiazem, verapamil, or digoxin are recommended as first-choice drugs in patients with AF and LVEF >40% to control heart rate and reduce symptoms.",I,B,14,Recommendations for,Atrial Fibrillation,2024,38
"Beta-blockers and/or digoxin are recommended in patients with AF and LVEF ≤40% to control heart rate and reduce symptoms.40,185,463–",I,B,14,Recommendations for,Atrial Fibrillation,2024,38
"Combination rate control therapy should be considered if a single drug does not control symptoms or heart rate in patients with AF, providing that bradycardia can be avoided, to control heart rate and reduce symptoms.",IIa,C,14,Recommendations for,Atrial Fibrillation,2024,38
"Lenient rate control with a resting heart rate of < 110 b.p.m. should be considered as the initial target for patients with AF, with stricter control reserved for those with continuing AF-related symptoms.",IIa,B,14,Recommendations for,Atrial Fibrillation,2024,38
"Atrioventricular node ablation in combination with pacemaker implantation should be considered in patients unresponsive to, or ineligible for, intensive rate and rhythm control therapy to control heart rate and reduce symptoms.467–",IIa,B,14,Recommendations for,Atrial Fibrillation,2024,38
"Atrioventricular node ablation combined with cardiac resynchronization therapy should be considered in severely symptomatic patients with permanent AF and at least one hospitalization for HF to reduce symptoms, physical limitations, recurrent HF hospitalization, and mortality.",IIa,B,14,Recommendations for,Atrial Fibrillation,2024,38
"Intravenous amiodarone, digoxin, esmolol, or landiolol may be considered in patients with AF who have haemodynamic instability or severely depressed LVEF to achieve acute control of heart rate.",IIb,B,14,Recommendations for,Atrial Fibrillation,2024,38
management of bleeding in anticoagulated patients (see also Evidence Table 13) Interrupting anticoagulation and performing diagnostic or treatment interventions is recommended in AF patients with active bleeding until the cause of bleeding is identified and resolved.,I,C,13,Recommendations for,Atrial Fibrillation,2024,38
"Prothrombin complex concentrates should be considered in AF patients on VKAs who develop a life-threatening bleed, or bleed into a critical site, to reverse the antithrombotic effect.",IIa,C,13,Recommendations for,Atrial Fibrillation,2024,38
"Specific antidotes should be considered in AF patients on a DOAC who develop a life-threatening bleed, or bleed into a critical site, to reverse the antithrombotic effect.",IIa,B,13,Recommendations for,Atrial Fibrillation,2024,38
"antiarrhythmic drugs for long-term maintenance of si­ nus rhythm (see also Evidence Table 18) Amiodarone is recommended in patients with AF and HFrEF requiring long-term antiarrhythmic drug therapy to prevent recurrence and progression of AF, with careful consideration and monitoring for extracardiac toxicity.577,585–",I,A,18,Recommendations for,Atrial Fibrillation,2024,45
"Dronedarone is recommended in patients with AF requiring long-term rhythm control, including those with HFmrEF, HFpEF, ischaemic heart disease, or valvular disease to prevent recurrence and progression of AF.",I,A,18,Recommendations for,Atrial Fibrillation,2024,45
"Flecainide or propafenone is recommended in patients with AF requiring long-term rhythm control to prevent recurrence and progression of AF, excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease.",I,A,18,Recommendations for,Atrial Fibrillation,2024,45
"Concomitant use of a beta-blocker, diltiazem, or verapamil should be considered in AF patients treated with flecainide or propafenone, to prevent 1:1 conduction if their rhythm is transformed to atrial flutter.",IIa,C,18,Recommendations for,Atrial Fibrillation,2024,45
Antiarrhythmic drug therapy is not recommended in patients with advanced conduction disturbances unless antibradycardia pacing is provided.,III,C,18,Recommendations for,Atrial Fibrillation,2024,45
"catheter ablation of AF (see also Evidence Table 19) Shared decision-making Shared decision-making is recommended when considering catheter ablation for AF, taking into account procedural risks, likely benefits, and risk factors for AF recurrence.",I,C,19,Recommendations for,Atrial Fibrillation,2024,46
"AF patients resistant or intolerant to antiarrhythmic drug therapy Catheter ablation is recommended in patients with paroxysmal or persistent AF resistant or intolerant to antiarrhythmic drug therapy to reduce symptoms, recurrence, and progression of AF.",I,A,19,Recommendations for,Atrial Fibrillation,2024,46
"First-line rhythm control therapy Catheter ablation is recommended as a first-line option within a shared decision-making rhythm control strategy in patients with paroxysmal AF, to reduce symptoms, recurrence, and progression of AF.16,591–",I,A,19,Recommendations for,Atrial Fibrillation,2024,46
"Catheter ablation may be considered as a first-line option within a shared decision-making rhythm control strategy in selected patients with persistent AF to reduce symptoms, recurrence, and progression of AF.",IIb,C,19,Recommendations for,Atrial Fibrillation,2024,46
AF catheter ablation should be considered in selected AF patients with HFrEF to reduce HF hospitalization and prolong survival.,IIa,B,19,Recommendations for,Atrial Fibrillation,2024,46
Sinus node disease/tachycardia–bradycardia syndrome AF catheter ablation should be considered in patients with AF-related bradycardia or sinus pauses on AF termination to improve symptoms and avoid pacemaker implantation.595–,IIa,C,19,Recommendations for,Atrial Fibrillation,2024,46
"Recurrence after catheter ablation Repeat AF catheter ablation should be considered in patients with AF recurrence after initial catheter ablation, provided the patient’s symptoms were improved after the initial PVI or after failed initial PVI, to reduce symptoms, recurrence, and progression of AF.643–",IIa,B,19,Recommendations for,Atrial Fibrillation,2024,46
"anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20) Initiation of oral anticoagulation is recommended at least 3 weeks prior to catheter-based ablation in AF patients at elevated thromboembolic risk, to prevent peri-procedural ischaemic stroke and thromboembolism.",I,C,20,Recommendations for,Atrial Fibrillation,2024,47
Uninterrupted oral anticoagulation is recommended in patients undergoing AF catheter ablation to prevent peri-procedural ischaemic stroke and thromboembolism.,I,A,20,Recommendations for,Atrial Fibrillation,2024,47
"Continuation of oral anticoagulation is recommended for at least 2 months after AF ablation in all patients, irrespective of rhythm outcome or CHA2DS2-VA score, to reduce the risk of peri-procedural ischaemic stroke and thromboembolism.",I,C,20,Recommendations for,Atrial Fibrillation,2024,47
"Continuation of oral anticoagulation is recommended after AF ablation according to the patient’s CHA2DS2-VA score, and not the perceived success of the ablation procedure, to prevent ischaemic stroke and thromboembolism.",I,C,20,Recommendations for,Atrial Fibrillation,2024,47
Cardiac imaging should be considered prior to catheter ablation of AF in patients at high risk of ischaemic stroke and thromboembolism despite taking oral anticoagulation to exclude thrombus.,IIa,B,20,Recommendations for,Atrial Fibrillation,2024,47
improve patient experience (see also Evidence Table 23) Evaluating quality of care and identifying opportunities for improved treatment of AF should be considered by practitioners and institutions to improve patient experiences.49–,IIa,B,23,Recommendations to,Atrial Fibrillation,2024,51
"patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24) General recommendations for patients with AF and an indication for concomitant antiplatelet therapy For combinations with antiplatelet therapy, a DOAC is recommended in eligible patients in preference to a VKA to mitigate bleeding risk and prevent thromboembolism.",I,A,24,Recommendations for,Atrial Fibrillation,2024,53
Rivaroxaban 15 mg once daily should be considered in preference to rivaroxaban 20 mg once daily when combined with antiplatelet therapy in patients where concerns about bleeding risk prevail over concerns about stent thrombosis or ischaemic stroke.,IIa,B,24,Recommendations for,Atrial Fibrillation,2024,53
Dabigatran 110 mg twice daily should be considered in preference to dabigatran 150 mg twice daily when combined with antiplatelet therapy in patients where concerns about bleeding risk prevail over concerns about stent thrombosis or ischaemic stroke.,IIa,B,24,Recommendations for,Atrial Fibrillation,2024,53
Carefully regulated VKA dosing with a target INR of 2.0–2.5 and TTR >70% should be considered when combined with antiplatelet therapy in AF patients to mitigate bleeding risk.,IIa,C,24,Recommendations for,Atrial Fibrillation,2024,53
"Recommendations for AF patients with ACS Early cessation (≤1 week) of aspirin and continuation of an oral anticoagulant (preferably DOAC) with a P2Y12 inhibitor (preferably clopidogrel) for up to 12 months is recommended in AF patients with ACS undergoing an uncomplicated PCI to avoid major bleeding, if the risk of thrombosis is low or bleeding risk is high.764–",I,A,24,Recommendations for,Atrial Fibrillation,2024,53
"Triple therapy with aspirin, clopidogrel, and oral anticoagulation for longer than 1 week after an ACS should be considered in patients with AF when ischaemic risk outweighs the bleeding risk, with the total duration (≤1 month) decided according to assessment of these risks and clear documentation of the discharge treatment plan.",IIa,C,24,Recommendations for,Atrial Fibrillation,2024,53
"Triple therapy with aspirin, clopidogrel, and an oral anticoagulant for longer than 1 week should be considered after PCI when the risk of stent thrombosis outweighs the bleeding risk, with the total duration (≤1 month) decided according to assessment of these risks and clear documentation.",IIa,B,24,Recommendations for,Atrial Fibrillation,2024,53
"Recommendations for AF patients with chronic coronary or vascular disease Antiplatelet therapy beyond 12 months is not recommended in stable patients with chronic coronary or vascular disease treated with oral anticoagulation, due to lack of efficacy and to avoid major bleeding.",III,B,24,Recommendations for,Atrial Fibrillation,2024,53
trigger-induced AF (see also Evidence Table 25) Recommendation Long-term oral anticoagulation should be considered in suitable patients with trigger-induced AF at elevated thromboembolic risk to prevent ischaemic stroke and systemic thromboembolism.,IIa,C,25,Recommendations for,Atrial Fibrillation,2024,55
patients with embolic stroke of unknown source (see also Evidence Table 27) Prolonged monitoring for AF is recommended in patients with ESUS to inform on AF treatment decisions.861–,I,B,27,Recommendations for,Atrial Fibrillation,2024,56
Initiation of oral anticoagulation in ESUS patients without documented AF is not recommended due to lack of efficacy in preventing ischaemic stroke and thromboembolism.,III,A,27,Recommendations for,Atrial Fibrillation,2024,56
"patients with AF and congenital heart disease (see also Evidence Table 29) Recommendation Oral anticoagulation should be considered in all adult congenital heart disease patients with AF/AFL and intracardiac repair, cyanosis, Fontan palliation, or systemic right ventricle to prevent ischaemic stroke and thromboembolism, regardless of other thromboembolic risk factors.",IIa,C,29,Recommendations for,Atrial Fibrillation,2024,57
prevention of thromboembolism in atrial flutter (see also Evidence Table 30) Recommendation Oral anticoagulation is recommended in patients with atrial flutter at elevated thromboembolic risk to prevent ischaemic stroke and thromboembolism.,I,B,30,Recommendations for,Atrial Fibrillation,2024,58
"screening for AF (see also Evidence Table 31) Review of an ECG (12-lead, single, or multiple leads) by a physician is recommended to provide a definite diagnosis of AF and commence appropriate management.1091,1121–",I,B,31,Recommendations for,Atrial Fibrillation,2024,61
Routine heart rhythm assessment during healthcare contact is recommended in all individuals aged ≥65 years for earlier detection of AF.,I,C,31,Recommendations for,Atrial Fibrillation,2024,61
"Population-based screening for AF using a prolonged non-invasive ECG-based approach should be considered in individuals aged ≥75 years, or ≥65 years with additional CHA2DS2-VA risk factors to ensure earlier detection of AF.6,1135–",IIa,B,31,Recommendations for,Atrial Fibrillation,2024,61
"primary prevention of AF (see also Evidence Table 32) Recommendation Maintaining optimal blood pressure is recommended in the general population to prevent AF, with ACE inhibitors or ARBs as first-line therapy.1205–",I,B,32,Recommendations for,Atrial Fibrillation,2024,63
"Appropriate medical HF therapy is recommended in individuals with HFrEF to prevent AF.133,136,1208–",I,B,32,Recommendations for,Atrial Fibrillation,2024,63
Maintaining normal weight (BMI 20–25 kg/m2) is recommended for the general population to prevent AF.,I,B,32,Recommendations for,Atrial Fibrillation,2024,63
"Maintaining an active lifestyle is recommended to prevent AF, with the equivalent of 150–300 min per week of moderate intensity or 75–150 min per week of vigorous intensity aerobic physical activity.1214–",I,B,32,Recommendations for,Atrial Fibrillation,2024,63
Avoidance of binge drinking and alcohol excess is recommended in the general population to prevent AF.1220–,I,B,32,Recommendations for,Atrial Fibrillation,2024,63
"Metformin or SGLT2 inhibitors should be considered for individuals needing pharmacological management of diabetes mellitus to prevent AF.1210,1211,1224–",IIa,B,32,Recommendations for,Atrial Fibrillation,2024,63
"Weight reduction should be considered in obese individuals to prevent AF.1212,1227–",IIa,B,32,Recommendations for,Atrial Fibrillation,2024,63
"tory taking, risk factor assessment, and resting electro­ cardiogram in individuals with suspected chronic coronary syndrome (see also Evidence Table 1) History taking and risk factor assessment In individuals reporting symptoms of suspected myocardial ischaemic origin, a detailed assessment of cardiovascular risk factors, medical history, and symptom characteristics (including onset, duration, type, location, triggers, relieving factors, time of day) is recommended.",I,C,1,Recommendations for his­,Chronic Coronary Syndromes,2024,22
"Symptoms like chest pain triggered by emotional stress; dyspnoea or dizziness on exertion; pain in the arms, jaw, neck, or upper back; or fatigue should be considered as potential angina equivalents.",IIa,B,1,Recommendations for his­,Chronic Coronary Syndromes,2024,22
"Resting ECG If clinical or ECG assessment suggests ACS rather than CCS, immediate referral to the emergency department and/or repeated measurement of blood troponin, preferably using high-sensitivity or ultrasensitive assays, to rule out acute myocardial injury, is recommended.",I,B,1,Recommendations for his­,Chronic Coronary Syndromes,2024,22
"A resting 12-lead ECG is recommended in all individuals reporting chest pain (unless an obvious non-cardiac cause is identified), particularly during, or immediately after, an episode suggestive of myocardial ischaemia.",I,C,1,Recommendations for his­,Chronic Coronary Syndromes,2024,22
"Using ST-segment deviations during supraventricular tachyarrhythmias, particularly during re-entrant atrioventricular tachycardias, per se, as reliable evidence of obstructive CAD, is not recommended.80–",III,B,1,Recommendations for his­,Chronic Coronary Syndromes,2024,22
"sic biochemistry in the initial diagnostic management of in­ dividuals with suspected chronic coronary syndrome (see also Evidence Table 2) The following blood tests are recommended in all individuals to refine risk stratification, diagnose comorbidities, and guide treatment: • lipid profile including LDL-C;",I,A,2,Recommendations for ba­,Chronic Coronary Syndromes,2024,23
• full blood count (including haemoglobin);129–,I,B,2,Recommendations for ba­,Chronic Coronary Syndromes,2024,23
• creatinine with estimation of renal function;,I,B,2,Recommendations for ba­,Chronic Coronary Syndromes,2024,23
• glycaemic status with HbA1c and/or fasting plasma glucose.,I,B,2,Recommendations for ba­,Chronic Coronary Syndromes,2024,23
"In patients with suspected CCS, it is recommended to assess thyroid function at least once.",I,B,2,Recommendations for ba­,Chronic Coronary Syndromes,2024,23
"Additionally, hs-CRP and/or fibrinogen plasma levels should be considered.109–",IIa,B,2,Recommendations for ba­,Chronic Coronary Syndromes,2024,23
"resting transthoracic ultrasound and cardiac magnetic resonance imaging in the initial diagnostic management of individuals with suspected chronic coronary syn­ drome (see also Evidence Table 4) A resting transthoracic echocardiogram is recommended: to measure LVEF, volumes and diastolic function; • identify regional wall motion abnormalities; • identify non-coronary cardiac disease (e.g. hypertrophy, cardiomyopathy, valve disease, pericardial effusion); • assess right ventricular function and estimate systolic pulmonary artery pressure; to refine risk stratification and guide treatment.",I,B,4,Recommendations for,Chronic Coronary Syndromes,2024,26
"CMR, if available, may be considered as an alternative imaging test in individuals with inconclusive echocardiographic evaluation.",IIb,C,4,Recommendations for,Chronic Coronary Syndromes,2024,26
"exercise ECG in the initial diagnostic management of in­ dividuals with suspected chronic coronary syndrome (see also Evidence Table 5) Exercise ECG is recommended in selected patientsc for the assessment of exercise tolerance, symptoms, arrhythmias, BP response, and event risk.",I,C,5,Recommendations for,Chronic Coronary Syndromes,2024,27
Exercise ECG may be considered as an alternative test to rule in and rule out CAD when non-invasive imaging tests are unavailable.,IIb,B,5,Recommendations for,Chronic Coronary Syndromes,2024,27
An exercise ECG may be considered to refine risk stratification and treatment.,IIb,B,5,Recommendations for,Chronic Coronary Syndromes,2024,27
"In individuals with a low (>5%–15%) pre-test likelihood of obstructive CAD, an exercise ECG may be considered to identify patients in whom further testing can be deferred.",IIb,C,5,Recommendations for,Chronic Coronary Syndromes,2024,27
"Exercise ECG is not recommended for diagnostic purposes in patients with ≥0.1 mV ST-segment depression on resting ECG, left bundle branch block or who are being treated with digitalis.",III,C,5,Recommendations for,Chronic Coronary Syndromes,2024,27
"In individuals with a low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, an exercise ECG is not recommended to rule out CAD if CCTA or functional imaging tests are available.",III,C,5,Recommendations for,Chronic Coronary Syndromes,2024,27
"chest X-ray in the initial diagnostic management of indi­ viduals with suspected chronic coronary syndrome (see also Evidence Table 6) A chest X-ray should be considered for individuals with: • signs and symptoms suggestive of heart failure; • suspected acute pulmonary disease; • suspected aortic, non-coronary cardiac, or other thoracic causes of chest pain.",IIa,C,6,Recommendations for,Chronic Coronary Syndromes,2024,27
bulatory ECG monitoring in the initial diagnostic manage­ ment of individuals with suspected chronic coronary syndrome (see also Evidence Table 7) Ambulatory ECG monitoring is recommended in subjects with chest pain and suspected arrhythmias.,I,C,7,Recommendations for am­,Chronic Coronary Syndromes,2024,27
Ambulatory ECG monitoring should be considered in subjects with suspected vasospastic angina.192–,IIa,B,7,Recommendations for am­,Chronic Coronary Syndromes,2024,27
"non-invasive anatomical imaging tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome—coronary computed tom­ ography angiography, if available, and supported by local expertise (see also Evidence Table 8) In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to diagnose obstructive CAD and to estimate the risk of MACE.33,34,145,212,214–",I,A,8,Recommendations for,Chronic Coronary Syndromes,2024,28
CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD to refine diagnosis if another non-invasive test is non-diagnostic.,I,B,8,Recommendations for,Chronic Coronary Syndromes,2024,28
"CCTA is not recommended in patients with severe renal failure (eGFR <30 mL/min/1.73 m2), decompensated heart failure, extensive coronary calcification, fast irregular heart rate, severe obesity, inability to cooperate with breath-hold commands, or any other conditions that can make obtaining good imaging quality unlikely.",III,C,8,Recommendations for,Chronic Coronary Syndromes,2024,28
"non-invasive tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome —stress echocardiography, if available, and supported by local expertise (see also Evidence Table 9) In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress echocardiography is recommended to diagnose myocardial ischaemia and to estimate the risk of MACE.33,241–",I,B,9,Recommendations for,Chronic Coronary Syndromes,2024,29
"During stress echocardiography, myocardial perfusion using commercially available intravenous ultrasound contrast agents (microbubbles) is recommended to improve diagnostic accuracy and to refine risk stratification beyond wall motion.177,230,232,236,249–",I,B,9,Recommendations for,Chronic Coronary Syndromes,2024,29
"During stress echocardiography, Doppler left anterior descending coronary artery flow reserve may be considered to improve risk stratification beyond wall motion and to assess microvascular function.",IIb,B,9,Recommendations for,Chronic Coronary Syndromes,2024,29
"non-invasive functional myocardial imaging tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome—resting and stress single-photon emission computed tomography/ positron emission tomography—cardiac magnetic resonance imaging, if available, and supported by local expertise (see also Evidence Table 10) In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress SPECT or, preferably, PET myocardial perfusion imaging is recommended to: • diagnose and quantify myocardial ischaemia and/or scar; • estimate the risk of MACE; • quantify myocardial blood flow (PET).33,44,223,257,263,268,270,271,281–",I,B,10,Recommendations for,Chronic Coronary Syndromes,2024,30
"In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress CMR perfusion imaging is recommended to diagnose and quantify myocardial ischaemia and/or scar and estimate the risk of MACE.148,273,276,278,294–",I,B,10,Recommendations for,Chronic Coronary Syndromes,2024,31
"invasive coronary angiography in the diagnostic manage­ ment of individuals with suspected chronic coronary syndrome (see also Evidence Table 11) When ICA is indicated, radial artery access is recommended as the preferred access site.327–",I,A,11,Recommendations for,Chronic Coronary Syndromes,2024,32
"When ICA is indicated, it is recommended to have coronary pressure assessment available and to use it to evaluate the functional severity of intermediate non-left main stem stenosesc prior to revascularization.49,195,308,313,321,322,325,331–",I,A,11,Recommendations for,Chronic Coronary Syndromes,2024,32
"Invasive coronary angiography is recommended to diagnose obstructive CAD in individuals with a very high (>85%) clinical likelihood of disease, severe symptoms refractory to guideline-directed medical therapy, angina at a low level of exercise, and/or high event risk.",I,C,11,Recommendations for,Chronic Coronary Syndromes,2024,32
"In individuals with de novo symptoms highly suggestive of obstructive CAD that occur at a low level of exercise, ICA with a view towards revascularization is recommended as first diagnostic test after clinical assessment by a cardiologist.",I,C,11,Recommendations for,Chronic Coronary Syndromes,2024,32
"When ICA is indicated, measurement of FFR/iFR should be considered to evaluate the functional severity of intermediate left main stem stenosesc prior to revascularization.",IIa,A,11,Recommendations for,Chronic Coronary Syndromes,2024,32
"When ICA is indicated, IVUS should be considered to evaluate the severity of intermediate stenoses of left main stemc prior to revascularization.",IIa,B,11,Recommendations for,Chronic Coronary Syndromes,2024,32
"functional assessment of epicardial artery stenosis severity during invasive coronary angiography to guide revascularization (see also Evidence Table 12) During ICA, selective assessment of functional severity of intermediatec diameter stenoses is recommended to guide the decision to revascularize, using the following techniques: • FFR/iFR (significant ≤0.8 or ≤0.89, respectively);49,308,310,311,313,321–",I,A,12,Recommendations for,Chronic Coronary Syndromes,2024,33
• QFR (significant ≤0.8).,I,B,12,Recommendations for,Chronic Coronary Syndromes,2024,33
"In addition: • CFR/HSR/CFC should be considered as a complementary investigation;359,360,366–",IIa,B,12,Recommendations for,Chronic Coronary Syndromes,2024,33
"• resting invasive measurement of Pd/Pa, dPR, RFR, or angiography-derived vessel FFR may be considered as alternative parameters.",IIb,C,12,Recommendations for,Chronic Coronary Syndromes,2024,33
Systematic and routine wire-based coronary pressure assessment of all coronary vessels is not recommended.,III,A,12,Recommendations for,Chronic Coronary Syndromes,2024,33
"definition of high risk of adverse events (see also Evidence Table 14) An initial stratification of risk of adverse events is recommended based on basic clinical assessment (e.g. age, ECG, anginal threshold, diabetes, CKD, LVEF).406–",I,B,14,Recommendations for,Chronic Coronary Syndromes,2024,40
"The use of one or more of the following test results is recommended to identify individuals at high risk of adverse events:405 • exercise ECG: ⚬Duke Treadmill Score < −10;191 • stress SPECT or PET perfusion imaging: ⚬area of ischaemia ≥10% of the LV myocardium;287,315,422,423,435 • stress echocardiography: ⚬≥3 of 16 segments with stress-induced hypokinesia or akinesia;435 • stress CMR: ⚬≥2 of 16 segments with stress perfusion defects or ≥3 dobutamine-induced dysfunctional segments;435 • CCTA: ⚬left main disease with ≥50% stenosis, three-vessel disease with ≥70 stenosis, or two-vessel disease with ≥70% stenosis, including the proximal LAD or317one-vessel disease of the proximal LAD with ≥70% stenosis and FFR-CT ≤0.8.",I,B,14,Recommendations for,Chronic Coronary Syndromes,2024,40
"In individuals at high risk of adverse events (regardless of symptoms), ICA—complemented by invasive coronary pressure (FFR/iFR) when appropriate—is recommended, with the aim of refining risk stratification and improving symptoms and cardiovascular outcomes by revascularization.",I,A,14,Recommendations for,Chronic Coronary Syndromes,2024,40
"cardiovascular risk reduction, lifestyle changes, and ex­ ercise interventions in patients with established chronic coronary syndrome (see also Evidence Table 15) An informed discussion on CVD risk and treatment benefits tailored to individual patient needs is recommended.",I,C,15,Recommendations for,Chronic Coronary Syndromes,2024,43
"Multidisciplinary behavioural approaches to help patients achieve healthy lifestyles, in addition to appropriate pharmacological management, are recommended.484,498–",I,A,15,Recommendations for,Chronic Coronary Syndromes,2024,43
A multidisciplinary exercise-based programme to improve cardiovascular risk profile and reduce cardiovascular mortality is recommended.480–,I,A,15,Recommendations for,Chronic Coronary Syndromes,2024,43
Aerobic physical activity of at least 150–300 min per week of moderate intensity or 75–150 min per week of vigorous intensity and reduction in sedentary time are recommended.,I,B,15,Recommendations for,Chronic Coronary Syndromes,2024,43
"Home-based cardiac rehabilitation and mobile health interventions should be considered to increase patients’ long-term adherence to healthy behaviours, and to reduce hospitalizations or cardiac events.",IIa,B,15,Recommendations for,Chronic Coronary Syndromes,2024,43
"antianginal drugs in patients with chronic coronary syn­ drome (see also Evidence Table 16) General strategy It is recommended to tailor the selection of antianginal drugs to the patient’s characteristics, comorbidities, concomitant medications, treatment tolerability, and underlying pathophysiology of angina, also considering local drug availability and cost.",I,C,16,Recommendations for,Chronic Coronary Syndromes,2024,45
Selection of antianginal medication Short-acting nitrates are recommended for immediate relief of angina.,I,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
Initial treatment with beta-blockers and/or CCBs to control heart rate and symptoms is recommended for most patients with CCS.c,I,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
"If anginal symptoms are not successfully controlled by initial treatment with a beta-blocker or a CCB alone, the combination of a beta-blocker and a DHP-CCB should be considered, unless contraindicated.",IIa,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
"Long-acting nitrates or ranolazine should be considered as add-on therapy in patients with inadequate control of symptoms while on treatment with beta-blockers and/or CCBs, or as part of initial treatment in properly selected patients.d",IIa,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
"Ivabradine should be considered as add-on antianginal therapy in patients with left ventricular systolic dysfunction (LVEF <40%) and inadequate control of symptoms, or as part of initial treatment in properly selected patients.",IIa,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
"Nicorandil or trimetazidine may be considered as add-on therapy in patients with inadequate control of symptoms while on treatment with beta-blockers and/or CCBs, or as part of initial treatment in properly selected patients.543–",IIb,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
"Ivabradine is not recommended as add-on therapy in patients with CCS, LVEF >40%, and no clinical heart failure.",III,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
Combination of ivabradine with non-DHP-CCB or other strong CYP3A4 inhibitors is not recommended.,III,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
Nitrates are not recommended in patients with hypertrophic cardiomyopathy or in co-administration with phosphodiesterase inhibitors.,III,B,16,Recommendations for,Chronic Coronary Syndromes,2024,45
"drome (see also Evidence Table 17) Long-term antithrombotic therapy in patients with chronic coronary syndrome and no clear indication for oral anticoagulation In CCS patients with a prior MI or remote PCI, aspirin 75–100 mg daily is recommended lifelong after an initial period of DAPT.",I,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,51
"In CCS patients with a prior MI or remote PCI, clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin monotherapy.562,564–",I,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,51
"After CABG, aspirin 75–100 mg daily is recommended lifelong.",I,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,51
"In patients without prior MI or revascularization but with evidence of significant obstructive CAD, aspirin 75–100 mg daily is recommended lifelong.557–",I,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,51
"Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be considered in patients at enhanced ischaemic riskc and without high bleeding riskd (options and definitions in Table 8 and in the Supplementary data online, Tables S2 and S3).592–",IIa,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,51
"In CCS or stabilized post-ACS patients who underwent PCI and were initially treated with ticagrelor-based DAPT, who remain at high ischaemic risk and are not at high bleeding risk, ticagrelor monotherapy 90 mg b.i.d. may be considered as an alternative to dual or other single antiplatelet therapy.563,570–",IIb,C,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,51
"In patients at high bleeding riskd but not at high ischaemic risk,c it is recommended to discontinue DAPT 1–3 months after PCI and to continue with single antiplatelet therapy.",I,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"Stopping DAPT after 1–3 months from PCI-stenting may be considered in patients who are not at high bleeding risk nor at high risk of ischaemic events.588,655–657,c,d",IIb,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"In CCS patients undergoing high-thrombotic risk stenting (e.g. complex left main stem, 2-stent bifurcation, suboptimal stenting result, prior stent thrombosis, previously known CYP2C19 *2/*3 polymorphisms), prasugrel or ticagrelor (in addition to aspirin) may be considered instead of clopidogrel, for the first month, and up to 3–6 months.",IIb,C,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"Long-term antithrombotic therapy in patients with chronic coronary syndrome and an indication for oral anticoagulation In CCS patients with a long-term indication for OAC, an AF therapeutic dose of VKA alone or, preferably, of DOAC alone (unless contraindicated) is recommended lifelong.",I,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"Antithrombotic therapy post-percutaneous coronary intervention in chronic coronary syndrome patients with an indication for oral anticoagulation In patients with an indication for OAC who undergo PCI, initial low-dose aspirin once daily is recommended (loading dose when not on maintenance dose) in addition to OAC and clopidogrel.",I,C,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"In patients who are eligible for OAC, DOAC (unless contraindicated) is recommended in preference to VKA.",I,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
After uncomplicated PCI in CCS patients with concomitant indication for OAC: • early cessation of aspirin (≤1 week); • followed by continuation of OAC and clopidogrel: ⚬up to 6 months in patients not at high ischaemic risk;c or ⚬up to 12 months in patients at high ischaemic risk;c • followed by OAC alone; is recommended.616–,I,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"Continuation of aspirin up to 1 month after PCI, in addition to OAC and clopidogrel, should be considered in patients at high ischaemic riskc or with anatomical/procedural characteristics judged to outweigh the bleeding risk.620–622,e",IIa,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
When concerns about high bleeding risk prevail over concerns about stent thrombosis or ischaemic stroke: rivaroxaban 15 mg daily should be considered in preference to rivaroxaban 20 mg daily for the duration of concomitant antiplatelet therapy;,IIa,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
dabigatran 110 mg twice daily should be considered in preference to dabigatran 150 mg twice daily for the duration of concomitant antiplatelet therapy.,IIa,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"In patients with an indication for VKA in combination with single or dual antiplatelet therapy, targeting VKA intensity to an INR in the lower part of the recommended range and to a time in therapeutic range >70% should be considered.615,660–",IIa,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
The use of ticagrelor or prasugrel is generally not recommended as part of triple antithrombotic therapy with aspirin and an OAC.,III,C,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
Antithrombotic therapy post-coronary artery bypass grafting It is recommended to initiate aspirin post-operatively as soon as there is no concern over bleeding.,I,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
DAPT may be considered after CABG in selected patients at greater risk of graft occlusionf and at low risk of bleeding.,IIb,B,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
Use of proton pump inhibitors A proton pump inhibitor is recommended in patients at increased risk of gastrointestinal bleeding for the duration of combined antithrombotic therapy (antiplatelet therapy and/or OAC).646–,I,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
"A proton pump inhibitor should be considered when a single antithrombotic (antiplatelet or anticoagulant) drug is used, considering the gastrointestinal bleeding risk of the individual patient.646,665–",IIa,A,17,Recommendations for antithrombotic therapy in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,52
lipid-lowering drugs in patients with chronic coronary syndrome (see also Evidence Table 18) Lipid-lowering treatment with an LDL-C goal of <1.4 mmol/L (55 mg/dL) and a ≥50% reduction in LDL-C vs. baseline is recommended.,I,A,18,Recommendations for,Chronic Coronary Syndromes,2024,53
A high-intensity statin up to the highest tolerated dose to reach the LDL-C goals is recommended for all patients with CCS.,I,A,18,Recommendations for,Chronic Coronary Syndromes,2024,53
"If a patient’s goal is not achieved with the maximum tolerated dose of statin, combination with ezetimibe is recommended.",I,B,18,Recommendations for,Chronic Coronary Syndromes,2024,53
"For patients who are statin intolerant and do not achieve their goal on ezetimibe, combination with bempedoic acid is recommended.",I,B,18,Recommendations for,Chronic Coronary Syndromes,2024,53
"For patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with a PCSK9 inhibitor is recommended.",I,A,18,Recommendations for,Chronic Coronary Syndromes,2024,53
"For patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with bempedoic acid should be considered.",IIa,C,18,Recommendations for,Chronic Coronary Syndromes,2024,53
"For patients with a recurrent atherothrombotic event (not necessarily of the same type as the first event) while taking maximally tolerated statin therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) may be considered.",IIb,B,18,Recommendations for,Chronic Coronary Syndromes,2024,53
"anti-inflammatory drugs in patients with chronic coron­ ary syndrome (see also Evidence Table 20) Recommendation In CCS patients with atherosclerotic CAD, low-dose colchicine (0.5 mg daily) should be considered to reduce myocardial infarction, stroke, and need for revascularization.714–",IIa,A,20,Recommendations for,Chronic Coronary Syndromes,2024,55
"also Evidence Table 22) Informed and shared decisions It is recommended that patients scheduled for percutaneous or surgical revascularization receive complete information about the benefits, risks, therapeutic consequences, and alternatives to revascularization, as part of shared clinical decision-making.",I,C,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"For complex clinical cases, to define the optimal treatment strategy, in particular when CABG and PCI hold the same level of recommendation, a Heart Team discussion is recommended, including representatives from interventional cardiology, cardiac surgery, non-interventional cardiology, and other specialties if indicated, aimed at selecting the most appropriate treatment to improve patient outcomes and quality of life.",I,C,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
It is recommended to communicate the proposal of the Heart Team in a balanced way using language that the patient can understand.,I,C,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"It is recommended that the decision for revascularization and its modality be patient-centred, considering patient preferences, health literacy, cultural circumstances, and social support.849–",I,C,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
It is recommended that the Heart Team (on site or with a partner institution) develop institutional protocols to implement the appropriate revascularization strategy in accordance with current guidelines.,I,C,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"Revascularization to improve outcomes In chronic coronary syndrome patients with left ventricular ejection fraction >35% In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for patients with functionally significant left main stem stenosis to improve survival.",I,A,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for patients with functionally significant three-vessel disease to improve long-term survival and to reduce long-term cardiovascular mortality and the risk of spontaneous myocardial infarction.55,56,317,732–",I,A,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for patients with functionally significant single- or two-vessel disease involving the proximal LAD, to reduce long-term cardiovascular mortality and the risk of spontaneous myocardial infarction.55,56,317,719,732–",I,B,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"In chronic coronary syndrome patients with left ventricular ejection fraction ≤35% In CCS patients with LVEF ≤35%, it is recommended to choose between revascularization or medical therapy alone, after careful evaluation, preferably by the Heart Team, of coronary anatomy, correlation between coronary artery disease and LV dysfunction, comorbidities, life expectancy, individual risk-to-benefit ratio, and patient perspectives.",I,C,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"In surgically eligible CCS patients with multivessel CAD and LVEF ≤35%, myocardial revascularization with CABG is recommended over medical therapy alone to improve long-term survival.",I,B,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"In selected CCS patients with functionally significant MVD and LVEF ≤35% who are at high surgical risk or not operable, PCI may be considered as an alternative to CABG.",IIb,B,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"Revascularization to improve symptoms In CCS patients with persistent angina or anginal equivalent, despite guideline-directed medical treatment, myocardial revascularization of functionally significant obstructive CAD is recommended to improve symptoms.",I,A,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"Assessment of procedural risks and post-procedural outcomes In patients with complex CAD in whom revascularization is being considered, it is recommended to assess procedural risks and post-procedural outcomes to guide shared clinical decision-making.",I,C,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"Calculation of the STS score is recommended to estimate in-hospital morbidity and 30-day mortality after CABG.777,862–",I,B,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"In patients with multivessel obstructive CAD, calculation of the SYNTAX score is recommended to assess the anatomical complexity of disease.",I,B,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"Intracoronary imaging guidance by IVUS or OCT is recommended when performing PCI on anatomically complex lesions, in particular left main stem, true bifurcations, and long lesions.",I,A,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
Intracoronary pressure measurement (FFR or iFR) or computation (QFR) : • is recommended to guide lesion selection for intervention in patients with multivessel disease;,I,A,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
• should be considered at the end of the procedure to identify patients at high risk of persistent angina and subsequent clinical events;,IIa,B,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
• may be considered at the end of the procedure to identify lesions potentially amenable to treatment with additional PCI.,IIb,B,22,Recommendations for revascularization in patients with chronic coronary syndrome (see,Chronic Coronary Syndromes,2024,62
"drome (see also Evidence Table 23) Anatomically and clinically based recommendations for revascularization in CCS Left main disease In CCS patients at low surgical riskc with significant left main coronary stenosis, CABG: • is recommended over medical therapy alone to improve survival;",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"• is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and repeat revascularization.",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score ≤22), in whom PCI can provide equivalent completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and non-inferior survival.",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), in whom PCI can provide equivalent completeness of revascularization to that of CABG, PCI should be considered, given its lower invasiveness and non-inferior survival.",IIa,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"Left main with multivessel diseased In CCS patients at low surgical risk with suitable anatomy, CABG is recommended over medical therapy alone to improve survival.",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"In CCS patients at high surgical risk, PCI may be considered over medical therapy alone.",IIb,B,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"Multivessel diseased and diabetes In CCS patients with significant multivessel disease and diabetes, with insufficient response to guideline-directed medical therapy, CABG is recommended over medical therapy alone and over PCI to improve symptoms and outcomes.801,824,871–",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"In CCS patients at very high surgical risk, PCI should be considered over medical therapy alone to reduce symptoms and adverse outcomes.",IIa,B,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"Three-vessel disease, without diabetes In CCS patients with significant three-vessel disease, preserved LVEF, no diabetes, and insufficient response to guideline-directed medical therapy, CABG is recommended over medical therapy alone to improve symptoms, survival, and other outcomes.",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"In CCS patients with preserved LVEF, no diabetes, insufficient response to guideline-directed medical therapy, and significant three-vessel disease of low-to-intermediate anatomic complexity in whom PCI can provide similar completeness of revascularization to that of CABG, PCI is recommended, given its lower invasiveness, and generally non-inferior survival.",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"Single- or double-vessel disease involving the proximal LAD In CCS patients with significant single- or double-vessel disease involving the proximal LAD and insufficient response to guideline-directed medical therapy, CABG or PCI is recommended over medical therapy alone to improve symptoms and outcomes.",I,A,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"In CCS patients with complex significant single- or double-vessel disease involving the proximal LAD, less amenable to PCI, and insufficient response to guideline-directed medical therapy, CABG is recommended to improve symptoms and reduce revascularization rates.877–",I,B,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"Single- or double-vessel disease not involving the proximal LAD In symptomatic CCS patients with significant single- or double-vessel disease not involving the proximal LAD and with insufficient response to guideline-directed medical therapy, PCI is recommended to improve symptoms.",I,B,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"In symptomatic CCS patients with significant single- or double-vessel disease not involving the proximal LAD and with insufficient response to guideline-directed medical therapy, not amenable to revascularization by PCI, CABG may be considered to improve symptoms.",IIb,C,23,Recommendations for mode of revascularization in patients with chronic coronary syn­,Chronic Coronary Syndromes,2024,63
"heart failure (see also Evidence Table 24) Managing CCS in heart failure patients In HF patients with LVEF ≤35% in whom obstructive CAD is suspected, ICA is recommended with a view towards improving prognosis by CABG, taking into account the risk-to-benefit ratio of the procedures.",I,B,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,64
"In HF patients with LVEF >35% and suspected CCS with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA or functional imaging is recommended.",I,C,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,64
"In HF patients with LVEF >35% and suspected CCS with very high (>85%) pre-test likelihood of obstructive CAD, ICA (with FFR, iFR, or QFR when needed) is recommended.",I,C,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,64
"In selected patients with HFrEF undergoing high-risk PCI for complex CAD, the use of a microaxial flow pump may be considered in experienced centres.905–",IIb,C,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
"Managing heart failure in CCS patients It is recommended that CCS patients with HF be enrolled in a multidisciplinary HF management programme to reduce the risk of HF hospitalization and to improve survival.526,909–",I,A,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
"An ACE-I, an MRA, an SGLT2 inhibitor (dapagliflozin or empagliflozin), and, in stable conditions, a beta-blocker are recommended for CCS patients with HFrEF to reduce the risk of HF hospitalization and death.",I,A,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with Heart Failure with mildly reduced Ejection Fraction (HFmrEF) or HFpEF to reduce the risk of HF hospitalization or cardiovascular death.,I,A,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
An ARB is recommended in symptomatic patients with CCS and HFrEF unable to tolerate an ACE-I or ARNI to reduce the risk of HF hospitalization and cardiovascular death.,I,B,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
Sacubitril/valsartan is recommended as a replacement for an ACE-I or ARB in CCS patients with HFrEF to reduce the risk of HF hospitalization and of cardiovascular and all-cause death.,I,B,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
"Diuretics are recommended in CCS patients with HF and signs and/or symptoms of congestion to alleviate symptoms, improve exercise capacity, and reduce HF hospitalizations.",I,B,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
"An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II–III) of ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimized medical treatment, provided they are expected to survive substantially longer than 1 year with good functional status.",I,A,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
"An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after an MI. 917–",I,A,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
"CRT is recommended for CCS patients with symptomatic HF, sinus rhythm, LVEF ≤35% despite GDMT, and a QRS duration ≥150 ms with an LBBB QRS morphology to improve symptoms and survival and to reduce morbidity.",I,A,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
CRT rather than right ventricular pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high-degree AV block in order to reduce morbidity. This includes patients with AF. 923–,I,A,24,Recommendations for management of chronic coronary syndrome patients with chronic,Chronic Coronary Syndromes,2024,65
"diagnosis and management of patients with angina/ ischaemia with non-obstructive coronary arteries (see also Evidence Table 25) Diagnosis of ANOCA/INOCA endotypes In persistently symptomatic patients despite medical treatment with suspected ANOCA/ INOCA (i.e. anginal symptoms with normal coronary arteries or non-obstructive lesions at non-invasive imaging, or intermediate stenoses with normal FFR/iFR at coronary arteriography) and poor quality of life, invasive coronary functional testing is recommended to identify potentially treatable endotypes and to improve symptoms and quality of life, considering patient choices and preferences.",I,B,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"In persistently symptomatic patients with documented or suspected ANOCA/INOCA, transthoracic Doppler of the LAD, stress echocardiography, CMR, and PET may be considered for the non-invasive assessment of coronary/myocardial flow reserve.44,231,233–",IIb,B,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"Diagnostic tests for vasospastic angina In individuals with suspected vasospastic angina, a resting 12-lead ECG recording during angina is recommended.",I,C,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"In patients with suspected vasospastic angina and repetitive episodes of rest angina associated with ST-segment changes that resolve with nitrates and/or calcium antagonists, invasive coronary functional testing is recommended to confirm the diagnosis and to determine the severity of underlying atherosclerotic disease.",I,C,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"In individuals with suspected vasospastic angina and frequent symptoms, ambulatory ST-segment monitoring should be considered to identify ST-segment deviation during angina.192–",IIa,B,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"Management of ANOCA/INOCA In symptomatic patients with ANOCA/INOCA, medical therapy based on coronary functional test results should be considered to improve symptoms and quality of life.",IIa,A,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"For the management of endothelial dysfunction, ACE-I should be considered for symptom control.",IIa,B,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"For the management of microvascular angina associated with reduced coronary/myocardial blood flow reserve, antianginal medications aiming at preventing demand myocardial ischaemia should be considered for symptom control.",IIa,B,25,Recommendations for,Chronic Coronary Syndromes,2024,71
Nitrates should be considered to prevent recurrent episodes.,IIa,B,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"For the treatment of overlapping endotypes In patients with evidence of overlapping endotypes, combination therapy with nitrates, calcium channel blockers, and other vasodilators may be considered.",IIb,B,25,Recommendations for,Chronic Coronary Syndromes,2024,71
"screening for coronary artery disease in asymptomatic individuals (see also Evidence Table 27) Opportunistic screening of healthy individuals for cardiovascular risk factors and to estimate the risk of future cardiovascular events using scoring systems, e.g. SCORE2 and SCORE-OP, is recommended to detect individuals at high risk and guide treatment decisions.",I,C,27,Recommendations for,Chronic Coronary Syndromes,2024,74
"When coronary artery calcification findings are available from previous chest CT scans, using these findings to enhance risk stratification and guide treatment of modifiable risk factors should be considered.17,1108–",IIa,C,27,Recommendations for,Chronic Coronary Syndromes,2024,74
CACS may be considered to improve risk classification around treatment decision thresholds.1104–,IIb,C,27,Recommendations for,Chronic Coronary Syndromes,2024,74
An ultrasound of the carotid arteries may be considered as an alternative when CACS is unavailable or not feasible to detect atherosclerotic disease and to improve risk classification around treatment decision thresholds.,IIb,B,27,Recommendations for,Chronic Coronary Syndromes,2024,74
"adherence to medical therapy and lifestyle changes (see also Evidence Table 28) Mobile health interventions (e.g. using text messages, apps, wearable devices) are recommended to improve patient adherence to healthy lifestyles and medical therapy.",I,A,28,Recommendations for,Chronic Coronary Syndromes,2024,78
Behavioural interventions are recommended to improve adherence.,I,B,28,Recommendations for,Chronic Coronary Syndromes,2024,78
Simplifying medication regimens (e.g. using fixed-dose drug combinations) is recommended to increase patient adherence to medications.,I,B,28,Recommendations for,Chronic Coronary Syndromes,2024,78
"Multiprofessional and family involvement is recommended to promote adherence, in addition to patient education and involvement.",I,C,28,Recommendations for,Chronic Coronary Syndromes,2024,78
treatment of revascularization failure (see also Evidence Table 30) DES is recommended over drug-coated balloons for treatment of in-DES restenosis.1186–,I,A,30,Recommendations for,Chronic Coronary Syndromes,2024,82
LIMA is indicated as the conduit of choice for redo CABG in patients in whom the LIMA was not used previously.,I,B,30,Recommendations for,Chronic Coronary Syndromes,2024,82
Redo CABG should be considered for patients without a patent LIMA graft to the LAD.,IIa,B,30,Recommendations for,Chronic Coronary Syndromes,2024,82
PCI of the bypassed native artery should be considered over PCI of the bypass graft.,IIa,B,30,Recommendations for,Chronic Coronary Syndromes,2024,82
"recurrent or refractory angina/ischaemia (see also Evidence Table 31) In patients with refractory angina leading to poor quality of life and with documented or suspected ANOCA/INOCA, invasive coronary functional testing is recommended to define ANOCA/INOCA endotypes and appropriate treatment, considering patient choices and preferences.",I,B,31,Recommendations for,Chronic Coronary Syndromes,2024,82
"In patients with debilitating angina and obstructive CAD refractory to optimal medical and revascularization strategies, a reducer device for coronary sinus constriction may be considered to improve symptoms, in experienced centres.1199–",IIb,B,31,Recommendations for,Chronic Coronary Syndromes,2024,82
"measuring blood pressure (see Evidence Tables 1–8) It is recommended to measure BP using a validated and calibrated device, to enforce the correct measurement technique, and to apply a consistent approach to BP measurement for each patient.",I,B,1,Recommendations for,Hypertension,2024,24
"All adult patients (≥18 years) are recommended to have their office and/or out-of-office BP measured on an opportunistic basis and recorded in their medical file, and be told what their current BP is.",I,C,1,Recommendations for,Hypertension,2024,24
"Out-of-office BP measurement is recommended for diagnostic purposes, particularly because it can detect both white-coat hypertension and masked hypertension. Where out-of-office measurements are not logistically and/or economically feasible, then it is recommended that the diagnosis be confirmed with a repeat office BP measurement using the correct standardized measurement technique.",I,B,1,Recommendations for,Hypertension,2024,24
"It is recommended that office BP should be measured in both arms at least at the first visit, because a between-arm systolic BP difference of >10 mmHg is associated with an increased CVD risk and may indicate arterial stenosis.",I,B,1,Recommendations for,Hypertension,2024,24
"If a between-arm difference of >10 mmHg in systolic BP is recorded, then it is recommended that all subsequent BP readings use the arm with the higher BP reading.",I,B,1,Recommendations for,Hypertension,2024,24
"Out-of-office BP measurement is recommended for ongoing management to quantify the effects of treatment and guide BP-lowering medication titration, and/or identify possible causes of side effects (e.g. symptomatic hypotension). Where out-of-office measurements are not logistically and/ or economically feasible, then ongoing management is recommended to be based on repeated office BP measurements using the correct standardized measurement technique.",I,B,1,Recommendations for,Hypertension,2024,24
It is recommended that all patients undergoing BP measurement also undergo pulse palpation at rest to determine heart rate and arrhythmias such as AF.,I,C,1,Recommendations for,Hypertension,2024,24
Most automated oscillometric monitors have not been validated for BP measurement in AF; BP measurement should be considered using a manual auscultatory method in these circumstances where possible.47–,IIa,C,1,Recommendations for,Hypertension,2024,24
"Other BP measures and indices (pulse pressure, BP variability, exercise BP) may be considered to provide additional clinical information on CVD risk in some circumstances.",IIb,C,1,Recommendations for,Hypertension,2024,25
"categorizing blood pressure (see Evidence Table 9) Recommendation It is recommended that BP be categorized as non-elevated BP, elevated BP, and hypertension to aid treatment decisions.116,121,122,131–",I,B,2,Recommendations for,Hypertension,2024,25
"assessing cardiovascular disease risk among individuals with elevated blood pressure (office systolic blood pressure 120–139 mmHg or diastolic blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11) It is recommended to use a risk-based approach in the treatment of elevated BP, and individuals with moderate or severe CKD, established CVD, HMOD, diabetes mellitus, or familial hypercholesterolaemia are considered at increased risk for CVD events.31,153–159,161–",I,B,3,Recommendations for,Hypertension,2024,28
"SCORE2 is recommended for assessing 10-year risk of fatal and non-fatal CVD among individuals aged 40–69 years with elevated BP who are not already considered at increased risk due to moderate or severe CKD, established CVD, HMOD, diabetes mellitus, or familial hypercholesterolaemia.",I,B,3,Recommendations for,Hypertension,2024,28
"SCORE2-OP is recommended for assessing the 10-year risk of fatal and non-fatal CVD among individuals aged ≥70 years with elevated BP who are not already considered at increased risk due to moderate or severe CKD, established CVD, HMOD, diabetes mellitus, or familial hypercholesterolaemia.",I,B,3,Recommendations for,Hypertension,2024,28
"It is recommended that, irrespective of age, individuals with elevated BP and a SCORE2 or SCORE2-OP CVD risk of ≥10% be considered at increased risk for CVD for the purposes of risk-based management of their elevated BP.",I,B,3,Recommendations for,Hypertension,2024,28
"SCORE2-Diabetes should be considered to estimate CVD risk among type 2 diabetes mellitus patients with elevated BP, particularly if they are <60 years of age.",IIa,B,3,Recommendations for,Hypertension,2024,28
"refining cardiovascular disease risk (see Evidence Tables 12–14) Recommendation History of pregnancy complications (gestational diabetes, gestational hypertension, pre-term delivery, pre-eclampsia, one or more stillbirths, and recurrent miscarriage) are sex-specific risk modifiers that should be considered to up-classify individuals with elevated BP and borderline increased 10-year CVD risk (5% to <10% risk).",IIa,B,4,Recommendations for,Hypertension,2024,30
"High-risk ethnicity (e.g. South Asian), family history of premature onset atherosclerotic CVD, socio-economic deprivation, auto-immune inflammatory disorders, HIV, and severe mental illness are risk modifiers shared by both sexes that should be considered to up-classify individuals with elevated BP and borderline increased 10-year CVD risk (5% to <10% risk). 186–",IIa,B,4,Recommendations for,Hypertension,2024,30
blood pressure screening (see Evidence Table 15) Recommendation Opportunistic screening for elevated BP and hypertension should be considered at least every 3 years for adults aged <40 years.,IIa,C,5,Recommendations for,Hypertension,2024,32
Opportunistic screening for elevated BP and hypertension should be considered at least annually for adults aged ≥40 years.,IIa,C,5,Recommendations for,Hypertension,2024,32
"In individuals with elevated BP who do not currently meet risk thresholds for BP-lowering treatment, a repeat BP measurement and risk assessment within 1 year should be considered.",IIa,C,5,Recommendations for,Hypertension,2024,32
"confirming hypertension diagnosis In individuals with increased CVD risk where their screening office BP is 120–139/70–89 mmHg, it is recommended to measure BP out of office, using ABPM and/or HBPM or, if not logistically feasible, by making repeated office BP measurements on more than one visit.70,238–",I,B,6,Recommendations for,Hypertension,2024,32
"Where screening office BP is 140–159/90–99 mmHg, it is recommended that the diagnosis of hypertension should be based on out-of-office BP measurement with ABPM and/or HBPM. If these measurements are not logistically or economically feasible, then diagnosis can be made on repeated office BP measurements on more than one visit.70,238–",I,B,6,Recommendations for,Hypertension,2024,32
Where screening office BP is ≥160/100 mmHg: • It is recommended that BP 160–179/100–109 mmHg be confirmed as soon as possible (e.g. within 1 month) preferably by either home or ambulatory BP measurements; • It is recommended when BP ≥180/110 mmHg that hypertensive emergency be excluded.,I,C,6,Recommendations for,Hypertension,2024,32
"assessing adherence and persistence with treatment (see Evidence Table 16) Recommendation Objective evaluation of adherence (either directly observed treatment or detecting prescribed drugs in blood or urine samples) should be considered in the clinical work-up of patients with apparent resistant hypertension, if resources allow.261–",IIa,B,7,Recommendations for,Hypertension,2024,34
"assessing renal hypertension-mediated organ damage Recommendation It is recommended to measure serum creatinine, eGFR, and urine ACR in all patients with hypertension.",I,A,8,Recommendations for,Hypertension,2024,36
"If moderate-to-severe CKD is diagnosed, it is recommended to repeat measurements of serum creatinine, eGFR, and urine ACR at least annually.",I,C,8,Recommendations for,Hypertension,2024,36
"Renal ultrasound and Doppler examination should be considered in hypertensive patients with CKD to assess kidney structure and determine causes of CKD and to exclude renoparenchymal and renovascular hypertension.276,277 CT or magnetic resonance renal angiography are alternative testing options.",IIa,C,8,Recommendations for,Hypertension,2024,36
assessing cardiac hypertension-mediated organ damage Recommendation A 12-lead ECG is recommended for all patients with hypertension.,I,B,9,Recommendations for,Hypertension,2024,36
"Echocardiography may be considered in patients with elevated BP, particularly when it is likely to change patient management.",IIb,B,9,Recommendations for,Hypertension,2024,37
"assessing vascular hypertension-mediated organ dam­ age (see Evidence Table 17) Fundoscopy is recommended if BP >180/110 mmHg in the work-up of hypertensive emergency and malignant hypertension, as well as in hypertensive patients with diabetes.",I,C,10,Recommendations for,Hypertension,2024,37
Fundoscopy for detecting hypertensive retinopathy may be considered in patients with elevated BP or hypertension.,IIb,B,10,Recommendations for,Hypertension,2024,37
Ultrasound examination of the carotid or femoral arteries for detecting plaque may be considered in patients with elevated BP or hypertension when it is likely to change patient management.,IIb,B,10,Recommendations for,Hypertension,2024,37
Measurement of PWV may be considered in patients with elevated BP or hypertension when it is likely to change patient management.,IIb,B,10,Recommendations for,Hypertension,2024,37
genetic testing in hypertension management Genetic testing should be considered in specialist centres for patients suspected to have rare monogenic causes of secondary hypertension or for those with phaeochromocytoma/ paraganglioma.,IIa,B,11,Recommendations for,Hypertension,2024,37
Routine genetic testing for hypertension is not recommended.,III,C,11,Recommendations for,Hypertension,2024,37
resistant hypertension work-up (see Evidence Table 18) Recommendation Patients with resistant hypertension should be considered for referral to clinical centres with expertise in hypertension management for further testing.,IIa,B,12,Recommendations for,Hypertension,2024,39
"screening for secondary hypertension (see Evidence Tables 19 and 20) It is recommended that patients with hypertension presenting with suggestive signs, symptoms or medical history of secondary hypertension are appropriately screened for secondary hypertension.",I,B,13,Recommendations for,Hypertension,2024,43
Screening for primary aldosteronism by renin and aldosterone measurements should be considered in all adults with confirmed hypertension (BP ≥140/90 mmHg).,IIa,B,13,Recommendations for,Hypertension,2024,43
"screening for hypertension in children and adolescents (see Evidence Table 21) Recommendation Opportunistic screening with office BP measurements to monitor development of BP during late childhood and adolescence, especially if one or both parents have hypertension, should be considered to better predict development of adult hypertension and associated CVD risk.344–",IIa,B,14,Recommendations for,Hypertension,2024,43
non-pharmacological treatment of blood pressure and cardiovascular risk reduction (see Evidence Tables 22–26) Restriction of sodium to approximately 2 g per day is recommended where possible in all adults with elevated BP and hypertension [this is equivalent to about 5 g of salt (sodium chloride) per day or about a teaspoon or less].,I,A,15,Recommendations for,Hypertension,2024,47
"Moderate intensity aerobic exercise of ≥150 min/ week (≥30 min, 5–7 days/week) or alternatively 75 min of vigorous intensity aerobic exercise per week over 3 days are recommended and should be complemented with low- or moderate-intensity dynamic or isometric resistance training (2–3 times/ week) to reduce BP and CVD risk. 1,381,390–",I,A,15,Recommendations for,Hypertension,2024,47
It is recommended to aim for a stable and healthy BMI (e.g. 20–25 kg/m2) and waist circumference values (e.g. <94 cm in men and <80 cm in women) to reduce BP and CVD risk.399–,I,A,15,Recommendations for,Hypertension,2024,47
"Adopting a healthy and balanced diet, such as the Mediterranean or DASH diets, is recommended to help reduce BP and CVD risk.",I,A,15,Recommendations for,Hypertension,2024,47
"Men and women are recommended to drink less alcohol than the upper limit, which is about 100 g/week of pure alcohol. How this translates into number of drinks depends on portion size (the standards of which differ per country), but most drinks contain 8–14 g of alcohol per drink. Preferably, it is recommended to avoid alcohol to achieve the best health outcomes.",I,B,15,Recommendations for,Hypertension,2024,47
"It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake. It is also recommended to discourage consumption of sugar-sweetened beverages, such as soft drinks and fruit juices, starting at a young age.425–",I,B,15,Recommendations for,Hypertension,2024,47
"It is recommended to stop tobacco smoking, initiate supportive care and refer to smoking cessation programmes, as tobacco use strongly and independently causes CVD, CVD events, and all-cause mortality.",I,A,15,Recommendations for,Hypertension,2024,47
"In patients with hypertension without moderate to advanced CKD and with high daily sodium intake, an increase of potassium intake by 0.5–1.0 g/day—for example through sodium substitution with potassium- enriched salt (comprising 75% sodium chloride and 25% potassium chloride) or through diets rich in fruits and vegetables—should be considered.",IIa,A,15,Recommendations for,Hypertension,2024,47
"In patients with CKD or taking potassium-sparing medication, such as some diuretics, ACE inhibitors, ARBs, or spironolactone, monitoring serum levels of potassium should be considered if dietary potassium is being increased.",IIa,C,15,Recommendations for,Hypertension,2024,47
"pharmacological treatment of hypertension (see Evidence Tables 27, 28, and 29) Among all BP-lowering drugs, ACE inhibitors, ARBs, dihydropyridine CCBs, and diuretics (thiazides and thiazide-like drugs such as chlorthalidone and indapamide) have demonstrated the most effective reduction of BP and CVD events, and are therefore recommended as first-line treatments to lower BP.",I,A,16,Recommendations for,Hypertension,2024,51
"It is recommended that beta-blockers are combined with any of the other major BP-lowering drug classes when there are other compelling indications for their use, e.g. angina, post-myocardial infarction, heart failure with reduced ejection fraction, or for heart rate control.122,448–",I,A,16,Recommendations for,Hypertension,2024,51
It is recommended to take medications at the most convenient time of day for the patient to establish a habitual pattern of medication taking to improve adherence.,I,B,16,Recommendations for,Hypertension,2024,51
"Given trial evidence for more effective BP control vs. monotherapy, combination BP-lowering treatment is recommended for most patients with confirmed hypertension (BP ≥140/90 mmHg) as initial therapy. Preferred combinations are a RAS blocker (either an ACE inhibitor or an ARB) with a dihydropyridine CCB or diuretic. Exceptions to consider include patients aged ≥85 years, those with symptomatic orthostatic hypotension, moderate-to-severe frailty, or elevated BP (systolic BP 120–139 mmHg or diastolic BP 70–89 mmHg) with a concomitant indication for treatment.",I,B,16,Recommendations for,Hypertension,2024,51
"If BP is not controlled with a two-drug combination, increasing to a three-drug combination is recommended, usually a RAS blocker with a dihydropyridine CCB and a thiazide/thiazide-like diuretic, and preferably in a single-pill combination.",I,B,16,Recommendations for,Hypertension,2024,51
"If BP is not controlled with a three-drug combination, adding spironolactone should be considered.",IIa,B,16,Recommendations for,Hypertension,2024,51
"If BP is not controlled with a three-drug combination and in whom spironolactone is not effective or tolerated, treatment with eplerenone instead of spironolactone,503 or the addition of a beta-blocker if not already indicated459 and, next, a centrally acting BP-lowering medication,515 an alpha-blocker,515 hydralazine, or a potassium-sparing diuretic should be considered.",IIa,B,16,Recommendations for,Hypertension,2024,51
Combining two RAS blockers (ACE inhibitor and an ARB) is not recommended.498–,III,A,16,Recommendations for,Hypertension,2024,51
"initiating blood pressure-lowering treatment (see Evidence Tables 30–32) In adults with elevated BP and low/medium CVD risk (<10% over 10 years), BP lowering with lifestyle measures is recommended and can reduce the risk of CVD.",I,B,17,Recommendations for,Hypertension,2024,52
"In adults with elevated BP and sufficiently high CVD riskc, after 3 months of lifestyle intervention, BP lowering with pharmacological treatment is recommended for those with confirmed BP ≥130/ 80 mmHg to reduce CVD risk.",I,A,17,Recommendations for,Hypertension,2024,52
"It is recommended that in hypertensive patients with confirmed BP ≥140/90 mmHg, irrespective of CVD risk, lifestyle measures and pharmacological BP-lowering treatment are initiated promptly to reduce CVD risk.",I,A,17,Recommendations for,Hypertension,2024,52
"It is recommended to maintain BP-lowering drug treatment lifelong, even beyond the age of 85 years, if well tolerated.523–",I,A,17,Recommendations for,Hypertension,2024,52
"Because the benefit in reducing CVD outcomes is uncertain in these settings, and noting that close monitoring of treatment tolerance is advised, BP-lowering treatment should only be considered from ≥140/90 mmHg among persons meeting the following criteria: pre-treatment symptomatic orthostatic hypotension, age ≥85 years, clinically significant moderate-to-severe frailty, and/or limited predicted lifespan (<3 years).",IIa,B,17,Recommendations for,Hypertension,2024,52
"follow-up in patients with treated hypertension (see Evidence Table 33) Recommendation Once BP is controlled and stable under BP-lowering therapy, at least a yearly follow-up for BP and other CVD risk factors should be considered.",IIa,C,19,Recommendations for,Hypertension,2024,55
"managing hypertension in young adults (see Evidence Tables 36 and 37) Comprehensive screening for the main causes of secondary hypertension is recommended in adults diagnosed with hypertension before the age of 40 years, except for obese young adults where it is recommended to start with an obstructive sleep apnoea evaluation.",I,B,21,Recommendations for,Hypertension,2024,58
"Since SCORE2 has not been validated for individuals <40 years, screening for HMOD may be considered in such young individuals with elevated BP without other increased CVD risk conditions to identify additional individuals for possible medical treatment.",IIb,B,21,Recommendations for,Hypertension,2024,58
"managing hypertension in pregnancy (see Evidence Tables 38–40) In women with gestational hypertension, starting drug treatment is recommended for those with confirmed office systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg.",I,B,22,Recommendations for,Hypertension,2024,60
"In pregnant women with chronic hypertension, starting drug treatment is recommended for those with confirmed office systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg.",I,B,22,Recommendations for,Hypertension,2024,60
"Dihydropyridine CCBs (preferably extended-release nifedipine), labetalol, and methyldopa are recommended first-line BP-lowering medications for treating hypertension in pregnancy.",I,C,22,Recommendations for,Hypertension,2024,60
"In consultation with an obstetrician, low- to moderate-intensity exercise is recommended in all pregnant women without contraindications to reduce the risk of gestational hypertension and pre-eclampsia.",I,B,22,Recommendations for,Hypertension,2024,60
"Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in pregnancy can indicate an emergency, and immediate hospitalization should be considered.",IIa,C,22,Recommendations for,Hypertension,2024,60
"HBPM and ABPM should be considered to exclude white-coat and masked hypertension, which are more common in pregnancy.",IIa,C,22,Recommendations for,Hypertension,2024,60
RAS blockers are not recommended during pregnancy.,III,B,22,Recommendations for,Hypertension,2024,60
"managing hypertension in patients who are very old or frail (see Evidence Table 41) It is recommended that treatment of elevated BP and hypertension among older patients aged <85 years who are not moderately to severely frail follows the same guidelines as for younger people, provided BP-lowering treatment is well tolerated.",I,A,23,Recommendations for,Hypertension,2024,62
"Because the benefit in reducing CVD outcomes is uncertain in these settings, and noting that close monitoring of treatment tolerance is advised, BP-lowering treatment should only be considered from ≥140/90 mmHg among persons meeting the following criteria: pre-treatment symptomatic orthostatic hypotension, age ≥85 years, clinically significant moderate-to-severe frailty, and/or limited predicted lifespan (<3 years).",IIa,B,23,Recommendations for,Hypertension,2024,62
"As the safety and efficacy of BP treatment is less certain in individuals with moderate or severe frailty, clinicians should consider screening older adults for frailty using validated clinical tests; frail patients’ health priorities and a shared-decision approach should be considered when deciding on BP treatments and targets.",IIa,C,23,Recommendations for,Hypertension,2024,62
"When initiating BP-lowering treatment for patients aged ≥85 years, and/or with moderate-to-severe frailty (at any age), long-acting dihydropyridine CCBs or RAS inhibitors should be considered, followed if necessary by low-dose diuretic if tolerated, but preferably not a beta-blocker (unless compelling indications exist) or an alpha-blocker.",IIa,B,23,Recommendations for,Hypertension,2024,62
"If BP drops with progressing frailty, deprescription of BP-lowering medications (and other drugs that can reduce BP, such as sedatives and prostate-specific alpha-blockers) may be considered.",IIb,C,23,Recommendations for,Hypertension,2024,62
"managing hypertension in patients with orthostatic hypotension Recommendation Before starting or intensifying BP-lowering medication, it is recommended to test for orthostatic hypotension, by first having the patient sit or lie for 5 min and then measuring BP 1 and/or 3 min after standing.",I,B,24,Recommendations for,Hypertension,2024,64
"It is recommended to pursue non-pharmacological approaches as the first-line treatment of orthostatic hypotension among persons with supine hypertension. For such patients, it is also recommended to switch BP-lowering medications that worsen orthostatic hypotension to an alternative BP-lowering therapy and not to simply de-intensify therapy.",I,A,24,Recommendations for,Hypertension,2024,64
"managing hypertension in patients with diabetes In most adults with elevated BP and diabetes, after a maximum of 3 months of lifestyle intervention, BP lowering with pharmacological treatment is recommended for those with confirmed office BP ≥130/80 mmHg to reduce CVD risk.",I,A,25,Recommendations for,Hypertension,2024,64
"BP-lowering drug treatment is recommended for people with pre-diabetes or obesity when confirmed office BP is ≥140/90 mmHg or when office BP is 130–139/80–89 mmHg and the patient is at predicted 10-year risk of CVD ≥10% or with high-risk conditions, despite a maximum of 3 months of lifestyle therapy.",I,A,25,Recommendations for,Hypertension,2024,64
"In persons with diabetes who are receiving BP-lowering drugs, it is recommended to target systolic BP to 120–129 mmHg, if tolerated.136,146,445,747,749–",I,A,25,Recommendations for,Hypertension,2024,64
"managing hypertension in patients with chronic kidney disease In patients with diabetic or non-diabetic moderate-to-severe CKD and confirmed BP ≥130/ 80 mmHg, lifestyle optimization and BP-lowering medication are recommended to reduce CVD risk, provided such treatment is well tolerated.",I,A,26,Recommendations for,Hypertension,2024,65
"In adults with moderate-to-severe CKD who are receiving BP-lowering drugs and who have eGFR >30 mL/min/1.73 m2, it is recommended to target systolic BP to 120–129 mmHg, if tolerated. Individualized BP targets are recommended for those with lower eGFR or renal transplantation.",I,A,26,Recommendations for,Hypertension,2024,65
"In hypertensive patients with CKD and eGFR >20 mL/min/1.73 m2, SGLT2 inhibitors are recommended to improve outcomes in the context of their modest BP-lowering properties.",I,A,26,Recommendations for,Hypertension,2024,65
ACE inhibitors or ARBs are more effective at reducing albuminuria than other BP-lowering agents and should be considered as part of the treatment strategy for patients with hypertension and microalbuminuria or proteinuria.780–,IIa,B,26,Recommendations for,Hypertension,2024,65
"managing hypertension in patients with cardiac disease In patients with a history of myocardial infarction who require BP-lowering treatment, beta-blockers and RAS blockers are recommended as part of that treatment.",I,A,27,Recommendations for,Hypertension,2024,67
"In patients with symptomatic angina who require BP-lowering treatment, beta-blockers and/or CCBs are recommended as part of that treatment.",I,A,27,Recommendations for,Hypertension,2024,67
"In patients with symptomatic HFrEF/HFmrEF, the following treatments with BP-lowering effects are recommended to improve outcomes: ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) or ARNi, beta-blockers, MRAs, and SGLT2 inhibitors.",I,A,27,Recommendations for,Hypertension,2024,67
"In hypertensive patients with symptomatic HFpEF, SGLT2 inhibitors are recommended to improve outcomes in addition to their modest BP-lowering properties.",I,A,27,Recommendations for,Hypertension,2024,67
"In patients with a history of aortic valve stenosis and/ or regurgitation who require BP-lowering treatment, RAS blockers should be considered as part of that treatment.",IIa,C,27,Recommendations for,Hypertension,2024,67
"In patients with a history of moderate-to-severe mitral valve regurgitation who require BP-lowering treatment, RAS blockers should be considered as part of that treatment.",IIa,C,27,Recommendations for,Hypertension,2024,67
"In patients with symptomatic HFpEF who have BP above target, ARBs and/or MRAs may be considered to reduce heart failure hospitalizations and reduce BP.",IIb,B,27,Recommendations for,Hypertension,2024,67
managing hypertension in patients with chronic cere­ brovascular disease and cognitive impairment It is recommended that the BP-lowering drug treatment strategy for preventing recurrent stroke should comprise a RAS blocker plus a CCB or a thiazide-like diuretic.,I,A,28,Recommendations for,Hypertension,2024,68
"In patients with confirmed BP ≥130/80 mmHg with a history of TIA or stroke a systolic BP target of 120– 129 mmHg is recommended to reduce CVD outcomes, provided treatment is tolerated.",I,A,28,Recommendations for,Hypertension,2024,68
"managing hypertension in different ethnic groups Recommendation In black patients from Sub-Saharan Africa who require BP-lowering treatment, combination therapy including a CCB combined with either a thiazide diuretic or a RAS blocker should be considered.",IIa,B,29,Recommendations for,Hypertension,2024,68
"treating resistant hypertension (see Evidence Tables 42 and 43) In patients with resistant hypertension and uncontrolled BP despite use of first-line BP lowering therapies, the addition of spironolactone to existing treatment should be considered.",IIa,B,30,Recommendations for,Hypertension,2024,70
"To reduce BP, and if performed at a medium-to-high volume centre, catheter-based renal denervation may be considered for resistant hypertension patients who have BP that is uncontrolled despite a three BP-lowering drug combination, and who express a preference to undergo renal denervation after a shared risk-benefit discussion and multidisciplinary assessment.564,566–568,586–",IIb,B,30,Recommendations for,Hypertension,2024,71
managing hypertension in patients with renovascular hypertension (see Evidence Tables 44 and 45) Renal artery angioplasty without stenting should be considered for patients with hypertension and haemodynamically significant renal artery stenosis due to fibromuscular dysplasia.,IIa,C,31,Recommendations for,Hypertension,2024,71
"Renal artery angioplasty and stenting may be considered in patients with haemodynamically significant, atherosclerotic, renal artery stenosis (stenosis of 70%–99%, or 50%–69% with post-stenotic dilatation and/or significant trans-stenotic pressure gradient) with: • Recurrent heart failure, unstable angina, or sudden onset flash pulmonary oedema despite maximally tolerated medical therapy; • Resistant hypertension; • Hypertension with unexplained unilaterally small kidney or CKD; • Bilateral renal artery stenosis or unilateral renal artery stenosis in a solitary viable kidney.",IIb,C,31,Recommendations for,Hypertension,2024,71
Renal artery angioplasty is not recommended in patients without confirmed haemodynamically significant renal artery stenosis.c,III,A,31,Recommendations for,Hypertension,2024,72
"acutely managing blood pressure in patients with intra­ cerebral haemorrhage or acute ischaemic stroke For patients with ischaemic stroke or TIA and an indication for BP lowering, it is recommended that BP-lowering therapy be commenced before hospital discharge.",I,B,32,Recommendations for,Hypertension,2024,73
"In patients with acute ischaemic stroke, early BP lowering with BP-lowering therapy should be considered in the first 24 h in the following settings: • In patients who are eligible for re-perfusion therapy with intravenous thrombolysis or mechanical thrombectomy, BP should be carefully lowered and maintained at <180/105 mmHg for at least the first 24 h after treatment.956–",IIa,B,32,Recommendations for,Hypertension,2024,73
"In patients with intracerebral haemorrhage, immediate BP lowering (within 6 h of symptom onset) should be considered to a systolic target 140– 160 mmHg to prevent haematoma expansion and improve functional outcome.",IIa,A,32,Recommendations for,Hypertension,2024,74
"In patients with intracerebral haemorrhage presenting with systolic BP ≥220 mmHg, acute reduction in systolic BP >70 mmHg from initial levels within 1 h of commencing treatment is not recommended.950,951,960–",III,B,32,Recommendations for,Hypertension,2024,74
"acutely managing blood pressure in patients with severe hypertension in pregnancy and pre-eclampsia (see Evidence Table 46) Recommendation In pre-eclampsia or eclampsia with hypertensive crisis, drug treatment with i.v. labetalol or nicardipine and magnesium is recommended.",I,C,33,Recommendations for,Hypertension,2024,74
"In pre-eclampsia or eclampsia associated with pulmonary oedema, nitroglycerin given as an i.v. infusion is recommended.",I,C,33,Recommendations for,Hypertension,2024,74
"In severe hypertension in pregnancy: • drug treatment with i.v. labetalol, oral methyldopa, or oral nifedipine is recommended. Intravenous hydralazine is a second-line option.666–",I,C,33,Recommendations for,Hypertension,2024,74
communicating consequences of treatment (see Evidence Table 47) Recommendation An informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended as part of hypertension management.,I,C,34,Recommendations for,Hypertension,2024,76
Motivational interviewing should be considered for patients with hypertension at hospitals and community health centres to assist patients in controlling their BP and to enhance treatment adherence.,IIa,B,34,Recommendations for,Hypertension,2024,76
"Physician–patient web communications are an effective tool that should be considered in primary care, including reporting on home BP readings.",IIa,C,34,Recommendations for,Hypertension,2024,76
self-measuring and monitoring blood pressure (see Evidence Table 48) Home BP measurement for managing hypertension by using self-monitored BP is recommended to achieve better BP control.,I,B,35,Recommendations for,Hypertension,2024,76
"Self-measurement, when properly performed, is recommended due to positive effects on the acceptance of a diagnosis of hypertension, patient empowerment, and adherence to treatment.",I,C,35,Recommendations for,Hypertension,2024,76
"Enhanced self-monitoring of BP using a device paired with a connected smartphone application may be considered, though evidence to date suggests that this may be no more effective than standard self-monitoring.",IIb,B,35,Recommendations for,Hypertension,2024,76
"multi/interdisciplinary blood pressure management (see Evidence Table 49) Recommendation Multidisciplinary approaches in the management of patients with elevated BP and hypertension, including appropriate and safe task-shifting away from physicians, are recommended to improve BP control.227,229,230,1012–",I,A,36,Recommendations for,Hypertension,2024,76
"ical and laboratory, and for functional and quality of life, as­ sessment in patients with peripheral arterial and aortic disease (see also Evidence Table 1) When managing PAAD, it is recommended to adopt a comprehensive approach that addresses the entirety of the arterial circulation.",I,B,1,Recommendations for clin­,Peripheral Arterial Aortic,2024,23
"To assess PAAD, it is recommended to perform thorough clinical, vascular, and CVRFs laboratory evaluation.",I,C,1,Recommendations for clin­,Peripheral Arterial Aortic,2024,23
Overall evaluation of functional (physical functioning) performance with objective tests should be considered in patients with symptomatic and asymptomatic chronic PAD.,IIa,B,1,Recommendations for clin­,Peripheral Arterial Aortic,2024,23
Overall evaluation of self-reported (i.e. by questionnaire) physical and mental/social HRQoL should be considered in patients with PAAD.34–,IIa,B,1,Recommendations for clin­,Peripheral Arterial Aortic,2024,23
"diagnostic tests in patients with peripheral arterial disease Measurement of the ABI is recommended as the first-line non-invasive test for screening and diagnosis of PAD, using an ABI ≤0.90 as a diagnostic criterion.",I,B,2,Recommendations for,Peripheral Arterial Aortic,2024,25
"In the case of non-compressible ankle arteries or ABI >1.40, additional methods such as TP, TBI or Doppler waveform analysis are recommended.",I,B,2,Recommendations for,Peripheral Arterial Aortic,2024,25
"imaging of the aorta (see also Evidence Table 2) It is recommended that aortic diameters are measured at pre-specified anatomical landmarks, and the largest diameter of the section be perpendicular to the longitudinal axis.",I,C,3,Recommendations for,Peripheral Arterial Aortic,2024,28
It is recommended in cases of serial imaging of the aorta over time to use the same imaging modality with the same measurement method.,I,C,3,Recommendations for,Peripheral Arterial Aortic,2024,28
"It is recommended to consider renal function, pregnancy, age, and history of allergy to contrast media to select the optimal imaging modality with minimal radiation exposure and lowest iatrogenic risk, except for emergency cases.159–",I,C,3,Recommendations for,Peripheral Arterial Aortic,2024,28
"Indexing aortic diameters to BSA, along with the use of nomograms, z-scores, or other indexing methods, should be considered for more accurate assessment of aortic size, especially for body sizes at the lower end of the normal distribution.156–",IIa,B,3,Recommendations for,Peripheral Arterial Aortic,2024,28
thoracic aortic measurements TTE is recommended as the first-line imaging technique in evaluating thoracic aortic diseases.,I,B,4,Recommendations for,Peripheral Arterial Aortic,2024,29
It is recommended to report aortic diameters using the leading-to-leading edge convention in end-diastole by echocardiography.,I,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
It is recommended to report aortic diameters using the inner-to-inner edge convention in end-diastole by CCT or CMR.,I,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
It is recommended to report aortic diameters from images obtained with the double-oblique technique (not axial images) by CCT or CMR.,I,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
"ECG-triggered CCT is recommended for comprehensive diagnosis, follow-up, and pre-invasive treatment assessment of the entire aorta, particularly the root and ascending aorta.",I,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
"CMR is recommended for diagnosis and follow-up of thoracic aortic diseases, especially when chronic follow-up is required.166–",I,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
"The aortic root should be measured using the cusp-to-cusp distance. Also, the presence of asymmetry (>5 mm) among distances should be reported.",IIa,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
"If an increase of ≥3 mm per year in aortic diameters by TTE is observed, confirmation by CCT/CMR should be considered.",IIa,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
"Chest X-ray may be considered in cases of low clinical probability of AAS; however, a negative exploration should not delay dedicated aortic imaging in high-risk patients.162–",IIb,C,4,Recommendations for,Peripheral Arterial Aortic,2024,29
abdominal aortic aneurysm screening Screening for AAA with DUS: Is recommended in men aged ≥65 years with a history of smoking to reduce the risk of death from ruptured AAA.221–,I,A,6,Recommendations for,Peripheral Arterial Aortic,2024,31
"May be considered in men aged ≥75 years (irrespective of smoking history) or in women aged ≥75 years who are current smokers, hypertensive, or both.227,228,235–",IIb,C,6,Recommendations for,Peripheral Arterial Aortic,2024,31
"Family AAA screening with DUS: Is recommended for FDRs of patients with AAA aged ≥50, unless an acquired cause can be clearly identified.",I,C,6,Recommendations for,Peripheral Arterial Aortic,2024,31
Opportunistic AAA screening with DUS: Should be considered in symptomatic/asymptomatic PAD patients.,IIa,B,6,Recommendations for,Peripheral Arterial Aortic,2024,31
Should be considered in men aged ≥65 years and in women aged ≥75 years during TTE.,IIa,B,6,Recommendations for,Peripheral Arterial Aortic,2024,31
"lifestyle, physical activity, and patient education (see also Evidence Table 4) In patients with PAAD, cessation and abstinence from smoking of any kind is recommended to reduce the risk of AD, MI, death, and limb ischaemia.119,261–",I,A,7,Recommendations for,Peripheral Arterial Aortic,2024,33
"A healthy diet rich in legumes, dietary fibre, nuts, fruits, and vegetables, with a high flavonoid intake (Mediterranean diet), is recommended for CV disease prevention in patients with PAAD.239– 241,249,290–",I,A,7,Recommendations for,Peripheral Arterial Aortic,2024,33
Low- to moderate-intensity (or high if tolerated)c aerobic activities are recommended in patients with PAD to increase overall and pain-free walking distance.,I,A,7,Recommendations for,Peripheral Arterial Aortic,2024,33
"In patients with PAAD, behavioural counselling to promote healthy diet, smoking cessation, and physical activity is recommended to improve the CV risk profile.",I,B,7,Recommendations for,Peripheral Arterial Aortic,2024,33
It is recommended to promote patient and caregivers’ education and empowerment through tailored guidance on lifestyle adjustments and the importance of regular physical activity.,I,C,7,Recommendations for,Peripheral Arterial Aortic,2024,33
"In patients with PAAD, avoidance of exposure to second-hand smoke and air pollution should be considered.",IIa,C,7,Recommendations for,Peripheral Arterial Aortic,2024,33
"Physical exercise and sports activities should be considered in patients with aortic diseases based on prior risk stratification (based on the extent of the aneurysm, risk of dissection, and BP control).",IIa,C,7,Recommendations for,Peripheral Arterial Aortic,2024,33
Use of web- or app-based secondary prevention risk calculators should be considered in the shared decision-making to improve patient adherence to treatment and lifestyle changes.,IIa,C,7,Recommendations for,Peripheral Arterial Aortic,2024,33
"E-cigarettes may be considered as an aid to quit tobacco smoking, but it is advisable to limit their use and avoid simultaneous use with conventional cigarettes due to unknown long-term effects.",IIb,C,7,Recommendations for,Peripheral Arterial Aortic,2024,33
"antihypertensive therapy in patients with peripheral and aortic disease In patients with PAAD and hypertension an SBP target towards 120–129 mmHg, if tolerated, is recommended.301–",I,A,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"In unilateral RAS patients, it is recommended that antihypertensive medication include ACEIs/ ARBs.307,320–",I,B,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"In patients with PAAD and hypertension, ACEIs or ARBs should be considered as first-line antihypertensive therapy.",IIa,B,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"In RAS-related hypertension, the combination of ACEIs/ARBs with diuretics and/or calcium channel blockers should be considered.",IIa,B,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"An individualized, more lenient BP goal (e.g. <140/ 90 mmHg) should be considered in:301 • Age ≥85 years • Residential care • Symptomatic orthostatic hypotension",IIa,C,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"An individualized, more lenient BP goal (e.g. <140/ 90 mmHg) may be considered in:301 • Clinically severe frailty at any age • Limited life expectancy (<3 years)",IIb,C,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"In patients with bilateral RAS, antihypertensive medication including ACEIs/ARBs may be considered if close patient monitoring (renal function) is feasible.",IIb,B,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"ACEIs/ARBs may be considered in all patients with PAD, regardless of BP levels, in the absence of contraindications.",IIb,B,8,Recommendations for,Peripheral Arterial Aortic,2024,34
"lipid-lowering therapy in patients with peripheral arterial and aortic diseases In patients with atherosclerotic PAAD, lipid-lowering therapy is recommended.242,334–",I,A,9,Recommendations for,Peripheral Arterial Aortic,2024,35
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50% reduction in LDL-C vs. baseline are recommended in patients with atherosclerotic PAAD.,I,A,9,Recommendations for,Peripheral Arterial Aortic,2024,35
Statins are recommended in all patients with PAD.,I,A,9,Recommendations for,Peripheral Arterial Aortic,2024,35
"If the target LDL-C level is not achieved on maximally tolerated statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended in patients with atherosclerotic PAAD, to achieve target values.",I,A,9,Recommendations for,Peripheral Arterial Aortic,2024,35
"If the target LDL-C level is not achieved, a combination of statins and ezetimibe is indicated in patients with atherosclerotic PAAD, to achieve the given target values.",I,B,9,Recommendations for,Peripheral Arterial Aortic,2024,35
"For statin-intolerant patients with atherosclerotic PAAD, at high CV risk, who do not achieve their LDL-C goal on ezetimibe, it is recommended to add bempedoic acid either alone or in combination with a PCSK9 inhibitor.",I,B,9,Recommendations for,Peripheral Arterial Aortic,2024,35
Statins for the reduction of growth and rupture of AAA should be considered.347–,IIa,B,9,Recommendations for,Peripheral Arterial Aortic,2024,35
"In high-risk patients with PAAD and triglycerides >1.5 mmol/L despite lifestyle measures and statin therapy, icosapent ethyl 2 g b.i.d. may be considered in addition to a statin.",IIb,B,9,Recommendations for,Peripheral Arterial Aortic,2024,36
Fibrates are not recommended for cholesterol lowering.,III,B,9,Recommendations for,Peripheral Arterial Aortic,2024,36
"the medical management of patients with peripheral arterial and aortic diseases and diabetes It is recommended to apply tight glycaemic control (HbA1c <53 mmol/mol [7%]) to reduce microvascular complications in patients with PAAD.374,394–",I,A,10,Recommendations for,Peripheral Arterial Aortic,2024,36
"SGLT2i with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or target HbA1c and concomitant glucose-lowering medication.382,386,398–",I,A,10,Recommendations for,Peripheral Arterial Aortic,2024,36
"GLP-1RAs with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or target HbA1c and concomitant glucose-lowering medication.381,403–",I,A,10,Recommendations for,Peripheral Arterial Aortic,2024,36
"It is recommended to avoid hypoglycaemia in patients with PAAD.374,408–",I,B,10,Recommendations for,Peripheral Arterial Aortic,2024,36
"It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy.",I,C,10,Recommendations for,Peripheral Arterial Aortic,2024,36
"It is recommended to prioritize the use of glucose-lowering agents with proven CV benefits,c,d followed by agents with proven CV safety,e over agents without proven CV benefit or safety.",I,C,10,Recommendations for,Peripheral Arterial Aortic,2024,36
"If additional glucose control is needed, metformin should be considered in patients with T2DM and PAAD.",IIa,B,10,Recommendations for,Peripheral Arterial Aortic,2024,36
"diagnostic tests in patients with peripheral arterial dis­ ease and diabetes, renal failure, and wounds Measuring TP or TBI is recommended in patients with diabetes or renal failure if resting ABI is normal.",I,C,11,Recommendations for,Peripheral Arterial Aortic,2024,40
"In patients with PAD and chronic wounds, the WIfI classification system should be considered to estimate individual risk of amputation.417,444–",IIa,C,11,Recommendations for,Peripheral Arterial Aortic,2024,40
imaging in patients with peripheral arterial disease DUS is recommended as the first-line imaging method to confirm PAD lesions.,I,C,12,Recommendations for,Peripheral Arterial Aortic,2024,40
"In symptomatic patients with aorto-iliac or multisegmental/complex disease, CTA and/or MRA are recommended as adjuvant imaging techniques for preparation of revascularization procedures.",I,C,12,Recommendations for,Peripheral Arterial Aortic,2024,40
Analysis of anatomical imaging tests in conjunction with symptoms and haemodynamic tests prior to an invasive procedure is recommended.,I,C,12,Recommendations for,Peripheral Arterial Aortic,2024,40
"exercise therapy in patients with peripheral arterial disease (see also Evidence Table 5) In patients with symptomatic PAD, SET is recommended.294,453,456–",I,A,13,Recommendations for,Peripheral Arterial Aortic,2024,45
"In those patients undergoing endovascular revascularization, SET is recommended as an adjuvant therapy.",I,A,13,Recommendations for,Peripheral Arterial Aortic,2024,45
"When SET is not available or feasible, a structured and monitored (calls, logbooks, connected devices) HBET programme should be considered.",IIa,A,13,Recommendations for,Peripheral Arterial Aortic,2024,45
"Walking should be considered as a first-line training modality. When walking exercise is not an option, alternative exercise modes (strength training, arm cranking, cycling, and combinations of different training modes) should also be considered.",IIa,A,13,Recommendations for,Peripheral Arterial Aortic,2024,45
"Walking training performed at high intensity (77%– 95% of maximal heart rate or 14–17 self-perceived exertion on Borg’s scale) should be considered to improve walking performance,294 and high-intensity exercise training (various aerobic training modes) should be considered to improve cardiorespiratory fitness.",IIa,A,13,Recommendations for,Peripheral Arterial Aortic,2024,45
"Training frequency of at least three times per week, training session duration of at least 30 min, and training programme duration of at least 12 weeks should be considered.",IIa,B,13,Recommendations for,Peripheral Arterial Aortic,2024,45
"In patients with PAD, exercise training to moderate-severe claudication pain may be considered to improve walking performance.37,454,456,458 However, improvements are also achievable with lesser claudication pain severities (low-mild pain or pain-free).",IIb,B,13,Recommendations for,Peripheral Arterial Aortic,2024,45
"Based on patient’s tolerance, a progressive increase (every 1–2 weeks) in exercise training load may be considered.",IIb,C,13,Recommendations for,Peripheral Arterial Aortic,2024,45
antithrombotic therapy in patients with peripheral arterial disease (see also Evidence Table 6) Use of antiplatelet therapy with aspirin alone (range 75–160 mg o.d.) or clopidogrel alone (75 mg o.d.) is recommended for the reduction of MACE in patients with symptomatic PAD.488–,I,A,14,Recommendations for,Peripheral Arterial Aortic,2024,45
"Treatment with combination rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered for patients with PAD, high ischaemic risk,c and non-high bleeding risk.d",IIa,A,14,Recommendations for,Peripheral Arterial Aortic,2024,45
"Use of antiplatelet therapy with clopidogrel alone (75 mg o.d.) may be considered over aspirin to reduce MI, stroke, and vascular death.",IIb,B,14,Recommendations for,Peripheral Arterial Aortic,2024,46
"Aspirin (75–100 mg) for primary prevention may be considered in patients with asymptomatic PAD and DM, in the absence of contraindications.",IIb,A,14,Recommendations for,Peripheral Arterial Aortic,2024,46
DAPT for at least 1 month after revascularization may be considered to reduce limb events.,IIb,B,14,Recommendations for,Peripheral Arterial Aortic,2024,46
Long-term DAPT in patients with PAD is not recommended.,III,A,14,Recommendations for,Peripheral Arterial Aortic,2024,46
Oral anticoagulant monotherapy for PAD (unless for another indication) is not recommended.,III,A,14,Recommendations for,Peripheral Arterial Aortic,2024,46
The routine use of ticagrelor in patients with PAD is not recommended.,III,A,14,Recommendations for,Peripheral Arterial Aortic,2024,46
It is not recommended to systematically treat patients with asymptomatic PAD without any sign of clinically relevant ASCVD with antiplatelet drugs.,III,B,14,Recommendations for,Peripheral Arterial Aortic,2024,46
"interventional treatment of asymptomatic and symp­ tomatic peripheral arterial disease (general) In patients with symptomatic PAD, after a 3 month period of OMT and exercise therapy, PAD-related QoL assessment is recommended.",I,B,15,Recommendations for,Peripheral Arterial Aortic,2024,47
"It is recommended to adapt the mode and type of revascularization options to anatomical lesion location, lesion morphology, and general patient condition.",I,C,15,Recommendations for,Peripheral Arterial Aortic,2024,47
"In patients with symptomatic PAD and impaired PAD-related quality of life after a 3 month period of OMT and exercise therapy, revascularization may be considered.",IIb,B,15,Recommendations for,Peripheral Arterial Aortic,2024,47
"In patients with PAD, revascularization is not recommended if the reason is to solely prevent progression to CLTI.541–",III,B,15,Recommendations for,Peripheral Arterial Aortic,2024,47
"In patients with asymptomatic PAD, revascularization is not recommended.",III,C,15,Recommendations for,Peripheral Arterial Aortic,2024,47
"interventional treatment of patients with symptomatic peripheral arterial disease (per arterial bed) In femoro-popliteal lesions, drug-eluting treatment should be considered as the first-choice strategy.534–",IIa,A,16,Recommendations for,Peripheral Arterial Aortic,2024,48
"In iliac lesions, balloon angioplasty with or without stenting in external iliac arteries, or primary stenting in common iliac arteries, should be considered.545–",IIa,B,16,Recommendations for,Peripheral Arterial Aortic,2024,48
"In femoro-popliteal lesions, if revascularization is indicated, endovascular therapy should be considered.119,529–",IIa,B,16,Recommendations for,Peripheral Arterial Aortic,2024,48
"In femoro-popliteal lesions, if revascularization is indicated, an open surgical approach should be considered when an autologous vein (e.g. GSV) is available in patients with low surgical risk.",IIa,C,16,Recommendations for,Peripheral Arterial Aortic,2024,48
"In patients with severe IC undergoing endovascular femoro-popliteal revascularization, treatment of BTK arteries may be considered in the same intervention.",IIb,C,16,Recommendations for,Peripheral Arterial Aortic,2024,48
"patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease It is recommended to regularly, at least once a year, follow up patients with PAD, assessing clinical and functional status, medication adherence, limb symptoms, and CVRFs, with DUS assessment as needed.",I,C,17,Recommendations in,Peripheral Arterial Aortic,2024,48
"the management of chronic limb-threatening ischaemia For limb salvage in patients with CLTI, revascularization is recommended.",I,B,18,Recommendations for,Peripheral Arterial Aortic,2024,49
Early recognition of CLTI and referral to the vascular team are recommended for limb salvage.,I,C,18,Recommendations for,Peripheral Arterial Aortic,2024,49
"In patients with CLTI, imaging of the entire affected limb should be considered.",IIa,C,18,Recommendations for,Peripheral Arterial Aortic,2024,49
medical treatment in patients with chronic limb- threatening ischaemia (see also Evidence Table 7) It is recommended that patients with CLTI are managed by a vascular team.,I,C,19,Recommendations for,Peripheral Arterial Aortic,2024,49
"In patients with CLTI and ulcers, offloading mechanical tissue stress is recommended to allow wound healing.",I,C,19,Recommendations for,Peripheral Arterial Aortic,2024,49
It is recommended to treat infection with antibiotics.,I,C,19,Recommendations for,Peripheral Arterial Aortic,2024,49
Lower-limb exercise training is not recommended in patients with CLTI and wounds.,III,C,19,Recommendations for,Peripheral Arterial Aortic,2024,49
"interventional treatment of chronic limb-threatening ischaemia Recommendation In CLTI patients, it is recommended to perform revascularization as soon as possible.",I,B,20,Recommendations for,Peripheral Arterial Aortic,2024,50
"In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery.",I,B,20,Recommendations for,Peripheral Arterial Aortic,2024,50
"In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions.",I,C,20,Recommendations for,Peripheral Arterial Aortic,2024,50
An individual risk assessment (weighing the patient’s individual procedural risk of endovascular vs. surgical revascularization) by a multidisciplinary vascular team is recommended.,I,C,20,Recommendations for,Peripheral Arterial Aortic,2024,50
"In CLTI patients with good autologous veins and low surgical risk (<5% peri-operative mortality, >50% 2 year survival), infra-inguinal bypass may be considered.",IIb,B,20,Recommendations for,Peripheral Arterial Aortic,2024,50
"In CLTI patients, endovascular treatment may be considered as first-line therapy, especially in patients with increased surgical risk or inadequate autologous veins.",IIb,B,20,Recommendations for,Peripheral Arterial Aortic,2024,50
"follow-up in patients with chronic limb-threatening ischaemia In patients with CLTI, following revascularization it is recommended to follow up patients on a regular basis.",I,C,21,Recommendations for,Peripheral Arterial Aortic,2024,50
"At follow-up, it is recommended to assess clinical, haemodynamic and functional status, limb symptoms, treatment adherence, and CVRFs.552,625–",I,C,21,Recommendations for,Peripheral Arterial Aortic,2024,50
"the management of patients presenting with acute limb ischaemia (see also Evidence Table 8) In patients with ALI, it is recommended that an urgent evaluation is performed by a vascular clinician with sufficient experience to assess limb viability and implement appropriate therapy.",I,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
"In cases of neurological deficit, urgent revascularization is recommended; diagnostic imaging is recommended to guide treatment, provided it does not delay treatment, or if the need for primary amputation is obvious.",I,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
"In the absence of severe neurological deficit, revascularization is recommended within hours of initial imaging in a case-by-case decision.",I,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
Treatment with analgesics is recommended as soon as possible for pain control.,I,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
It is recommended to monitor for compartment syndrome after revascularization and treat (fasciotomy).,I,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
It is recommended to assess clinical and haemodynamic success following revascularization.,I,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
"In patients with ALI, it is recommended to obtain a comprehensive medical history and determine the cause of thrombosis and/or embolization.",I,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
"In patients with ALI, following revascularization if not on anticoagulation for other reasons, DAPT or rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered.",IIa,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
"Upon confirmation of ALI diagnosis, treatment with heparin may be considered.635,654–",IIb,C,22,Recommendations for,Peripheral Arterial Aortic,2024,53
carotid artery stenosis assessment It is recommended to use the NASCET method or its non-invasive equivalent to assess ICA stenosis.,I,B,23,Recommendations for,Peripheral Arterial Aortic,2024,53
It is recommended to use DUS as first-line imaging to diagnose ICA stenosis.,I,C,23,Recommendations for,Peripheral Arterial Aortic,2024,53
It is not recommended to use the ECST method for ICA stenosis assessment.,III,C,23,Recommendations for,Peripheral Arterial Aortic,2024,53
"antithrombotic treatment in patients with carotid stenosis Carotid artery disease In patients with symptomatic CS, not undergoing carotid endarterectomy or stenting, DAPT with low-dose aspirin and clopidogrel (75 mg) is recommended for the first 21 days or longer, followed by clopidogrel 75 mg or long-term aspirin to reduce the risk of stroke.667–",I,A,24,Recommendations for,Peripheral Arterial Aortic,2024,55
"In patients with asymptomatic >50% CS, long-term antiplatelet therapy (commonly low-dose aspirin) should be considered if bleeding risk is low.",IIa,C,24,Recommendations for,Peripheral Arterial Aortic,2024,55
"interventional treatment in patients with asymptomatic carotid artery stenosis When ICA revascularization is considered, documented peri-operative stroke/death rates should be <3% and the patient’s life expectancy should be considered >5 years after careful consideration of the risks and benefits by a vascular team.",IIa,B,25,Recommendations for,Peripheral Arterial Aortic,2024,57
"In ‘average surgical risk’ patients over 75 years of age with a CS of 60%–99%, in the presence of high-risk features, CEA, in addition to OMT, should be considered.",IIa,B,25,Recommendations for,Peripheral Arterial Aortic,2024,57
"In ‘high surgical risk’ patients with a CS of 60%–99%, in the presence of high-risk features, CAS, in addition to OMT, may be considered.",IIb,B,25,Recommendations for,Peripheral Arterial Aortic,2024,57
"In ‘average surgical risk’ patients with a CS of 60%– 99%, in the presence of high-risk features, CAS, in addition to OMT, may be considered as an alternative to CEA.",IIb,B,25,Recommendations for,Peripheral Arterial Aortic,2024,57
"In asymptomatic patients with ICA stenosis, in the absence of high-risk features and with a life expectancy <5 years, routine revascularization is not recommended.",III,A,25,Recommendations for,Peripheral Arterial Aortic,2024,57
"evaluation and medical treatment in patients with symptomatic carotid artery stenosis DAPT is recommended in the early phase of minor strokes in patients with ICA stenosis, if not revascularized, for at least 21 days, considering the bleeding risk.",I,A,26,Recommendations for,Peripheral Arterial Aortic,2024,57
It is recommended that symptomatic ICA stenosis patients are assessed by a vascular team including a neurologist.,I,C,26,Recommendations for,Peripheral Arterial Aortic,2024,57
Long-term treatment with SAPT should be considered following ICA revascularization.,IIa,C,26,Recommendations for,Peripheral Arterial Aortic,2024,57
"DAPT may be considered in the early phase of minor stroke in patients with ICA stenosis for up to 90 days, considering the bleeding risk.",IIb,B,26,Recommendations for,Peripheral Arterial Aortic,2024,57
interventions in patients with symptomatic carotid artery stenosis It is recommended to perform CEA of symptomatic 70%–99% ICA stenosis provided a documented 30 day risk of procedural death/stroke is <6%.,I,A,27,Recommendations for,Peripheral Arterial Aortic,2024,59
"If indicated, it is recommended to perform CEA within 14 days in symptomatic ICA stenosis patients.",I,B,27,Recommendations for,Peripheral Arterial Aortic,2024,59
OMT is recommended for all symptomatic ICA stenosis patients.,I,A,27,Recommendations for,Peripheral Arterial Aortic,2024,59
CEA of symptomatic 50%–69% ICA stenosis should be considered provided a documented 30 day risk of procedural death/stroke is <6%.,IIa,A,27,Recommendations for,Peripheral Arterial Aortic,2024,59
"For symptomatic patients at high risk for CEA with a 70%–99% ICA stenosis, CAS should be considered provided a documented 30 day risk of procedural death/stroke is <6%.",IIa,B,27,Recommendations for,Peripheral Arterial Aortic,2024,59
"For symptomatic patients <70 years of age with a 70%–99% ICA stenosis, CAS may be considered provided a documented 30 day risk of procedural death/stroke is <6%.",IIb,A,27,Recommendations for,Peripheral Arterial Aortic,2024,59
Revascularization is not recommended in patients with ICA lesions <50%.,III,A,27,Recommendations for,Peripheral Arterial Aortic,2024,59
follow-up in patients with carotid artery stenosis Once-yearly follow-up is recommended to check for CVRFs and treatment compliance.,I,A,28,Recommendations for,Peripheral Arterial Aortic,2024,59
"After ICA stent implantation, DAPT with aspirin and clopidogrel is recommended for at least 1 month.",I,A,28,Recommendations for,Peripheral Arterial Aortic,2024,59
"After ICA revascularization, long-term aspirin or clopidogrel is recommended.",I,B,28,Recommendations for,Peripheral Arterial Aortic,2024,59
"During follow-up, it is recommended to assess neurological symptoms, CVRFs, and treatment adherence at least yearly in patients with CS.",I,C,28,Recommendations for,Peripheral Arterial Aortic,2024,59
"After ICA revascularization, surveillance with DUS is recommended within the first month.",I,C,28,Recommendations for,Peripheral Arterial Aortic,2024,59
the management of subclavian artery stenosis (see also Evidence Table 9) Bilateral arm BP measurement is recommended for all patients with PAAD.,I,B,29,Recommendations for,Peripheral Arterial Aortic,2024,60
"In symptomatic patients with atherosclerotic subclavian artery disease (TIA/stroke, coronary subclavian steal syndrome, ipsilateral haemodialysis access dysfunction, severe ischaemia), both revascularization options (endovascular ± stenting or surgery) should be considered and discussed case by case by a vascular team.",IIa,B,29,Recommendations for,Peripheral Arterial Aortic,2024,60
"Endovascular revascularization may be considered over surgery, despite similar long-term outcomes, due to lower complication rates.",IIb,B,29,Recommendations for,Peripheral Arterial Aortic,2024,60
"In patients with atherosclerotic subclavian artery disease, revascularization: Should be considered in cases of proximal stenosis in patients undergoing CABG using the ipsilateral internal mammary artery.777–",IIa,C,29,Recommendations for,Peripheral Arterial Aortic,2024,60
Should be considered in cases of proximal stenosis in patients who already have the ipsilateral internal mammary artery grafted to coronary arteries with evidence of myocardial ischaemia.,IIa,C,29,Recommendations for,Peripheral Arterial Aortic,2024,60
Should be considered in cases of ipsilateral haemodialysis arteriovenous access.,IIa,C,29,Recommendations for,Peripheral Arterial Aortic,2024,60
Routine revascularization in patients with atherosclerotic subclavian artery disease is not recommended.,III,C,29,Recommendations for,Peripheral Arterial Aortic,2024,60
"diagnostic strategies for renal artery disease DUS is recommended as the first-line imaging modality in patients with suspicion of RAS.787,789–",I,B,30,Recommendations for,Peripheral Arterial Aortic,2024,63
"In cases of DUS-based suspicion of RAS or inconclusive DUS, MRA, or CTA are recommended.",I,B,30,Recommendations for,Peripheral Arterial Aortic,2024,63
"In patients with atherosclerotic RAS, it is recommended to assess clinical high-risk features and kidney viability when evaluating renal artery revascularization.",I,B,30,Recommendations for,Peripheral Arterial Aortic,2024,63
treatment strategies for renal artery disease (see also Evidence Table 10) Medical therapy In patients with atherosclerotic RAS the use of low-dose aspirin may be considered.,IIb,C,31,Recommendations for,Peripheral Arterial Aortic,2024,63
"Revascularization In patients with atherosclerotic unilateral >70% RAS, concomitant high-risk features, and signs of kidney viability, renal artery revascularization should be considered after OMT has been established.",IIa,B,31,Recommendations for,Peripheral Arterial Aortic,2024,63
"In patients with atherosclerotic bilateral (>70%) RAS or RAS in a solitary kidney, concomitant high risk features, and signs of kidney viability, renal artery revascularization should be considered.800–",IIa,B,31,Recommendations for,Peripheral Arterial Aortic,2024,63
"In patients with an indication for renal artery revascularization and complex anatomy, or after failed endovascular revascularization, open surgical revascularization should be considered.",IIa,B,31,Recommendations for,Peripheral Arterial Aortic,2024,63
"In patients with atherosclerotic unilateral RAS, routine revascularization is not recommended.324,800–",III,A,31,Recommendations for,Peripheral Arterial Aortic,2024,63
"patients with visceral artery stenosis In patients with acute mesenteric ischaemia due to acute occlusion of the SMA, endovascular revascularization is recommended.829–",I,B,32,Recommendations in,Peripheral Arterial Aortic,2024,65
"In patients with suspected acute or chronic mesenteric ischaemia, CTA is recommended.",I,C,32,Recommendations in,Peripheral Arterial Aortic,2024,65
"In patients with acute or chronic mesenteric ischaemia, assessment by a vascular team is recommended.",I,C,32,Recommendations in,Peripheral Arterial Aortic,2024,65
Revascularization of asymptomatic atherosclerotic visceral artery stenosis is not recommended.,III,C,32,Recommendations in,Peripheral Arterial Aortic,2024,65
"primary and secondary prevention in aortic atheroma­ tous plaques Primary prevention In patients with severe/complex aortic atheromatous plaques, statins should be considered to decrease progression and risk of CV events.",IIa,C,33,Recommendations for,Peripheral Arterial Aortic,2024,65
SAPT with clopidogrel or low-dose aspirin should be considered in severe/complex plaques.,IIa,C,33,Recommendations for,Peripheral Arterial Aortic,2024,65
Anticoagulation861 or DAPT863 are not recommended in aortic plaques since they present no benefit and increase bleeding risk.,III,C,33,Recommendations for,Peripheral Arterial Aortic,2024,65
"Secondary prevention after an embolic event related to aortic atherosclerosis In patients with an embolic event and evidence of an aortic arch atheroma, intensive lipid management to an LDL-C target <1.4 mmol/L (<55 mg/dL) is recommended to prevent recurrences.",I,A,33,Recommendations for,Peripheral Arterial Aortic,2024,65
"In patients with an embolic event and evidence of an aortic arch atheroma, SAPT is recommended to prevent recurrences.",I,C,33,Recommendations for,Peripheral Arterial Aortic,2024,65
"initial evaluation of thoracic aortic aneurysm and abdominal aortic aneurysm When an aortic aneurysm is identified at any location, assessment of the entire aorta is recommended at baseline and during follow-up.",I,C,34,Recommendations for,Peripheral Arterial Aortic,2024,66
"When a TAA is identified, assessment of the aortic valve (especially for BAV) is recommended.",I,C,34,Recommendations for,Peripheral Arterial Aortic,2024,66
"When an AAA is identified, evaluation of the presence of aneurysm in the femoro-popliteal arterial segment should be considered.876–",IIa,C,34,Recommendations for,Peripheral Arterial Aortic,2024,66
"Patients with aortic aneurysm are at increased risk of CVD, thus general CV prevention should be considered.",IIa,C,34,Recommendations for,Peripheral Arterial Aortic,2024,66
"for the surveillance of patients with thoracic aortic an­ eurysms (non-heritable thoracic aortic disease) In thoracic aortic dilatation, TTE is recommended at diagnosis to assess aortic valve anatomy and function, aortic root, and ascending aorta diameters. Additionally, a global aortic evaluation using all echocardiographic views is recommended.",I,C,35,Recommendation,Peripheral Arterial Aortic,2024,70
"CMR or CCT is recommended for surveillance of patients with aneurysm at the distal ascending aorta, aortic arch, DTA, or TAAA.70,159,172,912–",I,C,35,Recommendation,Peripheral Arterial Aortic,2024,70
"In thoracic aortic dilatation, CCT or CMR is recommended to confirm TTE measurements, rule out aortic asymmetry, and determine baseline diameters for follow-up.",I,C,35,Recommendation,Peripheral Arterial Aortic,2024,70
"TTE is not recommended for the surveillance of aneurysms in the distal ascending aorta, aortic arch, or DTA.",III,C,35,Recommendation,Peripheral Arterial Aortic,2024,70
surveillance of patients with abdominal aortic aneurysm DUS surveillance is recommended every 6 months in men with AAA of 50–55 mm and in women with AAA of 45–50 mm.,I,B,36,Recommendations for,Peripheral Arterial Aortic,2024,72
"CCT or CMR is recommended if DUS does not allow adequate measurement of AAA diameter.148,939–",I,B,36,Recommendations for,Peripheral Arterial Aortic,2024,72
DUS is recommended for AAA surveillance.,I,C,36,Recommendations for,Peripheral Arterial Aortic,2024,72
DUS surveillance every 3 years should be considered in patients with AAA of 30–<40 mm.,IIa,B,36,Recommendations for,Peripheral Arterial Aortic,2024,72
DUS surveillance should be considered annually in women with AAA of 40–<45 mm and in men with AAA of 40–<50 mm.,IIa,B,36,Recommendations for,Peripheral Arterial Aortic,2024,72
DUS surveillance should be considered every 4 years in patients with aortic diameter ≥25 mm and <30 mm and life expectancy >2 years.,IIa,C,36,Recommendations for,Peripheral Arterial Aortic,2024,72
"medical treatment in patients with thoracic aorta or abdominal aortic aneurysms In patients with aortic aneurysm (TAA and/or AAA), optimal implementation of CV risk management and medical treatment (see detailed recommendations in dedicated Tables of Recommendationsc) are recommended to reduce MACE.",I,C,37,Recommendations for,Peripheral Arterial Aortic,2024,72
"Fluoroquinolones, while generally discouraged for patients with aortic aneurysms, may be considered if there is a compelling clinical indication and no other reasonable alternative.951–",IIb,B,37,Recommendations for,Peripheral Arterial Aortic,2024,72
surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve (see also Evidence Table 11) Surgery is recommended in patients with dilatation of the aortic root or ascending aorta with a tricuspid aortic valve and a maximum diameter of ≥55 mm.,I,B,38,Recommendations for,Peripheral Arterial Aortic,2024,74
Valve-sparing aortic root replacement is recommended in patients with aortic root dilatation if performed in experienced centres and durable results are expected.961–,I,B,38,Recommendations for,Peripheral Arterial Aortic,2024,74
VKAs are recommended lifelong for all patients with a Bentall procedure with an MHV prosthesis.,I,B,38,Recommendations for,Peripheral Arterial Aortic,2024,74
"In patients with dilatation of the tubular ascending aorta who can be offered surgery with low predicted risk,c ascending aortic replacement should be considered at a maximum diameter >52 mm.",IIa,B,38,Recommendations for,Peripheral Arterial Aortic,2024,74
"In patients undergoing surgery for tricuspid aortic valve disease who have concomitant dilatation of the aortic root or ascending tubular aorta, and low predicted surgical risk, ascending aorta or root replacement should be considered at a maximum diameter ≥45 mm, otherwise ≥50 mm.70,987–",IIa,B,38,Recommendations for,Peripheral Arterial Aortic,2024,74
"In patients undergoing non-aortic-valve cardiac surgery who have concomitant dilatation of the ascending aorta or aortic root with a maximum diameter ≥50 mm, concomitant aortic surgery should be considered.",IIa,C,38,Recommendations for,Peripheral Arterial Aortic,2024,74
"Ascending aortic or root replacement may be considered at a maximum diameter of ≥50 mm in patients with proximal aorta dilatation who can be offered surgery with low predicted riskc and present with any of the following:153–155,891,892 • Growth of the aortic diameter ≥3 mm per year • Resistant hypertensiond • Short stature <1.69 m • Root phenotype • Aortic lengthe >11 cm • Age <50 years • Desire for pregnancy • Aortic coarctation",IIb,B,38,Recommendations for,Peripheral Arterial Aortic,2024,74
"surgery in aortic arch aneurysms In patients with low or intermediate operative risk with an aortic arch aneurysm and recurrent episodes of chest pain not attributable to non-aortic causes, open surgical replacement of the arch is recommended.",I,C,39,Recommendations for,Peripheral Arterial Aortic,2024,74
"In patients undergoing open surgical repair of an ascending aortic aneurysm, concomitant hemi-arch replacement should be considered if the dilatation extends into the proximal aortic arch (>50 mm).",IIa,C,39,Recommendations for,Peripheral Arterial Aortic,2024,75
"In patients undergoing open surgical repair of an aortic arch aneurysm, an elephant trunk or frozen elephant trunk procedure should be considered if the aneurysmal disease extends into the proximal descending thoracic aorta.",IIa,C,39,Recommendations for,Peripheral Arterial Aortic,2024,75
"In patients undergoing open surgical repair of an ascending aortic aneurysm, concomitant hemi-arch or arch replacement may be considered in experienced centres if the dilatation extends into the aortic arch (>45 mm).",IIb,C,39,Recommendations for,Peripheral Arterial Aortic,2024,75
"In patients with an aortic arch aneurysm who meet criteria for intervention but have high surgical risk, a hybrid or endovascular approach may be considered.",IIb,C,39,Recommendations for,Peripheral Arterial Aortic,2024,75
"the management of patients presenting with descending thoracic aortic and thoracoabdominal aortic aneurysms In patients with unruptured DTA aneurysm (without HTAD), elective repair is recommended if diameter ≥55 mm.",I,B,40,Recommendations for,Peripheral Arterial Aortic,2024,76
"In patients without HTAD with unruptured DTA aneurysm, when elective repair is indicated and anatomy is suitable, TEVAR is recommended over open repair.",I,B,40,Recommendations for,Peripheral Arterial Aortic,2024,76
"In patients with DTA aneurysm who undergo TEVAR with planned LSA coverage, it is recommended to revascularize the LSA before TEVAR to reduce the risk of SCI and stroke.",I,B,40,Recommendations for,Peripheral Arterial Aortic,2024,76
"In patients with unruptured degenerative TAAA, elective repair is recommended when the diameter is ≥60 mm.",I,B,40,Recommendations for,Peripheral Arterial Aortic,2024,76
"In patients without significant comorbidities and with unruptured DTA aneurysm, when elective repair is indicated and anatomy is unsuitable for TEVAR, open repair should be considered if life expectancy exceeds 2 years.",IIa,B,40,Recommendations for,Peripheral Arterial Aortic,2024,76
"In TAAA, surgical repair should be considered at diameters ≥55 mm if patients present with high-risk features, are at very low risk, and are under the care of experienced surgeons in a multidisciplinary aorta team.",IIa,B,40,Recommendations for,Peripheral Arterial Aortic,2024,76
"In patients with unruptured degenerative TAAA and suitable anatomy, when elective repair is indicated, endovascular repair using fenestrated and/or branched endografts should be considered in experienced centres.1051,1052,1055–",IIa,B,40,Recommendations for,Peripheral Arterial Aortic,2024,76
the management of patients presenting with abdominal aortic aneurysm Elective repair is recommended if AAA diameter is ≥55 mm in men or ≥50 mm in women.1064–,I,A,41,Recommendations for,Peripheral Arterial Aortic,2024,78
"In ruptured AAA with suitable anatomy, endovascular repair is recommended over open repair to reduce peri-operative morbidity and mortality.1116–",I,B,41,Recommendations for,Peripheral Arterial Aortic,2024,78
"Prior to AAA repair, DUS assessment of the femoro-popliteal segment, to detect concomitant aneurysms, should be considered.",IIa,B,41,Recommendations for,Peripheral Arterial Aortic,2024,78
"In patients with AAA with suitable anatomy and reasonable life expectancy (>2 years), EVAR should be considered as the preferred therapy, based on shared decision-making.910,1096,1141–",IIa,B,41,Recommendations for,Peripheral Arterial Aortic,2024,78
"In patients with unruptured AAA and aneurysm growth ≥5 mm in 6 months or ≥10 mm per year, repair may be considered.",IIb,C,41,Recommendations for,Peripheral Arterial Aortic,2024,78
Elective repair for patients presenting with a saccular aneurysm ≥45 mm may be considered.,IIb,C,41,Recommendations for,Peripheral Arterial Aortic,2024,78
"In patients with AAA and limited life expectancy (<2 years), elective AAA repair is not recommended.",III,B,41,Recommendations for,Peripheral Arterial Aortic,2024,78
"Prior to AAA repair, routine evaluation with coronary angiography and systematic revascularization in patients with chronic coronary syndromes is not recommended.",III,C,41,Recommendations for,Peripheral Arterial Aortic,2024,78
"the management of patients presenting with endoleaks It is recommended to perform 30 day imaging after TEVAR/EVAR, by CCT and DUS/CEUS, to assess the success of intervention.",I,B,42,Recommendations for,Peripheral Arterial Aortic,2024,80
It is recommended to re-intervene to achieve a seal in patients with type I endoleak after TEVAR/ EVAR.,I,B,42,Recommendations for,Peripheral Arterial Aortic,2024,80
"It is recommended to re-intervene, principally by endovascular means, to achieve a seal in patients with type III endoleak after TEVAR/EVAR.",I,B,42,Recommendations for,Peripheral Arterial Aortic,2024,80
"Re-intervention, principally with an endovascular approach or embolization, should be considered in patients with type II or V endoleak and significant sac expansion ≥10 mm or significantly decreasing proximal or distal seal.",IIa,C,42,Recommendations for,Peripheral Arterial Aortic,2024,80
"follow-up after treatment of aortic aneurysms (see also Evidence Table 12) Thoracic aortic aneurysm After open repair of TAA, an early CCT is recommended within 1 month, and then yearly CCT follow-up for the first 2 post-operative years and every 5 years thereafter is recommended if findings are stable.c",I,B,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"After TEVAR, follow-up imaging is recommended at 1 and 12 months post-operatively, then yearly until the fifth post-operative year if no abnormalitiesd are documented.",I,B,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"After 5 post-operative years without complications, continuing long-term follow-up of TEVAR by CCT every 5 years should be considered.",IIa,B,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"If growth of the excluded aneurysm is observed, without evidence of type I or III endoleak, repeating CCT every 6–12 months, depending on the growth rate observed, should be considered.",IIa,C,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"When frequent controls are required in TAA patients treated either by open or endovascular repair, CMR should be considered instead of CCT after the first year of follow-up. However, the choice between these imaging modalities should be based on individual patient factors, the potential for artefacts, and the local availability and expertise in specific imaging techniques.",IIa,C,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"Abdominal aortic aneurysm After open repair of AAA, first follow-up imaging is recommended within 1 post-operative year, and every 5 years thereafter if findings are stable.",I,A,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"After EVAR, follow-up imaging is recommended with CCT (or CMR) and DUS/CEUS at 1 month and 12 months post-operatively, then, if no abnormalitiesd are documented, DUS/CEUS is recommended every year, repeating CCT or CMR (based on potential artefacts) every 5 years.70,1079,1100,1163–",I,A,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"In higher-risk patients, i.e. with inadequate sealing or type II endoleak at first CCT control, more frequent DUS/CEUS imaging should be considered.e",IIa,B,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"In low-riskf patients, from 1 year post-operatively after EVAR, repeating DUS/CEUS every 2 years should be considered.",IIa,B,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"In post-treatment surveillance, administration of OMT (see 8.1.2.2 and 8.2.4) and assessment of aneurysm development/growth in other arterial segments should be considered.",IIa,C,43,Recommendations for,Peripheral Arterial Aortic,2024,81
"diagnostic work-up of acute aortic syndromes In unstable patients who cannot be transferred to CCT, TOE is recommended for diagnosis1204,1208,1209 and evaluation of the coeliac trunk and mesenteric artery.",I,B,44,Recommendations for,Peripheral Arterial Aortic,2024,85
"In patients presenting with clinical features compatible with possible AAS, a multiparametric algorithm for ruling in or out AAS using the ADD-RS is recommended.1196–",I,B,44,Recommendations for,Peripheral Arterial Aortic,2024,85
"ECG-gated CCT from neck to pelvis is recommended as the first-line imaging technique in patients with a suspected AAS since it is widely available, accurate, and provides information about the entry tear, extension, and possible complications (malperfusion, dilatation, or rupture).",I,C,44,Recommendations for,Peripheral Arterial Aortic,2024,85
"In patients with suspected AAS, focused TTE (with use of contrast if feasible) is recommended during the initial evaluation.",I,C,44,Recommendations for,Peripheral Arterial Aortic,2024,85
"In patients with suspected AAS, TOE is recommended to guide peri-operative management and detect complications.",I,C,44,Recommendations for,Peripheral Arterial Aortic,2024,85
"In patients with suspected AAS, CMR should be considered as an alternative imaging technique if CCT is not available.",IIa,C,44,Recommendations for,Peripheral Arterial Aortic,2024,85
"medical treatment in acute aortic syndromes In patients with AAS, immediate anti-impulse treatment targeting SBP <120 mmHg and heart rate ≤60 b.p.m. is recommended. In cases of spinal ischaemia or concomitant brain injury, maintaining higher MAP is recommended.1214–",I,B,45,Recommendation for,Peripheral Arterial Aortic,2024,86
"Intravenous BBs (e.g. labetalol or esmolol) are recommended as first-line agents. If necessary, i.v. vasodilators (e.g. dihydropyridine calcium blockers or nitrates) could be added.",I,B,45,Recommendation for,Peripheral Arterial Aortic,2024,86
"Invasive monitoring with an arterial line and continuous three-lead ECG recording, as well as admission to an intensive care unit, is recommended.",I,B,45,Recommendation for,Peripheral Arterial Aortic,2024,86
"In patients with AAS who can be managed conservatively and who achieved haemodynamic targets with i.v. anti-impulse therapy, switching to oral BBs and, if necessary, up-titration of other BP-lowering agents, is recommended after 24 h if gastrointestinal transit is preserved.",I,B,45,Recommendation for,Peripheral Arterial Aortic,2024,86
Adequate pain control to achieve haemodynamic targets is recommended.,I,C,45,Recommendation for,Peripheral Arterial Aortic,2024,86
"If the patient has a contraindication for BBs, a non-dihydropyridine calcium blocker should be considered.",IIa,B,45,Recommendation for,Peripheral Arterial Aortic,2024,86
"intervention in type A acute aortic dissection In patients with acute TAAD, emergency surgical consultation and evaluation and immediate surgical intervention is recommended.",I,B,46,Recommendations for,Peripheral Arterial Aortic,2024,87
"In patients with acute TAAD who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aortic disorder, aortic root replacement is recommended with a mechanical or biological valved conduit.1251–",I,B,46,Recommendations for,Peripheral Arterial Aortic,2024,87
"In patients presenting with acute TAAD, transfer from a low- to a high-volume aortic centre with the presence of a multidisciplinary team should be considered to improve survival if transfer can be accomplished without significant delay in surgery.",IIa,B,46,Recommendations for,Peripheral Arterial Aortic,2024,87
"In selected patients, a valve-sparing root repair may be considered, when performed by experienced surgeons.",IIb,B,46,Recommendations for,Peripheral Arterial Aortic,2024,87
"aortic repair strategies in type A acute aortic dissection In patients with acute TAAD and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is recommended over valve replacement.1251–",I,B,47,Recommendations for,Peripheral Arterial Aortic,2024,87
"In patients with acute TAAD undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase FL thrombosis rates. 1266–",I,B,47,Recommendations for,Peripheral Arterial Aortic,2024,87
"In patients with acute TAAD without an intimal tear in the arch or a significant arch aneurysm, hemi-arch repair is recommended over more extensive arch replacement.1270–",I,B,47,Recommendations for,Peripheral Arterial Aortic,2024,87
"In patients with acute TAAD and a secondary intimal tear in the arch or proximal DTA, an extended aortic repair with stenting of the proximal DTA (e.g. by using the frozen elephant trunk technique) may be considered to reduce late distal aortic complications (e.g. aneurysm evolution of the remaining dissected descending aorta).",IIb,C,47,Recommendations for,Peripheral Arterial Aortic,2024,87
"the management of malperfusion in the setting of acute aortic dissection In patients with acute TAAD presenting with malperfusion (cerebral, mesenteric, lower limb, or renal), immediate aortic surgery is recommended.",I,B,48,Recommendations for,Peripheral Arterial Aortic,2024,91
"In patients with acute TAAD presenting with cerebral malperfusion or non-haemorrhagic stroke, immediate aortic surgery should be considered to improve neurological outcome and reduce mortality.",IIa,B,48,Recommendations for,Peripheral Arterial Aortic,2024,91
"In patients with acute TAAD presenting with clinically significant mesenteric malperfusion syndrome, immediate invasive angiographic diagnostics to evaluate percutaneous malperfusion repair before or directly after aortic surgery, in aortic centres with expertise, should be considered.1278–",IIa,C,48,Recommendations for,Peripheral Arterial Aortic,2024,91
the management of patients presenting with acute type B aortic dissection Medical therapy including pain relief and blood pressure control is recommended in all patients with acute TBAD.,I,B,49,Recommendations for,Peripheral Arterial Aortic,2024,92
"In patients with complicated acute TBAD, emergency intervention is recommended.1193,1250,1284,1285,1288,1289,1291–",I,B,49,Recommendations for,Peripheral Arterial Aortic,2024,92
"In patients with complicated acute TBAD, TEVAR is recommended as the first-line therapy.c,910,1288–",I,B,49,Recommendations for,Peripheral Arterial Aortic,2024,92
"In patients with acute TBAD, BBs should be considered as the first-line medical therapy.",IIa,B,49,Recommendations for,Peripheral Arterial Aortic,2024,92
"In patients with uncomplicated acute TBAD, TEVAR in the subacute phase (between 14 and 90 days) should be considered in selected patients with high-risk featuresd to prevent aortic complications.",IIa,B,49,Recommendations for,Peripheral Arterial Aortic,2024,92
the management of patients presenting with chronic type B aortic dissection Antihypertensive therapy is recommended in all patients with chronic TBAD.1331–,I,B,50,Recommendations for,Peripheral Arterial Aortic,2024,92
"In chronic TBAD with acute symptoms of malperfusion, rupture, or progression of disease, emergency intervention is recommended.",I,C,50,Recommendations for,Peripheral Arterial Aortic,2024,92
"In patients with chronic TBAD and a descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable surgical risk.",I,B,50,Recommendations for,Peripheral Arterial Aortic,2024,92
"In patients with chronic TBAD and a descending thoracic aortic diameter ≥55 mm, an indication for intervention should be considered in patients with low procedural risk.",IIa,C,50,Recommendations for,Peripheral Arterial Aortic,2024,92
"In patients with chronic post-dissection thoracoabdominal aortic aneurysms, the use of fenestrated/branched stent grafts may be considered, when treatment is indicated.1062,1327–",IIb,C,50,Recommendations for,Peripheral Arterial Aortic,2024,92
"the management of intramural haematoma In patients with IMH, medical therapy including pain relief and blood pressure control is recommended.",I,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"In type A IMH, urgent surgery is recommended.",I,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"In type B IMH, initial medical therapy under careful surveillance is recommended.",I,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"In uncomplicatedc type B IMH, repetitive imaging (CCT or CMR) is indicated.",I,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"In complicatedc type B IMH, TEVAR is recommended.",I,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"In uncomplicatedc type B IMH but with high-risk imaging featuresd, TEVAR should be considered.",IIa,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"In complicatedc type B IMH, surgery may be considered in patients with anatomy unfavourable for TEVAR.",IIb,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"In selected patients with increased operative risk and uncomplicatedc type A IMH without high-risk imaging featuresd, a ‘wait and see’ strategy may be considered.1348,1354–",IIb,C,51,Recommendations for,Peripheral Arterial Aortic,2024,94
"the management of penetrating atherosclerotic ulcer In all patients with PAU, medical therapy including pain relief and blood pressure control is recommended.",I,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In cases of type A PAU, surgery is recommended.",I,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In cases of type B PAU, initial medical therapy under careful surveillance is recommended.",I,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In uncomplicated type B PAU, repetitive imaging (CMR, CCT, or TOE) is recommended.",I,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In complicated type B PAU, endovascular treatment (TEVAR) is recommended.",I,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In uncomplicated type B PAU with high-risk imaging features,c endovascular treatment should be considered.",IIa,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In selected patients with increased operative risk and uncomplicated type A PAU without high-risk imaging features,c a ‘wait-and-see’ strategy may be considered.",IIb,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In complicated type B PAU, surgery may be considered based on anatomy and medical comorbidities.",IIb,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"In isolated, asymptomatic, small PAUs with no high-risk features,c conservative management with regular surveillance and medical treatment may be considered.",IIb,C,52,Recommendations for,Peripheral Arterial Aortic,2024,94
"traumatic aortic injury In cases of severe aortic injury (grade 4), immediate repair is recommended.",I,A,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"In cases of TAI with suitable anatomy requiring intervention, TEVAR is recommended over open surgery.",I,A,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"In all TAI patients, medical therapy including pain relief, and blood pressure and heart rate control, is recommended.",I,C,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"In cases of TAI suspicion, CCT is recommended.",I,C,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"In cases of moderate aortic injury (grade 3), repair is recommended.",I,C,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"If CCT is not available, TOE should be considered.",IIa,C,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"In minimal aortic injury (grades 1 or 2), initial medical therapy under careful clinical and imaging surveillance should be considered.",IIa,C,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"In cases of progression of the IMH (grade 2), semi-elective repair (within 24–72 h) should be considered.",IIa,C,53,Recommendations for,Peripheral Arterial Aortic,2024,96
"follow-up after treatment of acute aortic syndrome After TEVAR for AAS, follow-up imaging is recommended at 1, 6, and 12 months post-operatively, then yearly until the fifth post-operative year if no abnormalitiesc are documented.",I,B,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"In medically treated type B AAS or IMH, follow-up imaging is recommended at 1, 3, 6, and 12 months after onset, then yearly if imaging findings are stable.",I,C,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"In medically treated PAU, follow-up imaging is recommended at 1 month after diagnosis, then every 6 months if imaging findings are stable.",I,C,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"After open surgery for AAS, follow-up imaging by CCT and TTE within 6 months, then CCT at 12 months and then yearly if findings are stable,d should be considered.",IIa,B,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"If no complicationsc occur within the first 5 years, CCT every 2 years thereafter should be considered.",IIa,B,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"If no residual patent FL is documented for 3 post-operative years, subsequent surveillance by CCT every 2–3 years should be considered.",IIa,C,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"If abnormalitiesc are documented at any time of follow-up after TEVAR for AAS, then CCT should be considered every 3–6 months.",IIa,C,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"When frequent controls are required in AAS patients treated either by open or endovascular repair, CMR should be considered instead of CCT after the first-year follow-up.",IIa,C,54,Recommendations for,Peripheral Arterial Aortic,2024,100
"In the follow-up of medically treated PAU, after 2 years of imaging stability, larger intervals should be considered in low-risk patientse.",IIa,C,54,Recommendations for,Peripheral Arterial Aortic,2024,100
the management of patients with heritable thoracic aor­ tic disease It is recommended that medical management of patients with HTAD is individualized and based on shared decision-making.,I,C,55,Recommendations for,Peripheral Arterial Aortic,2024,100
It is recommended that patients with known or suspected syndromic or non-syndromic HTAD are evaluated in a centre with experience in the care of this patient group.,I,C,55,Recommendations for,Peripheral Arterial Aortic,2024,100
"imaging in women with Turner syndrome To take the smaller body size of women (≥15 years) with TS into account, the use of the ascending ASI (ratio of aortic diameter [mm] to BSA [m2]), AHI (ratio of aortic diameter [mm] to height [m]), or aortic z-score is recommended to define the degree of aortic dilatation and assess the risk of aortic dissection.",I,C,57,Recommendations for,Peripheral Arterial Aortic,2024,101
"It is recommended to define imaging and clinical surveillance intervals according to the estimated risk for dissection, based on the ascending ASI and concomitant lesions.c",I,C,57,Recommendations for,Peripheral Arterial Aortic,2024,101
"genetic testing and aortic screening in aortic disease Genetic testing In patients with aortic root/ascending aneurysms or thoracic aortic dissection, gathering family history information for at least three generations about TAD, unexplained sudden deaths, and peripheral and intracranial aneurysms is recommended.880,1396–",I,B,56,Recommendations for,Peripheral Arterial Aortic,2024,101
"In patients with aortic root/ascending aortic aneurysms or thoracic aortic dissection and risk factors for HTAD,c genetic counselling at an expert centre and subsequent testing, if indicated, is recommended.1399,1403–",I,B,56,Recommendations for,Peripheral Arterial Aortic,2024,101
"In patients with HTAD who have a pathogenic/likely pathogenic variant, genetic testing of at-risk biological relatives (i.e. cascade testing) is recommended, irrespective of age.",I,C,56,Recommendations for,Peripheral Arterial Aortic,2024,101
"In patients with HTAD, guidance of clinical management by the underlying gene/variant, when known, should be considered.70,1391,1410–",IIa,B,56,Recommendations for,Peripheral Arterial Aortic,2024,101
"Aortic imaging screening In patients with TAD with risk factors for HTAD,c with a negative family history of TAD and in whom no (likely) pathogenic variant is identified, TTEd screening aortic imaging of FDRse is recommended.",I,B,56,Recommendations for,Peripheral Arterial Aortic,2024,101
"aortic surgery in women with Turner syndrome Elective surgery for aneurysms of the aortic root and/ or ascending aorta should be considered in women with TS who are ≥15 years of age, have an ascending ASI >23 mm/m2, an AHI >23 mm/m, a z-score >3.5, and have associated risk factors for aortic dissectionc or are planning pregnancy.",IIa,C,58,Recommendations for,Peripheral Arterial Aortic,2024,103
"medical treatment in patients with vascular Ehlers– Danlos syndrome (see also Evidence Table 13) In patients with vEDS, regular vascular surveillance of the aorta and peripheral arteries by DUS, CCT, or CMR is recommended.",I,C,59,Recommendations for,Peripheral Arterial Aortic,2024,104
Treatment with celiprolol should be considered in patients with vEDS.,IIa,B,59,Recommendations for,Peripheral Arterial Aortic,2024,104
"vascular imaging in Marfan syndrome In patients with MFS, TTE is recommended:70,171,1458,1459 • At least annually in patients with an aortic root diameter <45 mm in the absence of additional risk factorsc • At least every 6 months in patients with an aortic root diameter <45 mm in the presence of additional risk factorsc • At least every 6–12 months in patients with an aortic root diameter ≥45 mm in the absence of additional risk factorsc",I,C,60,Recommendations for,Peripheral Arterial Aortic,2024,105
"In patients without previous aortic surgery, complete peripheral vascular and thoracoabdominal aorta imaging by CMR or CCT and DUS is recommended at the first evaluation, and subsequently every 3–5 years if stable.",I,C,60,Recommendations for,Peripheral Arterial Aortic,2024,105
"In patients with MFS who have undergone aortic root replacement, surveillance imaging of the thoracic aorta by CMR (or CCT) is recommended at least every 3 years.",I,C,60,Recommendations for,Peripheral Arterial Aortic,2024,105
"aortic surgery in Marfan syndrome Surgery is indicated in patients with MFS who have aortic root disease with a maximal aortic sinus diameter ≥50 mm.70,172,1466–",I,B,62,Recommendations for,Peripheral Arterial Aortic,2024,105
"Surgery to replace the aortic root and ascending aorta, using the valve-sparing surgery technique, is recommended in patients with MFS or related HTAD with aortic root dilatation when anatomical features of the valve allow its preservation and the surgeon has specific expertise.",I,B,62,Recommendations for,Peripheral Arterial Aortic,2024,105
Surgery should be considered in patients with MFS who have an aortic root aneurysm with a maximal aortic sinus diameter ≥45 mm and additional risk factors.c,IIa,C,62,Recommendations for,Peripheral Arterial Aortic,2024,105
"In patients with MFS and an aneurysm of the ascending aorta, aortic arch, descending thoracic aorta, or abdominal aorta of ≥50 mm, surgical replacement of the aneurysmal segment by a surgeon with specific expertise should be considered.",IIa,C,62,Recommendations for,Peripheral Arterial Aortic,2024,105
"medical treatment in Marfan syndrome (see also Evidence Table 14) In patients with MFS, treatment with either a BB or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to reduce the rate of aortic dilatation.",I,A,61,Recommendations for,Peripheral Arterial Aortic,2024,105
"In patients with MFS, the use of both a BB and an ARB, in maximally tolerated doses (unless contraindicated), should be considered to reduce the rate of aortic dilatation.",IIa,A,61,Recommendations for,Peripheral Arterial Aortic,2024,105
pregnancy in women with Marfan syndrome It is recommended that all women with MFS: • Have a pre-conception evaluation to address the risks of maternal CV and other complications • Have follow-up in a centre with access to a pregnancy heart and vessel team.,I,C,63,Recommendations for,Peripheral Arterial Aortic,2024,106
It is recommended that couples in which a partner has or is at risk for HTAD be offered pre-conception genetic counselling.,I,C,63,Recommendations for,Peripheral Arterial Aortic,2024,106
Imaging of the whole aorta (by CMR/CCT) is recommended prior to pregnancy.,I,C,63,Recommendations for,Peripheral Arterial Aortic,2024,106
Follow-up during pregnancy is recommended with a frequency determined by aortic diameter and growth.,I,C,63,Recommendations for,Peripheral Arterial Aortic,2024,106
Intake of BBs during pregnancy is recommended.,I,C,63,Recommendations for,Peripheral Arterial Aortic,2024,106
Prophylactic aortic root surgery is recommended in women desiring pregnancy with aortic diameters >45 mm.,I,C,63,Recommendations for,Peripheral Arterial Aortic,2024,106
Prophylactic aortic root surgery may be considered in women desiring pregnancy with aortic diameters of 40–45 mm.,IIb,C,63,Recommendations for,Peripheral Arterial Aortic,2024,106
ARBs are not recommended during pregnancy.1478–,III,B,63,Recommendations for,Peripheral Arterial Aortic,2024,106
"physical exercise in patients with Marfan syndrome It is recommended to individualize physical activity in patients with MFS based on aortic diameter, family history of aortic dissection, and pre-existing fitness.",I,C,64,Recommendations for,Peripheral Arterial Aortic,2024,106
Regular moderate aerobic exercise with a level of intensity informed by aortic diameter is recommended in most patients with MFS.,I,C,64,Recommendations for,Peripheral Arterial Aortic,2024,106
"For patients who present with aortic dissection and/ or have undergone aortic surgery, post-operative cardiac rehabilitation aiming at improving both physical and mental health should be considered.",IIa,B,64,Recommendations for,Peripheral Arterial Aortic,2024,106
"aortic root surgery in Loeys–Dietz syndrome Aortic root replacement should be considered for patients with Loeys–Dietz syndrome if the aortic root diameter exceeds 45 mm.1388,1390,1489–",IIa,C,66,Recommendations for,Peripheral Arterial Aortic,2024,107
"It may be considered to adjust the threshold for surgery according to the underlying gene, taking associated risk featuresc into account.",IIb,C,66,Recommendations for,Peripheral Arterial Aortic,2024,107
"imaging follow-up in Loeys–Dietz syndrome In patients with Loeys–Dietz syndrome, TTE at baseline and subsequently every 6–12 months, depending on aortic diameter and growth,c is recommended.",I,C,65,Recommendations for,Peripheral Arterial Aortic,2024,107
"In patients with Loeys–Dietz syndrome, a baseline arterial imaging study from head to pelvis with CMR or CCT and subsequent surveillance with CMR or CCT or DUS every 1–3 years is recommended.",I,C,65,Recommendations for,Peripheral Arterial Aortic,2024,107
imaging and surgery in ACTA2-related heritable thoracic aortic disease (see also Evidence Table 11) Annual monitoring of the aortic root/ascending aorta with TTE to evaluate aortic root/ascending aorta enlargement is recommended.,I,C,67,Recommendations for,Peripheral Arterial Aortic,2024,108
Imaging of the aorta with CMR/CCT every 3–5 years is recommended.,I,C,67,Recommendations for,Peripheral Arterial Aortic,2024,108
"Prophylactic aortic root surgery should be considered with an aortic diameter ≥45 mm, or lower in cases with other risk factors.c",IIa,C,67,Recommendations for,Peripheral Arterial Aortic,2024,108
"bicuspid aortic valve-associated aortopathy management When a BAV is first diagnosed, initial TTE to assess diameters of the aorta at several levels is recommended.",I,B,68,Recommendations for,Peripheral Arterial Aortic,2024,110
Surgery for bicuspid aortopathy is recommended when the maximum aortic diameter is ≥55 mm.,I,B,68,Recommendations for,Peripheral Arterial Aortic,2024,110
Surgery for bicuspid aortopathy of the root phenotypec is recommended when the maximum aortic diameter is ≥50 mm.,I,B,68,Recommendations for,Peripheral Arterial Aortic,2024,110
"CCT or CMR of the entire thoracic aorta is recommended at first diagnosis and when important discrepancies in measurements are found between subsequent TTE controls during surveillance, or when the diameter of the aorta exceeds 45 mm.",I,C,68,Recommendations for,Peripheral Arterial Aortic,2024,110
Screening by TTE in FDRs of BAV patients with root phenotypec aortopathy and/or isolated aortic regurgitation is recommended.,I,C,68,Recommendations for,Peripheral Arterial Aortic,2024,110
"Surveillance serial imaging by TTE is recommended in BAV patients with a maximum aortic diameter >40 mm, either with no indication for surgery or after isolated aortic valve surgery, after 1 year, then if stability is observed, every 2–3 years.",I,C,68,Recommendations for,Peripheral Arterial Aortic,2024,110
Screening by TTE in FDRs of all BAV patients should be considered.,IIa,B,68,Recommendations for,Peripheral Arterial Aortic,2024,110
"In patients with low surgical risk, surgery for bicuspid aortopathy of ascending phenotyped should be considered when the maximum aortic diameter is >52 mm.",IIa,B,68,Recommendations for,Peripheral Arterial Aortic,2024,110
"evaluation and medical treatment of patients with coarctation of the aorta In patients with native or repaired coarctation, lifelong follow-up is recommended, including regular imaging of the aorta with CCT/CMR every 3–5 years (adapted to clinical status and previous imaging findings).",I,B,69,Recommendations for,Peripheral Arterial Aortic,2024,111
"Coarctation or re-coarctation repair (either surgical or endovascular) is indicated in patients with hypertension with an increased non-invasive gradient between the upper and lower limbs (decreased ABI) confirmed with invasive measurement (peak-to-peak >20 mmHg), with a preference for stenting when technically feasible.",I,C,69,Recommendations for,Peripheral Arterial Aortic,2024,111
"In patients with coarctation, BP measurements at both arms and one lower extremity are recommended.",I,C,69,Recommendations for,Peripheral Arterial Aortic,2024,111
It is recommended to treat hypertension in patients with coarctation according to ESC hypertension guidelines.,I,C,69,Recommendations for,Peripheral Arterial Aortic,2024,111
"Endovascular treatment should be considered in patients with hypertension with >50% narrowing relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient is <20 mmHg, when technically feasible.",IIa,C,69,Recommendations for,Peripheral Arterial Aortic,2024,111
"Endovascular treatment should be considered in normotensive patients with an increased non-invasive gradient confirmed with invasive peak-to-peak gradient >20 mmHg, when technically feasible.",IIa,C,69,Recommendations for,Peripheral Arterial Aortic,2024,111
"screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases (see also Evidence Table 15) In patients with PVD, an LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.",I,A,70,Recommendations for,Peripheral Arterial Aortic,2024,115
"In patients with PAD and newly diagnosed AF with a CHA2DS2-VASc score ≥2, full oral anticoagulation is recommended.",I,C,70,Recommendations for,Peripheral Arterial Aortic,2024,115
Screening for ilio-femoral PAD is recommended in patients undergoing TAVI.,I,B,70,Recommendations for,Peripheral Arterial Aortic,2024,115
Carotid DUS should be considered for stable patients scheduled for CABG with TIA/stroke within the past 6 months without carotid revascularization.,IIa,B,70,Recommendations for,Peripheral Arterial Aortic,2024,115
Carotid DUS may be considered for stable patients scheduled for CABG without TIA/stroke within the past 6 months.,IIb,C,70,Recommendations for,Peripheral Arterial Aortic,2024,115
"vascular disease (see also Supplementary data online, Evidence Table 1) SCORE2 is recommended in apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or BP disorders for estimation of 10-year fatal and non-fatal CVD risk.2 c",I,B,1,Recommendations for cardiovascular risk estimation in persons without known cardio­,Dyslipidaemias Update,2025,9
"SCORE2-OP is recommended in apparently healthy people ≥70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or BP disorders for estimation of 10-year fatal and non-fatal CVD risk.3 c",I,B,1,Recommendations for cardiovascular risk estimation in persons without known cardio­,Dyslipidaemias Update,2025,9
"Presence of subclinical coronary atherosclerosis by imaging or increased CAC score by CT should be considered as risk modifiers in individuals at moderate risk or individuals around treatment decision thresholds to improve risk classification.24,27,28,36 d",IIa,B,1,Recommendations for cardiovascular risk estimation in persons without known cardio­,Dyslipidaemias Update,2025,9
"Risk modifierse should be considered in individuals at moderate risk or individuals around treatment decision thresholds to improve risk classification.17,27,37 f",IIa,B,1,Recommendations for cardiovascular risk estimation in persons without known cardio­,Dyslipidaemias Update,2025,9
"In primary prevention,g pharmacological LDL-C-lowering therapy is recommended in persons: • at very high risk and LDL-C ≥1.8 mmol/L (70 mg/dL), or • at high risk and LDL-C ≥2.6 mmol/L (100 mg/dL) despite optimization of non-pharmacological measures, to lower CVD risk.",I,A,1,Recommendations for cardiovascular risk estimation in persons without known cardio­,Dyslipidaemias Update,2025,9
"In primary prevention,g pharmacological LDL-C-lowering therapy should be considered in persons: • at very high risk and LDL-C ≥1.4 mmol/L (55 mg/dL) but <1.8 mmol/L (70 mg/dL), or • at high risk and LDL-C ≥1.8 mmol/L (70 mg/dL) but <2.6 mmol/L (100 mg/dL), or • at moderate risk and LDL-C ≥2.6 mmol(L (100 mg/dL) but <4.9 mmol/L (190 mg/dL), or • at low risk and LDL-C ≥3.0 mmol/L (116 mg/dL) but <4.9 mmol/L (190 mg/dL) despite optimization of non-pharmacological measures, to lower CVD risk.",IIa,A,1,Recommendations for cardiovascular risk estimation in persons without known cardio­,Dyslipidaemias Update,2025,9
"lipid-lowering therapy in patients with acute coronary syndromes (see also Supplementary data online, Evidence Table 3) Intensification of lipid-lowering therapy during the index ACS hospitalization is recommended for patients who were on any lipid-lowering therapy before admission in order to further lower LDL-C levels.",I,C,3,Recommendations for,Dyslipidaemias Update,2025,12
Initiating combination therapy with high-intensity statin plus ezetimibe during index hospitalization for ACS should be considered in patients who were treatment-naïve and are not expected to achieve the LDL-C goal with statin therapy alone.,IIa,B,3,Recommendations for,Dyslipidaemias Update,2025,12
"measurement of lipoprotein(a) (see also Supplementary data online, Evidence Table 4) Lp(a) levels above 50 mg/dL (105 nmol/L) should be considered in all adults as a CV risk-enhancing factor, with higher Lp(a) levels associated with a greater increase in risk.",IIa,B,4,Recommendations for,Dyslipidaemias Update,2025,12
"Supplementary data online, Evidence Table 5) High-dose icosapent ethyl (2 × 2 g/day) should be considered in combination with a statin in high-risk or very high-risk patients with elevated triglyceride levels (fasting triglyceride level 135–499 mg/dL or 1.52–5.63 mmol/L) to reduce the risk of cardiovascular events.",IIa,B,5,Recommendations for drug treatment of patients with hypertriglyceridaemia (see also,Dyslipidaemias Update,2025,14
"Volanesorsen (300 mg/week) should be considered in patients with severe hypertriglyceridaemia (>750 mg/dL or >8.5 mmol/L) due to familial chylomicronaemia syndrome, to lower triglyceride levels and reduce the risk of pancreatitis.",IIa,B,5,Recommendations for drug treatment of patients with hypertriglyceridaemia (see also,Dyslipidaemias Update,2025,14
"statin therapy in primary prevention for people with hu­ man immunodeficiency virus infection (see also Supplementary data online, Evidence Table 6) Recommendation Statin therapy is recommended for people in primary prevention aged ≥40 years with HIV, irrespective of estimated cardiovascular risk and LDL-C levels, to reduce the risk of cardiovascular events; the choice of statin should be based on potential drug interactions.",I,B,6,Recommendations for,Dyslipidaemias Update,2025,15
"statin therapy in patients receiving cancer therapy (see also Supplementary data online, Evidence Table 7) Recommendation Statins should be considered in adult patients at high or very high risk of developing chemotherapy-related cardiovascular toxicityc to reduce the risk of anthracycline-induced cardiac dysfunction.9,132–",IIa,B,7,Recommendations for,Dyslipidaemias Update,2025,15
"dietary supplements (see also Supplementary data online, Evidence Table 8) Recommendation Dietary supplements or vitamins without documented safety and significant LDL-C-lowering efficacy are not recommended to lower the risk of ASCVD.",III,B,8,Recommendations for,Dyslipidaemias Update,2025,16
"clinical evaluation of myocarditis and pericarditis (see Evidence Table 1) Complete clinical evaluation, including history, physical examination, chest X-ray, biomarkersc, ECG, and echocardiography is recommended in all patients with a suspicion of myocarditis and/or pericarditis for the initial diagnostic assessment.",I,C,1,Recommendations for,Myocarditis Pericarditis,2025,28
CMR is recommended in patients with the clinical suspicion of myocarditis (using updated LL criteria)30 and/or pericarditis for the non-invasive diagnosis of inflammatory reaction.,I,B,1,Recommendations for,Myocarditis Pericarditis,2025,28
Hospital admission is recommended for patients with high-risk pericarditisd for monitoring and treatment.,I,B,1,Recommendations for,Myocarditis Pericarditis,2025,28
Hospital admission is recommended for patients with moderate- to high-risk myocarditisd for monitoring and treatment.,I,C,1,Recommendations for,Myocarditis Pericarditis,2025,28
"EMBe is recommended in patients with high-risk myocarditisd and/or haemodynamic instability, and/or in patients with intermediate-risk myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral genome for treatment.",I,C,1,Recommendations for,Myocarditis Pericarditis,2025,28
"Invasive coronary angiography or coronary CT, depending on clinical likelihood, is recommended in patients with IMPS if an acute coronary syndrome is suspected to rule out obstructive coronary artery disease.",I,C,1,Recommendations for,Myocarditis Pericarditis,2025,28
Hospital admission should be considered for patients with low-risk myocarditisd for monitoring and treatment.,IIa,C,1,Recommendations for,Myocarditis Pericarditis,2025,28
Pericardial or epicardial biopsy may be considered in relapsing pericardial effusion as part of the diagnostic work-up when the diagnosis cannot be reached with multimodality imaging and laboratory examinations.,IIb,C,1,Recommendations for,Myocarditis Pericarditis,2025,28
"Routine serology is not recommended in patients with myocarditis and/or pericarditis for the evaluation of viral aetiology except for hepatitis C, HIV, and Lyme disease.",III,C,1,Recommendations for,Myocarditis Pericarditis,2025,28
"genetic testing (see Evidence Table 2) It is recommended to obtain family history including pedigrees in cases of recurrent IMPS to provide clues to the underlying aetiology, determine inheritance pattern, and identify relatives at risk.",I,C,2,Recommendations for,Myocarditis Pericarditis,2025,30
"Genetic testing should be considered in patients with definite myocarditis/pericarditis in cases of:50,51,64,94,150 • family history of IMPS, inherited or suspected cardiomyopathy • severe ventricular arrhythmiac • significant left/right LGE (e.g. ring-like pattern or septal LGE) or persistent LVEF systolic dysfunction • recurrent myocarditis or persistent troponin elevation • recurrent pericarditis with an inflammatory phenotype, refractory to conventional treatmentd, with the aim to detect an underlying genetic cause.",IIa,B,2,Recommendations for,Myocarditis Pericarditis,2025,30
"use of cardiovascular magnetic resonance imaging (see Evidence Table 3) Myocarditis CMR is recommended in patients with suspected myocarditis to reach a clinical diagnosis and to determine the cause of acute myocardial injury, including assessment of oedema, ischaemia, and necrosis/fibrosis/scarring.115,164,169–",I,B,3,Recommendations for the,Myocarditis Pericarditis,2025,32
"CMR is recommended for follow-up at least within the first 6 months in patients with myocarditis to identify a healed or ongoing process, for risk stratification and personalized therapy, and to enable a return to exercise.10,62,184–",I,C,3,Recommendations for the,Myocarditis Pericarditis,2025,32
"Pericarditis CMR is recommended in patients with suspected pericarditis when a diagnosis cannot be made using clinical criteria to assess evidence of pericardial thickening, oedema, LGE, and to assess the persistence of disease during follow-up in selected cases.110,129,165,187–",I,B,3,Recommendations for the,Myocarditis Pericarditis,2025,32
"computed tomography (see Evidence Table 4) CT is recommended to evaluate pericardial thickness, calcifications, masses, and loculated pericardial effusions, as well as concomitant pleuropulmonary diseases and chest abnormalities.",I,C,4,Recommendations for,Myocarditis Pericarditis,2025,32
Carb-free 18F-FDG-PET or 18F-FDG-PET/CT should be considered for the diagnostic work-up in patients with suspected myocarditis and/or pericarditis in whom echocardiography and CMR are inconclusive for the clinical diagnosis.,IIa,C,5,Recommendations for nuclear medicine (see Evidence Table 5),Myocarditis Pericarditis,2025,33
"EMBc is recommended in patients with high-risk myocarditisd, and/or haemodynamic instability, and/or in patients with intermediate-risk myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral genome for treatment.",I,C,6,Recommendations for endomyocardial biopsy (see Evidence Table 6),Myocarditis Pericarditis,2025,34
"autopsy (see Evidence Table 7) Comprehensive autopsy is recommended in all patients <50 years of age with SCD to evaluate the presence of acute myocarditis as a cause and to detect potential underlying inherited cardiac diseases.87,243–246c",I,B,7,Recommendations for,Myocarditis Pericarditis,2025,35
"Retaining samples suitable for DNA extraction and consulting a cardiac pathologist is recommended in cases of SCD, when an inherited cause is suspected, or the cause of death remains unexplained.243,247c",I,B,7,Recommendations for,Myocarditis Pericarditis,2025,35
"electro-anatomical mapping (see Evidence Table 8) Electro-anatomical mapping should be considered in cases of suspected myocarditis (especially cardiac sarcoidosis) to guide endomyocardial biopsy.218,220,221,253,256–",IIa,C,8,Recommendations for,Myocarditis Pericarditis,2025,36
medical therapy in myocarditis (see Evidence Table 9) Management of symptoms NSAIDs (together with proton pump inhibition) should be considered in patients with associated symptoms of pericarditis to reduce symptoms.,IIa,C,9,Recommendations for,Myocarditis Pericarditis,2025,39
Colchicine should be considered in patients with myopericarditis to reduce recurrences.,IIa,B,9,Recommendations for,Myocarditis Pericarditis,2025,39
Management of heart failure Adherence to the ESC HF guidelines is recommended in cases of myocarditis with LV systolic dysfunction and/or HF to reduce symptoms and to improve LV function.,I,C,9,Recommendations for,Myocarditis Pericarditis,2025,39
HF therapy should be considered in patients with myocarditis and LV systolic dysfunction for at least 6 months upon complete LV functional recovery to stabilize LV function.,IIa,C,9,Recommendations for,Myocarditis Pericarditis,2025,39
"Management of arrhythmias β-Blockers, with a continuation for at least 6 months, should be considered in patients with acute myocarditis, especially those with troponin elevation, to control symptoms and prevent arrhythmias.",IIa,C,9,Recommendations for,Myocarditis Pericarditis,2025,39
"Anti-arrhythmic treatment should be considered in post-myocarditis patients with recurrent, symptomatic VT to reduce arrhythmic burden.",IIa,C,9,Recommendations for,Myocarditis Pericarditis,2025,39
"Immunosuppressive therapy Corticosteroids should be considered in patients with fulminant, non-infectious forms of myocarditis to stabilize the patients.",IIa,C,9,Recommendations for,Myocarditis Pericarditis,2025,39
Routine use of immunosuppressive therapy is not recommended in acute myocarditis with preserved LV function because no outcome benefit has been shown.,III,C,9,Recommendations for,Myocarditis Pericarditis,2025,39
"medical therapy in pericarditis (see Evidence Table 10) Colchicine is recommended as first-line therapy in patients with pericarditis as an adjunct to aspirin/NSAID or corticosteroid therapy to reduce subsequent recurrences.24,25,108,275–",I,A,10,Recommendations for,Myocarditis Pericarditis,2025,42
"Anti-IL-1 agents (anakinra or rilonacept) are recommended for patients with recurrent pericarditis after failure of first-line therapies and corticosteroids and elevation of C-reactive protein levels to reduce recurrences and allow corticosteroid withdrawal.108,275,282–",I,A,10,Recommendations for,Myocarditis Pericarditis,2025,42
High-dose aspirin or NSAIDs with proton pump inhibitors are recommended as first-line therapy in patients with pericarditis to control symptoms and reduce recurrences.,I,B,10,Recommendations for,Myocarditis Pericarditis,2025,42
"A β-blocker should be considered in symptomatic patients, despite full anti-inflammatory therapy, and heart rate at rest >75 b.p.m. in order to improve symptom control.",IIa,C,10,Recommendations for,Myocarditis Pericarditis,2025,42
"Anti-IL-1 agents (anakinra or rilonacept) should be considered in cases of incessant/recurrent pericarditis with evidence of pericardial inflammation on CMR after failure, contraindications, and intolerance to first-line therapies and corticosteroids regardless of C-reactive protein levels to reduce recurrences and allow corticosteroid withdrawal.",IIa,C,10,Recommendations for,Myocarditis Pericarditis,2025,42
"Low- to medium-dosec corticosteroids should be considered for patients with pericarditis only in cases of contraindication/failure of aspirin/NSAIDs and colchicine, or when there is a specific indication to control symptoms and reduce recurrencesd.",IIa,C,10,Recommendations for,Myocarditis Pericarditis,2025,42
Hydroxychloroquine may be considered in patients with recurrent pericarditis refractory to standard therapy (including corticosteroids and anti-IL-1 agents) to prolong recurrence-free survival.,IIb,B,10,Recommendations for,Myocarditis Pericarditis,2025,42
Corticosteroids are not recommended as the first option for patients with pericarditis therapy without a specific indicationd.,III,C,10,Recommendations for,Myocarditis Pericarditis,2025,42
"interventional techniques including circulatory support in myocarditis (see Evidence Table 11) A timely and dedicated Shock Team discussion is recommended in patients with myocarditis in the presence of haemodynamic compromise, to decide on the need for escalation to MCS and to determine a long-term management plan.",I,C,11,Recommendations for,Myocarditis Pericarditis,2025,42
Temporary MCSc should be considered in patients with myocarditis and cardiogenic shock or acute decompensation in chronic myocarditis to stabilize the patients.,IIa,C,11,Recommendations for,Myocarditis Pericarditis,2025,42
surgical therapy (see Evidence Table 13) Surgical pericardiectomy is recommended in patients with chronic pericardial constriction or persistent constrictive pericarditis despite medical therapy to improve symptoms and survival.,I,C,13,Recommendations for,Myocarditis Pericarditis,2025,44
Tricuspid valve repair is recommended in patients with pericardial constriction and severe tricuspid valve regurgitation to improve symptoms and survival.,I,C,13,Recommendations for,Myocarditis Pericarditis,2025,44
management of arrhythmias and prevention of sudden cardiac death in myocarditis (see Evidence Table 14) Pacing in myocarditis Temporary transvenous external pacing should be considered in patients with acute myocarditis and high-degree conduction disorders as a bridge to recovery.,IIa,C,14,Recommendations for,Myocarditis Pericarditis,2025,45
"Ablation in myocarditis Catheter ablation, performed in specialized centres, should be considered in post-myocarditis patients with recurrent symptomatic SMVT or ICD shocks in whom AAD are ineffective, not tolerated, or not desired.",IIa,C,14,Recommendations for,Myocarditis Pericarditis,2025,45
ICD in myocarditis Secondary prevention ICD implantation is recommended in patients with non-activec myocarditis and haemodynamically not-tolerated sustained VT to prevent SCD.,I,C,14,Recommendations for,Myocarditis Pericarditis,2025,45
ICD implantation should be considered in patients with non-activec myocarditis and haemodynamically tolerated sustained VT to prevent SCD.,IIa,C,14,Recommendations for,Myocarditis Pericarditis,2025,45
"ICD implantation may be considered in patients with acute myocarditis and sustained VA (VT/VF) in the acute phase to prevent SCD.71,79,89,222,323–",IIb,C,14,Recommendations for,Myocarditis Pericarditis,2025,45
"Primary prevention ICD implantation may be considered in patients with myocarditis after the acute phase (3–6 months) and persistent risk factors for VAd to prevent SCD.89,332–334,336.",IIb,C,14,Recommendations for,Myocarditis Pericarditis,2025,45
"giant-cell myocarditis (see Evidence Table 16) EMB is recommended in patients with suspected GCM due to unexplained new-onset HF of up to 2 weeks associated with a normal or dilated left ventricle and new ventricular arrhythmias, second- or third-degree AVB, or failure to respond to usual care within 1 to 2 weeks to initiate specific treatment.",I,C,16,Recommendations for,Myocarditis Pericarditis,2025,51
Combined immunosuppressive therapy is recommended in patients with a diagnosed GCM.,I,C,16,Recommendations for,Myocarditis Pericarditis,2025,51
"myocarditis in sarcoidosis (see Evidence Table 17) Diagnosis CMR, using tissue characterization techniques, is recommended in patients with suspected CS to assess cardiac inflammation and myocardial involvement.408,421–",I,B,17,Recommendations for,Myocarditis Pericarditis,2025,52
"18F-FDG-PET is recommended for the diagnostic work-up, including detection of inflammation, as well as for follow-up and assessment of therapeutic response in patients with CS.426–",I,B,17,Recommendations for,Myocarditis Pericarditis,2025,52
Therapy ICD implantation is recommended in patients with CS and sustained ventricular arrhythmia (VT/VF) or aborted CA to prevent SCD.,I,B,17,Recommendations for,Myocarditis Pericarditis,2025,52
ICD implantation is recommended in patients with CS and LVEF ≤35% to prevent SCD.,I,C,17,Recommendations for,Myocarditis Pericarditis,2025,52
immune checkpoint inhibitor-associated myocarditis (see Evidence Table 18) Diagnostic triage within 24 h is recommendedc in patients with suspected myocarditis induced by ICI to initiate treatment rapidly.,I,C,18,Recommendations for,Myocarditis Pericarditis,2025,55
Immediate disruption of ICI and administration of high-dosage corticosteroids are recommended in patients with ICI-associated myocarditis in order to stop the inflammatory reaction and stabilize the patient.,I,C,18,Recommendations for,Myocarditis Pericarditis,2025,55
Second-line immunosuppression treatment should be considered in patients with steroid-refractory ICI-associated myocarditis.,IIa,C,18,Recommendations for,Myocarditis Pericarditis,2025,55
Second-line immunosuppression treatment may be considered in patients with fulminant/severe ICI-associated myocarditis.,IIb,C,18,Recommendations for,Myocarditis Pericarditis,2025,55
inflammatory cardiomyopathy (see Evidence Table 19) Guideline-directed heart failure treatments are recommended in patients with inflammatory cardiomyopathy to improve and/or stabilize left ventricular function.,I,C,19,Recommendations for,Myocarditis Pericarditis,2025,56
Specific medical therapy for the potentially underlying systemic disease is recommended in inflammatory cardiomyopathy.,I,C,19,Recommendations for,Myocarditis Pericarditis,2025,56
"Immunosuppressive therapy, guided by endomyocardial biopsy, should be considered in virus-negative inflammatory cardiomyopathies to suppress the autoimmune response.34,131,551–",IIa,B,19,Recommendations for,Myocarditis Pericarditis,2025,56
tuberculous pericarditis (see Evidence Table 20) Diagnosis and treatment of tuberculous pericarditis and effusion Diagnostic pericardiocentesis is recommended in all patients with suspected tuberculous pericarditis when diagnosis is not confirmed by non-invasive tests to identify the aetiological agent in pericardial fluid.,I,C,20,Recommendations for,Myocarditis Pericarditis,2025,57
Empirical antituberculosis chemotherapy is recommended in patients living in endemic areas with exudative pericardial effusion after excluding other causes to treat the most likely cause.,I,C,20,Recommendations for,Myocarditis Pericarditis,2025,57
Standard antituberculosis multidrug treatment for 6 months is recommended in patients with tuberculous pericarditis for the prevention of pericardial constriction.,I,C,20,Recommendations for,Myocarditis Pericarditis,2025,57
Pericardiectomy is recommended in patients with tuberculous pericarditis if the condition is not improving or is deteriorating after 4–8 weeks of antituberculosis therapy to change the course of disease.,I,C,20,Recommendations for,Myocarditis Pericarditis,2025,57
Adjunctive steroid therapy should be considered in HIV-negative cases to prevent the development of constrictive TB pericarditis.,IIa,C,20,Recommendations for,Myocarditis Pericarditis,2025,57
In non-endemic areas a pericardial biopsy may be considered in patients with >3 weeks of illness without aetiologic diagnosis.,IIb,C,20,Recommendations for,Myocarditis Pericarditis,2025,57
Empirical antituberculosis treatment is not recommended in patients living in non-endemic areas.,III,C,20,Recommendations for,Myocarditis Pericarditis,2025,57
post-cardiac injury syndrome (see Evidence Table 22) Anti-inflammatory therapy is recommended in patients with PCIS to hasten symptom remission and reduce recurrences.,I,B,22,Recommendations for,Myocarditis Pericarditis,2025,59
IL-1 antagonists are recommended in patients with refractory PCIS to prevent recurrences and progression to constriction.,I,B,22,Recommendations for,Myocarditis Pericarditis,2025,59
High-dose aspirin is recommended as the first-choice anti-inflammatory therapy for post-myocardial infarction pericarditis and in patients being already on antiplatelet therapy.,I,C,22,Recommendations for,Myocarditis Pericarditis,2025,59
"Colchicine, started 48 to 72 h before cardiac surgery, should be considered for 1 month in patients after cardiac surgery for the prevention of PCIS if there are no contraindications and if it is tolerated.",IIa,A,22,Recommendations for,Myocarditis Pericarditis,2025,59
Careful follow-up should be considered in patients with PCIS to exclude possible evolution towards constrictive pericarditis.,IIa,C,22,Recommendations for,Myocarditis Pericarditis,2025,59
purulent pericarditis (see Evidence Table 23) Urgent pericardiocentesis and/or a surgical window is recommended in patients with suspicion of purulent pericarditis to establish a diagnosis.,I,C,23,Recommendations for,Myocarditis Pericarditis,2025,60
Intrapericardial fibrinolysis should be considered in patients with purulent pericarditis to allow complete drainage of purulent fluid and to prevent constriction.,IIa,B,23,Recommendations for,Myocarditis Pericarditis,2025,60
"constrictive pericarditis (see Evidence Table 24) Diagnosis Multimodality imaging is recommended in all patients with suspected constrictive pericarditis to make the diagnosis and assess pericardial thickening, calcifications, and active inflammation.",I,C,24,Recommendations for,Myocarditis Pericarditis,2025,64
Cardiac catheterization for haemodynamic assessment should be considered in patients with suspected constrictive pericarditis when multimodality imaging is inconclusive.,IIa,C,24,Recommendations for,Myocarditis Pericarditis,2025,64
Therapy Anti-inflammatory therapy is recommended in haemodynamically stable patients with a transient or new diagnosis of constriction with concomitant evidence of pericardial inflammationc to prevent progression to constriction and avoid pericardiectomy.,I,C,24,Recommendations for,Myocarditis Pericarditis,2025,64
Pericardiectomy is recommended in patients with permanent constriction if there is no active inflammation or anti-inflammatory treatment is not successful after 3–6 months.,I,C,24,Recommendations for,Myocarditis Pericarditis,2025,64
"pregnancy, lactation, and reproductive issues (see Evidence Table 25) Pre-conception counselling is recommended in women with recurrent pericarditis or myocarditis to assess disease activity and to review therapy.",I,C,25,Recommendations for,Myocarditis Pericarditis,2025,65
NSAIDs should be considered in pregnant patients with pericarditis until the 20th week to treat an incessant/recurrent course.,IIa,C,25,Recommendations for,Myocarditis Pericarditis,2025,65
"During pregnancy and breastfeeding, corticosteroids at the minimal effective dose (preferably up to 20 mg prednisone daily) should be considered in patients with active pericarditis, despite NSAID (if feasible), to prevent an incessant/recurrent course.",IIa,C,25,Recommendations for,Myocarditis Pericarditis,2025,66
"Colchicine may be considered in pregnant patients with pericarditis, especially in patients already receiving this drug to prevent recurrences.",IIb,C,25,Recommendations for,Myocarditis Pericarditis,2025,66
Anakinra may be considered through pregnancy and lactation in pregnant patients with recurrent pericarditis who are not able to use alternative therapies to prevent an incessant/recurrent course.,IIb,C,25,Recommendations for,Myocarditis Pericarditis,2025,66
"physical activity and myocarditis/pericarditis (see Evidence Table 26) Recommendation Restriction of physical exercise until remission, for at least 1 month, is recommended in athletes and non-athletes after IMPS using an individualized approach to accelerate recovery.",I,C,26,Recommendations for,Myocarditis Pericarditis,2025,66
multidisciplinary teams in myopericardial syndromes (see Evidence Table 27) A multidisciplinary team discussion at a referral centre is recommended in patients with high-risk/ complicated IMPS to provide a patient-tailored approach.,I,C,27,Recommendations for,Myocarditis Pericarditis,2025,66
"Maternal risk assessment It is recommended to perform a risk assessment in all women with CVD of childbearing age using the mWHO 2.0 classificationc.44,45,47–",I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
"A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is recommended for women with mWHO 2.0c class IV conditions, including a shared decision-making process for pregnancy termination, involving psychological support.",I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
"It is recommended that women with CVD of mWHO 2.0c class II–III and above are evaluated and managed by a Pregnancy Heart Team from pre-pregnancy onwards through pregnancy and post-partum.44,45,47–",I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
"Methods of contraception It is recommended that women with CVD of mWHO 2.0c class II and above, or those at risk of developing CVD, receive individualized advice to determine the most suitable contraception method, including emergency contraception.",I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
"Progestin-only treatment, contraceptive implants, and/or levonorgestrel IUDs should be considered when there is any risk of thromboembolic events.73,92–",IIa,B,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
Genetic counselling Assessment by a clinical geneticist prior to pregnancy is recommended in women fulfilling diagnostic criteria for inherited cardiovascular disease to guide risk stratification and pre-natal genetic testing.,I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
"Pre-conception genetic counselling is recommended in couples with heritable CVD, whether genetic testing is being considered or not. It is recommended that this counselling is provided by an appropriately trained healthcare professional within a multidisciplinary team that offers psychological support and education to encourage decision-making.",I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
Reproductive technology It is recommended that single embryo transfer is performed in women with CVD.,I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
Pregnancy termination It is recommended to offer women with CVD access to termination of pregnancy that is tailored to their cardiac condition to minimize the risks of the procedure.,I,C,1,"Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)",Pregnancy CVD,2025,22
Echocardiography Transthoracic echocardiography is recommended as first-line imaging tool in any pregnant woman with unexplained or new cardiovascular signs or symptoms.,I,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
"Biomarkers Measurement of BNP and NT-proBNP levels should be considered prior to pregnancy in women with HF of any aetiology, including previous PPCM, cardiomyopathy, ACHD, and PAH, and be monitored during pregnancy according to the underlying disorder and in case of new-onset or worsening symptoms.",IIa,B,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
Ionizing radiation It is recommended to limit exposure to all medical ionizing radiation doses to ALARA levels.,I,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
"It is recommended to keep the radiation dose to the foetus as low as possible (preferably <50 mGy), particularly if the foetus is in the field of view.",I,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
A CT scan should be considered for PE when clinical benefits outweigh the risks to the mother and foetus.,IIa,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
A chest radiograph may be considered as a first-line imaging tool if other methods are not successful in clarifying the cause of dyspnoea.,IIb,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
Coronary angiography with minimal radiation may be considered during pregnancy if potential benefits outweigh the risks.,IIb,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
Cardiovascular magnetic resonance Discontinuation of lactation for 24 h should be considered in women in whom i.v. gadolinium is required.,IIa,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
"CMR imaging without gadolinium contrast should be considered for a definitive, clinically relevant diagnosis during pregnancy, if other non-invasive diagnostic measures are not sufficient.",IIa,C,2,Recommendations for diagnostic methods in pregnancy (see Evidence Table 2),Pregnancy CVD,2025,24
Timing and mode of delivery Vaginal delivery is recommended in most women with CVD.161–,I,B,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,26
Systemic antibiotic prophylaxis may be considered for delivery in women at high riskc.,IIb,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,26
Routine induction of labour prior to 39 weeks is not recommended in women with stable CVD.,III,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,26
Delivery in women on anticoagulants It is recommended that the timing of delivery is planned to ensure safe and effective peripartum anticoagulation.,I,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,26
It is recommended to discontinue VKAs and start therapeutic-dose LMWH or adjusted-dose i.v. UFH at the 36th week of gestation or 2 weeks before the planned delivery.,I,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,26
"In women at low riskd on therapeutic-dose LMWH, neuraxial anaesthesia and vaginal delivery (or caesarean section for obstetric indications) is recommended 24 h after the last dose of LMWH.",I,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,26
"If delivery starts while the mother is on VKAs or <2 weeks after discontinuation of VKAs, caesarean section is recommended for foetal protection.",I,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,27
"Post-delivery, it is recommended that the decision to restart LMWH or UFH is made after discussion with the Pregnancy Heart Team and the woman who gave birth.",I,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,27
"It is recommended to postpone the switch from heparin back to oral anticoagulants until 7–14 days post-partum when the wound area has healed, in consultation with the Pregnancy Heart Team.",I,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,27
"In women on therapeutic-dose LMWH, planned delivery should be considered at around 39 weeks to avoid the risk of spontaneous labour while fully anticoagulated.",IIa,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,27
"In women who are on antenatal anticoagulation, active management of the third stage of labour with oxytocin should be considered.",IIa,C,3,Recommendations for timing and mode of delivery (see Evidence Table 3),Pregnancy CVD,2025,27
Recommendation DOACs are not recommended during pregnancy.,III,C,4,Recommendation for direct oral anticoagulants and pregnancy,Pregnancy CVD,2025,31
"cardiomyopathies and pregnancy Clinical cardiological surveillance (ECG, echocardiogram, and Holter ECG monitoring) is recommended during pregnancy in women with CMPs, depending on individual risk.",I,C,5,Recommendations for,Pregnancy CVD,2025,35
"Vaginal delivery is recommended in most women with CMPs, unless there are obstetric indications for caesarean section, severe HF (EF <30% and/or NYHA class III/IV), uncontrolled arrhythmias, or severe outflow obstruction (≥50 mmHg) in women with HCM, or in women presenting in labour on VKAs.",I,C,5,Recommendations for,Pregnancy CVD,2025,35
"Continuation of beta-blockersc should be considered during pregnancy in women with CMPs, with close follow-up of foetal growth.",IIa,C,5,Recommendations for,Pregnancy CVD,2025,35
"Dilated cardiomyopathy In women with DCM and worsening of EF during pregnancy, counselling on the risk of recurrence during a subsequent pregnancy is recommended in all cases, even after recovery of LV function.",I,C,5,Recommendations for,Pregnancy CVD,2025,35
"Sotalol may be considered as an anti-arrhythmic drug in pregnant women with ARVC, with careful evaluation of QTc and while monitoring for foetal bradycardia and foetal growth and neonate hypoglycaemia.",IIb,C,5,Recommendations for,Pregnancy CVD,2025,35
Hypertrophic cardiomyopathy It is recommended to use the same risk stratification protocol for ventricular arrhythmias in pregnant women with HCM as for non-pregnant women with HCM.,I,C,5,Recommendations for,Pregnancy CVD,2025,35
It is recommended to start beta-blockersc in women with HCM who develop symptoms due to outflow tract obstruction or arrhythmia during pregnancy.,I,C,5,Recommendations for,Pregnancy CVD,2025,35
It is recommended that women with HCM with symptomatic LV dysfunction (EF <50%) and or severe LVOTO (≥50 mmHg) wishing to become pregnant are counselled by the Pregnancy Heart Team regarding the high risk of pregnancy-related adverse events.,I,C,5,Recommendations for,Pregnancy CVD,2025,35
Cardioversion for AF should be considered in pregnant women with HCM.,IIa,C,5,Recommendations for,Pregnancy CVD,2025,35
Disopyramide may be considered in pregnant women with HCM only when the potential benefits outweigh the risk of uterine contractions.,IIb,C,5,Recommendations for,Pregnancy CVD,2025,35
Myosin inhibitors are not recommended in women during pregnancy due to lack of safety data.,III,C,5,Recommendations for,Pregnancy CVD,2025,35
Tables 4–6) Monitoring and treatment of hypokalaemia and hypomagnesaemia is recommended in pregnant women with primary arrhythmia syndromes suffering from hyperemesis.,I,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,36
"Long QT syndrome Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in women with LQTS.312–",I,B,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,36
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk.,I,B,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,36
"Pre-pregnancy beta-blocker dose of nadolol or propranolol, is recommended in women with LQT2, particularly in the post-partum period, which represents a high-risk period for life-threatening arrhythmias.",I,B,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,36
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk woman with LQTS who are not adequately protected by pharmacological therapies or who have appropriate ICD shocks despite optimal medical therapy.,IIa,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
Brugada syndrome Quinidine therapy should be considered in pregnant women with BrS who have arrhythmic events during pregnancy.,IIa,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
"Catecholaminergic polymorphic ventricular tachycardia Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and lactation in women with CPVT.",I,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
"Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events such as syncope, VT, or cardiac arrest during pregnancy.",I,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
It is recommended that women with CPVT who are stable on beta-blockers (nadolol or propranolol as drugs of choice) and flecainide before pregnancy continue both drugs during pregnancy and post-partum.,I,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
The use of beta-blockersc during pregnancy and lactation should be considered in phenotype-negative women with a CPVT P/LP variant.,IIa,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk women with CPVT who are not adequately protected by pharmacological therapies or with appropriate ICD shocks despite optimal medical therapy.,IIa,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
Short QT syndrome It should be considered to continue quinidine therapy in women with SQTS throughout pregnancy and the post-partum period.,IIa,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
Quinidine therapy should be considered in pregnant women with SQTS and arrhythmic events during pregnancy.,IIa,C,6,Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence,Pregnancy CVD,2025,37
"peripartum cardiomyopathy (see Evidence Table 7) Counselling for women with PPCM about the risk of recurrence during a subsequent pregnancy and about contraception is recommended in all cases, even after recovery of LV function (LVEF >50%).",I,C,7,Recommendations for,Pregnancy CVD,2025,39
Adding at least prophylactic LMWH treatment to bromocriptine treatment in women with PPCM should be considered.,IIa,C,7,Recommendations for,Pregnancy CVD,2025,39
Genetic counselling and testing should be considered in women with PPCM.,IIa,C,7,Recommendations for,Pregnancy CVD,2025,39
"When a reversible course of HF is assumed, treatment in accordance with HF guidelines should be considered for at least 12 months after complete LV recovery (normalization of LV volumes and EF).",IIa,C,7,Recommendations for,Pregnancy CVD,2025,39
Bromocriptine treatment may be considered in addition to optimal HF treatment to enhance recovery of LV function in women with PPCM.358–,IIb,B,7,Recommendations for,Pregnancy CVD,2025,39
The use of a WCD may be considered in women with PPCM and LVEF <35%.,IIb,C,7,Recommendations for,Pregnancy CVD,2025,39
Counselling It is recommended that women with aortic disease have counselling about the risk of aortic dissection in pregnancy and the post-partum period.,I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an extended Pregnancy Heart Teamc considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of aortic dissection.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"It is recommended that women with vascular Ehlers–Danlos syndrome wishing to become pregnant are counselled regarding the very high risk of pregnancy-related adverse events by a multidisciplinary team, considering family history, genetic variant, and previous vascular events.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
Imaging Imaging of the entire aortad (CT or CMR) is recommended before pregnancy in women with known or suspected aortic disease.,I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"In women with aortic dilatation related to BAV, imaging (with TTE, and CMR/CT if needed) of the aortic root, ascending aorta, and descending aorta (to rule out coarctation) is recommended before pregnancy.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"In women with low-risk aortic disease (mWHO 2.0 classes II and II–III), one-time echocardiographic imaging between 20 and 30 weeks of gestation and imaging at 6 months post-partum is recommended.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"In women with moderate to high-risk aortic disease (mWHO 2.0 classes III and IV), repeated echocardiographic imaging every 4–12 weeks (depending on diagnosis and severity of dilatation) is recommended during pregnancy and until 6 months post-partum.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
CMR (without gadolinium) imaging of the entire aorta is recommended in pregnant women at risk of or with known aortic dilatation who have not had recent pre-pregnancy cross sectional imaging.,I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"Treatment—medical When a woman with known aortic dilatation, history of dissection, or P/LP variant associated with aortic disease becomes pregnant, strict and individualized BP control is recommended.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
Beta-blocker therapye throughout pregnancy and in the post-partum period is recommended in women with MFS and other HTADs.,I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
Celiprolol is recommended in women with vascular Ehlers–Danlos syndrome during pregnancy and lactation.,I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"Treatment—intervention/surgical It is recommended that indications for pre-pregnancy aortic root and/or ascending aortic surgery are guided by aortic morphology, underlying pathology, family history, genetic variant, previous vascular events, and patient’s preference.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
It is recommended that centres managing pregnancies in women with moderate to high-risk aortic disease (mWHO 2.0 class III/IV) can provide cardiovascular surgery in case of peripartum adverse events.,I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"Specific conditions In women with MFS and aortic root diameters >45 mm, surgery before pregnancy is recommended.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"In women with LDS with P/LP variants in TGFBR1, TGFBR2, and aortic root diameters ≥45 mm, surgery before pregnancy is recommended.437–",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,42
"In women with BAV and aortic root or ascending aortic diameter ≥50 mm, surgery before pregnancy is recommended.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women without an identifiable P/LP variant with aortic root or ascending aortic diameters ≥50 mm, surgery before pregnancy is recommended.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with HTAD and aortic arch, descending aortic, or abdominal aortic diameters ≥50 mm, surgery before pregnancy should be considered.",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with LDS with P/LP variants in TGFB2, TGFB3, SMAD2, and SMAD3, and aortic root diameters ≥45 mm, surgery before pregnancy should be considered.437–",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with BAV and root phenotype or family history of aortic aneurysm or dissection, surgery before pregnancy should be considered if the aorta is ≥45 mm.",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women without an identifiable P/LP variant with aortic root or ascending aortic aneurysm ≥45 mm, surgery before pregnancy should be considered in the presence of a family history of aortic aneurysm, aortic dissection, uncontrolled arterial hypertension, or on patient’s preference.",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with MFS and aortic root diameters between 40 and 45 mm, surgery before pregnancy may be considered if risk factors (growth >3 mm/year, family history of aortic dissection) are present.",IIb,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with LDS with P/LP variants in TGFBR1 or TGFBR2 and aortic root diameters ≥40 mm, surgery before pregnancy may be considered.",IIb,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with nsHTAD and aortic root diameters ≥40–44 mm, surgery before pregnancy may be considered depending on the genetic variant, family history, and aortic growth rate.",IIb,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"Delivery In women with an aorta <40 mm, vaginal delivery is recommended.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with vascular Ehlers–Danlos syndrome, caesarean section at 37 weeks is recommended for obstetrical reasons.",I,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with an aorta 40–45 mm, vaginal delivery with epidural anaesthesia and an expedited second stage should be considered.",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with an aorta ≥45 mm, caesarean section should be considered.",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with acute, subacute, or chronic aortic dissection, caesarean section should be considered.",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"In women with an aorta 40–45 mm, caesarean section may be considered.",IIb,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
The use of ergometrine post-delivery is not recommended in women with aortopathy.,III,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"Cardiac surgery during pregnancy Delivery before cardiac surgery should be considered as soon as the foetus is viable, taking gestational age, comorbidities, and the available level of neonatal care into account.",IIa,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"Cardiac surgery may be considered during pregnancy when conservative and medical therapy has failed, and in situations that threaten the mother’s life or that are not amenable to percutaneous treatment.",IIb,C,8,"Recommendations for aortopathies, cardiac surgery, and pregnancy",Pregnancy CVD,2025,43
"pulmonary arterial hypertension and pregnancy It is recommended that women of childbearing potential with PAH wishing to become pregnant are counselled by a multidisciplinary team regarding the very high risk of pregnancy-related adverse events, encouraging a shared decision-making process about whether to become pregnant.",I,C,10,Recommendations for,Pregnancy CVD,2025,48
It is recommended to provide clear contraceptive advice to women of childbearing potential with PAH.,I,C,10,Recommendations for,Pregnancy CVD,2025,48
"For women with PAH requiring pregnancy termination, it is recommended to perform this in PH centres.",I,C,10,Recommendations for,Pregnancy CVD,2025,48
Right-heart catheterization should be considered during pregnancy if there is diagnostic uncertainty or to assist with important therapeutic decisions.,IIa,C,10,Recommendations for,Pregnancy CVD,2025,48
"Endothelin receptor antagonists, riociguat, and selexipag are not recommended during pregnancy.",III,C,10,Recommendations for,Pregnancy CVD,2025,48
"Tables 9 and 10) For pregnant or post-partum women at high riskc of VTE, a prophylactic fixed dose of LMWH is recommended over a higher weight-adjusted dose to reduce the risk of VTE.",I,B,11,Recommendations for venous thromboembolic diseases and pregnancy (see Evidence,Pregnancy CVD,2025,52
"In pregnant women or women in the post-partum period with suspicion of VTE (DVT and/or PE), an immediate formal diagnostic assessment with validated methods is recommended and should not be postponed.",I,B,11,Recommendations for venous thromboembolic diseases and pregnancy (see Evidence,Pregnancy CVD,2025,52
"In pregnant women or women in the post-partum period with newly diagnosed VTE (DVT and/or PE), the involvement of the Pregnancy Heart Team, including a vascular specialist and a haematologist, is recommended.",I,C,11,Recommendations for venous thromboembolic diseases and pregnancy (see Evidence,Pregnancy CVD,2025,52
"In pregnant or post-partum women with a diagnosis of VTE without haemodynamic instability, anticoagulation is recommended by using therapeutic-dose LMWH based on early pregnancy body weight.",I,C,11,Recommendations for venous thromboembolic diseases and pregnancy (see Evidence,Pregnancy CVD,2025,52
"In pregnant women or women in the post-partum period with a strong clinical suspicion of VTE, initiation of treatment with a therapeutic dose of LMWH should be considered until the presence of VTE has been ruled out or confirmed.",IIa,C,11,Recommendations for venous thromboembolic diseases and pregnancy (see Evidence,Pregnancy CVD,2025,52
"In pregnant or post-partum women with a diagnosis of acute high-risk PE,d a catheter-based reperfusion strategy or systemic thrombolysis should be considered.533–",IIa,C,11,Recommendations for venous thromboembolic diseases and pregnancy (see Evidence,Pregnancy CVD,2025,52
"In pregnant or post-partum women with a diagnosis of acute high-risk PE,d surgical thrombectomy may be considered as an alternative to a catheter-based approach or systemic thrombolysis.533–",IIb,C,11,Recommendations for venous thromboembolic diseases and pregnancy (see Evidence,Pregnancy CVD,2025,52
"In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including SCAD), and acute aortic syndrome.",I,C,12,Recommendations for coronary artery disease and pregnancy (see Evidence Table 11),Pregnancy CVD,2025,55
"It is recommended to manage pregnant women with ACS in the same way as non-pregnant women, including diagnostic investigations and interventions.",I,C,12,Recommendations for coronary artery disease and pregnancy (see Evidence Table 11),Pregnancy CVD,2025,55
Low-dose ASA is recommended as the antiplatelet treatment of choice during pregnancy and lactation when single antiplatelet treatment is indicated.573–,I,B,12,Recommendations for coronary artery disease and pregnancy (see Evidence Table 11),Pregnancy CVD,2025,55
"If DAPT is required, clopidogrel is recommended as the P2Y12 inhibitor of choice during pregnancy.",I,C,12,Recommendations for coronary artery disease and pregnancy (see Evidence Table 11),Pregnancy CVD,2025,55
"The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks.",I,C,12,Recommendations for coronary artery disease and pregnancy (see Evidence Table 11),Pregnancy CVD,2025,55
"A vaginal delivery should be considered in most pregnant women with ACS, depending on LV function and clinical symptoms.",IIa,C,12,Recommendations for coronary artery disease and pregnancy (see Evidence Table 11),Pregnancy CVD,2025,55
Continuation of statins may be considered during pregnancy in women with established ASCVD.580–,IIb,C,12,Recommendations for coronary artery disease and pregnancy (see Evidence Table 11),Pregnancy CVD,2025,55
12–17) It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women.,I,B,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in a pregnant woman is an emergency, and treatment in a hospital setting is recommended.",I,C,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
Low-dose aspirin (75–150 mg daily) is recommended in women at moderate or high risk of pre-eclampsia (i.e. at least one high-risk factor or two moderate-risk factors for pre-eclampsia) from weeks 12 to 36/37.,I,A,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"In women with gestational hypertension, initiation of drug treatment is recommended at systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg.c583–",I,B,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
Methyldopa is recommended for the treatment of hypertension in pregnancy.,I,B,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"Labetalol, metoprolol, and dihydropyridine CCBs are recommended for the treatment of hypertension in pregnancy.",I,C,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short acting nifedipine or methyldopa is recommended for acute reduction in blood pressure.625,626 Intravenous hydralazine is a second-line option.",I,C,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"In pre-eclampsia associated with pulmonary oedema, nitroglycerine given as an i.v. infusion is recommended.",I,C,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"In women with pre-eclampsia without severe features, delivery is recommended at 37 weeks.",I,B,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
It is recommended to expedite delivery in women with pre-eclampsia associated with adverse markers such as haemostatic disorders.,I,C,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"In women with gestational hypertension, delivery is recommended at 39 weeks.",I,B,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
"Ambulatory BP or home BP monitoring should be considered to exclude white-coat and masked hypertension, which are common in pregnancy.",IIa,C,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
Home BP monitoring may be considered as an adjunct to office BP measurements in pregnant women to detect new-onset hypertension or for monitoring BP control.,IIb,B,13,Recommendations for hypertensive disorders and pregnancy (see Evidence Tables,Pregnancy CVD,2025,60
Acute management of SVT and AF Immediate electrical cardioversion is recommended for acute treatment of SVT with haemodynamic instability.,I,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Vagal manoeuvres and i.v. adenosine are recommended for conversion of haemodynamically stable supraventricular tachycardias.,I,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Intravenous beta-blockersc (e.g. metoprolol) are recommended as the first-line option for acute rate control in pregnant women with AF or AF with preserved LVEF and rapid ventricular rate.,I,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Intravenous digoxin or verapamil (if preserved LVEF) should be considered as a second-line option for initial rate control in pregnant women with AF or AFL and rapid ventricular rate.,IIa,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Ibutilide or flecainide may be considered for termination of AF and AFL in pregnant women without structural heart disease.,IIb,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Long-term management of SVT and AF Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated thromboembolic risk.,I,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
"Beta-1-selective blockersc are recommended for rate control in pregnant women with AF, AFL, or FAT.",I,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Beta-1-selective blockersc or verapamil are recommended for the prevention of SVT in women without pre-excitation on resting ECG.,I,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Flecainide or propafenone are recommended for the prevention of arrhythmias in pregnant women with WPW syndrome.,I,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
"Digoxin or verapamil should be considered for rate control in pregnant women with AF, AFL, or FAT when beta-blockers fail or are not tolerated.",IIa,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
"Flecainide, in addition to beta-blockers, should be considered for long-term AF rhythm control in pregnancy.",IIa,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
Sotalol may be considered for rhythm management of AF and AFL with controlling for pro-arrhythmic risk factors as in non-pregnant women.,IIb,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
"Catheter ablation may be considered in pregnant women with recurrent, long symptomatic SVT, or with contraindications to pharmacological therapies.",IIb,C,14,Recommendations for supraventricular tachycardia and pregnancy,Pregnancy CVD,2025,64
"ventricular tachycardia, device implantation, catheter ablation, and pregnancy Immediate electrical cardioversion is recommended for both unstable and stable ventricular tachycardias.",I,C,15,Recommendations for,Pregnancy CVD,2025,67
Beta-blockers or verapamil are recommended for the prevention of idiopathic sustained VT.,I,C,15,Recommendations for,Pregnancy CVD,2025,67
"If an ICD, pacemaker, or resynchronization therapy device is indicated during pregnancy, implantation is recommended with optimal radiation protection.",I,C,15,Recommendations for,Pregnancy CVD,2025,67
"In idiopathic RVOT-VT, flecainide should be considered if beta-blockers fail, to prevent recurrence.",IIa,C,15,Recommendations for,Pregnancy CVD,2025,67
"When performing catheter ablation during pregnancy, the use of non-fluoroscopic mapping and navigation systems should be considered.663–",IIa,C,15,Recommendations for,Pregnancy CVD,2025,67
"Catheter ablation with electro-anatomical mapping systems may be considered in experienced centres in the case of sustained drug-refractory, recurrent, and/ or poorly tolerated VT if there are no other alternatives.",IIb,C,15,Recommendations for,Pregnancy CVD,2025,67
cardiac arrest and pregnancy Recommendation Continuous manual left uterine displacement during CPR in pregnant women (≥20 weeks) with cardiac arrest is recommended to relieve aortocaval compression.,I,C,16,Recommendations for,Pregnancy CVD,2025,69
It is recommended to establish i.v. access above the diaphragm to ensure that the i.v. therapy is not obstructed by the gravid uterus.,I,C,16,Recommendations for,Pregnancy CVD,2025,69
It is recommended to perform the same chest compressions and defibrillation protocols in pregnant as in non-pregnant women.,I,C,16,Recommendations for,Pregnancy CVD,2025,69
Anterolateral defibrillator pad placement is recommended with the lateral pad placed under the breast.,I,C,16,Recommendations for,Pregnancy CVD,2025,69
It is recommended that no drugs are withheld in pregnant women with cardiac arrest due to concerns of teratogenicity.,I,C,16,Recommendations for,Pregnancy CVD,2025,69
"Immediate caesarean section at the site of the arrest should be considered and immediately prepared if ROSC has not been achieved in the mother after 4 min of resuscitative efforts and if the foetus is viable, taking gestational age, comorbidities, and the available level of medical care into account.",IIa,C,16,Recommendations for,Pregnancy CVD,2025,69
"congenital atrioventricular block and pregnancy Recommendation In pregnant women with asymptomatic congenital AV block, normal cardiac anatomy and function, a narrow QRS complex, and ventricular rate (≥50 b.p.m.), a prophylactic temporary pacemaker during delivery is not recommended.",III,C,17,Recommendation for,Pregnancy CVD,2025,69
Intervention is recommended before pregnancy in symptomatic patients with severe aortic stenosis.,I,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
Intervention is recommended before pregnancy in women with mitral stenosis and a valve area <1.5 cm2.,I,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
"In pregnant women with symptomatic mitral stenosis or pulmonary hypertension, restricted activities and beta-blockers are recommended.",I,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
"In pregnant women with mitral stenosis, diuretics are recommended when congestive symptoms persist despite beta-blockers.",I,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
"Full therapeutic-dose anticoagulation is recommended in women with mitral stenosis complicated by AF, left atrial thrombus, or prior embolism.",I,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
"Surgical treatment is recommended before pregnancy in women with severe aortic or mitral regurgitation with symptoms, impaired ventricular function, or marked ventricular dilatation.",I,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
Diuretics are recommended in pregnant women with regurgitant lesions when symptoms or signs of congestion occur.,I,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
Intervention should be considered before pregnancy in those with asymptomatic severe aortic stenosis after counselling on the risks and benefits.,IIa,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
Percutaneous mitral commissurotomy for mitral stenosis should be considered in pregnant women with severe symptoms or systolic pulmonary artery pressure >50 mmHg despite medical therapy.,IIa,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
Valve surgery during pregnancy should only be considered when there is a maternal mortality risk and other treatment options have failed.,IIa,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
"In very selected symptomatic pregnant women with severe aortic stenosis not responding to medical therapy, non-surgical options such as balloon valvuloplasty or TAVI may be considered.",IIb,C,18,Recommendations for native valve disease and pregnancy,Pregnancy CVD,2025,72
A bioprosthetic valve is recommended (over a mechanical valve) in young women contemplating pregnancy requiring a valve prosthesis.,I,B,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
It is recommended that the type of valve surgery or intervention for a woman contemplating pregnancy is chosen in consultation with the Pregnancy Heart Team.,I,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
Women with mechanical heart valves It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with an MHV prior to pregnancy or as soon as pregnancy is recognized.,I,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
It is recommended that pregnant women with an MHV are managed by the Pregnancy Heart Team.,I,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
"In pregnant women on VKAs, it is recommended to perform INR monitoring weekly or at a minimum every 2 weeks.",I,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
"In pregnant women with MHVs on therapeutic-dose LMWH, it is recommended to check peak anti-factor Xa levels and to target levels according to individualized risk.",I,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
"During the second and third trimesters until the 36th week, continuing VKAs should be considered in women with prosthetic heart valves at higher risk of thrombosis.",IIa,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
"During the second and third trimesters, continuing LMWH with anti-factor Xa level monitoring and dose adjustment may be considered in women at lower risk of thrombosis.",IIb,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
LMWH is not recommended when anti-factor Xa level monitoring is not available.,III,C,19,Recommendations for prosthetic valves and pregnancy (see Evidence Table 18),Pregnancy CVD,2025,73
chronic and acute heart failure and pregnancy (see Evidence Table 19) Chronic heart failure It is recommended that women with HFrEF are advised about the risk of deterioration of cardiac function during pregnancy and peripartum.,I,C,20,Recommendations for,Pregnancy CVD,2025,75
"In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta-1-selective blockers (metoprolol, bisoprolol) with close maternal and foetal monitoring.",I,C,20,Recommendations for,Pregnancy CVD,2025,75
Anticoagulation with therapeutic doses of LMWH is recommended in pregnant women with intracardiac thrombus or decreased LV function with EF <35%.,I,C,20,Recommendations for,Pregnancy CVD,2025,75
"It is recommended to optimize HF guideline-directed medical therapy after delivery, taking contraindicated drugs during lactation into accountc.",I,C,20,Recommendations for,Pregnancy CVD,2025,75
"Due to the high metabolic demands of lactation, avoiding lactation may be considered in women with severe HF.",IIb,C,20,Recommendations for,Pregnancy CVD,2025,75
"ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 inhibitors are not recommended during pregnancy due to adverse foetal effects.",III,C,20,Recommendations for,Pregnancy CVD,2025,75
"Acute heart failure Inotropes and/or vasopressors are recommended in pregnant women with cardiogenic shock with levosimendan, dobutamine, and milrinone as recommended agents.",I,C,20,Recommendations for,Pregnancy CVD,2025,75
"Urgent delivery with caesarean section is recommended in pregnant women with cardiogenic shock as soon as the foetus is viable, taking gestational age, comorbidities, and the available level of medical care into account.",I,C,20,Recommendations for,Pregnancy CVD,2025,75
Early transfer of pregnant women in cardiogenic shock to a facility providing mechanical circulatory support should be considered.,IIa,C,20,Recommendations for,Pregnancy CVD,2025,75
Preventing lactation may be considered in women with severe HF due to the high metabolic demands of lactation.,IIb,B,20,Recommendations for,Pregnancy CVD,2025,75
"heart transplantation and pregnancy It is recommended to postpone pregnancy until at least 1 year after heart transplantation, taking individual risk factors into account.",I,C,21,Recommendations for,Pregnancy CVD,2025,77
"In women with a heart transplant, it is recommended that immunosuppression serum drug levels are monitored during pregnancy every 4 weeks until the 32nd week, then every 2 weeks until the 36th week, then weekly until delivery, and for 6–12 months after delivery to guide dosing.",I,C,21,Recommendations for,Pregnancy CVD,2025,77
"It is recommended to perform weekly monitoring of donor-specific antibodies for at least 6–12 months after delivery.275,741,749–",I,C,21,Recommendations for,Pregnancy CVD,2025,77
Paternal HLA testing prior to conception should be considered due to the risk of developing donor-specific antibodies.,IIa,C,21,Recommendations for,Pregnancy CVD,2025,77
Mycophenolic acid therapy is not recommended in pregnancy and should be dis,III,C,21,Recommendations for,Pregnancy CVD,2025,77
cardio-oncology and pregnancy It is recommended that pregnant women with cancer who require cardiotoxic cancer therapy are jointly managed by the Pregnancy Heart Team and the cardio-oncology team.,I,C,22,Recommendations for,Pregnancy CVD,2025,78
Cardiac troponin and NP measurements may be considered at baseline and during anthracycline chemotherapy in pregnant women with cancer.,IIb,C,22,Recommendations for,Pregnancy CVD,2025,78
"Tables 20 and 21) It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health.",I,B,23,Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence,Pregnancy CVD,2025,81
"In women with persistent post-partum hypertension beyond 6 weeks to 3 months post-partum, initiation of antihypertensive therapy with reference to lactating status is recommended following current guidelines.",I,B,23,Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence,Pregnancy CVD,2025,81
"In cases where adoption of healthy lifestyle choices alone is inadequate to control post-partum glucose levels, initiation of pharmacotherapy following current guidelines is recommended.",I,C,23,Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence,Pregnancy CVD,2025,81
It is recommended that women with a history of GDM undergo a formal oGTT 6–12 weeks post-partum with a repeat assessment at 6–12 months and regular annual follow-up visits to screen for diabetes.,I,C,23,Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence,Pregnancy CVD,2025,81
Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum hypertension in the first 6 weeks after delivery.,I,C,23,Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence,Pregnancy CVD,2025,81
"In women with a history of any APO, cardiovascular risk assessment should be considered at 3 months post-partum with repeat assessment at 6–12 months after implementation of appropriate lifestyle interventions, and regular long-term follow-up thereafter.",IIa,C,23,Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence,Pregnancy CVD,2025,81
Breastfeeding may be considered in order to lower the future cardiovascular risk in women with APOs.,IIb,C,23,Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence,Pregnancy CVD,2025,81
"management of chronic coronary syndrome in patients with valvular heart disease (see also Supplementary data online, Evidence Table 1) Diagnosis of coronary artery disease CCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD.122–",I,B,1,Recommendations for the,Valvular Heart Disease,2025,22
Invasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of obstructive CAD.,I,C,1,Recommendations for the,Valvular Heart Disease,2025,22
Invasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR.,I,C,1,Recommendations for the,Valvular Heart Disease,2025,22
"Omission of invasive coronary angiography should be considered in TAVI candidates, if procedural planning CT angiography is of sufficient quality to rule out significant CAD.125–",IIa,B,1,Recommendations for the,Valvular Heart Disease,2025,22
"management of atrial fibrillation in patients with native valvular heart disease (see also Supplementary data online, Evidence Tables 2 and 3) Anticoagulation DOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC.156–",I,A,2,Recommendations for the,Valvular Heart Disease,2025,23
The use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2.,III,B,2,Recommendations for the,Valvular Heart Disease,2025,23
"Surgical interventions Concomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent symptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons.166–",I,A,2,Recommendations for the,Valvular Heart Disease,2025,23
Surgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent cardioembolic stroke and systemic thromboembolism.160–,I,B,2,Recommendations for the,Valvular Heart Disease,2025,23
"Concomitant surgical ablation should be considered in patients undergoing non-MV surgery with AF suitable for a rhythm control strategy to prevent symptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons.",IIa,B,2,Recommendations for the,Valvular Heart Disease,2025,23
"(see also Supplementary data online, Evidence Tables 4–8) Severe aortic regurgitation AV surgery is recommended in symptomatic patients with severe AR regardless of LV function.224–",I,B,3,Recommendations on indications for intervention in severe aortic regurgitation,Valvular Heart Disease,2025,28
AV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients with small body size (BSA <1.68 m2)] or resting LVEF ≤50%.,I,B,3,Recommendations on indications for intervention in severe aortic regurgitation,Valvular Heart Disease,2025,28
AV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending aorta.,I,C,3,Recommendations on indications for intervention in severe aortic regurgitation,Valvular Heart Disease,2025,28
"AV repair should be considered in selected patients with severe AR at experienced centres, when durable results are expected.",IIa,B,3,Recommendations on indications for intervention in severe aortic regurgitation,Valvular Heart Disease,2025,28
"AV surgery may be considered in asymptomatic patients with severe AR and LVESDi >22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2 [especially in patients with small body size (BSA <1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical risk is low.",IIb,B,3,Recommendations on indications for intervention in severe aortic regurgitation,Valvular Heart Disease,2025,28
"Concomitant surgery of the ascending aorta Valve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres, when durable results are expected.247,250–",I,B,3,Recommendations on indications for intervention in severe aortic regurgitation,Valvular Heart Disease,2025,28
"When AV surgery is indicated and the predicted surgical risk is low, replacement of the aortic root or ascending aorta should be considered if the maximal diameter is ≥45 mm.d",IIa,C,3,Recommendations on indications for intervention in severe aortic regurgitation,Valvular Heart Disease,2025,28
"aortic stenosis, and recommended mode of intervention (see also Supplementary data online, Evidence Tables 9–13) Symptomatic patients with severe aortic stenosis Intervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, Vmax ≥4.0 m/s, AVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)].388,471–",I,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Intervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF (<50%) after careful confirmation that AS is severe.",I,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Intervention should be considered in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with normal LVEF (≥50%) after careful confirmation that AS is severe.c 293,348,349,476–",IIa,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Asymptomatic patients with severe aortic stenosis Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause.14,354–",I,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS and LVEF ≥50% as an alternative to close active surveillance, if the procedural risk is low.360–",IIa,A,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Intervention should be considered in asymptomatic patients with severe AS and LVEF ≥50% if the procedural risk is low and one of the following parameters is present: • Very severe AS (mean gradient ≥60 mmHg or Vmax >5.0 m/s).14,362,363,482–484 • Severe valve calcification (ideally assessed by CCT) and Vmax progression ≥0.3 m/s/year.303,353,364 • Markedly elevated BNP/NT-proBNP levels (more than three times age- and sex-corrected normal range, confirmed on repeated measurement without other explanation).97,365 • LVEF <55% without another cause.14,354,356–",IIa,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
Intervention should be considered in asymptomatic patients with severe AS and a sustained fall in BP (>20 mmHg) during exercise testing.,IIa,C,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Mode of intervention It is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have on-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team.",I,C,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"It is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural characteristics, incorporating lifetime management considerations and estimated life expectancy.",I,C,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable.d 1–4,389–",I,A,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"SAVR is recommended in patients <70 years of age, if the surgical risk is low.e",I,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.2,4,396,397,429,488–",I,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Non-transfemoral TAVI should be considered in patients who are unsuitable for surgery and transfemoral access.417–423,491–",IIa,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"TAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable.430–432,434,499–",IIb,B,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
"Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those with severe AS who require urgent high-risk NCS.",IIb,C,4,Recommendations on indications for intervention in symptomatic and asymptomatic severe,Valvular Heart Disease,2025,36
the time of coronary artery bypass grafting or ascending aorta surgery SAVR is recommended in symptomatic and asymptomatic patients with severe AS undergoing CABG or surgical intervention on the ascending aorta.,I,C,5,Recommendations on indications for concomitant aortic valve replacement at,Valvular Heart Disease,2025,37
SAVR should be considered in symptomatic and asymptomatic patients with moderate ASc undergoing CABG or surgical intervention on the ascending aorta.,IIa,C,5,Recommendations on indications for concomitant aortic valve replacement at,Valvular Heart Disease,2025,37
"indications for intervention in severe primary mitral regurgitation (see also Supplementary data online, Evidence Tables 14–16) MV repair is the recommended surgical technique to treat patients with severe PMR when the result is expected to be durable.",I,B,6,Recommendations on,Valvular Heart Disease,2025,40
MV surgery is recommended in symptomatic patients with severe PMR considered operable by the Heart Team.,I,B,6,Recommendations on,Valvular Heart Disease,2025,40
MV surgery is recommended in asymptomatic patients with severe PMR and LV dysfunction (LVESD ≥40 mm or LVESDi ≥20 mm/m2 or LVEF ≤60%).,I,B,6,Recommendations on,Valvular Heart Disease,2025,40
"MV surgery should be considered in asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi <20 mm/m2, and LVEF >60%) in the presence of PH (SPAP at rest >50 mmHg), or AF secondary to MR.517,518,562,565 Ila Surgical MV repair should be considered in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi <20 mm/m2, and LVEF >60%) in the presence of significant LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm), when performed in a Heart Valve Centre and a durable repair is likely.",IIa,B,6,Recommendations on,Valvular Heart Disease,2025,41
TEER should be considered in symptomatic patients with severe PMR who are anatomically suitable and at high surgical risk according to the Heart Team.,IIa,B,6,Recommendations on,Valvular Heart Disease,2025,41
Minimally invasive MV surgery may be considered at experienced centres to reduce the length of stay and accelerate recovery.,IIb,B,6,Recommendations on,Valvular Heart Disease,2025,41
"for intervention in secondary mitral regurgitation (see also Supplementary data online, Evidence Tables 17–20) Severe atrial secondary mitral regurgitation MV surgery, surgical AF ablation, if indicated, and LAAO should be considered in symptomatic patients with severe atrial SMR under optimal medical therapy.627–",IIa,B,7,Recommendations on indications,Valvular Heart Disease,2025,45
"TEER may be considered in symptomatic patients with severe atrial SMR not eligible for surgery after optimization of medical therapy including rhythm control, when appropriate.",IIb,B,7,Recommendations on indications,Valvular Heart Disease,2025,45
MV surgery may be considered in patients with moderate SMR undergoing CABG.622–,IIb,B,7,Recommendations on indications,Valvular Heart Disease,2025,45
PCI followed by TEER after re-evaluation of MR may be considered in symptomatic patients with chronic severe ventricular SMR and non-complex CAD.,IIb,C,7,Recommendations on indications,Valvular Heart Disease,2025,45
"Severe ventricular secondary mitral regurgitation without concomitant coronary artery disease TEER is recommended to reduce HF hospitalizations and improve quality of life in haemodynamically stable, symptomatic patients with impaired LVEF (<50%) and persistent severe ventricular SMR, despite optimized GDMT and CRT (if indicated), fulfilling specific clinical and echocardiographic criteria.c",I,A,7,Recommendations on indications,Valvular Heart Disease,2025,45
"TEER may be considered for symptom improvement in selected symptomatic patients with severe ventricular SMR not fulfilling the specific clinical and echocardiographic criteria,c after careful evaluation of LVAD or HTx.203,608–",IIb,B,7,Recommendations on indications,Valvular Heart Disease,2025,45
MV surgery may be considered in symptomatic patients with severe ventricular SMR without advanced HF who are not suitable for TEER.,IIb,C,7,Recommendations on indications,Valvular Heart Disease,2025,45
"indications for percutaneous mitral commissurotomy, mitral valve surgery, and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis (see also Supplementary data online, Evidence Table 21) PMC is recommended in symptomatic patients in the absence of unfavourable characteristics for PMC.c 651–",I,B,8,Recommendations on,Valvular Heart Disease,2025,48
PMC is recommended in any symptomatic patients with a contraindication or at high risk for surgery.,I,C,8,Recommendations on,Valvular Heart Disease,2025,48
MV surgery is recommended in symptomatic patients who are not suitable for PMC.,I,C,8,Recommendations on,Valvular Heart Disease,2025,48
PMC should be considered as initial treatment in symptomatic patients with suboptimal anatomy but no unfavourable clinical characteristics for PMC.c,IIa,C,8,Recommendations on,Valvular Heart Disease,2025,48
"PMC should be considered in asymptomatic patients without unfavourable clinical and anatomical characteristics for PMC, and: • High thromboembolic risk (history of systemic embolism, dense spontaneous contrast in the LA, new-onset or paroxysmal AF), and/or • High risk of haemodynamic decompensation (SPAP >50 mmHg at rest, need for major NCS, pregnant or desire for pregnancy).",IIa,C,8,Recommendations on,Valvular Heart Disease,2025,48
TMVI may be considered in symptomatic patients with extensive MAC and severe MV dysfunction at experienced Heart Valve Centres with expertise in complex MV surgery and transcatheter interventions.,IIb,C,8,Recommendations on,Valvular Heart Disease,2025,48
"also Supplementary data online, Evidence Tables 22 and 23) Careful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk, and likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention.",I,C,9,Recommendations on indications for intervention in tricuspid regurgitation (see,Valvular Heart Disease,2025,53
"Concomitant TV repair should be considered in patients with moderate primary or secondary TR, to avoid progression of TR and RV remodelling.",IIa,B,9,Recommendations on indications for intervention in tricuspid regurgitation (see,Valvular Heart Disease,2025,53
"Concomitant TV repair may be considered in selected patients with mild secondary TR and tricuspid annulus dilatation (≥40 mm or >21 mm/m2), to avoid progression of TR and RV remodelling.723–",IIb,B,9,Recommendations on indications for intervention in tricuspid regurgitation (see,Valvular Heart Disease,2025,53
Patients with severe tricuspid regurgitation without left-sided valvular heart disease requiring surgery TV surgeryc is recommended in symptomatic patients with severe primary TR without severe RV dysfunction or severe PH.,I,C,9,Recommendations on indications for intervention in tricuspid regurgitation (see,Valvular Heart Disease,2025,53
"TV surgeryc should be considered in asymptomatic patients with severe primary TR who have RV dilatation/RV function deterioration, but without severe LV/RV dysfunction or severe PH.",IIa,C,9,Recommendations on indications for intervention in tricuspid regurgitation (see,Valvular Heart Disease,2025,53
"TV surgeryc should be considered in patients with severe secondary TR who are symptomatic or have RV dilatation/RV function deterioration, but without severe LV/RV dysfunction or PH.685,720,745–",IIa,B,9,Recommendations on indications for intervention in tricuspid regurgitation (see,Valvular Heart Disease,2025,53
"Transcatheter TV treatment should be considered to improve quality of life and RV remodelling in high-risk patients with symptomatic severe TR despite optimal medical therapy in the absence of severe RV dysfunction or pre-capillary PH.713,733,735,738,748–",IIa,A,9,Recommendations on indications for intervention in tricuspid regurgitation (see,Valvular Heart Disease,2025,53
indications for intervention in tricuspid stenosis Surgeryc is recommended in symptomatic patients with severe TS.d,I,C,10,Recommendations on,Valvular Heart Disease,2025,54
Surgeryc is recommended in patients with severe TS undergoing left-sided valve intervention.e,I,C,10,Recommendations on,Valvular Heart Disease,2025,54
indications for surgery of concomitant left-sided valvular heart diseasea Classb Levelc Concomitant aortic stenosis SAVR is recommended in patients with severe AS undergoing surgery for another valve.,I,C,11,Recommendations on,Valvular Heart Disease,2025,56
SAVR should be considered in patients with moderate ASd undergoing surgery for another valve.,IIa,C,11,Recommendations on,Valvular Heart Disease,2025,56
Concomitant aortic regurgitation AV surgery is recommended in patients with severe AR undergoing surgery for another valve.,I,C,11,Recommendations on,Valvular Heart Disease,2025,56
Concomitant mitral regurgitation MV surgery is recommended in patients with severe MR undergoing surgery for another valve.,I,C,11,Recommendations on,Valvular Heart Disease,2025,56
"indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation (see also Supplementary data online, Evidence Table 24) Intervention is recommended in symptomatic patients with mixed moderate AV stenosisc and moderate regurgitation, and a mean gradient ≥40 mmHg or Vmax ≥4.0 m/s.790–",I,B,12,Recommendations on,Valvular Heart Disease,2025,56
"Intervention is recommended in asymptomatic patients with mixed moderate AV stenosisc and moderate regurgitation with Vmax ≥4.0 m/s, and LVEF <50% not attributable to other cardiac disease.",I,C,12,Recommendations on,Valvular Heart Disease,2025,56
prosthetic valve selection Mechanical heart valve An MHV is recommended according to the desire of the informed patient and if there is no contraindication to long-term anticoagulation.,I,C,13,Recommendations for,Valvular Heart Disease,2025,57
"An MHV should be considered in patients with an estimated long life expectancy,c if there are no contraindications for long-term OAC.801,807–",IIa,B,13,Recommendations for,Valvular Heart Disease,2025,57
"An MHV should be considered in patients aged <60 years for prostheses in the aortic position and aged <65 years for prostheses in the mitral position.801,807–",IIa,C,13,Recommendations for,Valvular Heart Disease,2025,57
An MHV should be considered in patients with a pre-existing MHV in another position.,IIa,C,13,Recommendations for,Valvular Heart Disease,2025,57
An MHV may be considered in patients with a clear indication for long-term OAC.,IIb,C,13,Recommendations for,Valvular Heart Disease,2025,57
Biological heart valve A BHV is recommended according to the desire of the informed patient.,I,C,13,Recommendations for,Valvular Heart Disease,2025,57
"A BHV is recommended when an adequate quality of anticoagulation with VKA is unlikely, in patients at high bleeding risk, or with estimated short life expectancy.c",I,C,13,Recommendations for,Valvular Heart Disease,2025,57
A BHV should be considered in patients aged >65 years for prostheses in the aortic position or aged >70 years for prostheses in the mitral position.,IIa,C,13,Recommendations for,Valvular Heart Disease,2025,57
A BHV should be considered in women contemplating pregnancy.,IIa,C,13,Recommendations for,Valvular Heart Disease,2025,57
"mechanical heart valve Following cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as considered safe.815,816,832–",I,B,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
"Lifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications.821–823,835–",I,A,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
"INR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve efficacy.",I,A,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
"It is recommended that INR targets are based on the type and position of the MHV, patient risk factors, and comorbidities.c 818,819,835–",I,A,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
Patient education is recommended to improve the quality of OAC.827–,I,A,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
The addition of low-dose ASA (75–100 mg/day) to VKA should be considered in selected patients with MHVs in case of concomitant symptomatic atherosclerotic disease considering the individual bleeding risk profile.,IIa,B,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
Either an increase in INR target or the addition of low-dose ASA (75–100 mg/day) should be considered in patients with MHVs who develop a major thromboembolic complication despite documented adequate INR.,IIa,C,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
DOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV.821–,III,A,14,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,59
mechanical heart valve undergoing elective non-cardiac surgery or invasive procedures Continuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventionsc associated with no or minimal bleeding.851–,I,A,15,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,60
"It is recommended to discontinue VKA at least 4 days before major non-cardiac elective surgery, aiming for an INR <1.5, and to resume VKA treatment within 24 h after surgery, or as soon as considered safe.",I,B,15,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,60
VKA interruption and resumption with bridgingd should be considered in patients with an MHV and thromboembolic risk factorse undergoing major NCS.,IIa,B,15,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,60
"Interruption (3–4 days before surgery) and resumption of VKA without bridging may be considered to reduce bleeding in patients with new-generation aortic MHVs and no other thromboembolic risk factorse undergoing major NCS or invasive procedures.816,857,858,861–",IIb,B,15,Recommendations for the management of antithrombotic therapy in patients with a,Valvular Heart Disease,2025,60
the management of antithrombotic therapy in patients with a biological heart valve or valve repair Surgical biological heart valve without indication for oral anticoagulation Low-dose ASA (75–100 mg/day) or OAC using a VKA should be considered for the first 3 months after surgical implantation of an aortic BHV in patients without clear indication for OAC.,IIa,B,16,Recommendations for,Valvular Heart Disease,2025,62
A VKA should be considered for the first 3 months after surgical implantation of a mitral or tricuspid BHV in patients without clear indication for OAC.,IIa,B,16,Recommendations for,Valvular Heart Disease,2025,62
Lifelong low-dose ASA (75–100 mg/day) may be considered 3 months after surgical implantation of an aortic or mitral BHV in patients without clear indication for OAC.,IIb,C,16,Recommendations for,Valvular Heart Disease,2025,62
"Transcatheter aortic valve implantation without indication for oral anticoagulation Low-dose ASA (75–100 mg/day) is recommended for 12 months after TAVI in patients without indication for OAC.869,880–",I,A,16,Recommendations for,Valvular Heart Disease,2025,62
Long-term (after the first 12 months) low-dose ASA (75–100 mg/day) should be considered after TAVI in patients without clear indication for OAC.,IIa,C,16,Recommendations for,Valvular Heart Disease,2025,62
"DAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication.",III,B,16,Recommendations for,Valvular Heart Disease,2025,62
Routine use of OAC is not recommended after TAVI in patients without baseline indication.,III,A,16,Recommendations for,Valvular Heart Disease,2025,62
"Surgical repair without indication for oral anticoagulation OAC, with either VKAs or DOACs, should be considered during the first 3 months after surgical MV or TV repair.884–",IIa,B,16,Recommendations for,Valvular Heart Disease,2025,62
Low-dose ASA (75–100 mg/day) should be considered for the first 3 months after surgical AV repair in patients without indication for OAC.,IIa,C,16,Recommendations for,Valvular Heart Disease,2025,62
Low-dose ASA (75–100 mg/day) may be considered after surgical MV or TV repair in preference to OAC in patients without clear indication for OAC and at high bleeding risk.884–,IIb,B,16,Recommendations for,Valvular Heart Disease,2025,62
Surgical biological heart valve with indication for oral anticoagulation OAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation.,I,B,16,Recommendations for,Valvular Heart Disease,2025,62
DOACs should be considered over VKAs after 3 months following surgical implantation of a BHV in patients with AF.872–,IIa,B,16,Recommendations for,Valvular Heart Disease,2025,62
DOAC continuation may be considered after surgical BHV implantation in patients with an indication for DOAC.,IIb,B,16,Recommendations for,Valvular Heart Disease,2025,62
Surgical repair with indication for oral anticoagulation and/or antiplatelet therapy Continuation of OAC or antiplatelet therapy should be considered after surgical valve repair in patients with a clear indication for an antithrombotic therapy.,IIa,B,16,Recommendations for,Valvular Heart Disease,2025,63
"Supplementary data online, Evidence Table 25) Haemolysis and paravalvular leak It is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team evaluation, including patient risk, leak morphology, and local expertise.",I,C,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"Reoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF symptoms.",I,C,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
Transcatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.,IIa,B,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
Mechanical heart valve failure Reoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis.,I,C,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
Biological heart valve failure Reintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis.,I,C,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"Transcatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve dysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart Team.",IIa,B,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"Transcatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction at intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–",IIa,B,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"Reoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low.",IIa,C,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"Valve thrombosis TOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis.914,918,923,925,945–",I,C,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"Mechanical heart valve thrombosis Heart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine appropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis).923,926–929,931,949–",I,B,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
Surgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.,IIa,C,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"Biological heart valve thrombosis OAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–",I,B,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
"OAC should be considered in patients with leaflet thickening and reduced leaflet motion leading to elevated gradients at least until resolution.918,920–",IIa,B,17,Recommendations for the management of prosthetic valve dysfunction (see also,Valvular Heart Disease,2025,66
